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Abstract 
Interparticulate interactions playa significant role in determining the down stream behaviours 
of all pharmaceutical formulations and are therefore essential considerations when approaching 
formulation design. Inhalation product formulation in particular is inherently bound to an 
understanding of these forces. Delivery of drugs to the lower airways to treat conditions like 
asthma and COPD requires a particle size of below SJ,lm. This implicitly demands micronization 
of the active pharmaceutical ingredients (APls) and this process renders many particles of large 
surface area with high surface energies and an auto-adhesive tendency. There is therefore a 
concurrent. reduction in the flowability and dispersion properties of these systems. The 
interactive character predisposes agglomeration, flocculation or device retention and will 
compromise manufacture, stability, device function, and the aerosolization behavior of a 
formulation. Ultimately the ability of any aerosolized API to reach the deep airways is 
dependent upon adhesion force dynamics. As such, an appreciation of the forces of attraction 
and scale of particulate interactions within inhaler technology is critical if a successful drug 
delivery device is to be realized. 
The advancement of the atomic force microscope (AFM) as a force probing apparatus, has 
meant that it is now possible to measure the force of adhesion between two particles of 
interest. However these measurements could not easily be compared, because there is no 
simple means to account for differences in the contact regime (geometrics) between 
measurements. However, the development of the cohesive adhesive balance (CAB) approach by 
Begat, Morton, Stainforth and Price in 2004 has offered a means to negate this limitation. Using 
a colloidal probe microscopy (CPM) derived technique a particle of a selected material of 
interest (API, carrier molecule etc.) is attached to an AFM cantilever and ramped onto and off 
the surface of another material of interest (adhesion measurement), and to a surface of the 
same material as the tip (cohesion measurement). By graphically plotting the adhesive force 
values of a series of tips, as a function of the cohesive force values of the same tips, a 
representation of the relative particle interaction can be obtained. Quantitative information 
regarding the adhesive/cohesive nature of the interaction can then be extracted from the graph 
and a description of the interaction formulated that can be compared to other material 
combinations. 
Abstract 
The CAB work carried out to date has used recrystallized model substrates. These molecularly 
flat surfaces ensured there would be no difference between the contact geometry of a 
functionalised AFM probe and the adhesive and cohesive surfaces of the study respectively. In 
this fashion the only variable between the two measurements would be the chemical 
interactivity, and not the interactive surface area. However while using such methodology 
guarantees the validity of the approach, it is not necessarily a true representation of the 
materials 'in-situ' and requires more complex sample preparation and complex experimental 
design. For a variety of reasons this can be misleading in its own right. 
This thesis details the .investigation into the application of an adapted CAB approach in 
characterizing the force balance between APls for inhalation in their real state. In so doing, the 
aim was to see whether such a CAB would offer a quicker and simpler, yet relevant and 
informative assessment of a drug system force balance. It was hoped that said force balance 
could in turn be associated with a measurable impact upon the formulation performance of the 
characterised ingredients as measured 'in-vitro'. This interest was particularly directed at the 
lesser characterized pressurized metered dose inhaler (pMOI) systems. While these 
formulations are solvent based, it was of interest to identify whether a simple API to API 
challenge'could infer a descriptive balance that could link to'in-vitro' performance. Furthermore 
there was interest in evaluating the use of a range of surface specific i m a g i n ~ ~ techniques to 
analyse the deposition dynamics of the combination formulations. It was hoped that by doing 
so, the localisation of the individual components within the binary deposits could again be 
associated back to the force balance of that system, and that an appreciation of the capability of 
the techniques involved would be gained. 
The work that follows therefore commences with the evaluation and description of the capacity 
. . 
for the CAB approach to be adapted to measure force relationships between real 
beclomethasone dipropionate (BOP) particles and pMOI component surfaces. From this 
assessment it was found that even with relatively smooth substrates, the combination of bulky 
functional particles and the inherent substrate roughness caused a critical failure in the CAB 
model. The parity b e t ~ e e n n cohesive and adhesive geometries of contact was excessively 
stretched, leading to a loss of force normalisation which was reflected in uncorrelated CAB 
plots. As a consequence little could be confidently gleaned from the force data acquired, 
II 
Abstract 
although there was the suggestion that the use of a fluorinated ethylene proplylene (FEP) 
coating reduced the adhesive interaction between the APls and the pMDI canister wall. 
This was then followed by an attempt to find a compromise between the model crystal 
substrates of a pure CAB process and the real particle morphologies that had caused the CAB 
model to fail. Using a compression process to form API powder compacts, in conjunction with 
small and discreet functional particles, a confident CAB was achieved for two combinations of 
APls selected on the basis of surface energy and physical stability analysis. Salbutamol sulphate 
was characterised with beclomethasone dipropionate, and salmeterol xinafoate with fluticasone 
propionate. Both combinations showed CAB plots with a sufficiently strong linear regression 
analysis to suggest a broad accuracy of force balance assessment. Both ~ 2 - a g o n i s t s s showed 
cohesively dominated relationships with respect to the paired glucocortiocoids, while in reverse 
both glucocorticoids showed adhesively dominated relationships with the ~ r a g o n i s t s . . There 
was concern raised over the compression process of the powder discs, and its impact on the 
physicochemical state of the APls, with some thermodynamic evidence of polymorphic changes 
that required further work. 
The next chapter looks at the 'in-vitro' depOSition performance of the two API combinations 
from a HFA134a pMDI system by analysis in an Andersen Cascade Impactor (ACI). The co-
formulation of salmeterol with fluticasone induced an improvement in the fine particle 
performance of fluticasone, with a concurrent decrease in the fine particle performance of 
salmeterol. This impact was hypothesised to be related to alterations in the structure and 
strength of particle-particle agglomerates. The impact on deposition performance of co-
formulating beclomethasone and salbutamol was unclear, as a critical unexplained loss of 
beclomethasone by total recovered mass was seen from all beclomethasone containing 
formulations. This instability of beclomethasone within the HFA134a system, precluded an 
accurate assessment of a direct impact on salbutamol deposition. 
The final chapter, compared a range of surface specific imaging techniques, including scanning 
electron microscopy (SEM), desorption electrospray ionization mass spectrometry (DESI), Raman 
spectrometry and time-of-flight secondary ion mass spectrometry (ToF-SIMS) in assessing the 
extent and nature of 'in-vitro' co-deposition from the salmeterol and fluticasone pMDI 
formulations. It was apparent that the deposition of the two APls on ACI plates was not likely to 
be directly comparable assessment of the incidence of particle co-deposition 'in-vivo' due to the 
III 
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forced nature of nozzle directed impaction. However the combination of techniques employed 
produce"d a wealth of physical and chemical data that did suggest that the two APls showed 
extensive co-ordination 'in-vitro'. Raman spectroscopy was able to identify individual particle 
character and showed frequent salmeterol and fluticasone particle combinations, but suffered 
from exceptionally long run times and anomalies from photoreactive surface elements. The use 
of a multivariate approach to ToF-SIMs analysis defined the strong co-association of the two 
APls, although could not differentiate particle to particle deposition. Multivariate curve 
resolution (MeR) was used and produced distinct components that segregated ions from both 
APIS from the background plate but not from each other. SEM imaging was able to define the 
morphologies of the deposited particles, but was unable to differentiate the two. DES I imaging 
showed the presence of the two APls together within several drug spots, but could not be used 
to investigate individual drug spots, and the distribution within, due to inadequate spatial 
resolution and differences in desorption efficacy. While the co-association of the two APls was 
observed, the lack of a comparator in another combination of APls made the link between 
, 
deposition performance and force balance purely descriptive. It was unclear as to whether the 
force balance of the system lends itself to a particular increase in co-deposition behaviour. 
However it was apparent that the analytical techniques employed all had respective strengths 
and weaknesses as mapping tools, and with further work with other formulations could be used 
to provide a tailored formulation screening process, if subsequent links to force balances could 
be made. 
To conclude, the work in this thesis details the successful process of adapting an AFM technique 
. in characterising the broad force balance of combinations of APls. In so doing a force balance 
has been linked to the alteration in deposition behaviour of two APls when co-formulated in a 
HFA134 formulation. The subsequent co-deposition of the two APls was then analysed by a 
series of surface analytical techniques. This highlighted a general co-deposition trend, but the 
collective results were unable to definitively link to the force balance of the system. The 
information obtained forms the beginnings of what could be utilised as a fast and facile broad 
predictor of pMDI formulation performance, and an indication of appropriate analytical 
techniques for investigating particle association 'in-vitro'. 
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Thesis Aims and Objectives 
The aim of this thesis was to investigate the application of the atomic force microscopy derived 
cohesive adhesive balance approach to inhalation based (pMDI) API particles with 'non-ideal' 
surfaces (i.e. those with real particle character). In so doing it was hoped that the tolerance for 
substrate roughness of the model could be described, and that broad force balances could be 
achieved between combinations of APls and pMDI device components more representative of 
'in-situ' states. If these force balances could then be linked to 'in-vitro' measures of formulation 
performance, such as aerodynamic particle size profiling, It would open up the potential for 
predicting deposition performance success or failure from simple AFM based methodologies. It 
was further expected that a range of complementary surface specific analytical techniques could 
be employed in conjunction; so as to better understand API particle characterisation and the link 
between a force balance and aerosol deposition mechanics. 
The primary objectives of this work were therefore as follows: 
o Investigate the use of a CAB approach to real particulate materials. 
o Define the limits of the CAB approach with regards substrate roughness. 
o Describe the force balance of a combination of APls. 
o Describe the force balance of APls with pMDI device components. 
o Link the force balances measured to changes In 'In-vitro' deposition performance. 
o Use multiple surface specific techniques to analyse the deposition character of API 
combinations and link this with the force balances achieved. . 
XXXVII 
Chapter 1 - Introduction 
1.0 Introduction 
1.1 Drug Delivery via Inhalation 
The delivery of therapeutic agents via inhalation to treat respiratory disorders can be traced 
back over 4000 years (Grossman et ai, 1994). Early documented examples included the use of 
volatile aromatics such as menthol, thymol and eucalyptus to aid breathing, or the fumes from 
burning leaves such as Atropa belladonna and Datura strammonium as hallucinogens (Zeng et 
ai, 2001). The invention of the glass bulb nebuliser during the industrial revolution of the 
nineteenth century heralded a significant proliferation in p h y s i o l o g i c a ~ , , formulation and device 
understanding in relation to what we now consider modern inhalation therapy (Grossman et ai, 
1994). Indeed, such has the field developed that prevalent respiratory disorders such as asthma 
and chronic obstructive pulmonary disorder (COPO) have become synonymous with the use of 
sophisticated inhaler devices and a range of associated respirable active pharmaceutical agents 
(APls). 
The attraction of treating such conditions via this particular route is in essence linked to the 
simple facility of being able to target the site of disease directly. The predominant sites of 
disease in the above conditions are within the tracheobronchial tree and the lungs themselves. 
Therefore with the use of inhalation therapy it is possible to deliver APls directly to these sites, 
allowing for a rapid and predictable onset of pharmacodynamic action with negation of the 
adverse pharmacokinetic issues of systemic treatments (Virchow et aI, 2008). These principally 
include degradation within the digestive tract, system wide biodistribution and first pass 
metabolism (Timsina et ai, 1994). As a consequence smaller doses than would otherwise have to 
be delivered can be used, and the rest of the body is much less likely to see any of the API by 
distribution, thereby significantly decreasing the likelihood of adverse side effects. In addition 
inhalation therapy is generally considered patient friendly, being a non invasive route of 
delivery, and with the high solute permeability of the airways, large surface area (70 - 140 m2 
(Groneberg et ai, 2003)) and limited proteolytic activity (Sung et ai, 2007) it can be considered 
an attractive target for a broad range of APls in local disease treatment. Furthermore because 
the lungs possess a very large vascular supply for gaseous exchange, separated from the air 
space by only a thin layer of epithelial cells, there has been significant interest in using 
inhalation therapy as a means to deliver agents for systemic treatments (Zeng et ai, 2001). Of . 
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particular interest is the inhalation of biopharmaceutics (DNA, RNA, genes, polypeptides etc). 
Such materials have little or no oral bioavailability and attempts to deliver APls such as insulin to 
treat conditions like diabetes would avoid invasive administration (subcutaneous injections) and 
potentially offer better bioavailability and pharmacodynamics. However this area of research is 
still in it's infancy in comparison to the established delivery of topical agents .. 
1.2 The Human Respiratory Tract 
1.2.1 Physiology of the Respiratory Tract 
The respiratory system is a complex region of the human body responsible for the gaseous 
exchange between the atmosphere and the systemic circulation of oxygen and carbon dioxide 
necessary for cellular respiration. By association it is also critical in the blood pH homeostasis 
mechanism and the provision of vocal expression (Zeng et ai, 2001). 
The respiratory tract can be divided into three main regions (Finlay, 2001): 
• The Extrathoraclc Region - The upper airways proximal to the trachea consisting of the 
nose, mouth and throat (nasopharanyx and oropharynx) and the larynx. 
• The Tracheo-Bronchlcal Region - The branching conducting airways that include the 
trachea, bronchi and bronchioles. 
• The Alveolar Region - All parts of the lung containing alveoli starting at the respiratory 
bronchioles and progressing to the alveolar ducts, and alveolar sacs. 
Each of these regions has particular roles within the system as a whole. The upper extrathoracic 
airway is responsible primarily for inspiratory air intake, conditioning and filtration, as well as 
playing a role in olfactory sensation and vocal expression. The tracheo-bronchial region serves 
to conduct air from the larynx to the alveolar region where gas exchange takes place. Taken 
together the extrathoracic and tracheo-bronchial airways· can be termed the conducting 
airways, in respect to the above functions. However they also provide structural support and are 
2 
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responsible for the removal of particulate matter that has passed the extrathoracic region by 
constant epithelial mucocililary clearance. 
The alveolar region is directly responsible for the gaseous exchange essential for blood 
oxygenation. The anatomical arrangement of these regions often gives rise to the term of the 
'pulmonary tree' . This is because the system may be viewed as a series of irregularly 
dichotomous branching passageways, from below the trachea down to the alveoli (figure 1.1). 
These branches are dichotomous because each 'mother' passage leads to two 'daughter' 
passages, but irregular because the 'daughter' branches are not necessarily of the same size. 
(Davies et ai, 2003). There are approximately 23 generations before the respiratory bronchioles 
give way to the alveoli where gaseous exchange ultimately takes place (Hindle, 2010). 
NASAL CAVITY 
MUCUS 
PVLMONAItY VIIN 
CSLLS 
Figure 1.1 Diagram of the respiratory system. Adapted from lung.ca Accessed on the 1/11/11 
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As the respiratory system moves down from the mouth, through the trachea to the alveolar sac, 
there develops a significant airflow dynamic due to this dichotomous branching. Whilst the 
conducting airways decrease in diameter with each branching generation, there is a massive 
increase in cross sectional area, (particularly between the terminal bronchiole and alveolar sac) 
as a consequence of the propagation of new branches. The velocity of air as it progresses 
through the tract is therefore rapidly reduced and within the alveolar region, flow velocity falls 
below that of diffusing oxygen molecules, allowing the maximum diffusive capability to be 
established (Hickey, Thompson, 1992). This sequential decreasing airways calibre is also 
essential in developing a controlled penetration of air to the deep lung on tidal breathing that 
allows lung (and therefore chest) expansion (Hickey, Thompson, 1992). There is also established 
a maximum alveolar surface area in conjunction with the minimum volume possible (Davies et 
al,2003). 
1.3 Active Pharmaceutical Agents for Respiratory Diseases 
1.3.1 Common Classes of Active Pharmaceutical Agent 
The most prominent respiratory conditions experienced are asthma and COPD. It is therefore 
the case that the most commonly used active pharmaceutical agents, are those designed to 
treat these conditions. Fundamentally the hallmark of both conditions is a reduction in local 
airway calibre and marked airway Inflammatory responses. Consequently the crux of treatment 
is based around the local delivery of two fundamental categories of therapeutic agent; 
bronchodilators and anti-inflammatory agents. Bronchodilators are responsible for maintaining 
airway calibre or reversing airway constriction. Anti-inflammatory agents are used to inhibit or 
prevent the inflammatory response of the local airway environment that may compromise 
airway calibre. In broad terms both agent types are often used in combination to bring patients 
long term control over their condition. Bronchodilators predominantly include ~ 2 2 adrenoceptor 
agonists and muscarinic-receptor antagonists, while anti-inflammatory agents are confined to a 
group of glucocortiocoids. Further bronchodilatory (such as the xanthine theophylline), and 
anti-inflammatory agents (such as the leukotriene receptor antagonists, montelukast and 
zafirlukast) are used at more advanced stages of disease, but are administered systemically via 
the oral route and much less prominent. 
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1.3.2 Betaz-Adrenoceptor Agonists 
The primary responsibility of the J32-agonists is to illicit direct action of the J32-adrenoceptors on 
the smooth . muscle in the bronchi. The J32-adrenoceptors are physiological antagonists, 
responsible for smooth muscle relaxation that is initiated via a G-protein coupled response and 
an adenylate cyclase based secondary messenger system. Their effect occurs even in the 
presence of spasmogens. They also have a secondary effect in working to inhibit inflammatory 
mediator release from mast cells (such as histamine) and monocytes (such as TNFa). It is also 
believed they may directly increase mucus clearance by effects on the cilia (Rang et ai, 2003). 
There are two distinct categories of J3ragonist; short acting and long acting (LABAs). This 
distinction is straightforwardly based upon the time taken to reach maximal effect. Short acting 
~ 2 - a g o n i s t s s include salbutamol sulphate and terbutaline sulphate, and these reach maximum 
effect within 30 minutes of administration, with a duration of action of 4-6 hours. lABAs include 
salmeterol xinafoate and formoterol fumerate, and have an extended duration of effect of 
around 12 hours (Rang et ai, 2003). Consequentially, short acting ~ r a g o n i s t s s are used as rescue, 
or 'as required' reliever therapy for episodes of breathlessness while LABAs are used in regular 
dosing regimes as a 'preventer to maintain airway calibre over longer periods of time. Two of 
the most common ~ 2 - a g o n i s t s s that were used in this body of work are discussed in more detail 
below: 
1.3.2.1 Salbutamol Sulphate 
I H2S04 and enantiomer 
HO 
2 
Figure 1.2: Salbutamol Sulphate Monograph (British Pharmacopoeia, 2012) 
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Salbutamol sulphate (figure 1.2) is a short acting ~ r a g o n i s t t which is typically delivered via the 
inhalation route for local and immediate bronchial smooth muscle relaxation. Chemically the 
meta phenol group of the catecholamine skeleton is substituted with a hydroxymethylene group 
that hides the molecule from rapid metabolism by the enzyme catechol-o-methyl-transferase 
(Patrick, 2005). It is typically dosed at 200-400j..lg as required for asthma sufferers but may be 
used regularly in COPO patients, or increased in dose and frequency in severe episodes of 
airways challenge (BNF, 2012). It is available as a solution for nebulisation, dry powder 
inhalation (OPI) and pressurised metered dose inhalation (pMOI). It can be delivered 
systemically, via either the oral or parenteral routes, but these modes of administration are 
reserved for refractory airways disease, emergency management in critical care or uterine 
smooth muscle relaxation to delay pregnancy. Typically it may induce side effects such as a fine 
tremor, nervous tension, headaches, tachycardia or palpitations due to some residual ~ 1 1
adrenoceptor agonism (BNF, 2012). It is metabolised hepatically and renally excreted, with a 
half-life of 1.6 hours (European Pharmacopeia, 2012). 
1.3.2.2 Salmeterol Xlnafoate 
H OH H 
HO 
~ N ~ ~
and enantiomer 
Figure 1.3 Salmeterol Xinafoate Monograph (British Pharmacopoeia, 2012). 
Salmeterol xinafoate (figure 1.3) is a LABA, delivered exclusively by inhalation for prolonged 
airways smooth muscle relaxation. It is added to asthma therapy when short acting ~ 2 - a g o n i s t s s
alone and in combination with low dose glucocorticoids have been insufficient to control 
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symptoms (BTS, SIGN, 2011). As such, it is most commonly prescribed as a combination 
formulation witha concurrent glucocorticoid (e.g. with fluticasone propionate in Seretide®) and 
is available as both pMOI and. OPI formulations. It's additional lipophilicty, by virtue of a 
lengthened N-substituent with a further hydrocarbon chain and aromatic ring, allows stronger 
binding to the tissues surrounding the ~ r a d r e n o c e p t o r s . . This results in double the potency of 
salmeterol as compared to salbutamol and an extended duration of action of 12 hours (Patrick, 
2005). Hence, given its long time of action it is unsuitable for 'as required' relief, and therefore 
commonly used at doses of 50-1001lg twice a day as a regular prophylactic. It can induce side 
effects in the same fashion as salbutamol, and is metabolized and excreted in the same manor 
with a half-life of 5.5 hours (European Pharmacopeia, 2012). 
1.3.3 Glucocorticoids 
These agents are not used in the immediate phase of an asthma attack, but are employed to 
suppress the immune response capability of the bronchial region. This has a twofold impact, 
preventing attacks occurring in the first instance and also suppressing the inflammatory 'late' 
phase reaction of an asthma attack. Their mode of action is based in glucocortiocoid receptor 
mediated alterations to genetic transcription that result in a cascade response with a reduction 
in a vast array of inflammatory cytokines. In particular, with respect to asthma and COPO this 
includes the Th2 cytokines responsible for eosinophil recruitment and activation, IgE production 
and IgE receptor expression. The inhibition of the arachiadonic acid pathway enzyme 
cyclooxygenase-2 also results in reduced production of the vasodilating prostaglandins P G E ~ ~ and 
PGI 2. And by the induction of lipocortin there is a reduction in the production of the spasmogens 
LTC4 and L TD4 as well as the leukocyte chemotaxins LTB4 and platelet activating factor. 
Glucocorticoids will also upregulate the expression' of the ~ 2 - a d r e n o c e p t o r s , , increasing the 
facility for smooth muscle relaxation, as well as decreasing microvascular permeability and 
reducing eosinophil mediator release (Rang et ai, 2003). Because these effects are related to 
genetic repression or induction, the effects take several days to take effect, therefore further 
establishing these APls as regular dosed prophylactics. The commonly employed inhaled 
glucocorticoids include beclomethasone dipropionate, budesonide and fluticasone propionate. 
All three of these corticosteroids were used in this thesis, and are discussed briefly below. 
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1.3.3.1 Beclomethasone Oipropionate 
o 
Figure 1.4 Bec1omethasone Dipropionate Monograph (British Pharmacopoeia 2012) 
Bec/omethasone dipropionate (figure 1.4) is a potent glucocorticoid that is utilised for the 
regular symptom maintenance of asthmatics (or some COPO sufferers). It is considered the 
reference standard for corticosteroid dosing in airways disease and is prescribed when short 
acting 132-agonists alone are not enough to control a patients symptoms (BTS SIGN, 2011). It is 
commonly dosed at between 200-800\.1.8 daily, usually split into a twice daily regimen. More 
refractory disease can see doses of up to 2000\.l.g a day. It is available currently as both pMOI 
(Clenil ModuliteiPI, QvariPI) and OPt formulations (AsmabeciPI, BecodiskiPI). It can also be 
formulated in combination with LABAs (with formoterol fumerate in Fostair lPl ) to increase 
compliance where appropriate. It has uses topically for the treatment of inflammatory skin 
disorders, or as a nasal formulation for allergic and vasomotor rhinitis (BNF, 2012). Side effects 
of beclomethasone are typical of all corticosteroids. Large doses can be associated with systemic 
effects such as adrenal suppression, bone mineral density depression or glaucoma. More 
commonly, due to significant local impaction from inhaled formulations, oropharyngeal 
candidiasis may occur (BNF, 2012). It is metabolised hepatically and has a half-life of 2.8 hours. 
It's mode of excretion is not yet fully characterised (European Pharmacopeia, 2012). 
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1.3.3.2 Budesonide 
OH 
CH 3 •• 0 * . , ~ C H 3 3
.. r H and epimer at C* 
o 
Figure 1.S Budesonide Monograph (British Pharmacopoeia, 2012). 
Budesonide (figure 1.5) is a glucocorticoid used for the regular management of inflammatory 
airways disease. It is only available in DPI formulations in the UK (Pulmicort ®) and is usually 
dosed at 1 0 0 - 8 0 0 ~ g g twice' a day. Given enterally it treats inflammatory bowel disorders such as 
Crohn's disease and ulcerative colitis or as a nasal treatment for rhinitis or nasal polyps (BNF, 
2012). It is more often co-formulated with the LABA formoterol fumerate (Symbicort®), which 
due to formoterol's abridged character between a short acting ~ 2 - a g o n i s t t and LABA may be used 
both as a regular prophylactic and as a when required reliever. It is metabolised hepaticaliy, 
excreted renally and has a half-life of 2-3.6 hours (European Pharmacopeia, 2012). 
1.3.3.3 F/uticasone Propionate 
o 
Figure 1.6 Fluticasone Propionate Monograph (British Pharmacopoeia, 2012). 
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Fluticasone propionate (figure 1.6) is another glucocorticoid used via inhalation for the 
management of inflammatory airways disease. It is available as a nebulised solution, pMDI and 
DPI formulation on its own (Flixotide lll ). It is also widely prescribed in combination with the LABA 
salmeterol xinafoate (Seretide lll ) as both a pMDI and DPI formulation for regular prophylaxis 
only. It is twice as potent as beclomethasone and budesonide and is therefore commonly dosed 
at 100-5001-1g twice a day. It is absorbed to a very small extent from the digestive tract and 
undergoes almost complete first-pass metabolism, therefore being less associated with systemic 
side effects (Rang et ai, 2003). Fluticasone can also be used as a nasal treatment for rhinitis or 
polyps, and is occasionally used as a potent treatment for refractory inflammatory skin 
conditions such as eczema or dermatitis. It has the longest half-life of the inhaled corticosteroids 
at 7.8 hours, but remains hepatically metabolised and renally excreted. 
1.4 Delivering Active Pharmaceutical Agents to the Respiratory System 
The APls described above can only elicit the desired physiological effect if delivered successfully 
to the tracheo-bronchical region of the respiratory tract where the problem occurs. One of the 
principal difficulties in dOing this is how to break up the bulk amounts of compound in the 
formulation Into micron sized particles suitably sized to reach this region of the respiratory tract. 
To do so requires energy to overcome the attractive forces between the molecules (as discussed 
below). The number of bonds broken Is proportional to the amount of a new surface being 
created. Therefore the amount of energy required to break up a bulk compound into respirable 
droplets or particles Is proportional to the Increase in surface area (Finlay, 2001). Currently 
there are three methods utilised to achieve aerosolization. These are via nebulisation, dry 
powder inhalation or pressurized metered dose inhalation. These delivery systems are discussed 
briefly below: 
1.4.1 Nebulisers 
Nebulisers are one of the oldest and simplest means to aerosolize an API. If an API can be 
suspended or dissolved into a liquid media such as water, then by blowing air at high speed over 
the surface of the suspension or solution, sufficient energy to break up the bulk liquid into 
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droplets will be provided (Finlay, 2001). Devices working on such a principle are termed jet 
nebulisers, and there are several different models. In basic terms, each utilises a pressurized air 
supply with subsequent baffle induced particle size reduction to obtain a suitable respirable 
particle stream that a user inhales with normal tidal breathing for a given period of time. These 
devices are large and bulky by nature and therefore not easily transported. They are also 
functionally noisy in operation, and require several minutes operation for a given dose to be 
taken. For this reason they are often the choice for patients with end stage, or advanced disease 
states that are hospitalised or house bound. Their principal benefit is that by the use of a 
facemask delivery system, they are a passive means of delivering the API, that requires little 
patient co-ordination or inspiratory effort. 
While· jet nebulisers are the most predominant nebuliser in use, there is also a subsequent 
nebuliser technique. Ultrasonic nebulisers use piezoelectric crystals vibrating at a high frequency 
(1-3 MHz) to provide the energy to aerosolize droplets. This mechanism is based on' a fixed 
crystal causing sufficiently strong vibrations through the media to illicit a fountain of liquid at 
the surface from which droplets will escape as a respirable 'mist' (Hindle, 2010). These devices 
will then either use a fan based system, or simply the inspiratory flow from the user to draw 
these droplets out of the device for inhalation. While these devices are much quieter than jet 
nebulisers, they often suffer from large dose wastage as much of the droplet cloud will coalesce 
and return to the reservoir. Even when the device is run to 'dry', much of the particulate dose 
can be left behind in the nebuJiser. Most recently a type of ultrasonic nebuliser called a 
'vibrating mesh nebuliser' has adapted this technique to use an ultrasonic horn to force the 
reservoir suspension through a simultaneously vibrating mesh with a controlled pore size. This 
has resulted in improved particle sizing and subsequently better dosing efficiencies. 
1.4.2 Dry Powder Inhalers 
Dry powder Inhalers are unique among respiratory API delivery systems, as they do not use a 
dissolved or suspended API reservoir. Rather they depend on the direct formulation of blended 
API and excipient powders into capsules or blisters that are pierced by the device immediately 
prior to inhalation. A patient's inspiratory flow is used to aerosolize the powder bed. Because of 
the intrinsic adhesive character of micronized particles, using the API powder alone results in 
11 
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excessive agglomeration, poor flowability and aerodynamic particle sizing. This problem is 
usually addressed by using a large coarse carrier molecule of an inert excipient such as a-lactose 
monohydrate (>60Ilm) (Hooton et ai, 2006). In this scenario the carrier and drug are blended 
with the intention that the API particles adhere to the surface of the larger carrier rather than 
themselves. The lack of small particle cohesion results in a marked improvement in powder flow 
and homogeneity, enabling successful manufacture, dosing and fluidization of the API (Jones et 
ai, 2008a). Upon fluidization the two particulate species disassociate in the air stream and while 
the API ideally reaches its respiratory target, the larger carrier harmlessly impacts on the throat 
and is swallowed. However the application of a carrier molecule will only be useful in terms of 
powder behavior if the forces of adhesion between the carrier and API are greater than the 
forces of cohesion between the API molecules (i.e. adhesion> autoadhesion) (Podczeck et ai, 
1994). As a clinical device OPls require less co-ordination than other types of inhalation device. 
However they also require greater levels of cleaning, and a large inspiratory effort to aerosolize 
the powder bed, which may not be possible for those who are infirm. Furthermore, some 
people can't tolerate the excessive impaction sensation in the oropharynx. Nether less OPI 
formulations often offer the most stable API combinations, where suspension or dissolution of 
an ingredient has proved challenging. 
1.4.3 Pressurized Metered Dose Inhalers 
Pressurized metered dose inhalers (pMOls) are the most commonly used device for delivering 
APls to the airways. The concept is based upon the API being dissolved or suspended within a 
volatile propellant (with other excipients for lubrication, stabilization etc) which is then metered 
and expelled from a canister upon actuation via a mouthpiece (actuator). The propellant which 
is liquefied under pressure in the canister vaporizes rapidly on a release and carries with it the 
suspended or solubilised pharmaceutical agent (figure 1.7). The first pMOI devices (3M Riker's 
Medihaler Epi4D) were developed by Riker Laboratories and marketed in 1956 as a replacement 
for the inexact squeeze-bulb nebulizer (Newman, 2005). The device technology has now become 
the most commonly used for delivering APls to the airways. A great proportion of their success 
has been founded in their cheap cost to manufacture and that the propellant driven system 
does not require as great an inspiratory effort for effective aerosolization as with OPls. A pMOI 
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Figure 1.7: Schematic of a pMDI device (Vervaet, Byron, 1999) 
device consists of a canister containing the API solution or suspension, the metering valve and 
the actuator. To overcome problems of API adhesive character (inappropriate flocculation 
behavior, sedimentation and irreversible caking (Veravet, Byron, 1999)) as well as the 
interaction between the APls and the physical Inhaler components themselves (device 
entrainment, nucleation and crystallization) pMDI formulations are often stabilized by the use of 
, SUrfactants and co-solvents. Surfactants use sterle means to prevent interparticulate contact 
and agglomeration (Bower et aI, 1996), while co-solvents ensure the API remains solvated within 
the propellant. Traditionally these were non-ionic surfactants such as oleic acid, lecithin, and 
sorbitan tri- or mono-oleate. However the recent re-formulation of suspension pM DIs to 
fUnction without chlorine based propellants has demanded a rethink. 
1.4.4 Hydrofluoroalkane (HFA) Propellants 
1.4.4.1 CFC to HFA Transition 
The original pMDI formulations were based on chlorofluorocarbon (CFC) propellants (figure 1.8). 
These were considered ideal due to their chemical inertness, non-toxicity. high vapour pressure 
(constant under storage), compatibility with common APls, appropriate boiling points and 
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Figure 1.8: The chemical structures of CFC and HFA propellants (Veravet, Byron, 1999). 
densities (Newman, 2005). Yet despite an excellent functional performance, it was subsequently 
proven that the release of chlorine in the degradation of the CFCs was contributing significantly 
to ozone depletion in the stratosphere (Molina, Rowland, 1974). As per the subsequent 
Montreal Protocol (1989) the use of CFCs was therefore phased out. pMDI inhalers were given a 
temporary exemption, to prevent the unavailability of essential medicines to patients, but it waS 
still necessary for the manufacturers of CFC based pMDI devices to consider reformulation. 
Emphasis was put on either finding an alternative propellant or using alternative technologies 
(such as DPls). Such an exemption for pMDI formulation CFC use has now passed, and it has 
been the emergence of Hydrofluoroalkanes (HFAs) as alternative propellants that haS 
dominated the new pMDI markets. The HFAs (figure 1.8) contain hydrogen, fluorine and carbon 
but no chlorine. Hence they are readily metabolized by the environment and will not cause 
ozone depletion (Manzer, 1990). 1,1,1,2-tetrafluoroethane (HFA134a) and 1,1,1,2,3,3,3-
heptafluoropropane (HFA227ea) have generally been accepted as the next generation CFe 
replacements. However as a consequence of not being fully halogenated and having one or twO 
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hydrogen atoms, in their structure, they confer a degree of polarity which has had consequences 
for the propellant interactions observed, namely an insolubility of non-polar surfactants 
(Veravet, Byron, 1999). A desire to formulate suspensions or solutions with acceptable stability 
coupled with the changes in physicochemical nature of the propellant (demanding the use of 
additional co-solvents or novel surfactants) places even more emphasis on an understanding of 
particle-particle adhesion. The use of a propellant means that the pMDI formulations exist as 
colloidal suspensions. As such pMDI formulations are subject to solvent based forces and these 
are highly important in determining physicochemical behavior and stability, as well as describing 
the contribution of the propellant itself, to a broader interparticulate force model. 
1.4.4.2 Solvent Forces 
Derjaguin, landau, Verwey and Overbeek (DVLO) (Derjaguin, Landau. 1941) theory describes the 
stability of colloidal suspensions and dictates that such formulations will see particulate surfaces 
in a liquid medium (HFA) developing an interfacial relationship depending on the relative 
genesis of attractive and repulsive forces. The model describes the contributions from the 
attractive dispersive (London) van der Waals forces (discussed in more detail below) and the 
repulsive electrostatic interaction. (Traini et ai, 2005). The essential difference to the adhesion 
forces between the constituent particles in air comes principally from the nature and extent of 
sUrface charging and the electrostatics involved at the solid-liquid interface. Charging can occur 
as a result of one of several processes. For example solvent ions can absorb to a surface, or 
charged ions on the solid surface can dissociate into the medium (Florence, Attwood 2012). 
Resultant surface charges can cause an electric field, which in turn can lead to the attraction of 
counter ions from the medium, and in so doing develop an 'electrostatic double layer' (Butt, 
2010). For example a particle surface that possesses or generates a negative charge will attract 
POsitive ions to the surface. This develops what is known as the 'Stern' layer (Florence, Attwood, 
2012). Thermal motion within this layer leads to a perpetual movement of these counter ions 
away and back to the surface that in turn creates a 'diffuse' layer, extending further Into the 
liquid media containing both positive and negative i?ns. It is the interaction of these double 
layers between particulates that can affect and govern ~ d h e s i v e e character, with like surface 
charges leading to repulsion and opposite charges leading to attraction (lsraelachvili, 1991). The 
modification of interparticulate forces between particles in liquids is therefore driven by the 
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chemical character of the solvent in relation to that of the solutes. Polar media have the 
capacity, through their potential for polarization to either facilitate or suppress the attraction 
between two surfaces (Stone, 2013). 
HFAs are however low dielectric solvents, despite being significantly more polar than traditional 
CFCs (HFA 134a has a dielectric constant of 9.5, where CFC-ll is 2.3). The potential for 
significant double layer induced repulsion is therefore significantly lower than in aqueous media 
(Veravet, Byron, 1999). Assuming uncharged API particles (essential for respiratory delivery), 
low polar contributions and interparticle distances well in excess of electronic van der Waals 
radii, the dominant pre-disposition (assuming no moisture ingress) of a suspended API in a HFA 
will usually remain the attractive London van der Waals forces. This lends the suspended API 
towards agglomeration, flocculation or caking without the introduction of additional stabilizing 
excipients. Steric stabilization is therefore common place using a range of surfactants, which in 
turn, given the Increased polarity of the HFAs, are often co-formulated with co-solvents. The 
resultant formulation is therefore a complex relationship between API surface chemistry, 
solvent chemistry, the steric repulsion of surfactants and the degree of solubility of all the 
solutes. 
This thesis will move on to examine the fundamental force balance between the APls in a binary 
HFA134a formulation. It is obvious that the adhesion forces at work between APls in suspension 
will undoubtedly be influenced by the contribution of the HFA media and it's manipulation of 
surface forces. However this body of work was designed to try and quantify a basal dispersive 
Interaction between co-formulated APls and in turn see if this could be related this to 'in-vitro' 
performance outcomes. As such the force balances carried out were done so outside of a model 
propellant to characterize dispersive forces, the impact of co-formulation upon them and any 
discernible relationship to deposition studies. The contribution of the HFA solvent should not be 
ignored however and further work beyond this thesis to accommodate the impact of the liquid 
and gaseous media upon a force balance will be of interest and essential to expand upon the 
relationships observed. 
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1.S The Deposition of Drugs Delivered to the Respiratory Tract 
'The passage of aerosolized API from an inhalation device to the respiratory tract or lung is 
governed by a complicated relationship of factors. These can broadly be grouped into the 
physical factors that determine the deposition of the drug from the mouth and onto the surface 
of the airway lumen, and the pharmacokinetic factors that determine the amount of the 
deposited API that passes from the airway lumen into the smooth muscle cells (Hickey, 1992). 
The adsorption, distribution, metabolism and excretion (pharmacokinetics) of the APls delivered 
for inhaled use are not in the scope of this thesis and will therefore not be considered here. 
However it is worth pointing out that the pharmacokinetics of APls in the airways differ 
according to the site of deposition, and this places an emphasis on the correct physical 
characteristics of an aerosol in reaching the targeted location of deposition. Particles deposit on 
the airways by three main mechanisms. These are inertial impaction, gravitational 
sedimentation and diffusion (Hindle, 2010). 
1.5.1 Inertial Impaction 
Inertial impaction is the depOSition of particles onto a surface as a consequence of their own 
inertia. As inspired air moves down the respiratory tract, it will change direction due to the 
physiological structure of the airways. Every time this occurs, particles or particle agglomerates 
will travel a given distance in the original direction of the airflow due their momentum. This is 
dependent upon the particle velocity and mass. If a particle has sufficient inertia, it may not be 
able to relax back into the air stream before travelling a distance that results in Impaction on a 
structural surface in front of them (Gonda, 1990). If a particle with mass m is moving with an 
initial velocity Vo through still air then it can be shown that as a result of frictional forces it will 
stop after travelling distance 5: 
S=B xmxVo (1.1) 
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Where B is the mechanical mobility of the particle as velocity per unit force (Hickey, 1992). As 
such the greater the particle mobility, mass and initial velocity the further it will travel in its 
original trajectory. As such, aerosolized particles with an aerodynamic particle size in excess of 
1 0 ~ m m will inertially impact at the oropharynx and be swallowed. Those with an aerodynamic 
particle size of less than this will generally be able to pass down towards the central airways. 
Further impaction occurs at the higher phYSiological structures, such as the branching of the 
trachea and left and right bronchus. This accounts for smaller and smaller particles. 
1.5.2 Gravitational Sedimentation 
As the airways progress, and airstream velocity decreases, inertial impaction becomes less 
important and it is gravitational sedimentation that becomes more critical for smaller particles 
of 2 - 5 ~ m . . These will often deposit on the bronchioles or alveoli, where they can elicit the 
desired physiological effects for appropriate treatment of such ailments as asthma (Hindle, 
2010). These smaller particulates will settle under gravity, after acceleration to a terminal 
velocity when the gravitational force is balanced by the resistance of the air through which it is 
travelling. A sphere of diameter D, and density d under the influence of gravitational force 
F gwill have a terminal settling velocity Vts in the laminar region governed by Stokes law: 
Vts = (d X D2 X 0)/(18 X 11) = B X F 9 (1.2) 
Where 9 is the gravitational acceleration and" is the viscosity of air (Hickey, 1992). Therefore 
this process is shown to be more likely with increasing particle mobility. It is also time 
dependent and therefore aided by breath holding (Hindle, 2010). 
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1.5.3 Diffusion (Brownian Motion) 
Particles with even smaller aerodynamic particle sizes « 0 . 5 ~ m ) ) may be subject to diffusive 
processes. Here it is gas molecule bombardment that initiates random movements, which in 
turn leads to deposition. In contrast to impaction and sedimentation diffusional deposition is 
indirectly proportional to the particle diameter (Finlay, 2001). That is to say that with decreasing 
particle size we see increasing diffusional deposition. 
1.5.4 Assessing Formulation Deposition 'In-vitro' 
Characterizing the particle size and distribution of discharged aerosols has become one of the 
key tests applied to inhaled products. This is because, as shown above, these variables are 
explicitly linked to the deposition efficiency and location within the respiratory tract of the 
formulation 'i'!-vivo'. A variety of methods exist to do so. Such methods can be broadly split into 
two groups; inertial impaction and optical scattering. Optical methods such as particle time of 
flight (TOF), laser diffractometry (LD), and Phase-Doppler particle size analysis (POA) provide a 
rapid collection of particle size distribution over a small number of actuations. However, they 
are unable to distinguish API particles from excipient, or Indeed a combination API. Furthermore 
they determine volume-equivalent particle size, rather than the more important aerodynamic 
particle size. This is a significant drawback, as it means that particle sizing is non-specific and can 
generate a biased impression of the true particle size (Copley, 2008). 
Inertial impactors are the most predominantly used means of characterizing aerosol particle 
sizes. They function on the basis of separating particles according to their inertia, which is In 
turn intrinsically linked to the particle mass (size) and velocity. Therefore In a controlled airflow, 
and with a given size exclusion mechanism it is possible to Infer the particle size distribution of a 
formulation. Such devices allow the collection of entire actuations of API, and Importantly give 
the operator the ability to independently assess the particle size distribution of several APIS 
from within the same formulation. The most commonly used Inertial impactor Is the Anderson 
cascade impactor (ACI), originally developed for the analysis of environmental pollutants 
(Munroe, 2007). The ACI consists of stack of sequential nozzle sets with precisely controlled 
reducing nozzle sizes, calibrated to define given aerodynamic particle sizes. These are fitted with 
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metal plates below each stage. Airflow is drawn through the stack, and a formulation is actuated 
into the stack via a throat piece. On entering the impactor, the aerosol is passed through 
successive nozzles and over impaction plates. Air velocity increases as the particles pass further 
down the stack due to a reduction in nozzle size and number. Eventually this generates 
sufficient particle inertia to prevent the aerosolized particle relaxing back into the airstream 
before travelling in its normal direction and impacting onto the relevant plate. Other impactor 
types such as the next generation impactor (NGI), or the multi stage liquid impinger (MSLI) do 
exist and offer specific stack attributes that compliment certain experimental designs. However 
in essence all the impaction techniques work by broadly the same mechanism, and both the ACI 
and NGI are included within the United States and European Pharmacopeia as standard tests for 
aerosol assessment. 
1.6 Interparticulate Interactions within Inhalation Formulations 
From the above it is explicitly evident that the predominant factors that determine API particle 
deposition location and efficiency will be the aerosol particle size and polydispersity. While 
there are other significant variables that come into play, such as patient manoeuvres and airway 
disease state etc., in terms of formulation design we are aware that only particles sized below 
5j.lm will be able to reach the tracheobronchial region and initiate the requisite physiological 
effect. Therefore control over the aerodynamic particle size of an aerosol is critical and will 
determine to a significant degree the effectiveness off that formulation. Aerodynamic particle 
size is however not simply a reflection of the parent API particle size. Fundamentally, it is an 
interplay that represents the particle size and the interactivity of that particle with its 
surroundings. These may be other particles of API or excipient, the propellant, the device 
components or even contaminants. Indeed it is the size, scale and frequency of interparticulate 
interaction that ultimately dictates the final aerodynamic sizing and aerosol structure of an 
inhalation API. 
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1.6.1Interparticulate Interaction 
Understanding the nature and scale of interparticulate interaction within pharmaceutical 
compounds and formulations is a matter of huge importance for all current industrial practice. 
This has its genesis in the realization of the imperative contribution of particle-particle and 
particle-surface interactions to critical formulation downstream process specific behaviors. In 
real terms, such interactions are represented by the forces of adhesion (Fadh) between the 
micro-scale particulates (and associated surfaces) in pharmaceutical systems. Therefore 
characterizing the Fadh between formulation components is a potentially crucial tool in defining 
the character, extent and significance of fine particle-particle interaction and the impact these 
can have (Roberts, 2005). The scope of impact of particle Fadh is very broad ranging, and can be a 
means to exploit and refine a successful drug delivery system, or an' unintentional driver for 
failure at multiple levels of production and utilization. For example the success of powder mixing 
and powder flow behavior in the production of dosage forms is highly dependent upon the 
strength of interaction (or lack thereof) between the material components involved (George, 
Goddard, 2006). Equally, further downstream, formulation stability and performance is 
inherently linked to particle Fadh. 
API flocculation from suspensions or creaming and sedimentation from solutions, product-
device retention; API release profiles etc. are just a small number of examples where behaviors 
can be linked to the management of intrinsic adhesive forces between the particulate 
components and their associated delivery devices (Hooton et ai, 2004). Therefore it is obvious 
that managing Fadh is an essential consideration when approaching pharmaceutical system 
design, formulation and therapeutic efficacy. As a result there Is increasing demand for 
characterization processes which accurately map the adhesive character of particle interactions. 
These can serve as a hugely significant research and pre-formulation indicator, with specific 
regard to potential new pharmaceutical systems (Roberts, 2005). 
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1.6.2 The Forces of Adhesion and Cohesion 
Before considering further the implications of particle-particle interaction and associated 
adhesive forces it is important to exactly define the fundamental terms involved. Adhesion is 
( 
well accepted to be the attractive interaction of two dissimilar molecules or particles. It should 
be differentiated from the concept of cohesion. The force of cohesion (Fcoh) in its purest sense 
refers to the attractive interaction of two like-molecules within a single solid body (Zimon, 
1982). However within recent research, particularly into interparticulate interaction of powders, 
the term has very often been used to describe the attractive interaction between two like-
molecules or particles in two separate bodies I.e. between two particles of the same API. This is 
technically better described as a force of auto-adhesion (Podczeck et ai, 1994). Given the 
frequent use of 'cohesion' instead of 'auto-adhesion' within key literature and techniques 
associated with this thesis, the terms will be used interchangeably but fundamentally reflect the 
interactive force between two particles, or particle agglomerates of the same material. 
The Fadh (or Fcoh) between pharmaceutical particles is dependent on a hugely complex 
combination of physical and chemical forces. When two particles contact each other the Fadh 
that results between the bodies can be most basically be described as the result of the 
deformation of those bodies in contact and the surface forces that develop between them at 
this interface (Kappl, Butt, 2002). As such the two fundamental drivers of adhesion force upon 
interparticle contact are particle contact geometry and the physicochemical environment of that 
contact process. These two factors are intrinsically related through a complicated 
interdependence i.e. surface forces will develop according to changes in particle geometry upon 
contact (deformation) and contact geometry will often develop in response to the surface forces 
(Derjaguin et ai, 1975). Significant work has been done into modeling such relationships, and 
this is discussed in more detail below. However due to the array of contributing factors to both 
j' 
these attributes in their own right, it is overtly apparent that this relationship is not necessarily a 
universal one and theoretical particle-particle adhesion forces are difficult to predict accurately. 
However the importance of the fundamental principles involved still remains paramount and 
understanding them gives crucial insight to adhesion force development and the potential 
consequences for a pharmaceutical system. 
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1.7 Interfacial Surface Forces 
The three primary components of interfacial particle adhesion (in air) are universally recognized 
as van der Waals forces (Fvdw), electrostatic forces (Fes) and capillary forces (Fe): 
Fadh = Fvdw + Fe + Fes (1.3) 
The relative contributions of each of these components to the total Fadh are dependent in turn 
on the environmental and physicochemical properties of the contacting bodies. These include 
surface chemistry and surface free energy, particle size and morphology, the viscoelastic / 
plastic behavior of the contacting bodies, surface roughness, effective contact area and contact 
geometry as well as environmental conditions (temperature and humidity) (Davies et ai, 2005, 
, 
Podczeck et ai, 1994 ). Because of the breadth of these influential factors, it is a highly complex 
procedure to predict interparticulate forces accurately. These interactive forces are discussed In 
more detail below but fundamentally van der Waals forces are considered the dominant 
interaction that define the Fadh, as they occur between all surfaces and in all conditions (Morris 
et ai, 1999). Capillary forces will be prominent only above a threshold concentration of moisture 
at the interacting interface, and electrostatic forces may often be negligible in pharmaceuticals 
due to low dielectric constants, low ionic strengths and the absence of an electric field (Salazar-
Banda et ai, 2007). 
1.7.1 Capillary forces 
Capillary forces are the result of dynamic condensation of water molecules onto particle 
surfaces. On approach of one particle to another, if such condensation to the gap between the 
two surfaces is sufficient, a meniscus is created. As liquid is drawn around the contact points by 
capillary action, this forms an attractive force via surface tension effects on a relatively large 
scale (Begat et ai, 2004a, Coelho and Harnby, 1978) . The exact size of such capillary forces are 
dependent upon numerous factors, including the surface free energy, the geometry of the 
23 
Chapter 1 - Introduction 
contact area and the resultant gap geometry, surface chemistry, surface hydrophilicity and the 
meniscus curvature (Hooton et ai, 2004). Fisher and Israelachvili proposed the following 
equation to determine the capillary interaction between two spherical particles (Fisher, 
Israelachvili, 1981): 
(1.4) 
Where R" is the harmonic mean of the particle radius (or contact radius), VL is the water surface 
tension, VSL is the solid-liquid interfacial free energy and e is the contact angle of the liquid with 
the particle surface. Whilst the contact radius is evidently of particular significance in Fe 
generation it is also obvious that the most significant influence on the generation of capillary 
forces will be the availability of water molecules to form capillary bridges and the meniscus 
curvature (Young et ai, 2006). In this regard the relative humidity (RH) of the environment is 
therefore crucial, as this dictates the amount of moisture available. It is therefore reasonable to 
suggest that depending upon the physicochemical nature of a particle surface, increasing the 
relative humidity will have a direct influence on the interparticulate interaction (Hooton et ai, 
2004) so that in a completely dry environment (RH 0%) capillary forces will be non-existent, but 
in a very humid atmosphere capillary forces may dominate adhesive character. It is also 
important to realize that the presence of water at a contact interface may lead to structural 
changes in the contacting particulates. Dissolution of water soluble material is possible, or 
indeed the water may act as a plasticizing agent that affects the deformation of the contacting 
bodies and in this fashion adhesive character will be affected by changes to surface chemistry or 
contact geometry (Buckton, 1995). 
1.7.2 Electrostatic Forces 
Electrostatic forces (Coulombic) are formed between surfaces that acquire a charge. This is 
usually by either frictional force or artificially by the existence of an electric field around a 
surface. They are by far the strongest of the physical forces, stronger indeed than most chemical 
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binding forces and have a very long range (lsraelachvili, 1991). Should a charged particle contact 
an uncharged surface then an equal but opposite charge will be generated on the surface, 
leading to adhesion. Such a force can be determined by (Butt et ai, 2005): 
(1.5) 
Where Q is the charge on the particle and l is the distance between the centers of charge. It is 
rare in pharmaceutical formulations that any particles are adept at maintaining charge as this 
would often be counterproductive. Therefore electrostatic charges are usually negligible due to 
low dielectric constants, and rapid charge dissipation (Salazar-Banda et ai, 2007). The presence 
of moisture will rapidly eliminate any electrostatic charge that does exist, as the interface at the 
surfaces becomes conductive and charge will be lost by dissipation (Coelho, Harnby, 1978). Thus 
in humid environments electrostatic charges will be negated. 
1.7.3 Van der Waals Forces 
Van der Waals forces are usually the most important contributor to Fadh in pharmaceutical 
materials and systems. They are somewhat ambiguous as a single term, indicating the 
summation of attractive (or repulsive) forces between molecules, and are better described 
themselves as three types of distinct interaction force that all show an inverse sixth power 
relationship with respect to the separation distance of the bodies involved. 
1.7.3.1 Keesom Forces 
Permanent dipole to permanent dipole interactions. These are based on the electrostatic 
attraction that exists between molecules with a permanent dipole moment. -Here two atoms 
constituting a bond within a molecule have significantly different electronegativities, making the 
bond permanently polar in nature and capable of attracting other molecules with permanently 
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polar domains if correctly charge orientated. By this virtue these interactions tend to result in 
molecular alignment (reduction in potential energy) with a net attraction and are sometimes 
termed orientational forces. 
1.7.3.2 Oebye Forces 
Permanent dipole to induced dipole interactions. A permanently polar bond in one molecule can 
induce a dipole in a neighboring molecule (of polar or non-polar nature). The permanent dipole· 
generates an electric field which will disrupt neighboring molecules electron charges. Charge 
separation occurs and this results in an induced dipole which is attracted to the permanent 
dipole. As a consequence these interactions are sometimes termed induction forces. 
1.7.3.3 London Forces 
These are considered the most important of the three Van der Waals constituents, as they occur 
on all surfaces at all times (Israelachvili, 1991). They are instantaneous dipole to instantaneous 
dipole interactions, more commonly known as dispersion forces because the natural frequencies 
of resonance that result in dipole formation and interaction have the same physical foundation 
as that of the absorption spectrum I.e. the wavelength-dependent manipulation of light that 
leads white light to disperse into the spectrum of the rainbow (Parsegian, 2006). They are 
interaction outcomes of transient dipole moments of molecules without permanent multipole 
moments. Whilst still dependent upon the attraction of opposite charges on the contacting 
surfaces, these derive from electron fluctuations that render transiently electron dense and 
electron deficient areas of the molecular surface. Such instantaneous dipoles generate an 
electric field that polarizes other neutral atoms or molecules, inducing a dipole moment in 
them. The resulting interaction gives rise to an instantaneous attractive force that is time 
limited. The main characteristics of dispersion forces can be described as thus (Israelachvili, 
1991): 
• They are effective from relatively large distances (>10nm) down to interactomic 
separations (-0.2nm). 
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• They may be repulsive or attractive, and often cannot be described by simple power 
laws. 
• They usually incur a weak alignment of molecules in addition to their attraction. 
• The presence of other bodies nearby influences the dispersion interaction between two 
set bodies, and therefore these forces are not additive. 
Fritz london (for whom the forces are named) proposed that the dispersion energy of 
interaction between two molecules V can be given as (Finlay 2001): 
3 a2 V = --hvO-4 d6 (1.6) 
Where a is the polarisability, his Planck's constant, Vo the characteristic frequency and d the 
separation distance between the two molecules. Hamaker (Hamaker, 1937) developed this work 
to describe those interactions occurring between macroscale bodies based on their component 
molecular interactions. By pair-wise integration of the dispersion energies over the volumes of 
the bodies involved he calculated the interaction energy between two solid objects as: 
(1.7) 
Where E is the total energy of interaction, VI v2 are the total volumes of the particles bodies in 
fontact, qlq2 the number of atoms per unit volume of those particle bodies, r the separation 
distance and 1 ~ . 2 2 is the london dispersion constant born from eq. 1.8: 
d3hf 2 A1,2 = '2 a 
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Where f is the vibration frequency of the interacting electronic oscillators. Using this approach, 
van der Waals forces could then be described between bodies of differing but distinct 
geometries (sphere, cylinder, planar surface etc.) as follows: 
Sphere - Sphere 
Sphere - Planar Surface 
F - A (d1dz ) 
- 12rz d 1+dz 
F = Al1dl 
6rz 
(1.9) 
(1.10) 
Where d 1 d z are the sphere diameters, r is the separation distance between the contacting 
bodies (in a vacuum) and A is the Hamaker constant, a material property representing the 
strength of the consequent van der Waals interaction (Hamaker, 1937): 
(1.11) 
Whilst adaptations of these equations were devised to describe the Van der Waals force of 
interaction between macroscale bodies of varying geometries there remained several 
limitations. Firstly, the Hamaker equation (eq. 1.7) assumed simple pairwise addition between 
contacting bodies. As already stated however, dispersive forces are non-additive. Secondly there 
is no consideration of pre-existing differences in electronegativities or polarizabilities between 
the atoms concerned, which would lead to increased contributions from Keesom and Oebye 
forces. In response to these weaknesses the Lifshitz theory (Lifshitz, 1956) derived the forces 
between large bodies from bulk properties rather than atomic properties, by treating the solids 
as continuous materials. In effect this was defined by a different calculation of the Hamaker 
constant. While the detail behind such macroscopic theory is beyond the scope of this 
introduction, such an approach results in the following equation: 
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. . d 
F-A*-
- 12D2 (1.12) 
Where A"is the modified Hamaker constant (Lifshitz-van der Waals constant adapted) d is the 
diameter of a spherical particle, and D is the distance between this sphere and a planar wall. 
1.8 Adhesion Theory 
1.S.1 The Hertz Approximation 
Figure 1.9: The Hertz Model of contact 
Lifshitz theory remains too basic to model accurately real pharmaceutical contacts, as it assumes 
uniform physical properties and does not account for separation distances of molecular 
dimensions (Butt et ai, 2003). Furthermore, such equations can account for the genesis of 
adhesive forces, but neglect the fact that real contacting bodies do not remain rigid on contact. 
In reality all solids have a finite elasticity, and will deform on contact, thereby altering the 
geometry of that contact regime (Butt et ai, 2003). This deformation process has itself been 
modeled. Most models are derived from the Hertz approximation which described the spherical 
contact of elastic bodies. He proposed a relationship between the contact radius and the 
applied load (force) as follows (Hertz, 1881): 
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3 3R* 
a =- F 4E" • (1.13) 
Where a is the contact radius, F is the load, R* is the effective particle radius, and E* the 
reduced Young's Modulus as defined by (Butt et al., 2003): 
1 l - v ~ ~ l - v ~ ~
-=-+-E* El Ez 
(1.14) 
(1.15) 
Where Rl is the radius of sphere 1 and Rz is the radius of sphere 2 and, El.Ez,vland 'I1z are the 
Young's modulus and Poisson ratio of sphere 1 and 2 respectively. The contact radius at the 
same time determines the indentation: 
aZ 8=-
R* (1.16) 
However the Hertz model does not account for the surface forces described above, that often 
attract two surfaces with no load. It also assumes small contact radii with a normal loading 
direction without any frictional forces. This thereby prevents its application to complex particle 
contacts (Davies, 2005). 
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1.S.2 The Johnson-Kendall-Roberts Model 
Figure 1.10: The JKR model of contact 
Johnson, Kendall and Roberts (Johnson et al., 1971) adapted the Hertz model to account for 
surface forces between the contacting bodies. The JKR model assumes that two elastic spheres, 
with smooth surfaces experience surface forces inside the contact region, causing a non-
, 
Hertzian deformation. This deformation is conceptualized as a 'neck', due to the contact stress 
being compressive only in the centre of the contact spot, but tensile around the outside. This 
gives rise to bulging, instead of simple Hertzian flattening (Podczeck,1998). The model predicts 
that the two surfaces will separate from a given contact area only when a defined pull-off force 
is reached to overcome the adhesion ofthe two solids. This force can be calculated as follows: 
F adh = 3j21lWR* (1.17) 
Where F adhis the force of adhesion and W is the work of adhesion. The work of adhesion can in 
turn be expressed in terms of the surface energies of the contacting solids Yt and Yz by: 
W = 2YIY2 (1.18) 
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This can therefore be related to the F adh by inserting eq. 1.18 into 1.17 as follows: 
(1.19) 
This model has therefore been widely used in both calculating the force of interaction between 
solids, and therefore on the calculation of effective surface free energy. The model is 
particularly applicable in systems with high surface energies, low elastic moduli, and low loading 
forces (Podczeck, 1998). 
1.8.3 The Derjaguin-Muller-Toporov Model 
Soft Sphere 
Figure 1.11: The OMT contact model 
The JKR model is often used but assumes there is no surface interaction outside of the contact 
'neck'. In reality surface forces are active outside of the direct contact between solids. 
Derjaguin, Muller and Toporov took this into account and developed the DMT theory (Derjaguin 
et ai, 1975) where the shape of the deformed surface of the sphere in the contact zone follows 
the Hertz theory, but surface forces outside of the contact region are predicted. The theory 
predicts the force needed to pull a sphere and surface apart, considering a point contact only. 
This can be calculated as follows: 
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F adh = 21l'R*W (1.20) 
The DMT model is more suitable for less rigid materials of a low surface energy (Podczeck, 1998) 
1.8.4 The Tabor Number 
In effect the DMT and JKR models represent opposite ends of the same scale, and the choice of 
model is vastly importaflt, as for the same interaction both may offer very different results. The 
discrepancy between the models was clarified by the advent of the dimensionless parameter 
the Tabor number, which describes the ratio of the elastic deformation resulting from adhesion 
to the effective range of surface forces (Zheng, Zu, 2007). The two models correspond to the 
opposite extremes of the Tabor number, and therefore it can be used to aid the selection of an 
appropriate model (Tabor, 1976): 
(1.21) 
Where (/I Is the Tabor number, W is the work of adhesion, R is the particle radius, E* is the 
reduced Young's modulus and Zo is the distance of closest approach. If (/I > 0.3 then the JKR is 
more suitable, while if (/I < 0.3 the DMT would be better suited (Bunker, 2005). Further work has 
also suggested other models and parameters that refine the base assumptions of both these 
models. For example the Maugis-Dugdale model was designed to describe behavior between 
the extremes of the JKR and DMT models, and is regarded by some to better characterize 
interactive forces in many circumstances (Bunker, 2005) .. 
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1.9 Other Factors Affecting Adhesion 
1.9.1 Surface Roughness 
Surface and particle roughness is of great importance in determining interparticulate interaction 
(Bunker, 2005). This is simply because if two particle surfaces make contact, the contact regime 
is dependent upon the topography of both surfaces at the contact point. Real particles are not 
perfectly spherical, and asperities on their surfaces can serve to either increase or decrease the 
effective contact area on interparticulate contact. If a particle is smaller than the distance 
between asperities on an infinite surface, the particle may enter a trough, thus leading to an 
effective increase in contact area. Furthermore such asperities may prevent lateral forces 
facilitating the separation of that particle (Podczeck, 1998). Yet if the particle is larger than the 
distance between asperities it will be unable to contact the dominant surface structure, thereby 
reducing the effective contact area and the prospective force generation between particle and 
. surface. Surface roughness can therefore give rise to significant variability between the 
predicted of and experimentally measured force of adhesion. 
1.9.2 Young's Modulus 
The Young's modulus of a material represents it's resistance to elastic deformation. It is the 
ratio of a materials stress to strain (Podczeck, 1998). Materials with large Young's moduli are 
particularly stiff, I.e. showing low strain under high stress, and therefore resistant to 
deformation. Materials with low Young's moduli are less stiff and more susceptible to elastic 
deformation i.e. showing large strain under low stress. The Young's moduli of contacting 
particles will therefore playa role in determining the extent of deformation on contact, and this 
in turn will define to some degree the scale of interactive force that develops between the two 
surfac·es. 
1.9.3 Surface Free Energy 
The surface free energy reflects the potential interactivity of a surface, which arises from the 
difference in net force acting upon molecules at the surface of a material from the bulk material 
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below and the phase·state above it. In air, as the strength of interaction with the vapor phase is 
Usually less than the surrounding molecules there will be an inward attraction of the molecule. 
As this force is effectively contracting the surface it is said to have generated a tension. If the 
surrounding medium is liquid, this net force becomes a surface tension. If the surrounding 
medium is solid however it becomes a surface free energy as it is describing the force stretching 
the surface. Consequently the surface free energy of a material can be defined as the energy 
required to increase the surface energy of a substance by one unit area in a vacuum (Podczeck, 
1998). This measure is very important as it describes the 'desire' of the surface to aggregate 
together or interact with another material so as to reduce the surface free energy. if we 
consider the goal to generate aerosols with well dispersed particles, it is obvious that high 
surface free energies will contradict an ideal suspension, or aerosol, and as such knowledge of 
this attribute is key in predicting formulation efficacy and behavior 
1.10 Experimental Methods of Surface Forces Determination 
With an appreciation of how important the forces of adhesion are in pharmaceutical 
applications it is appreciable that methods of experimentally quantifying these forces have long 
been sought. Estimations of the Fadh have been carried out by a number of contrasting 
experimental techniques for some years now. Some of the traditional methods include 
impaction, centrifugation, tensiometry and other various direct and indirect manipulation 
techniques (Lohrmann et ai, 2007). The most significant of these are overviewed briefly below. 
1.10.1 Centrifugation 
The centrifuge technique is perhaps the most popular of the older techniques, and involves the 
particles of an interactive mixture being adhered to a disc in a special device rotating in a 
centrifuge. An example of such a setup is given in figure 1.12: 
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Figure 1.12: Basic design of a centrifuge cell. (Kulvanlch, Stewart, 1987) 
The principle is that above a critical centrifugal speed, the resulting force from the angular 
I speed rotation of a particle with a defined mass, in a known distance to the rotation centre, will 
exceed the adhesion force between the particle and the surface (Salazar-Banda et ai, 2007). 
Particles will therefore detach from the disc or substrate at a given centrifugal force, from which 
the Fadh can be calculated. In essence the technique is based upon the assumption that the Fadh is 
of the same magnitude, but opposite signal to the centrifugal detachment force i.e. (Felicetti et 
al,2008): 
Fadb = -Fcentrifugal (1.22) 
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The centrifugal detachment force (FeentrlfulIsl) applied is directed outwards from the center of 
rotation through the center of gravity of the particle and is governed by Newton's second law 
(Kulvanich, Stewart, 1987): 
F centrifugal = M (a + g) (1.23) 
Where M is the mass of the particle, a is the centrifugal acceleration and g is the acceleration 
due to gravity. Centrifugal acceleration is dependent upon angular velocity (Wd) and the distance 
between the particle and axis of rotation (de): 
(1.24) 
Angular velocity is derived from the particle geometry and the centrifugal speed (5): 
(1.25) 
Hence when wlde» g our original equation can be rewritten as: 
(1.26) 
Therefore the F.dh can be calculated accordingly. It is essential to analyze the amount of particles 
adhering to the surface at each incremental level of centrifugal speed, and this is usually done 
by some form of optical imagery and data analysis software. This technique was considered an 
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easily acce.ssible method for adhesion force measurement with a good deal of credibility. Indeed 
it does offer the advantage of allowing measurements between real particles with both regular 
and irregular shape and size on smooth or rough surfaces, which is one of the primary 
limitations of atomic force microscopy (see below) (Felicetti et ai, 2008). Furthermore it is 
capable of determining the Fadh based on the distribution of the adhesion force within a very 
large group of particles on a substrate. This is very useful in bulk characterization (Salazar-Banda 
et ai, 2007). However there are several problems with the centrifugation technique. Perhaps 
most significantly, the very nature of the physics involved, as simplistically indicated above, 
means that particles are not necessarily separated from the substrate as a function of their Fadh' 
Indeed if two particles with the same Fadh, but different masses are conceptualized, it is obvious 
that they will not separate simultaneously. The particle with the larger mass will be subject to an 
increased centrifugal force at a lower centrifugal speed than the smaller massed particle, and 
hence will separate sooner. Furthermore, it is almost realistically impossible to characterize a 
polydisperse system by mass so that the centrifugal force can be calculated. This would require 
a determination of particle size distribution of the particles detached at each speed of 
centrifugation, which is incredibly complex (Kulvanich, Stewart, 1987). As such only 
homogeneous particle matter is an ideal candidate for such a technique. Yet even in this case 
because the arbitrary form of centrifugal force (in the form of rotor speed squared) is often used 
due to the difficulty in assessing particle size in a simple system, it may be impossible to 
calculate true adhesion force values (Kulvanich, Stewart, 1987). Furthermore some experimental 
work has indicated that the detachment force for particles of the same size, mass, and Fadh will 
not be the same depending upon their position on the carrier due to changes in the angle 
between the direction of the applied force and the plane of the surface (St. John, Montgomery, 
1971). 
1.10.2 Tensile Stress Methods 
The tensile strength method is one that has perhaps had a narrower application to 
pharmaceutics and has only been applied to a small range of materials. It has traditionally been 
used to measure the Fcoh acting between two powder layers. In this situation a measuring device 
based on a suspended plate with a flat sticky surface attached to a micro-balance is dipped into 
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a loose powder bed. After a determined contact time the device is removed and the force 
required for separation of the two powder layers (Le. that of the powder bed and that coating 
the device surface) is measured (Lohrmann et ai, 2007). However adhesive measurements can 
be performed by adapting the technique. Figure 1.13 below describes a modified tensiometer 
designed for such work. Here, the two powder surfaces are prepared before measurement by 
fixing one to a measuring device of known weight, suspended from a micro-balance and the 
other on another disc parallel to the surface upon a moveable table. The layers are brought into 
contact by raising the table, and contact causes a decrease of load on the balance. User 
definition determines to what extent this decrease is continued, before the surfaces are left in 
motionless contact for a set contact time and then separated again on table lowering. The 
adhesive force upon withdrawal is registered by the micro-balance as a hyper-extension of the 
force beyond its free level (Lohrmann et ai, 2007). 
'---- Integrated 
micro balance 
--- Measuring 
" ' 3 ~ ~ ~ ~ device 
t'- -- Lower disc 
I -- Movable table 
-_ ...... _-- ---
- - ~ ~
time 
Figure 1.13: A modified tensiometer designed for F.dh measurements. (Lohrmann et ai, 2007) 
This technique is quick and Simple to perform and has the benefit of being able to vary the 
conditions in which it is employed so that the effect of important factors such as humidity can 
be observed. However, it does have several limitations. The first is that the system only provides 
an appreciation of bulk behavior, and there is no capability to map the interaction on a particle 
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by particle basis or investigate the effects of changing contact geometry, surface roughness etc. 
Secondly the technique relies upon a perfectly parallel contact, or rather detachment, of the 
two surfaces to ensure all the contact points between the materials separate simultaneously. If 
this is not the case there will be an inaccurate reading of the Fadh from the microbalance 
(Lohrmann et ai, 2007). There is also a degree of reliance of the Fadh recorded on the speed of 
detachment. This is suggested to be due to air pressure effects, where too rapid detachment 
causes a low pressure gap between plates that 'sucks' the plates back together again (Lohrmann 
et al,2007). 
1.10.3 Surface Forces Apparatus 
The surface forces apparatus (SFA) device (Tabor, Winterton, 1969) allows a direct 
measurement of the Fadh in air, or liquids and vapors at Angstrom resolution level (Forces "'lOnN, 
distances "'lA). It consists of two crossed atomically smooth mica cylinders of about 1cm radii 
between which forces are measured. Prior to positioning in the apparatus the mica surfaces are 
coated with a s e m i ~ r e f l e c t i n g g layer of silver to allow optical determination of the separation 
distance. One mica cylinder is mounted to a piezoelectric translator through which the distance 
between cylinders Is adjusted while the other cylinder is mounted to a spring of known and 
adjustable spring constant. The separation between the surfaces is measured by an 
interferometric technique (multiple beam superposition analysis) and by knowing this 
separation the deflection of the spring and the force can be calculated (Butt et ai, 2005). The 
surfaces can then be coated with various materials to investigate their interaction force with 
excellent force resolution. In a solvent environment, SFA can even measure the oscillatory 
solvation and structural forces arising from the packing of individual layers of solvent molecules 
and can be employed to measure the electrostatic 'double layer' forces between charged 
surfaces in an aqueous medium with an electrolyte. However the drawback of the approach is 
that it requires materials with very good lateral homogeneity (i.e. no rough surfaces) and a well-
controlled thickness that can be applied to the mica (Leckband, 1995). It is also a highly complex 
piece of apparatus to utilize that requires a great degree of operational competence, and while 
being surface specific, does not allow an individual particle-particle adhesion force assessment. 
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Figure 1.14: Schematic of a Surface Forces Apparatus device. (Leckband, 1995) 
1.10.4 Total Internal Reflection Microscopy 
Total Internal Reflection Microscopy (TIRM) allows the instantaneous changes in distance 
between a single microscopic sphere immersed in a liquid, and a transparent plate to be 
determined. This can be achieved to nanometre resolution by using an evanescent wave 
produced through the plate to illuminate the sphere, and by calculating the resulting intensity of 
light scatter (Axelrod et ai, 1984). The principle is that when a sphere with a refractive index 
different from that of the liquid medium is in proximity to a surface where total internal 
reflection occurs, some of the evanescent wave is scattered as a result of what is termed 
'frustrated' total internal reflection. The amount of light scattered is sensitive to the proximity of 
the sphere to the surface and thus can be used to map the interaction of the two bodies 
(Axelrod et ai, 1984). 
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Figure 1.15: Basic concept of evanescent wave generation. Adapted from www.microscopyu.com 
accessed 25/11/2008 
The primary disadvantage of using this technique is the incredibly complicated nature of the 
process and precision required to carry it out, particularly in orientating the incident light source 
to produce an effective evanescent wave. It is also constrained by the requirement of a liquid 
media with particular optical properties, reducing its application to solid-state based 
investigations. 
1.10.5 Osmotic Stress Method 
The osmotic stress method employs an indirect measurement of F adh between macromolecules. 
A dispersion of selected macromolecules or biological lipids is first equilibrated to a reservoir 
solution containing water and other small solutes which are capable of free exchange into the 
dispersion phase. The reservoir then has a polymer incapable of diffusion added, the 
concentration of which determines the osmotic stress acting upon the dispersion. The proximity 
of the macromolecules is measured (using x-ray diffraction) as a function of increasing osmotic 
pressure to generate pressure-distance curves that can be analyzed in a similar fashion to force 
distance curves in atomic force microscopy (LeNeveu et ai, 1977). This method is predominantly 
useful when studying vesicle or macromolecular interactions in organic systems and is almost 
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inapplicable to inorganic solid phase systems. Those systems under study all require liquid 
stability and need to be immune to interaction with the other elements of the dispersion phase. 
1.10.6 Impaction Methods 
There are several less technically specific techniques that rely on applying various means of an 
impaction force (e.g. hammer fall) to the opposite side of a substrate with particles adhered, 
,and quantifying the amount of particulate loss as a function of the increasing impaction force. 
This type of set up is very easy to arrange, but relatively non-specific in force determination and 
in reality only has relevance if interest lies in the state of the particles that have been lost from 
the substrate (e.g. examining the electric charge present) (Derjaguin, 1968). 
1.10.7 The Limitations of Bulk Adhesion Measurement 
As indicated by the brief overview of the techniques mentioned above, they are all based on 
experimentation citing bulk systems and/or multiple particulate surfaces. They also suffer from 
very specific material property requirements. This poses several key problems. Firstly any Fadh 
experiment technique where there is a very precise prerequisite for given material tolerances or 
physical states can In turn only have a very limited scope for use. While coherent and relevant 
data may be generated for very specific materials there is little room for more complicated 
multi-particulate formulations. When considering the realm of inhaled drug delivery this is very 
appreciable, and obviously many of the techniques outlined would struggle to be adapted for 
use. DPI formulations will not tolerate liquid based analysis, but equally pMDI systems may 
require measurement in a liquid state under pressure for a true force appreciation. Furthermore 
whilst bulk material adhesion data is useful in describing the general effects of adhesion and 
coheSion on formulation, manufacture and performance there is little characterization of the 
nature of the component attractive forces Involved. (Davies et aI, 200S). Being able to assess the 
individual particle to particle adhesion in addition to bulk behavior would allow much more 
depth in understanding of the complex interplay of the forces and factors Involved in dictating 
particle interactions, and potentially a view to beneficial modifications or critical constraints 
(Roberts, 2005). Critically many of the methods above lack any delicate control over the critical 
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parameters cited in adhesion force theory (i.e. environment, surface roughness, contact 
geometry etc.) to allow a more precise assessment of the fundamental forces of interaction. In 
an ideal situation, the ability to subtly alter these individual variables and characterize the 
changes to the result would be employed. Some drug systems are much more sensitive to 
micro- and even nano-scale interaction than others. For example in some inhaler systems very 
small amounts of material or drug are used (e.g. formoterol fumerate) , and interactions on an 
individual particle basis become more significant, as problems such as dose reproducibility and 
the use of bulking agents complicate issues (James et ai, 2008). In such instances an 
appreciation of bulk behavior can only be of a limited degree of assistance in evaluating the 
system dynamics. The ability to study single particle interactions, the forces involved, and to do 
so within a system with scope for control over important variables is therefore very desirable. 
Realizing this desire has however become possible with the advent of the atomic force 
microscope (AFM) (Binnig et ai, 1986). 
1.11 Atomic Force Microscopy 
The atomic force microscope (AFM) is an example of a scanning probe microscope, which allows 
the imaging and analysis of molecular surfaces with sub-nanometre resolution (Allen et ai, 
1997). In AFM a sample is scanned by a very sharp micron-sized tip mounted on a cantilever 
spring. When scanning, the force between the tip and the sample can be measured bY 
monitoring the deflection of the cantilever. This is quantified by a laser signal focused on the 
cantilever tip and reflected onto a position sensitive photodiode. By plotting the deflection of 
the cantilever against its position on the sample, it is possible to map the samples topographY· 
Alternatively the height of the translation stage can be mapped in maintaining a constant force 
against the surface, where a feedback loop is initiated using piezoelectric input (Butt et ai, 
2005). In this way images of nano-scale can be generated. Figure 1.16 shows a simplified AFM 
setup: 
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Figure 1.16: A schematic of an atomic force miscroscope (Allen et aI1997). 
AFM imaging can traditionally be done using two separate techniques; contact mode or tapping 
mode. In contact mode the AFM tip is raster scanned across the surface of the interest whilst in 
constant contact. Whilst this method ensures the highest resolution of imaging, as the tip 
responds to the changes in surface topography directly, it is also the most likely to cause 
damage to a fragile surface or even the tip itself. The applied force of the tip on the surface can 
be exaggerated extensively due to the very small surface area involved (Butt et ai, 2003). 
Tapping mode can to some extent avoid this problem. Here the cantilever is oscillated at its 
resonant frequency. As the tip approaches a surface, there will be a dampening of the vibration 
amplitude because the tip either starts to hit the surface or is affected by attractive or repulsive 
surface forces. Therefore if the surface is scanned by a constant reduction in tip vibration 
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amplitude the laser signal will plot the effective topography of the surface. This therefore 
reduces the direct contact between tip and surface and can better preserve fragile substrates. 
The downside to this technique is a loss in resolution, but significantly by monitoring the surface 
effects on the wave mechanics of the tip oscillation, additional information about the local 
mechanical properties of the surface can be generated (Butt et ai, 2003). 
Significantly however the AFM not only has a role as an imaging tool, but can also be used to 
measure surface and interfacial forces (Ducker, Cook, 1990). If the cantilever and sample are 
kept in fixed lateral positions, the substrate (or cantilever depending upon the particular AFM 
arrangement used) can be rastered up and down by the piezo translation stage it is carried 
upon, onto and off the cantilever (or substrate) by applying a voltage. When nearing contact the 
sample will very often attract the tip prior to a fixed level contact, causing a 'jump in' deflection 
(i.e. tip bends under attractive forces into contact). The piezo input then continues the 
sample/cantilever movement until a pre-set value for the stage height (z-coordinate) is reached. 
The stage then reverses, and the sample and tip will separate. However this separation will 
occur only when the restoring force of the cantilever (spring constant) surpasses the interaction 
force of the tip and sample, and as such the negative deflection of the cantilever below the non-
contact output can be used to quantify the interaction force described (Sindel, Zimmermann, 
2001). By applying Hooke's law: 
F= -kz (1.21) 
where k is the spring constant of the cantilever and z is the cantilever deflection at the moment 
of separation, the force of interaction F can be calculated. This method of operation is called 
'force' mode and figure 1.17 shows a representation of the generation and interpretation of a 
single force curve and the relative deflection signals involved: 
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Figure 1.17: Force deflection (displacement) plot of an atomic force microscope - a.) Non-contact area 
b.) 'Jump in' of tip under attraction of substrate c.) Maximum height of substrate d.) Maximum 
interaction force e.) Separation of tip and sample. (Sin del, Zimmermann, 2001) 
Hence running AFM in force mode allows characteristic work to be done on the interaction 
between a surface and tip. However this is only of limited use when considering the aspects of 
pharmaceutical interaction that concern inhaler technology. While some material properties can 
be gleaned from such a procedure, such as the surface free energy or Young's modulus of that 
material, the interaction between a cantilever and tip (usually silicon nitride) and a material of 
interest will not provide characterization of the multi-particulate forces involved in API-excipient 
mix or those of an API with a device component. 
1.12 Colloidal Probe Microscopy 
It was with the advent of colloidal probe microscopy (CPM) that the capacity to adapt AFM to 
measuring the interaction between two materials of interest was borne. CPM involves the 
attachment of a well-defined colloidal particle to the tip of the AFM cantilever, and performing 
force measurements between that particle and a given surface (Ducker et ai, 1991). Such 
materials as silica gave special spherical probes that allowed fine geometric definition and 
extensive work to be done on colloidal contact mechanics and force measurement (Bunker et ai, 
2005). Whilst undoubtedly of great value for theoretical advancement such work was not 
capable of characterizing broader systems. Critically the CPM method was the precursor to a 
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more recent 'real particle' technique, where individual particles of interest e.g. drug molecules, 
cells, polymers etc. are attached to a cantilever and used to produce force measurements 
(Ibrahim et ai, 2000). The distinction between colloidal particle probes and real particle probes 
has been somewhat blurred so as that the use of real particles is still often referred to as 'colloid 
probe microscopy'. Therefore for the purpose of this thesis the term will be used to refer to the 
use of drug particle probes. Such a technique allows direct measurement of the Fadh / Fcoh 
between two particles. This has the facility to be inherently applicable to pharmaceutical 
formulations, especially inhalation therapy, and has therefore been utilized in many studies to 
analyze interparticulate adhesion within DPI and pMDI formulations. 
Essentially this technique affords a method of experimentally determining the Fadh on a single 
particle level, and a means to explore the very nature of the interfacial forces involved. The AFM 
therefore fulfills many of the ideal properties that former adhesion force techniques failed to. 
Primarily it has the advantage of allowing a large number of essential parameters to be adjusted 
or maintained on an experimental basis. For example environmental chambers allow control of 
temperature, humidity etc., and therefore allow a direct assessment of the effect of these 
individual factors, or the removal of force critical components (e.g. preventing capillary 
interaction by removing residual moisture). More critically, the technique analyzes micro-scale 
contact, and prospectively individual particie-particle contact. This offers a unique chance to 
manipulate substrate size, shape, geometry etc. and characterize resulting changes to adhesion 
force trends. While other techniques may offer certain controls on individual variables, AFM 
offers the chance to manipulate several. One of the most basic advantages with AFM is that 
force measurements can be taken in liquid or air, without compromising any other element of 
the technique. This is of particular importance to inhalation pharmaceutics as it offers a means 
to evaluate adhesion forces in both pMDI formulations with the use of model propellants (i.e. 
chemically and physically similar but non-volatile) and DPI formulations. Additionally AFM 
software is fairly well advanced following several seminal years of work in many areas of 
adapted used. Hence it is capable of running force m e a s u r ~ m e n t s s at a multitude of points over a 
defined area of the substrate surface very quickly so that many measurements with a tip on a 
surface may be taken with consummate ease (concept of force volume mode). 
However the use of real particles to probe surfaces still has obvious problems associated with it. 
Firstly by using a 'real' particle, there is an almost complete loss of control of the morphology of 
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your tip. Considering the importance of contact geometry upon such fine scale interaction, as 
described above, this has rendered adhesion measurements made by this technique specific on 
a probe by probe basis. Hence, even adhesion measurements on the same substrate made with 
two different tips of the same material, may often exhibit huge differences in the forces 
calculated, and therefore it is very difficult to compare experimental data (Farschchi-Tabrizi et 
ai, 2006). To allow any relative conclusions to be drawn between two sample materials, the 
same tip therefore needs to be employed for force measurement. This can be problematic in 
itself, as continued tip use pre-disposes to tip-wear, which in turn alters the geometry of the 
scanning particle and hence the surface contact mechanics (Butt et ai, 2005). This has a 
significant effect upon the validity of the force values observed. 
Secondly there is a fundamental change to the cantilever'S physical characteristics with the 
attachment of a particle. The spring constant quoted or calculated for the unmodified cantilever 
may no longer be applicable, as the added mass of the particle can have an impact. As such the 
spring constant of the modified cantilever may require re-calculation. A method based on the 
intensity of thermal noise (Hutter, Bechhofer, 1993) has become particularly popular due to its 
non-invasive character. Other methods such as a technique using the resonant frequency and 
quality factor of the cantilever (Sader et ai, 1999), an added mass method (Cleveland et ai, 1993) 
or various others based on alternate force applications e.g. gravitational force, hydrodynamic 
force, acoustic radiation (Butt et aI, 2005), are less attractive due to the complexities involved in 
maintaining the integrity of particulate tip. 
There is also an issue with the actual fixation of a particle to a cantilever. This is usually 
performed by a micromanipulation technique, where a tiny amount of glue ("'10.18 m3 epoxy 
based resin) is placed on the end of the cantilever and then the probe particle is brought into 
Contact with this spot. This requires using fine wires to either move the glue and particle around 
the cantilever or the cantilever to the glue and particle (Kappl, Butt, 2002). Such manipulation 
Usually occurs under control of a light microscope and therefore there is a limit to the size of 
particle that can be attached to around lj..lm or above. Where bare AFM tips are a matter of 
nanometres in size this potentially massive increase in tip size incurs much greater forces of 
adhesion (increased radius, contact area etc.) By virtue of the limited range of the piezo-
movement and dynamic range of the split photodiode detector, stiffer cantilevers than normal 
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are therefore required to ensure that the particle detaches from the surface on withdrawal 
(Kappl, Butt, 2002). This is to the detriment of force resolution. 
Furthermore it is crucial that no excessive resin is left accessible to the tip's substrate or coats 
the attached particle surface, otherwise the adhesion measurement could be compromised. It is 
also essential to ensure successful attachment of the particle, and therefore tip characterization 
by further imaging is usually undertaken (e.g. SEM, TEM) after fixation. Indeed this is repeated 
after each set of adhesion results to verify the continued presence of the tip and any potential 
changes to it (Jones et ai, 2008b). All in all therefore the process is very time consuming and 
labour intensive, which will often limit the number of probes that will be produced on an 
experiment by experiment basis (Roberts, 2005). 
These problems all occur in addition to those that generally impair AFM force measurements. 
Such issues as hysteresis and creep are persistently a problem and affect the accuracy of 
distance determination (Davies et ai, 2005). There can be difficulties in making measurements 
on very 'sticky' substrates (although unlikely in inhalation therapy to be significant) where the 
tip becomes trapped on the surface, or operation in liquids can induce hydrodynamic 
interference, with the tip approach and retraction inducing liquid perturbation and liquid 
dumping that impedes measurements (Butt et ai, 2005). Lack of sensitivity of the photo-diode 
itself is possible, especially as this is dependent upon the size and shape of the laser beam. 
Hence distortion of the beam for any reason can lead to a poor sensitivity and reduced accuracY 
of force measurement. 
1.13 The Cohesive-Adhesive Balance Approach 
1.13.1 The CAB Method 
With an inability to directly compare results from CPM based work it seemed that AFM, despite 
all its positives, remained fundamentally quite a relative process with a limited application in 
force determination. However an approach developed by Begat, Morton, Stainforth and Price in 
2004 (Begat et ai, 2004a) offered an extension to real particle probing that would potentially 
allow data from different probes and different experiments to be compared (Roberts, 2005). 
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The cohesive-adhesive balance approach (CAB) is a CPM adaptation based in a change of 
analysis rather than an extensive change to practical process. Instead of trying to compare 
probe to probe results in Fadh directly, the technique compares the ratio of a probe's cohesive 
character to its adhesive character with a given substrate. As already highlighted, experimental 
and theoretical adhesion force measurements are often several orders of magnitude different, 
and this is assumed to be due to the differences in the predicted and actual contact area of the 
two interacting surfaces. However with the application of the CAB approach the severe difficulty 
in determining or accounting for the probe-substrate contact area is precluded by treating the 
adhesion forces as a function of the cohesive forces of the same probe (Jones et ai, 2008). From 
the equations cited when we considered the contributions to Interparticulate interactions, the 
cohesive-adhesive balance can be expressed as a ratio of the summation of capillary and van der 
Waals forces (3,5) (Begat et ai, 2004a): 
Feoh RA-A[llnWA-A+(41fYwater cos 8A-A+41fYA-water)] 
F adh - RA_B[ll1fW A-B+(41fYwater cos 8A-B+41fY A-water)] (1.28) 
Where F eoh and F adh are the cohesive and adhesive forces respectively, RA-A and RA-B are 
the contact radii, 11 is the contact model specific constant (JKR, OMT etc), W A-A and W A-B are 
the cohesive and adhesive thermodynamic work of adhesion values, 8 A-A and 8 A-B are the 
measured contact angles of the liquid with the relative particle surfaces, Ywater is the surface 
tension of water and YA-water is the particle liquid interfacial free energy. 
From this equation it can be concluded that in a constant environment (temperature, humidity 
etc.) the W A and 8 will only be dependent upon the material's physical characteristics. Hence in 
such a set up the only parameters liable to vary will be the contact radii RA-A and RA-B • 
Therefore as long as there is a gross similarity between the surface geometrics of the two 
substrates used and assuming the same probe is used on both with no alteration to its 
morphology, the cohesion-adhesion ratio should theoretically remain constant between a 
number of probes (Traini et ai, 2005a). Therefore by plotting the Fcoh as a function of the Fadh for 
several probes on a substrate, the force balance within a system of interest can be quantified 
through the regression of these values (Begat et ai, 2004a). 
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In essence therefore, force measurements are performed between a series of functional probes 
(of a given material of interest) and molecularly smooth crystal faces of the other material of 
interest. Quantitative AFM measurements of the cohesive forces versus the adhesive forces for 
that series of probes are then plotted graphically (Hooton et ai, 2006). In such a fashion a CAB 
plot is compiled from which, with some basic statistical analysis a quantitative measurement of 
the specific cohesive/adhesive ratio can be calculated. An example of a CAB plot is given below 
in fig 1.18: 
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Figure 1.18: Theoretical CAB graph for a binary system. (P.Begat et ai, 2004a) 
.* 
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Here the adhesive force measurements for a number of probes of interacting materials F Al-8 
and F 82- A are plotted on the x-axis against the relative cohesive force measurements of the 
same probe materials F Al-A and F 82- 8' Assuming the contact geometries are the same, the 
force data of several probes (I.e. tip 1, tip 2 and tip 3) should follow a linear fit because of a 
consistency in the cohesive-adhesive ratio (F Al-BI F Al-A and F B2-AIFin-B)' The bisecting line 
therefore represents equilibrium between Fadh and Fcoh, and serves to divide the plots into two 
distinct regions. That above the line is the cohesive domain where Fcoh>Fadh, and that below the 
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line is the adhesive domain where Fadh>Fcoh. Hence the relative position of a series of aligned 
plots to this bisection represents either an affinity (as a larger force of adhesion) of a probe 
material for itself or for the substrate respectively (Traini et ai, 2005a). 
By linear regression analysis of the respective slopes of the plot values from a tip series, the 
relative strength of the adhesive/cohesive interactions can be measured (Begat et ai, 2004a). 
The difference in the gradients between tip series of different probe-substrate measurements 
can be used to directly compare the cohesive and adhesive tendencies (Hooton et ai, 2006). It is 
also possible to use the coefficient of determination (R2) to assess the uniformity of contact 
between the surfaces and the tips in evaluating the legitimacy of the mathematical outcomes 
(Begat et ai, 2004a). 
The most obvious benefit of this technique is that it allows quantification of the relationship 
between the theoretical work of adhesion and cohesion and corresponding AFM measurements 
(Traini et ai, 2?05a). As c r i t i q u e ~ , , the principle hindrance to AFM based real particle force data 
was the lack of control over the tip geometry leading to an unknown contact area. This meant' 
massive variations in Fadh that couldn't be calibrated for to allow fair comparison with other 
substrates, and subsequently limited the conclusions possible. The CAB technique manages to 
solve this redundancy by using the cohesive force of the probe as a means of normalization for 
the adhesion force. In so doing the predominant adhesive-cohesive character of a system (e.g. 
API and carrier molecule) can be qualified and quantified by a CAB value. Potentially therefore 
this technique offers a means to answer some of the critical pre-formulation questions that thus 
far no other method has accurately provided: How does the drug-drug cohesion compare to the 
drug-carrier/excipientldevice adhesion? Will this system therefore have adequate stability, 
reproducibility and in vivo performance? How does the force balance of one combination of API 
and carrier, or of two APls compare and how does this influence the formulation performance. 
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1.13.2 CAB Studies 
Thus far the CAB approach has been used by several authors to critique the potential of and 'in-
vitro' performance of various inhaler APls and excipients in answering these questions. The 
examples given below highlight some of the key applications the approach has been put to use 
in, and the potential it has for furthering our understanding of the influence of interparticulate 
interaction. Begat et ai, in defining the technique, used it to characterize the interaction of DPI 
ingredients salbutamol and budesonide with the carrier molecule a-lactose monohydrate (Begat 
et ai, 2004a). The study suggested that the salbutamol-Iactose system was adhesive in nature 
(16.88 times greater interaction of salbutamol tip with lactose that salbutamol tip on 
salbutamol) and therefore that the two would exhibit good powder properties as a 
homogeneous blend. However the budesonide-Iactose system was cohesive in nature 
(budesonide probes exhibiting 3.84 fold greater affinity for budesonide surfaces than lactose) 
and this suggested that such a binary system would exhibit poor blend homogeneity without the 
introduction of large shear stresses to overcome the cohesive bonds (Begat et ai, 2004a). 
This simple but useful summation led the same group to then attempt to define the implied 
impact of such a cohesive-adhesive balance on DPI formulation aerosolization and delivery. By 
using the same APls and carrier molecule and formulating Inhalation powder blends that were 
subject to morphological, particle size, chemical, content uniformity and 'in-vitro' deposition 
characterization (Begat et ai, 2004b). These tests verified the initial work of the group, in that 
the budesonide-Iactose system exhibited less homogeneity than the salbutamol-Iactose blend 
(SD dose content uniformity 28.1% and 4.2% respectively). They also identified expected trends 
based on the cohesive-adhesive balance of the formulations upon emitted dose and fine particle 
fraction when in comparison to API only delivery. However more interestingly in the course of 
the 'in-vitro' impaction studies they discovered a paradoxical relationship, whereby budesonide 
alone and with lactose, evidenced a lower total emission efficacy, but produced a greater fine 
particle fraction {FPF) than salbutamol alone or with lactose. This was explained by factoring in 
the effect of air stream dynamiCS, whereby a more cohesive formulation leads to larger drug 
aggregates on inspiration that were subject to increased drag forces which in turn effectively 
gave rise to improved de-agglomeration and dispersion in the airstream. Hence the CAB 
approach was ratified in predicting the behavioral differences between separate formulations. 
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However this study also identified the complicated nature of its application to inhalation 
therapy as a whole and a need for more work. 
Traini, Rogueda, Young and Price adapted the CAB approach as a means to experimentally 
compare the derivation of particle cohesion and adhesion forces with other techniques, 
providing a theoretical measurement of the interfacial free energy of particulate interactions in 
multi-drug pM Dis (Traini et ai, 2005a). The work found the CAB approach to concur with the 
broad theoretical predictions in considering the cohesive/adhesive character of three APls with 
one another (Salbutamol, Formoterol, Budesonide) in the model propellant 2H, 3H 
perfluoropentane (HPFP). There was however not a consistent compliance with the actual 
values calculated. This discrepancy was put down to a slight polarity of HPFP that was not 
factored into the theoretical calculation (will effect liquid-liquid surface tension prediction) or 
the use of a single dominant crystal face in the AFM force measurements. Here there may be a 
discrepancy to the contact angle data derived from molecular compacts where surface free 
energy values may be higher. Despite this the study went some way to validating the CAB 
approach as an accurate means to characterize interparticulate interaction, and more 
specifically within a pMDI set up. 
The same authors later tried to determine a relationship between adhesive and cohesive 
character of the same API based pMDI systems and 'in-vitro' deposition ·testing using an 
Anderson Cascade Impactor (ACI) and flocculation studies. The CAB analysis suggested that 
salbutamol had a largely cohesive character with respect to other APls, while the budesonide 
and formoterol were more adhesive. This was supported with vast changes in single agent 
delivery to mUlti-agent delivery and these were associated with the nature of interaction 
involved. Salbutamol delivered alone exhibited strong relative cohesive character, seen as 
compact flocculation to a small sedimentation volume. But when combined with APls to which it 
demonstrated relatively lower adhesive character (budesonide, formoterol), there was 
aggregation to more loosely bound and easily re-dispersible flocs, capable of higher 
performance delivery (3 times greater as total emitted dose). Conversely budesonide and 
formoterol showed higher sedimentation volumes with loose flocs when examined alone, but 
when combined with salbutamol, flocculation was more compact and the emitted dose 
decreased. This interesting study highlighted the potential for CAB analysis to assess potential 
multi-drug pMDI formulations for expected delivery behaviors, and associated this to 
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flocculation behavior. However crucially it did not examine the effect of the CAB on the fine 
particle fraction (FPF) of the formulation which as it has been suggested previously, may tend to 
oppose the trend for total emitted dose. 
A CAB study by Hooton, Jones and Price attempted to predict the behavior of sugar carriers in 
DPI formulations (Hooton et ai, 2006). Using micronized salbutamol probes they performed a 
CAB analysis on S sugar molecules with potential for use as carrier molecules. They then 
compared the CAB graphs generated with 'in-vitro' performance data using an ACI. They 
discovered that the rank order of FPF performance of the /32-agonist and sugar carriers 
corresponded to the reverse trend in adhesive character. This association was found to be 
linearly correlated and was deemed to confirm that in adhesive systems the stronger the 
adhesive nature of an interaction the better the interactive mixture, but the less successful the 
detachment upon air stream entrainment. Therefore with decreasing adhesive character the 
balance of interactive forces may allow better disaggregation and dispersion efficacy. 
Importantly however this shift may induce instability in the system which may lead to 
segregation of the API within the formulation, giving higher device retention and potentially 
reduced dose reproducibility. The performance of cohesive systems remained unclear, although 
it was again hypothesized that agglomeration and segregation of the API in such a system is 
countered by drag force effects leading to higher eventual dispersion levels. 
Following on from this work, Jones, Hooton, Dawson, Ferrie and Price used the CAB approach to 
investigate the dispersion of DPI ternary formulations 'in-vitro' (Jones et ai, 2007). CAB ratioS 
'were produced for drug-'fine' and 'fine'-carrier probes and the results highlighted the 
importance of such carrier 'fines'. The work suggested that stronger API-fine adhesion led to 
larger combination agglomerates attached to carrier particles. These were then subject to 
greater deagglomeration forces during aerosolization than smaller API only agglomerates and 
were better dispersed. Furthermore the data suggested that ternary cohesive systems were 
associated with an increase in performance independent of a drug-fines interaction. This waS 
hypothesized to be due to increased deagglomeration forces as a consequence of increased 
particle-particle collisions. Here a more than 400% increase in individual particles over binarY 
formulations may result in many more interparticulate collisions, which are very effective in 
causing drug particle detachment from a carrier. 
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Another study from Hooton, Jones, Harris, Shur and Price then expanded upon a question ra.ised 
in the previous study; whether the particular crystal habit of a given API had an influence on the 
cohesive/adhesive character recorded? (Hooton et ai, 2008). In the DPI system studied the 
authors used the CAB approach to characterize two different crystal habits of budesonide 
formed by differing solvent and anti-solvent combinations with 5 different sugar carrier 
molecules. The results suggested that the CAB was very different for the two crystal habits with 
cohesive nature of the {102} faces being approximately twice that of the {002} faces. Although 
this did not directly affect the rank order of adhesive character with the sugars, there was a 
significant effect on FPF as recorded by an ACI. The loss of adhesive character with the {102} 
face led to an increase in FPF up to a plateau. The differences in CAB were attributed to the 
\ 
molecularly modeled surface chemistry differences of the two habits giving rise to increased 
contributions of the {102} face to van der Waals interactions. 
1.13.3 The Cohesive Adhesive Balance: A Summation 
As can be seen above, the CAB approach has been well adapted to suit some fundamental 
investigations into interactions on a micro-scale and would seem to offer the potential to 
drastically further our understanding of the area as a whole. It has proven a viable tool in 
assessing a number of concepts surrounding adhesion forces and their implications of inhalation 
formulation. Indeed the technique has to some extent already been validated in its accurate 
assessment of the adhesive/cohesive nature of compound formulations. However this is not to 
say that the technique is without limitations. It cannot be forgotten that the CAB approach is 
based in AFM methodology and therefore suffers the same inadequacies as those cited earlier 
which will serve to distort the results achieved. What is more of a specific problem with the 
approach is the necessity for crystalline smooth surfaces to perform measurements upon. As 
indicated, the principle of the CAB approach is that the surfaces of cohesion and adhesion are 
morphologically identical, and therefore the only way to ensure this has been to use crystalline 
material with validated surface homogeneity. This is of course not an accurate representation of 
actual particle morphology in formulation, and therefore it would be expected that AFM 
measurements on the lowest energy faces of crystalline substrates may either underestimate 
the forces of cohesion and adhesion, or through a deliberate ignorance of actual roughness, 
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indeed overestimate them (Jones et ai, 2008a). This has wider implications in that, as has been 
alluded to in several studies, the very handling of the tip material and substrate will in itself lead 
to changes in the force measurements made. This may be through providing different crystal 
. . 
habits (Hooton et ai, 2008) or any other chemical or physical difference (Jones et ai, 2008b). 
Furthermore, the necessity to recrystallize a substrate for use in a force balance experiment 
reduces its application to some materials, as well as reducing the capacity for use in a quick a 
simple assessment of an API mix. Such a facility would be invaluable if the capacity to measure a 
force balance was combined with real particle states and simple technical operation. If force 
balances between APls and inhaler components, APls and excipients or even multiple APls could 
be linked to the performance of an inhaled formulation this would then allow a simple CPM 
technique to offer a potentially rapid and accessible pre-formulation screen that would infer the 
potential of a blend of formulation components. 
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2.0 Materials and Methods 
2.1 General Introduction 
This chapter will introduce and explain the background to the materials and primary methods 
used within the experimental chapters and relevant to the area of research to follow. This will 
include the basic active pharmaceutical ingredients utilised, the pMDI components and 
formulation materials and the experimental and analytical techniques used in the subsequent 
chapters. Each of the following chapters will cover in more detail the precise methodologies and 
individual techniques employed but this chapter is designed to afford a basic description and 
understanding of the principals involved in the key analytical procedures as well as the general 
materials investigated. The techniques covered will principally include atomic force microscopY 
(AFM) and its variants, scanning electron microscopy (SEM), time-of flight secondary ion mass 
spectrometry (ToF-SIMS), Raman spectrometry, desorption electrospray ionization mass 
spectrometry (DESI) and Andersen cascade impaction (ACI). 
2.2 Materials 
2.2.1 Active Pharmaceutical Ingredients (APls), Propellants and Excipients 
The principal APls used throughout the course of these studies are described below: 
2.2.1.1 Salbutamol Sulphate 
H OH 
• H2S04 and enantiomer 
HO 
2 
Figure 2.1 Salbutamol Sulphate Monograph (British Pharmacopoeia, 2012) 
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Salbutamol sulphate is a beta2-adrenoceptor agonist, used as a rapid and short acting 
bronchodilator that exists as a white or almost white crystalline powder, freely soluble in water 
and virtually insoluble in ethanol. It has a chemical formula of (C13H21N03hHzS04 and molecular 
weight of 576.7 (British Pharmacopeia, 2012). Salbutamol sulphate was supplied by 3M 
Healthcare (Lough borough, UK). 
2.2.1.2 Beclomethasone Dipropionate 
o 
Figure 2.2 Beclomethasone Dipropionate Monograph (British Pharmacopoeia 2012) 
Beclomethasone dipropionate is a glucocorticoid, used in prophylaxis against inflaml1)atory 
airways conditions. It is a white or near white crystalline powder practically insoluble in water 
but freely soluble in acetone and methylene chloride while sparingly soluble in ethanol. It has 
the chemical formula C2sH37F07 and a molecular mass of 504.6. It is widely known to have 
several media dependent polymorphs, including a BOP hydrate, and clathrates with a variety of 
solvents (British Pharmacopeia, 2012). Beclomethasone Oipropionate was supplied by 3M 
Healthcare (Loughborough, UK) unless otherwise specified. 
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2.2.1.3 Salmeterol Xinafoate 
H OH H 
HO 
~ N ~ ~
and enantiomer 
Figure 2.3 Salmeterol Xinafoate Monograph (British Pharmacopoeia, 2012). 
Salmeterol Xinafoate is a beta2-adrenoceptor agonist used as a long acting bronchodilator. It is a 
white or almost white powder, practically insoluble in water but soluble in methanol and slightly 
soluble in ethanol. It has a chemical formula of C36H4SN07 and a molecular weight of 604. 
Salmeterol Xinafoate was supplied by 3M Healthcare (Lough borough, UK). 
2.2.1.4 Fluticasone Propionate 
o 
H 
Figure 2.4 F/uticasone Propionate Monograph (British Pharmacopoeia, 2012). 
Fluticasone propionate is a glucocorticoid used in prophylaxis against inflammatory airwaYS 
conditions and to treat inflammatory skin conditions. It is a white or almost white powder 
practically insoluble in water but soluble in methylene chloride and slightly soluble in alcohol. It 
has the chemical formula C2sH31F30SS and a molecular weight of 500.6. Fluticasone Propionate 
was supplied by 3M Healthcare (Loughborough, UK). 
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2.2.1.5 Budesonide 
OH 
CH3 CH 
.. 0 •.. ~ ~ 3 
__ -:' H and epimer at C· 
H 
H 
o 
Figure 2.S Budesonlde Monograph (British Pharmacopoeia, 2012). 
Budesonide is a glucocorticoid used in prophylaxis against inflammatory airways conditions and 
to treat inflammatory conditions of the bowels. It is a white or almost white crystalline powder 
practically insoluble in water but freely soluble in methylene chloride and sparingly soluble in 
ethanol. It has the chemical formula C2sH3406 and a molecular mass of 430.5. Budesonide was 
supplied by 3M Healthcare (Lough borough, UK). 
2.2.1.6 1,1,1,2-tetrafluoroethane (HFA 134a) 
F H 
I f/H 
C-C F'i , 
F F 
Figure 2.6 Structure of HFA134a 
1,1,l,2-tetrafluoroethane (HFA134a) is a chlorine free alkane with no ozone depleting 
. capabilities (Brindley 2003) widely used as a propellant in most modern pMDI devices as a 
replacement for the previously banned CFCs. It is utilised as a clear liquefied gas under pressure 
and with a boiling point of -26.5"C is also a colourless gas post actuation. HFA134a was supplied 
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by 3M Healthcare (Loughborough, UK) and BOC (Surrey, UK) as specified in the individual 
methods. 
2.2.2 Pressurised Metered Dose Inhaler Components 
Several pMDI components were used through this course of this study, either as part of a 
complete pMDI assembly for formulation handling and actuation or as representative substrates 
for force balance work. They key components with special consideration are as follows: 
2.2.2.1 Aluminium Canister (Un-coated) and Fluorinated Ethylene Propylene Coated Canisters 
A pMDI canister is the housing unit for the inhalation formulation to be delivered. As such it acts 
as a store for the API and excipient blends, either dissolved into or suspended within the chosen 
propellant. Its primary functional requirements are therefore to withstand the pressures of the 
liquefied gases ("'1500k kPa), to avoid interacting with the formulation components, and to 
protect the formulation from either escape, or contamination from ingress (I.e. moisture) 
(McDonald, Martin, 2000). The most widely used containers are made from aluminium alloys 
due to their light weight, strength, compactness and low interactivity with traditional 
formulation materials (Munroe, Cripps, 2007) • Stainless steel and glass canisters can be used in 
rare circumstances. As the largest surface area in contact with the formulation it is the most 
likely to experience interactions with the chemical constituents, and therefore will be 
considered as a surface of primary interest when assessing API-pMDI component adhesions and 
force balances. Some canisters are coated with sub-micron layers of modifying chemicals in an 
attempt to reduce surface-formulation interactions (Ashayer et af., 2004). One example is the 
use of fluoropolymers like fluorinated ethylene propylene (FEP). Such a coated canister waS 
therefore chosen for comparison to the un-coated canister in terms of adhesive contact force 
with the respective APls investigated. 
Trimline aluminium un-coated and FEP coated pMDI canisters used in this study were provided 
by 3M Healthcare (Loughborough, UK) unless otherwise specified. 
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2.2.2.2 Metering Chamber 
The metering valve in a pMDI is one of the most design critical elements in an aerosol 
formulation delivery system. It can be considered not as a singular part, but rathera collection 
of independent components that work in combination to achieve a goal. This is to measure and 
reproducibly deliver the formulation out of the canister upon actuation, whilst also forming the 
. seal on the top of the canister that prevents loss of the pressurized contents. The metering 
chamber is perhaps the most critical component of the valve, as it serves to portion and contain 
the exact quantity of formulation needed to deliver an established aerosolized dose. A typical 
MDI metering valve operates in a stem down position and consists of two coupled valves placed 
on either side of a volumetric metering chamber .. When the valve stem is depressed, the inner 
valve must close to isolate the rest of the formulation from the environment, while the outer 
valve opens to discharge the contents of the metering chamber (Munroe, Cripps, 2007). As such 
the metering chamber is nearly always in contact with the formulation, and by the very nature 
of its function; any interaction with the formulation can induce critical changes in the delivered 
dose efficacy of the API (McDonald, Martin, 2000). The metering chamber was therefore chosen 
as a device substrate for force based work. 
Bespak SOIlI metering valve assemblies (Bespak Europe Ltd, King's Lynn, UK) were used on all 
occasions within this thesis. 
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2.3 Methods 
2.3.1 Atomic Force Microscopy 
The science and extended applications of Atomic Force Microscopy (AFM) have been explored 
and explained in detail in chapter 1 and readers are directed to this section (1.11) for a full 
briefing on the experimental theory and its application to interparticulate interaction 
determination. 
2.3.2 Time of Flight Secondary Ion Mass Spectrometry and Multivariate Analysis 
2.3.2.1 ToF-SIMS 
If a solid surface is bombarded with energetic primary particles (electrons, ions, neutrals or 
photons) that surface will, as a product of a collision cascade and energy transfer, yield 
secondary particles. Where the primary ions and the surface undergo collision there is extensive 
fragmentation and bond breaking leading to the emission of atomic particles. Further from the 
collision site however, the direct and 'indirect (knock-on) collisions become less energetic and 
are less able to exceed all bond energies, resulting in less fragmentation and more molecular 
fragments (Belu et aI., 2003). As a result the emitted secondary particles may in turn be 
electrons, neutral species atoms and molecules or indeed atomic and cluster ions. While the 
vast majority of these particles will be neutral, a fraction is ionized and the mass spectrometrY 
of these secondary ions (SIMS) allows a detailed chemical determination of the surface area 
(Grams, 2007). ToF-SIMS is a particularly popular application of the SIMS technique, and 
conceptually a simple means of mass separation used in SIMS analysis. In this instance, pulses of 
the generated secondary ions 'sputtered' from the analytical surface are accelerated to a given 
potential (usually 3 to 8 keV) so that all the ions possess the same kinetic energy, and are then 
allowed to drift through a field free space before striking an ion detector. As the heavier masses 
travel slower than lighter masses through this space, the ions strike the detector at differing 
times and the detector can then calculate impact intensity as a function of time of flight, with a 
direct correlation to ion mass as indicated by equation 2.1: 
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( 
m )1/2 t=L -
2zV (2.1) 
Where t is the measured flight time of ions of mass to charge ratio (mjz) accelerated by a 
potential (V) down a flight path of length (L) (Vickerman, 1997). Figure 2.7 highlights the 
principle at work in a ToF-SIMS field free flight tube: 
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Figure 2.7 Schematic representation of ion mass separation in the ToF field-free drift tube 
(Belu et al., 2003) 
ToF-SIMS can either be run in a 'static' or 'dynamic' mode. The dynamic mode exploits the 
destructive nature of the incident primary ion beams to analyse the secondary ions emitted as a 
function of sputtering depth. This technique is very useful in either detecting trace deposits of 
elements, investigating the sequential composition of a material and layer composition, or 
simply in removing a surface layer in order to analyse those below. However the more modern 
static SIMS approach uses much lower primary ion doses, in an attempt to maintain sensitivity 
to the surface of the analyte. Often chemical surface specificity is of the greatest interest, as it is 
this interface that governs the largest component of physicochemical interactivity. Static SIMS 
better preserves the surface layers, albeit with a significant reduction in secondary ion yield and 
a loss of confidence in ion quantification (Grams, 2007). Significantly, by rastering the primary 
ion beam in a static mode across a surface of interest, it is also possible to develop a spatial set 
of SIMS spectra that can then be used to create elemental or chemical state images of a given 
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scan area. This process of ion imaging allows the relation of chemical analysis to surface 
topography and morphology. Figure 2.8 shows the basic experimental assembly of ToF-SIMS 
apparatus: 
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Figure 2.8 Schematic of a TOF-SIMS analysis (ION-TOF GmBH) 
The primary ion source in a ToF-SIMS set up can be customised with respect to the mode of 
SIMS to be run and the specific aims of the experiment at hand . Field ionizing liquid metal ion 
guns generating gallium (Ga+) or Bismuth (Bi 3+ ) allow for spatial resolutions down to 111m and 
below (although maintaining static conditions below this threshold is very difficult, and 
therefore this is practically not often the case) (Belu et aI., 2003) . Alternatively by thermally 
exciting elements such as caesium (Cs+) or carbon60 (C60) coated metal sources, much larger 
single ion or cluster ions can be generated giving rise to much more destructive surface 
bombardments, ideal for surface sputtering and analysis. 
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The principle advantage of ToF-SIMS is therefore the versatility to perform both high sensitivity 
destructive and high spatial resolution surface sensitive chemical analysis of organic and 
inorganic materials. In particular the potential to move beyond high sensitivity individual 
spectra, to map a given topography on an ion by ion specific basis as a chemical image, is of 
fantastic potential in relating chemical composition to surface localisation. Such a technique has 
great value in identifying API localisation with respect to other excipients or APls on an impacted 
surface, such as post actuated ACI plates. 
2.3.2.2 Multivariate Analysis 
One of the limitations of ToF-SIMS is that being a high energy process, fragment ions are 
dominant in the resultant spectra rather than whole molecular ions. This means that higher 
levels of data processing are required to identify accurate chemical composition (Scurr et aI., 
2010). Furthermore SIMS chemical images have the capacity to have generated a complete ion 
spectrum per pixel point (e.g. 256x256 pixels per image). This may amass to millions of spectra 
on an ion mass by ion mass basis, generating a vast hyperspectral data pool for analysis. This is 
complicated further with the fact that as a consequence of the low primary ion count and 
reduced acquisition times static SIMs employs to reduce surface degradation, there is often a 
low signal to noise ratio (Krzanowski, 2000). This means that with increasing spatial resolutions 
there is a decrease in available ion signal, and that noise from the counting statistics of the 
detector become much more significant (Lee, Gilmore, 2012). As a consequence, univariate 
analysis of this mass of subtle data, where each variable (secondary ion mass in this instance) is 
treated independently and analysed separately becomes very complicated and hugely time 
consuming. It is v ~ r y y easy for small chemical features that may still have great importance to be 
missed. Hence a multivariate approach to analysis is often employed in order that such data, 
with a huge number of dependent variables, can be considered in its entirety and then 
summarised using a smaller number of statistical variables. This has the benefit of allowing for a 
Simpler, more rapid and holistic interpretation of the results (Lee, Gilmore, 2012). 
In essence multivariate data analysis isa tool of chemometric pattern recognition, and can be 
described as organising results into groups based on their position. within a multivariate 
dataspace (Belu et aI., 2003). This is achieved by using matrix mathematics to arrange the 
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variables of a given set of experimental measurements, and then vector mathematics to 
describe these arrangements into a multidimensional graphical model (Krzanowski, 2000). It is 
then possible using one or several of a range of specifically chosen multivariate approaches (e.g. 
principal component analysis, multivariate curve resolution, maximum autocorrelation factoring 
etc.) to attempt to describe these modelled matrices in terms of 'factors', or directions in the 
virtual dataspace that account for the original dataset (Lee, Gilmore, 2012). Further statistical 
techniques can in turn be employed to calibrate, quantify and or cluster the datasets as per the 
desire of the experimental set up, but in basic terms all such algorithms will look to identify and 
summarise relationships between the multivariate data sets. 
2.3.2.3 Principal Component Analysis (PCA) 
Principal component analysis (PCA) is one form of factor analysis that tries to find the directions 
of greatest variation in the multivariate space defined by the data. As with other types of factor 
analysis it is employed to reduce the matrices of data to their lowest meaningful dimensionalitY, 
by describing them with the smallest number of factors, or 'principle components' possible (Lee, 
Gilmore, 2012). These directions are then used to define a new set of axes that explain how the 
samples and variables relate to each other, i.e. picking out the variates that correspond to the 
greatest degree of variability between data sets. Consequentially samples that are diversely 
spread along these new axis show less similarity than those that are grouped together with 
respect to that principal component (Belu et aI., 2003). Figure 2.9 shows an example graphical 
representation of PCA, where data for 28 samples over two variables (Xl and X2) has been 
described by two principal components (PCA 1 and PCA 2). PCA 1 describes the factor with the 
greatest variance, and PCA 2 is orthogonal to PCA 1 and picks up the largest remaining variation 
(Lee, Gilmore, 2012). In this fashion, it is possible to redefine the samples along the 'new' axeS 
in the data space by the principal components, and thereby determine the key contributions to 
the co-variance of the data. However whilst PCA can be used in its own right to look for trends in 
data variability, it is often used as a 'pre-processing' tool as a means of data reduction. As we 
infer higher and higher factors, it is possible to discard those that show the least variance as 
variability due to noise. This has a positive impact on analYSis as it will reduce the dimensionalitY 
of the data, thereby reducing the expression of highly correlated and theoretically less desirable 
data trending (Krzanowski, 2000). 
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peA Factor 1 
Figure 2.9: 20 representation of a principal component analysis (peA) (Lee, Gilmore, 2012) 
For example if we consider figure 2.9, we can ask whether it is necessary to describe the data in 
terms of the two factors (PCA 1 and PCA 2), or rather if the scatter observed is due to 
experimental noise. If the latter can be deduced or assumed, then the information in PCA 2 can 
be discarded and all the relevant chemical data can be provided by the projection of the data 
onto PCA 1. This is of benefit, as data that originally contained two variables can now be 
described by one factor and the most influential samples identified or the compacted data 
passed on for further modelling. As such PCA is a tool that can have a significant benefit if run 
before subsequent image analysis techniques like multivariate curve resolution in defining the 
number of factors to model for (Rao et aI., 2012). 
2.3.2.4 Multivariate Curve Resolution 
While PCA factors describe variance within a hyperspectral dataset, they can sometimes be 
difficult to interpret and may not necessarily describe chemical images in particular, with any 
desirable pattern. This is because while the technique identifies combinations of chemical 
spectra that reflect the correlations and anti-correlations of a variety of components across the 
image, certain chemical components may be projected onto multiple factors and therefore 
become difficult to categorise entirely. Multivariate curve resolution (MCR) is another 
multivariate data processing technique that is of more particular use in the analysis of 
hyperspectral ToF-SIMS images (Scurr et aI., 2010). With particular reference to SIMS spectra, it 
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assumes that each spectrum can be described as a linear sum of contributions, (MCR scores) 
from individual chemical components, each associated with a given spectral profile (MCR 
loading). While this is by no means guaranteed in a ToF-SIMs environment, as there are many 
other influences on ion peak position and intensity besides chemical composition, MCR does 
have the benefit of being able to resolve, identify and localize original chemical spectra from a 
mUlti-component mixture where very little is known about the composition. (Lee, Gilmore, 
2012) . The technique uses an 'iterative least squares' algorithm to extract solutions, while 
applying particular constraints, most notably one of non-negativity. This particular constraint 
applied to the loadings and scores matrices, ensures the MCR solution obtained better 
resembles the raw SIMS spectra, which has to return positive values. Consequentially MCR does 
not require the projected factors to be mutually orthogonal in the same way PCA does (Lee, 
Gilmore, 2012). Figure 2.10 shows a 2D representation of a MCR solution and it can be seen that 
all of the samples can be described by a positive mixture of the MCR factors MCR 1 and MCR2, 
which themselves are positive descriptors of the original axes Xl and X2. 
X2 MeR Factor 2 
Figure 2.10: 20 representation of multivariate curve resolution (Lee, Gilmore, 2012) 
These attributes make MCR a very useful tool in chemical image analysis, to pull out individual 
chemical contribut ions with respect to a given topography. However it should be borne in mind 
th at MCR is a much more computationally demanding technique than PCA. And unlike PCA, MCR 
solutions are not un ique for each data set, and are strongly open to bias from the initial user 
def ined est imates, constraints and other pre-processing criteria . The accuracy of the MeR 
solution relies upon pixels or samples with contributions from only one chemical component, 
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and as a consequence peaks for intense components may appear in spectral profiles resolved 
for weaker contributors (Lee, Gilmore, 2012). However, the technique if appropriately 
controlled, offers the capacity to define the variation in components of a chemical map with 
respect to the localization of constitutional secondary ions involved i.e. map the key chemical 
variations across a topography of interest. 
2.3.3 Raman Spectroscopy 
Raman spectroscopy is utilised to describe the unique vibrational modes of molecules, 
generating a specific fingerprint spectrum through which the molecule or compound can be 
identified. While capable of simply generating individual series of spectra for identification and 
comparison, it also has the capacity in newer devices, to be used hyperspectrally as a chemical 
mapping tool in the analysis of a material surface. The flexibility of the Raman set up can allow 
. the technique to model either general or site mapped changes in vibrational behaviours relating 
to numerous variables, principally (to date) temperature and time dependent stability, 
particularly with respect to phase and crystallinity changes. 
The technique monitors the interaction between a defined monochromatic light source, and the 
molecular vibrations of the material being analysed. In essence the technique is based upon the 
. 'inelastic' interaction between a photon and a molecule causing the returned photon to have 
gained or lost a vibrational quantum of energy (Larkin, 2011). More specifically a given 
molecular vibration can be excited by a given frequency of incident light to a higher virtual 
energy state by absorbing some of that light (M.Pelletier, C.Pelletier, 2010). This higher energy 
state will (almost always) relax back to a lower energy state, but while this is usually elastically 
to its original energy state (Rayleigh scattering), it may also be to a different vibrational energy 
level (Raman scattering) generating the release of a photon with an altered frequency to its 
incident state (Larkin, 2011). Figure 2.11 highlights the different potential changes in energy 
state in the differing scattering processes: 
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Figure 2.11 Possible energy state changes of the different scattering processes 
Rayleigh scattering is much more common place than Raman scattering and the scattered 
intensity is about 10-3 less than the incident radiation (Larkin, 2011) . It is considered elastiC 
because there is no change in energy i.e. occurs at the frequency of incident radiation. Raman 
scattering however, is less common, with a scattered intensity of about 10-6 less than the 
incident radiation (Larkin, 2011). As figure 2.11 shows, there are two types of Raman scattering, 
Stokes and Anti -Stokes. Stokes Raman scattering, produces photons with lower energies than 
the incident photons, as a consequence of a relaxation to a higher than previous vibrational 
energy level. Anti-Stokes Raman scattering produces photons with increased energies than 
those from the light source, due to relaxation of the vibrational energy level to one lower than 
the previous (M.Pelietier, C.Pelietier, 2010) . While both are important and measurable, the 
proportional ratio of Stokes to Anti -Stokes scattering is dependent upon the temperature and 
energy difference between the ground and excited energy states of a sample. In general Stokes 
scattering is most often explicitly measured as it usually exceeds Anti -Stokes scattering. This is 
because most samples are analysed at ambient temperatures with molecular vibrational modes 
at a ground state and less likely to subsequently loose energy by relaxation to a lower energy 
state. Subsequently, a Raman spectrum is built by measuring the changes in photon energy 
between incident and scattered light by plotting the scattered light intensity against the shift in 
light frequency and wavelength (the Raman shift). Stokes scattering will give rise to reductionS 
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in frequency that can be related to the specific molecular vibrations in the compound being 
analysed, which can then be solved to identify or characterize the material. 
A Raman system will usually consist of one or several monochromatic light sources (lasers), 
ranging from the ultraviolet (UV), visible (Vis) or near-infrared range (NIR) to offer a variety of 
incident wavelengths. These laser sources will be transmitted to the sample via an optics 
system, sometimes containing a series of optical filters and pinhole apertures to further refine 
the incident wavelength and illumination volume. Most systems will use an optical microscope 
to deliver the radiation to the sample and also collect the backscattered Raman light .. Dielectric 
interference filters or holographic notch filters are often used to remove the Rayleigh scattered 
light from the detection signal before the filtered light is presented to light dispersion or 
frequency isolation devices and then the detector (Nelson, Treado, 2010). Raman spectroscopy 
has several key features as a chemical mapping apparatus. Notably it is a non-invasive process 
that does not require any special sample preparation, and although shorter wavelengths of 
incident light can sometimes cause energetic damage to a sample, astute choices of laser and 
exposure times allow even biological samples to be run in an instrument. It can be run in a wide 
range of conditions (i.e. temperature humidity and pressure), or indeed with the appropriate 
sample holders/chambers while varying these. parameters for real time data collection. 
Background species such as water or carbon dioxide will not interfere with spectra as their 
Raman signal is very weak (Nelson, Treado, 2010). Finally by having a motorised stage it is 
Possible to 'step by step' analyse a given topography, and generate a hyperspectral image of a 
sample, that can then be mapped according to already known pure spectra, or to those 
identified in the analysis. Theoretically the spatial resolution of the Raman instrumentation 
could be the wavelength of the incident light. 
Raman spectroscopy does have weaknesses in use as mapping tool however. Firstly v,?ry high 
spatial resolutions are not always easily possible for a multitude of reasons. In attempting to 
generate a hyperspectral chemical map of a surface, a spectrum will be gathered at every 
specified period across the chosen image area. In most cases sample topographical analysis Is 
often macroscale, and therefore attempting to analyse large areas with an attempted spatial 
resolution under 11lm would lead to huge numbers of spectra, that because of the slow 
(relative) speed in analysing the scattering spectrum can lead to long mapping times. Similar to 
the processing of ToF-SIMS data, even once achieved, this is very time consuming and difficult to 
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analyse univariately, although multivariate analysis can be applied. Raman microscopes also 
require the sample to be in the vertical focus of the microscope lens delivering the radiation. 
This incurs two problems, firstly, significant surface topography requires repetitive realignment 
of the lens relative to the surface to maximise focus. While this can be achieved by using the 
R ~ m a n n signal as a basis for automatic or manual alignment, this again can significantly prolong a 
mapping procedure. While mapping speeds can be increased by reducing exposure times and 
repeat measurements, this leads to an increase in signal to noise ratio and susceptibility to 
anomalous feedback, and it is this that will determine image quality, not spatial resolution. Also 
because a microscope lens is used, if large mapping periods are required and automatic 
alignment is not used, focal drift can occur which can have a significant impact upon the Raman 
signal feedback. Finally but probably most significantly, Raman spectroscopy can suffer from 
significant interference from fluorescence (M.Pelietier, C.Pelietier, 2010). While originating from 
a different mechanism than Raman scattering it can occur at the same time, and the broad and 
intense nature of the phenomenon can easily dwarf the Raman signal obtained if it occurs in the 
same spectral window. While most fluorescent effects occur in the near-UV to visible range, 
moving to the NIR region can eliminate the effect, but as Raman intensity is proportional to the 
fourth power of the laser wavelength, this comes with a consequent reduction in Raman signal 
and therefore an increase in acquisition time. Furthermore in the NIR region the typical silicon 
CCO detectors show a reduction in detection efficiency. 
2.3.4 Scanning Electron Microscopy 
Scanning electron microscopy (SEM) is an imaging technique used to visualise sample surfaces 
with high depth of field and lateral resolutions of around 1-20nm (Butt et al., 2003). A fine beam 
of electrons is used to scan across the specimen surface in synchronism with the spot of a 
display cathode ray tube (CRT) (Chescoe, Goodhew, 1990). Unlike its sister instrument the 
transmission electron microscope (TEM) where electron transmission through the sample is 
analysed, SEM monitors the intensity of a chosen secondary signal consequent to the 
interaction of the primary electron beam on the sample surface. Such secondary signals may be 
in the form of secondary electrons, backscattered electrons, Auger electrons, 
cathodoluminescence or even x-rays, depending upon operational desires. However the 
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Figure 2.12 Schematic of a scanning electron microscope 
principle remains largely the same, that if the intensity of emitted secondary signal changes 
across the specimen, then the contrast is seen by adjusting the brightness of the CRT spot by the 
amplified version of this detected signal (Watt, 1997). Figure 2.12 shows a basic schematic of an 
SEM system. In SEM the primary electron beam may be emitted thermionically from a heated 
filament tip within an electron gun. Tungsten, lanthanum or cerium hexaboride filaments are 
heated to exceed the surface potential of the constitutional metal, increasing the ioncore 
vibrations and inducing increasing electron collisions (Chescoe, Goodhew, 1990). Alternatively 
field emission gun (FEG) sources are also in use, where a strong electric field is used to extract 
electrons from a metal filament. In both cases electrons will be given off by a filament, and can 
in turn be accelerated (10 - 400 kV) towards and through an anode to the condenser system of 
the microscope. Here using multiple lenses (usually three) the microscope first varies the 
strength of illumination in the specimen plane to suit the sample and magnification desired and 
then focuses the suitability diminished electron beam to the sample surface (Watt, 1997). The 
83 
Chapter 2 - Materials and Methods 
secondary ions produced by the primary electron beam raster, are usually collected by a 
cathode biased Everhart-Thornley scintillation secondary ion detector (Chescoe, Goodhew, 
1990). This in conjunction with a subsequent photomultiplier reconverts the created light 
impulses to an electrical signal that can then be displayed versus the position of the primary 
beam on the sample surface (Watt, 1997). 
Critically SEM has two principal constraints. Firstly it must be carried out under vacuum 
conditions (special adaptations excluded). This is because it is essential to prevent gas scattering 
of the incident electron beam travelling from the electron gun to the specimen. It is also 
because these conditions prevent the specimen, apertures or the electron gun becoming 
contaminated by debris in the microscope column (Hayat, 1974). Secondly, it is typicallY 
necessary that the objects being imaged are conductive at the surface; otherwise electric 
charging can take place as electrons are unable to dissipate under the incident beam (Butt et al., 
2003). This means that non-conductive or poorly conductive surfaces are often coated with a 
thin layer of metal, usually gold or carbon, to enable improved sample visualisation and imaging· 
However whilst this process allows for superior SEM imaging to take place without charging, it is 
a destructive process that prohibits the subsequent use of the material after imaging, and can in 
itself lead to topographical artefacts that may show up upon imaging. It is however possible with 
newer SEMs to operate the microscope in what is called a 'low voltage' mode. Here the beam 
voltage is decreased to the equilibrium point where no charging will occur. In this fashion 
charging is avoided and less conductive materials can be imaged without coatings. However this 
comes at the cost of a reduced secondary ion count and a reduction in spatial resolution. Some 
SEMs (Environmental SEMs) have the capability to image while using low gas pressures ("'30 
mbar) in the sample chamber. This allows less-conductive surfaces to be visualised without 
metallization, as positively charged gas ions neutralise excess negative charge that would 
otherwise build up at the surface (Butt et ai, 2003). 
The SEM's spatial resolution is dependent directly upon the spot size of the incident electron 
beam which in turn depends upon the electron beam wavelength and the interaction volume of 
the beam and sample (Hayat, 1974). The smaller the spot size the better the potential 
instrumental resolution, but as a consequence beam current will also decrease, reducing the 
production of the secondary signal (secondary electrons etc.) and increasing noise (Chescoe, 
Goodhew, 1990). While it is therefore possible to image to around the nanometre scale, this is 
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not often easily achievable, and unlike the TEM where shorter more penetrative wavelengths 
can be used and atomic resolutions become a possibility, this is unachievable with an SEM. 
However because secondary ions are low energy ("'20eV) it is only those from the top layers of 
the specimen that can escape for detection, making SEM a very surface specific imaging tool 
(Butt et aI., 2003) capable of imaging bulk materials. 
2.3.5 Andersen Cascade Impaction 
The use of an Andersen Cascade Impactor (ACI) has been described briefly in chapter 1. As 
already stated an ACI is one the most widely used means of inhaled formulation deposition 
analysis, particularly from pMDI formulations. It can be considered an 'in-vitro' airways model 
that evaluates formulation performance in terms of aerodynamic particle sizing. An ACI consists 
of a stack of eight separate stages, each with precisely calibrated nozzle of diminishing size and 
area, as the stack progresses down. Each stage Is removable, but on assembly they are all sealed 
with O-rings and clamped together, with inserted impaction plates 80mm in diameter below 
each grating. The topmost stage is attached via a preseparation jet stage to a 'throat' induction 
port that loosely reflects the induction geometry of the upper airways. The base of the ACI 
possesses an outlet to which a vacuum pump can be attached. A schematic of a complete eight 
stage assembled ACI is shown in figure 2.13. The working principal is relatively simple. As a 
vacuum pump draws air through the whole ACI stack at a predetermined airflow rate, a pMDI 
(or DPI with some technical changes to the set up) is actuated into the impactor via a 
mouthpiece adapter. The aerosolized formulation contents will pass into and down the ACI, with 
material impacting throughout the whole system. As the particles pass further down the ACI 
stack they are forced to pass through smaller and smaller gratings, thus separating out the 
particles by size discrimination. Figure 2.14 highlights this principal. 
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Figure 2.13 Schematic of an Andersen Cascade Impactor (European Pharmacopeia, 2012) 
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Figure 2.14 Aerodynamic particle separation in an ACI (Copley Scientific Ltd) 
More precisely, for particles to impact on a plate they must have enough inertia to break from 
the travelling airstream. This can be explained by considering that when the direction of airflow 
changes, i.e. as when moving over an impaction plate, aerosolized particles will continue to 
move in the original direction of flow unless they lose inertia due to friction with the travelling 
gas molecules (Hickey, 1992). Because particle inertia is a function of particle density, shape and 
velocity, larger particulate masses will have sufficient inertia to escape from the airstream 
earlier than smaller particles, which must pass to lower levels with higher nozzle airstream 
velocities (Copley, 2008). Because at each stage, nozzle size and area decrease while total 
volumetric airflow remains constant, each subsequent nozzle airstream becomes more rapid as 
more air is forced through less spacious and numerous pathways. Therefore smaller particles 
that have less inertia higher in the stack will continue to relax into the airstream until they 
eventually pick up enough velocity to carry sufficient inertia to impact. Consequentially particles 
of larger aerodynamic diameters will impact on plates further up the ACI stack, while smaller 
particles may progress further down the stack before impacting on lower plates. In this fashion 
the ACI functions as a rough 'in-vitro' model of the progressing human airways. By subsequently 
removing each ACI stage and impaction plate it is possible to quantify the amount of material 
impacted on each surface. As each stage has a calibrated nozzle diameter this provides a 
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deposition profile of the formulation which reflects the aerodynamic particle sizing of that 
formulation post-actuation. As already indicated in chapter 1, this parameter is critical in 
influencing the clinical efficacy of inhalation APls, as such pharmacological agents are of little 
use in combating airways disorders unless they can reach the deeper airways to modulate 
inflammatory and smooth muscle tone responses. Table 2.1 shows the standardised nozzle 
diameters used in an ACI. 
ACt Stage Nozzle Diameter Nozzle Number Particle Size Equivocal 
(mm) Collection Band Airway Location 
hIm) 
0 2.55 ±0.025 96 9.0 Upper airways 
1 1.89 ± 0.025 96 5.8-9.0 Upper airways 
2 0.914 ± 0.0127 400 4.7-5.8 Pharynx 
3 0.711 ± 0.0127 400 3.3-4.7 Trachea and 
." primary Bronchi 
4 0.533 ± 0.0127 400 2.1-3.3 Secondary 
Bronchi 
5 0.343 ± 0.0127 400 1.1- 2.1 Terminal 
Bronchi 
6 0.254 ± 0.0127 400 0.7-1.1 Alveoli 
7 0.254 ± 0.0127 201 0.4-0.7 Alveoli 
-Table 2.1: Standardized ACI stage definitions 
As such, good formulation performance will see significant deposition on plates 4, 5 and 6. 
Poorer formulation performances will see increased deposition on the higher,plates, or even on 
88 
Chapter 2 - Materials and Methads 
the inhaler device, and pre-separation stages. Nano-scale residual matter may pass through all 
the stages and plates and is collected on a filter at the bottom of the stack. The ACI is not able to 
give real time data on the impaction of the formulation however, and analysis requires 
disassembly into the individual components and plates, before some form of quantification. 
Most usually this is via a variation of HPLC, after the wash down and perturbation of each 
component with a controlled volume of solvent. 
The main advantages of compaction testing are that that it offers a specific means to quantify 
the API alone within a formulation, as opposed to techniques such as laser diffractometry or 
particle time of flight techniques which cannot differentiate between the API and accessory 
eXcipients (Copley, 2008). Furthermore, inertial impaction techniques should collect the total 
aerosolized dose across the experimental system, and therefore allow a user to investigate the 
localisation of an entire actuation. The technique also provides quantification of aerodynamic 
particle diameter which is much more pertinent than the calculated volume equivalent diameter 
which is often the measurement made by other techniques. There are issues with the ACI 
however, primarily the labour intensive nature of the technique. Automation of the apparatus is 
very difficult, and therefore manual operation is often necessary, and it may require a day's 
work just to deposition test four or five formulations. Furthermore nozzle damage or wear can 
lead to a significant impact on deposition performance as it upsets airflow dynamics. While 
stage mensuration is performed regularly in the pharmaceutical industry to validate nozzle 
parameters, it is undeniable that the whole concept of inertial impaction is dependent upon the 
calibration of the ACI apparatus, and any deviation will bias results. It is also worth highlighting 
that while the technique is often considered as an 'in-vitro' lung model, it is actually far from· 
representative. There is no accommodation for the principal variants of humidity, temperature 
changes, and flow rate variability that are significant factors 'in-situ' inhaler use. However this 
should not be considered a critical shortcoming, as the facility to identify aerodynamic particle 
diameter remains a significant tool in assessing the promise of a inhalation formulation (and 
device). 
The ACI in particular was designed f ~ r r testing of pMDls at a standardized flow rate of 28.3 Llmin 
and therefore is suited particularly for work with this inhaler type. DPI testing with an ACI is less 
frequent as the requisite higher flow rates ("'60 l/min) requires modification of the device, but is 
still possible. Other variations on impactors do exist, such as the more modern Next Generation 
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Impactor (NGI) and Multi Stage Liquid Impinger (MSLI). Each has its own benefits and drawbacks 
but the standardisation of the ACI by both the United States Pharmacopeia (USP) and European 
Pharmacopeia (EP) for inhalation formulation testing has made it a rock bed of regulatory and 
therefore investigatory testing. 
2.3.6 High Performance Liquid Chromatography 
High-performance liquid chromatography (HPLC) is a technique used for the quantitative 
analysis of drug formulations. As a chromatography procedure HPLC relies on the controlled 
separation of chemical mixtures. The technique begins with a liquid mobile phase, pumped at 
pressure through a small diameter column (3-10llm) filled ~ i t h h a specific stationary phase. The 
analyte of interest is passed through the column after injection into the mobile phase and 
separation of the mixture occurs according to the relative ease of progression of the analyte 
components through the stationary phase. The column elute is then analysed by uV 
spectroscopy (or other means) and the peaks corresponding to the constituents of the mixture 
can be solved and quantified according to their separation as function of run-time (Watson, 
200S). Figure 2.1S shows a schematic of a basic HPLC set up and an example chromatogram. 
The progression an analyte through the HPLC column is dependent upon the physicochemical 
properties of the solute in relation to the stationary phase and the environmental conditions 
(Lough, Wainer, 1996). There are several different separation mechanisms that HPLC can 
employ. Common variations include, normal phase liquid chromatography (hydrophilic. 
stationary phase with non-aqueous mobile phase), reversed phase liquid chromatographY 
(hydrophobic stationary phase with a polar aqueous mobile phase), ion-exchange liquid 
chromatography (charged stationary phase for charge based separations) and Size-exclusion 
liquid chromatography (stationary phase based pore size exclusion of ana/yte). Tailored to the 
separation mechanism employed, a variety of other variables can be altered to best separate 
and define a pharmacological compound including mobile phase composition and flow rate. The 
mobile phase is normally pumped through the column at flow rates of between 1-10ml/min, 
and if the composition of this phase is kept constant then the method is termed 'isocratic'. 
However it is possible to alter the composition with time to generate a 'gradient' elution, if 
retention times of the various components in an analyte would otherwise show dramatically 
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different retention times i.e. by increasing the polarity of a solvent during normal phase 
liquid chromatography to speed up the elution time of polar solutes (Lindsay 1992). 
HPLC is a readily automated process that allows for a very precise and controlled sample 
introduction which in turn ensures quantitative precision. With a variety of column 
types and easily adjustable flow and environmental conditions it has a wide application 
in pharmaceutical quantification. However there is the prerequisite that samples be 
extracted from their formulation prior to analysis i.e. into solution, which rules out an 
'in-situ' or as received measurement of inhalation products. Furthermore to best 
elucidate the quantities of multiple components of increasingly complex chemical 
mixtures requires more and more significant method development. 
2.3.7 Desorption Electrospray Ionization Mass Spectrometry 
Desorption Electrospray Ionization Mass Spectrometry (DESI) is a mass spectrometry technique 
where either solid or liquid samples can be ionized under ambient conditions without any 
special sample preparation. The technique is based around the use of an ,electrospray emitter to 
generate a cloud of charged microdroplets of a chosen solvent. This is in turn directed by a high 
velocity gas jet at a surface of a sample of interest. Subsequently the m,olecules at the surface of 
the sample are desorbed and ionized before being desolvated and drawn up into a mass 
spectrometer (Chernetsova, Morlock, 2011). This principle is highlighted in figure 2.16. The 
facility to raster the sample stage, allows that the technique be employed to produce a chemical 
Image map of an untreated or unaltered surface area. Similar to ToF-SIMS mapping analysis, a 
hyperspectral image can be generated as the electrospray is directed across the sample surface, 
from the mass spectrometry data. However the technique does suffer limitations in a role as an 
imaging tool. Its predominant use has been in bioanalytical work with a heavy emphasis 01'1 
method development and small signal mapping. In terms of broader pharmaceutical research 
there are some barriers to its use. Fundamentally due to the nature of the technique being 
based around incident solvent droplets, there are several issues relating (particularly) to the 
surface desorption process. Firstly electrospray generation may obliterate the analytical surface 
(i.e. pharmaceutical powders) via the inert gas propulsion or simply via extensive solvent 
92 
Chapter 2 - Materials and Methods 
Q.) 
v 
c: 
IV 
-,::, 
c: 
~ ~
.Q 
« 
HV Power Supply 
Sample 
• 
•• • Spray Droplets -- •••••• 
••• •• 
Surface 
A 
Inlet of Mass Spectrometer 
... _________ FreelyMoving _________ .... ~ ~
Sample Stage 
B 
100 303.4 
187.3 
281.5 
50 
255.5 327.4 834.4 
885.4 
788.5 
888.5 
0 
m/z 200 400 600 800 
Figure 2.16 A) Schematic of DESI in operation (Prolisa Inc.) and 8} an example point mass spect rum (Rao 
et al ., 2012) 
93 
Chapter 2 - Materials and Methods 
desorption. The technique can be tailored to try and reduce this effect, and with method 
refinement samples may only loose subnanogram amounts. But more problematic is the 
consistency of the desorption process. There is a heavy dependence of electrospray dynamics 
on numerous experimental variables (solvent choice, spray to sample distance, sample to 
spectrometer distance, gas pressure, spray angle, collection angle and solvent flow rate etc.). 
One particular consequence is that spatial resolution is currently not capable of exceeding 
around 200-250j.lm at best, and that the mass spectra produced may differ unpredictably by 
virtue of the electrospray to surface interactions (Chernetsova, Morlock, 2011). However an 
ambient· mass spectrometry mapping. facility can be seen as very useful complimentary 
technique to more commonplace pharmaceutical analytical methods such as Raman 
spectrometry, atomic force microscopy and ToF-SIMS. 
2.3.8 Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) is a thermoanalytical technique used to identify changes 
in the physical state of a material by its concurrent release or absorption of heat. It is a useful 
tool in looking at the phase transitions a material undergoes, as a means of event qualification 
or indeed quantification (enthalpies). It can be applied simply to look for differences in sample 
to sample behaviour, or in more sophisticated fashions to investigate very subtle physical 
changes and material behaviours. Modern differential scanning calorimeters function bY 
measuring the differential heat flow required to maintain a sample of interest and an inert 
reference at the same temperature. The sample and reference are heated by different heat 
sources, and as a scanning temperature gradient is increased at a pre-determined rate, anY 
differences in temperature between the two that develop as a result of exothermic or 
endothermic physical transitions (of the sample) are accommodated for by adjusting the heat 
flow to the sample to remove this difference. By plotting the difference between the heat floW 
to the sample and reference, against time or temperature a DSC thermogram can be produced 
(figure 2.17) that will identify the phYSical transitions the sample underwent through heating. 
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Figure 2.17: A DSC thermogram of Beclomethasone Monohydrate, showing the scanning differential 
heat flow adjustment to the sample with respect to a blank reference. 
In this figure, endothermic transitions are observable as downward peaks and exothermic 
transitions would be seen as upward peaks. The temperature at which these peaks occur can be 
associated with phase transition events, such as the melting point of a substance, and it is 
Possible to measure the enthalpy of these events. However more succinct changes in physical 
state can also be identified such as the molecular rearrangement of a material, for example glass 
transition and crystallization events, chemical reactions such as fusion reactions or 
decomposition behaviours such as desolvation etc. The reversibility of the events observed may 
also be investigated by cycling the temperature range through an event before cooling, and 
repeating the temperature ramp, and in so doing better defining the events under 
consideration. 
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2.3.9 X-Ray Powder Diffractometry 
X-ray powder diffractometry (XRPD) is a technique that is employed to reveal detailed 
information about the chemical composition and often the crystallographic structure of 
pharmaceutical powders. X-rays are short-wavelength (0.01 to 10nm), high energy, 
electromagnetic pulses (waves). As such, they can be described as an oscillating electric field 
with a perpendicular oscillating magnetic field (Jenkins, Snyder, 1996). The oscillating electric 
field can couple to charged electrons surrounding atoms and cause them to accelerate (or 
sometime decelerate). If any of the incident energy is reradiated (as accelerated electrons 
decelerate according to quantum physics) scattering has occurred. It is possible to observe the 
diffraction of the incident X-rays as a consequence of scattering. If the scattering of photons is 
elastic in nature i.e. resultant photons are of the same energy as the incident photons 
(Thompson or coherent scattering) then it becomes possible to collect the scattered X-rays as a 
function of the angle of incidence (theta) and use this data to infer the chemical and 
crystallographic structure of a powder (Jenkins, Snyder,1996). Scattered waves from different 
atoms will interfere constructively or destructively depending upon the spatial arrangement 
between the scattering atoms and the wavelength of incident light. Highly organised crystal 
structures (i.e. 3D crystal lattices) with a series of parallel planes with material specific distances 
between them, will induce much more co-ordinated interference, subject to Bragg's Law, giving 
rise to a unique pattern of well-defined peaks as theta changes. As such it is possible to 
determine from the level of interference observed, the degree of ordered structure 
(crystallinity) but also from where these peaks occur as theta varies to infer the specifiC 
polycrystalline elements that define the unique form of the powder being analysed. 
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3.0 Application of the CAB Approach to Inhalation Materials 
with 'Non-Ideal' Surfaces 
3.1 General Introduction 
3.1.1 Limitations of the Cohesive Adhesive Balance 
The CAB approach, as highlighted in chapter 1,. is subject to limitations in its analytical 
application to inhalation technologies. It cannot be forgotten that the CAB is based on AFM 
methodology and therefore suffers the same inadequacies which distort all AFM results such as 
drift, hysteresis, creep, etc. (Butt et ai, 2005). However outside of experimental error, what can 
be considered the most significant limitation of the approach is the necessity for smooth 
(typically crystalline) surfaces to perform measurements upon (Jones et ai, 2008a). The 
fundamental principle of the CAB approach demands that the surfaces of cohesion and adhesion 
should be morphologically Identical. This is so that with the same particulate tip, the same 
geometry of contact is achieved across both surfaces and therefore the only remaining variable 
in force determination will be chemical attraction (Begat et ai, 2004a). The only way to ensure 
this has been to use crystalline material with validated surface homogeneity and surfaces not 
exceeding a root mean square roughness of lnm (Rq). I.e. this negates the impact of geometrY 
on particle-surface force interaction, and validates the CAB approach as a means of force 
quantification in an 'ideal' model but is problematic when applied to rougher surfaces and 
materials with multiple crystalline faces of different surface properties. 
3.1.2 pMDI Formulation Topographies 
Crucially such CAB methodology is not an accurate representation of particle morphologies 'in-
situ'. Firstly as described in chapter 1, real parti,cles in inhalation formulations are typicallY 
micronized to generate a respirable particle size. As a consequence of the destructive nature of 
the micronization processes commonly used, there are generated many particles of high surface 
area, increased amorphous content, high surface energies and cohesive tendencies (Lohrmann 
et ai, 2007). Importantly these resultant particles also exhibit significant topographical 
roughness. It is therefore possible that a CAB balance developed using model crystalline 
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substrates, may not be a realistic appreciation of a force balance 'in-situ' because of the 
inherent lack of accommodation for the geometries of the particle-particle or particle surface 
contact regimes that are occurring. Secondly, the device materials used to house the inhalation 
formulations are of prime consideration when considering critical particle surface contacts in 
formulation. Poorly controlled adhesive interaction between the components of pMOls, such as 
the API and device materials (valve components, metering chamber, canister walls etc.) or other 
excipients can lead to flocculation in suspension systems, crystallization in solution systems, and 
inappropriate respirable particle size upon actuation. (Begat et ai, 2004b, Traini et ai, 2006, 
Traini et al 2005, James et ai, 2007, Eve et ai, 2002). Equally within OPls, uncontrolled 
interactions between a carrier particle and API may lead to heterogeneous powder mixing, poor 
dose uniformity or ineffective association/dissasociation of the carrier and API on inhalation. 
Such problems have long been recognised by manufacturers of inhalation formulations and 
significant work has gone into first describing and then combating inappropriate interactions 
within f o r m u l ~ t i o n s s and between the formulation and delivery devices. Various techniques have 
been employed, and regarding the potential for device-formulation interactions, strategies such 
as canister wall coatings have been developed. The principle here is that a tough but chemically 
and electrically inert, smooth coating to the metalwork, will, reduce interactions with the 
formulation components, reduce dose loss, and as a consequence improve dose reproducibility. 
One such example is the use of a fluorinated ethylene propylene (FEP) canister coating (3M 
Healthcare Ltd). In this instance the fluorocarbon derived polymer coating will show greater 
stability due to the many carbon-fluorine bonds (partial ionic character), and will be highly, 
chemically resistant through a reduction in dispersive van der Waals forces. This reduction is 
due to the electronegativity of the fluorine atoms rendering the molecules much less 
susceptible to transient polarization and dipole formation. However, despite the performance 
improvements such coatings, or selective material components can offer, they remain 
macroscale surfaces, that are factory made and will never exhibit uniform surface roughness on 
a microscale equivalent to that of a molecular crystal face. 
As such the CAB approach cannot be utilized in its purest form to model the force balances 
between APls and Inhaler components. It would be particularly useful if the model could be 
adapted from model pharmaceuticals to the materials that compose the device and formulat,ion 
themselves. In such fashion the efficacy of various coatings and indeed other device materials 
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could be examined with respect to the cohesive-adhesive tendancy of a particular API or 
excipient. 
3.1.3 Interpreting data from Recrystallized Substrates 
Being unable to account for the influence of contact geometry within the CAB approach is 
tolerated because a fundamental force balance based on chemical attraction can thereby be 
extracted from the materials in use. This should in principal be a constant driving factor behind 
the adhesive or cohesive interaction between two components. However beyond the disparitY 
between real material surfaces and recrystallized model surfaces in terms of developing 
reproducible contact geometries, there is also the possibility that recrystallized API surfaces 
used to model API force balances can in themselves be misleading in deriving a 'true' force of 
adhesion or cohesion. Different crystal faces exhibit different surface energies depending upon 
the molecular orientation at that given surface (Muster & Prestidge, 2002). The presentation of 
these surfaces will depend upon the crystal habit of the material being processed, which is in 
turn known to develop depending upon a multitude of variables inherent to the recrystallization 
process such as the levels of supersaturation, level of impurities" crystallization process 
parameters (e.g:, stirrer speed) and the solvents and antisolvents utilized in crystallization 
(Mullin, 2001). Of particular note Hooton et al. (2008) showed that by using two different 
solvents, N,N-dimethyl-formamide (DMF) and ethanol, two distinct habits of budesonide crystalS 
could be formed. These two habits exhibited dominant faces of different. molecular 
presentations, which in turn showed significantly different CAB ratios, although not rank 
affinities, when probed with a range of carrier APls. The dominant face of the DMF solvated 
crystal exhibited a CAB ratio approximately twice that of the dominant face from the ethanol 
solvated crystal. Therefore it is apparent that the force balance acquired using the CAB 
approach and model crystal substrates may be very sensitive to the recrystallization process 
used to develop the substrates. 
It would therefore be expected that AFM measurements on the different energy faces of model 
crystalline substrates could underestimate or overestimate the fundamental forces of cohesion 
and adhesion (Jones et ai, 2008a). This has wider implications in that, as has been alluded to In 
several studies, the very handling of the tip material and substrate will in itself lead to changeS 
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in the force measurements made. This may be through providing different crystal habits 
(Hooton et ai, 2008) or any other chemical or physical difference (Jones et ai, 2008b). Whilst the 
, CAB technique has already proven that it is capable of deriving functional adhesive relationships 
that can be linked to 'in-vitro' performance data in model systems, this is only of limited use if it 
cannot be applied to materials in a functional state. The assumption that a CAB approach has a 
prerequisite for molecularly flat surfaces, is justified theoretically, but what is not known is to 
what extent increases in surface roughness can be accommodated. Whilst a purely accurate 
chemical force balance description may not be generated if rougher surfaces are used, it 
remains possible that the a CAB plot might still hold true enough to imply a linear relationship 
that can function to describe the force balance in a 'non-ideal' formulation better than that 
from a recrystallized model system. 
3.1.4Clathrates 
Drug particles in the presence of CFCs or HFAs, have a tendency to form clathrates over time 
within formulation (Phillips, Byron, 1994). Clathrates are solid solutions that occur through the 
hydrogen bonding of host molecules within a structure that, via the creation of cavities in the 
crystal lattice, are capable of encaging a variety of guest molecules (Englezos, 1993). They are 
considered an 'inclusion compound' where two molecular species have arranged themselves so 
that one entraps the other (Englezos, 1993). The host molecules hydrogen bonding forms a 
regular 3D network with repetitive cavities, while an appropriate guest molecule will occupy a 
cavity either completely or partially and contributes to the physiochemical nature of the 
compound (Plum ridge, Waigh, 2002). Previous work into the stability and energetics of 
clathrates in inhaler formulations has identified that the clathration of propellant molecules 
within an API has led to greater thermodynamic stability of the compound and reduced surface 
energy (Bouhroum, 2009). This raises the possibility that certain clathrates may in fact be the 
most desirable polymorph for formulation development in inhaled products. Furthermore it is 
known that certain clathrates crystallize with large flat accessible surfaces e.g. Beclomethasone 
Dipropionate CFC-ll clathrate (Bouhroum, 2009). There is therefore interest and on-going work 
into the potential of clathrates in aerosol based formulation development, and significantly 
these molecular entities may offer an appropriate substrate for investigatory CAB studies. 
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3.2 Chapter Aims and Objectives 
3.2.1 Chapter Aim 
The aim of this chapter was to investigate the application of the CAB approach to a broader 
range of 'non-ideal' inhalation based products, including c1athrated entities, assessing whether a 
useful force balance could still be generated and if the CAB approach would still hold true. In 
such fashion, to determine to what extent the approach can help better characterize 
interparticulate interactions within inhalation formulations on an API-API'/ excipient or API-
component basis. 
3.2.2 Chapter Objectives 
The objectives of this chapter were as follows: 
To investigate the surface morphological properties of a common API, 
Beclomethasone Dipropionate, and two of its polymorphs; a CFC-ll and IPA 
clathrate 
To investigate the surface morphological properties of three key pMDI componentSi 
an FEP coated canister wall, an uncoated canister wall and the metering chamber. 
To investigate the force of interaction between the BOP APls and the pMDI 
components. 
To determine whether the CAB approach can be applied to such as received 'non-
ideal' micronized powders and inhaler components and generate a legitimate force 
balance. 
To assess the necessity for molecularly flat surfaces in validating the CAB approach. 
To characterize the structure and physicochemical behaviour of c1athrated APls 
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3.3 Materials and Methods 
3.3.1 Materials 
Beclomethasone Oipropionate (BOP) was chosen for use within this study due to its frequent 
use as an ICS in inhalation formulations and its known ability to clathrate in a variety of solvents. 
Micronized anhydrous BOP was purchased from Sicor (UK). The two solvents chosen for use 
were tricholorofluoromethane (CFC-11), supplied by Arkerma (UK), and isopropyl alcohol (IPA), 
supplied by Sigma-Aldrich Company Ltd (UK). These two solvents were known to generate 
inclusion compounds with BOP (Bouhroum, 2009). All other chemicals were purchased from 
Sigma Aldrich unless otherwise specified. The inhaler components used (uncoated aluminium 
canisters, fluorinated ethylene propylene (FEP) coated aluminium canisters and stainless steel 
metering chamber) were supplied by 3M Healthcare Ltd (Loughborough, UK). 
3.3.2 Methods 
3.3.2.1 Preparation of BOP Clathrates 
The preparation of clathrates was based on the process described by EM Philips (Philips, Byron 
1994). Both the 1.67% w/w BOP CFC-ll clathrates, and 3% BOP IPA clathrates were synthesized 
at room temperature by suspending the anhydrous BOP in the relevant propellant in a pressure 
resistant vial. This mixture was then shaken using a Stuart SFl Flask Shaker at 800 oscillations 
per minute for 2 hours. The resulting suspension was refrigerated for 24 hours before repeat 
vacuum filtration through a Buchner filter to obtain the crystals. Excess propellant was removed 
passively by evaporation for 24 hours at room temperature. 
3.3.2.2 AFM Tip Functionalization 
Contact mode DNP-S (short, thick) tips (BrukerNano, Coventry, UK) were used for 
functionalization. These tips are designed to have low spring constants (k ... 0.35 N/m) for very 
sensitive s u r f ~ c e e responses. In this study they were chosen because it was assumed that the v 
shaped cantilever would perform better as a functionalization scaffold, and that the lower 
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spring constant would be more sensitive to the functional particle-surface interactions. The 
resonant frequency and Q values of each tip were determined using the in-built AFM software 
(01 EnviroScope, NanoScope lila Controller, NanoScope version S.30 software, BrukerNano, 
Coventry, UK) for each cantilever before they were functionalized and the spring constants 
calculated by Saders method (Sader et aI, 1999). Nine functionalized tips were prepared in total, 
3 with anhydrous BOP, 3 with BOP CFC-ll clathrates and 3 with BOP IPA clathrates. In each 
instance the cantilevers were functionalized using the EnviroScope AFM. An epoxy resin (Loctite, 
Henkel Ltd, Hatfield, UK) was applied to a silica disk and placed onto the AFM stage. A sacrificial 
AFM tip was used to draw thin lines of the adhesive from bulk. The blank cantilevers were 
placed in the tip holder and manually lowered on to these glue strands until contact was 
observed via laser deflection or visually, then removed. The resin substrate was then removed 
and replaced with the appropriate powder sample. Using the AFM microscope small individual 
powder particles/crystals were resolved, identified and aligned with the position of the tip. The 
cantilever was then lowered manually onto the powder particles for attachment and then 
removed. The functionalized tips were left to dry for 24 hours. Successful tip functionalization 
was confirmed by low vacuum SEM imaging as described below. 
3.3.2.3 Scanning Electron Microscopy (SEM) 
The particle sizes and morphology of the anhydrous BOP, the BOP IPA clathrates and the BOP 
CFC-ll clathrates were imaged by a JEOL JSM-6060LV scanning electron microscope (JEOL Ltd, 
Tokyo, Japan) at various magnifications under vacuum. Powder samples were sprinkled ontO 
carbon stubs, lightly pressed with a glass cover slip, then nitrogen gassed to remove any excess. 
These stubs were sputter coated (Balzers Benchtop Sputter Coater SCO 030) with gold in an 
argon atmosphere (SOPa) at 30 mA for 4 minutes before SEM imaging. The pMOI componentS 
(FEP coated aluminium canister, uncoated aluminium canister and stainless steel metering 
chamber) were cut from bulk and then attached directly to carbon stubs and imaged in the 
same apparatus but without sputter coating, to preserve the samples for use. Imaging waS 
therefore carried out in low vacuum mode. All the BOP CFC-ll, BOP IPA and anhydrous BOP 
functionalized tips (3 of each) were also imaged both prior to and afte'r use in the SEM, to 
characterize successful functionalization and subsequent changes to morphology that might 
influence results. The tips were placed on a sliver of silica gel attached to a carbon stub. TheSe 
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were not sputter coated to allow use after imaging, and subsequently low vacuum mode was 
used. 
3.3.2.4 Differential Scanning Calorimetry (DSC) 
A TA Instruments DSC 2920 differential scanning calorimeter (TA Instruments, Delaware, US) 
was used to perform all DSC work. The DSC was used to help confirm the BOP clathrate 
synthesis, and the purity of the parent sample. This was achieved by determining the phase 
transitions of anhydrous BOP, BOP CFC-ll clathrates and BOP IPA clathrates. Accurately weighed 
samples of about 6 mg were sealed in aluminium hermetic pans, equilibrated at O·C, kept 
isothermal for 3 minutes and then heated at 10·C per minute under nitrogen to 300·C. DSC 
cycles were also performed on BOP CFC-ll clathrates and BOP IPA clathrates to check for 
reversibility of the phase transitions observed. In these instances accurately weighed samples of 
the two clathrate powders were again placed in sealed aluminium hermetic pans. The DSC was 
then equilibrated at O·C for three minutes and ramped at 10·C per minute to 150·C, at which 
point the temperature was then cooled by 20·C per minute to O·C before re-heating at 100C per 
minute to 220°C. Thermograms produced were analysed using TA universal analysis -NT 
software (TA Instruments, Delaware, US). 
3.3.2.5 X-Ray Powder Diffraction (XRPD) 
A Bruker 08 diffractometer (Bruker AXS, Madison, W1, USA), operating in a Debye-Scherrer 
. geometry, was used to collect XRPD patterns of the synthesized BOP clathrates. A ceramic X-ray 
tube with a copper target, wavelength A = 1.54059 A, equipped with a scintillation detector was 
operated at 40kV, 40mA to generate x-rays. Samples were filtered through a 1 J,.lm sieve before 
loading into a 0.7mm capillary tube. These tubes were then attached to a goniometer and 
visually aligned, before placement in the diffractometer. A BOP CFC-11 clathrate sample was 
analysed by XRPD to compare with the reported crystal structure and calculated diffractogram 
(Cambridge Structural Database) to prove synthesis. The sample was run for 24 hours, collecting 
1 diffractogram per hour. These diffractograms were plotted, merged and analysed using 
Xmgrace (Grace Development Team, Boston, US). 
107 
Chapter 3 - Application of the CAB Approach to Inhalation Materials with 'Non-Ideal' Surfaces 
3.3.2.6 Atomic Force Microscopy (AFM) 
AFM imaging was carried out using an EnviroScope AFM with a NanoScope lila Controller 
(BrukerNano, Coventry, UK) on the surface of all the CAB substrates to visually qualify surface 
topography and morphology before quantifying the microscale roughness. Images were 
performed in tapping mode AFM using TAP300 tips (BrukerNano, Coventry, UK). Images were 
taken at a scan size of Sllm x 5 Ilm, and at a scan rate of 1Hz. Surface roughness was determined 
using NanoScope 7.3 software (BrukerNano, Coventry, UK) and quantified using the arithmetiC 
mean (Ra) and the root mean square (Rq) of the average height deviations measured from the 
topographical data. 
AFM force data acquisition was performed on the same apparatus. In this instance the 
environmental chamber was used to maintain a relative humidity as close to 0% RH as possible 
to minimize the influence of capillary forces (Hooton et ai, 2004). At no point was the humidity 
allowed to rise above 5% RH. The functionalized tips were placed into the tip holder, opticallY 
aligned and then challenged to five sample surfaces using a defined set point voltage once the 
humidity chamber had reduced the humidity to an acceptable value. The samples were ordered 
as follows; the corresponding powder sample of the tip material (first cohesive measurement), 
followed by the FEP coated aluminium canister, the uncoated aluminium canister, the stainless 
steel metering chamber (adhesive measurements) and then a repeat of the powder sample. ThiS 
repeat cohesive measurement was used to either identify any significant changes that might 
implicate tip destruction or alteration, or highlight critical inherent variability of adhesive force 
genesis. Ten force curves were collected per tip at randomly selected sites over the sample 
surface at a scan rate of 1Hz. The Fadh/Fcoh was recorded by ramping the substrate surface intO 
and out of contact with the cantilever and measuring the deflection of the cantilever. Hooke'S 
law was then applied to the recorded values with the calculated spring constants of the tips and 
a quantitative measurement of the forces of adhesion/cohesion obtained. The cohesive and 
adhesive forces were then analysed using Begat et ai's (2008a) cohesive-adhesive balance 
approach outlined previously. 
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3.4 Results 
3.4.1 Characterization of Beclomethasone Dipropionate and the Beclomethasone 
Dlpropionate Clathrates 
3.4.1.1 SEM Analysis 
SEM images of the anhydrous BOP, the BOP CFC-ll clathrate and the BOP IPA clathrate are 
shown in figures 3.1,3.2 and 3.3 respectively. The scales presented are not consistent due to the 
significantly different particle sizes between the BOP particulates, but were chosen to best 
illustrate and allow description of the powder morphologies and topographies. The anhydrous 
micronized BOP (fig. 3.1) shows the most irregular and amorphous particle structure, with a 
particle size distribution of between 2j.lm - 40j.lm and consistent aggregation. The BOP CFC-ll 
clathrate (fig. 3.2) is readily identifiable as repeating hexagonal crystals with a large size 
distribution of Sj.lm-8Sj.lm and what appear to be well defined smooth surfaces. Some small 
cracks in these crystal faces can be seen across a large number of the particles imaged, and 
these were found at various sites across the sample in multiple Images. Notably, these well-
defined crystals have distinct faces, namely a predominant hexagonal face (fig. 3.2 BOP CFC 3) 
and a lateral more rectangular crystal face (fig. 3.2 BOP CFC 4). The BOP IPA c1athrates 
demonstrated a much less reproducible crystal structure with a flatter, fractured plate, irregular 
and more clustered morphology. Particle size distribution was in the region of 2-30j.lm (fig. 3.3). 
109 
Chapter 3 - Application of the CAB Approach to Inhalation Materials with 'Non-Ideal' Surfaces 
I ' ! R R ~ - " ' " " Initru men .JS""-6060 
heel Vol :\I) 10 
Photo iii 9 ~ . . 1 0 0
SEI 
WO 48 
$p S 40 
P 
o te 2009-02·09 
InstrumenI JSM·f,060 ( A ~ . . ~ ~ . r ' ' ; ; c ~ ~ ~ ~ ~ ; ; " 7 7 " " " - ' ~ " - " ' '
1 I I Y Y - ' ' I & . ' ~ ~•• ,}.-G"''''''IIoo'' PholO Ii( 9 117.340 
SEI 
WO 30 
SPO! 5 % ~ ~
-............ . P 
o tt 1009-02·0 
I st/umonIJSM·6060 
Ale I VOl 13 
PhOlO l.I \) x4,100 
SEI 
.... '0 26 
SPOl $j% 50 
P 
Delt 1\)09·02·09 
Figure 3.1 SEM images of the Anhydrous Beclomethasone Dlproplonate powder particles at 
various magnifications (as labelled) 
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Figure 3.2 SEM Images of the synthesized BOP CFC-ll Clathrate powder particles at various 
magnifications (as labelled) 
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Figure 3.3 SEM images of the synthesized BOP IPA clathrate powder particles at various magnifications 
(as labelled) 
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3.4.1.2 X-Ray Powder Diffraction Analysis 
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Figure 3.4: X-Ray Powder Diffractograms for the observed synthesized BOP CFC-ll Clathrate and the 
calculated Cambridge Structural Database reference. 
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Figure 3.5: X-Ray Powder Diffractogram for the synthesized BOP IPA Clathrate 
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A merged diffractogram (compiled from 24 diffractograms of 1 hour run time each) of the 
synthesised BOP CFC-ll clathrate is presented in figure 3.4. The calculated diffractogram from 
the Cambridge Structural Database is presented alongside as a reference to validate successful 
synthesis. Characteristic peaks for the BOP CFC-11 clathrate are known, and can be seen on the 
reference diffractogram to be at 2 Theta values of 7.2,8.5,9.6,11.2,13.8,16.8 and 18.5". While 
an x-ray powder diffractogram was compiled for the BOP IPA clathrate in fig 3.5 there does not 
exist a reference diffractogram for comparison, which would have allowed confirmation of 
synthesis. 
3.4.1.3 Differential Scanning Calorimetry 
Representative OSC thermograms for anhydrous BOP, BOP CFC-11 clathrate and BOP IPA 
clathrate are shown in figure 3.6. All traces for anhydrous BOP show a single endotherm at 
around 213·C (fig. 3.6 A), which corresponds to the literature melting point of BOP (212·C). The 
traces for the BOP CFC-11 clathrates (fig. 3.6 B) exhibit this melting event, but also a consistent 
exothermic event at 91.2·C, immediately before another endotherm at 94.6·C. The BOP IPA 
thermograms (fig. 3.6 C) also show the melting endotherm and another broader endothermiC 
transition maximizing at about 142"C, although no exothermic event was evident prior to this. 
Figure 3.7 shows cycled OSC traces where samples of the BOP CFC-11 clathrate and BOP IPA 
clathrate were heated to just below the observed melting point of BOP, before the temperature 
was cycled back to O·C and then re-ramped to sample melting. This process was designed to 
investigate whether the energetic events seen prior to melting in both samples, were 
reproducible or irreversible. As can be seen in these traces, these events· did not reoccur upon 
the reheating process. 
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Figure 3.6: OSC heating thermograms of (A) anhydrous BOP, (B) BOP CFCll clathrates and (e) BOP IPA 
clathrates. 
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Figure 3.7 Cycled OSC heating thermograms of (A) BOP IPA Clathrate and (B) BOP CFC-ll Clathrate 
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3.4.1.4 Atomic Force Microscopy Imaging 
Height and phase tapping mode AFM images of the BOP clathrates and anhydrous BOP are 
shown in figure 3.B. These images were all captured over a spatial area of S ~ m m x Sj.lm, to allow a 
direct comparison in root mean square and arithmetic mean roughness values as calculated by 
the instrument software. As observed in the SEM images the BOP CFC-11 clathrate has two very 
distinct crystal faces (dominant hexagonal face and lateral rectangular face) these were 
therefore both imaged separately to report any differences in surface roughness. The average 
calculated root mean square (Rq) and arithmetic mean roughness (Ra) values derived from the 
image analysis are displayed in table 3.1. The Rq roughness is generally accepted as being the 
most reliable indicator of surface roughness and is a statistical measure of the magnitude of a 
varying height. It was determined from the topographical AFM images by the instrument 
software via the following equation (James et ai, 200B): 
1 ~ n n 2 Rq = ;; "-'1=1 Y, (3.1) 
Where n is the number of points in the topography profile, i is the asperities and Yt is the 
distance between the asperities. The Ra is less often used in AFM based work but has been 
applied in many other fields and reflects the mean of the height variation around a zero pOint on 
a sample surface and is given by the following equation (James et ai, 200B): 
1 ~ n nRa = ;; "-'1=1 Y, (3.2) 
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Fig 3.8: Sl!m x Sl!m Tapping mode AFM height (left) and phase (right) images of (A) Anhydrous BOP powder bed, (e) 
BOP CFC-ll clathrate particle main face, (e) BOP CFC-ll clathrate particle lateral face and (0) BOP IPA clathrate 
particle face 
118 
Chapter 3 - Application of the CAB Approach to Inhalation Materials with 'Non-Ideal' Surfaces 
SAMPLE ARITHMETIC MEAN ROUGHNESS ROOT MEAN SQUARE 
(Ra) (nm±SD) ROUGHNESS 
(Rq) (nm±SD) 
ANHYDROUSBDP 91.9 ±39.0 117.6 ±S3.1 
BDPCFC-ll 9.7 ±7.7 12.0 ±8.7 
CLATHRATE 
(COMBINED FACES) 
BDP IPA CLATHRATE 22.3 ±6.6 29.S ±7.0 
Table 3.1: Arithmetic mean roughness and root mean square roughness values for Anhydrous BOP, BOP 
CFC-ll Clathrates and BOP IPA Clathrates over a SJ,lm x 5 J,lm area. 
Both the lateral and main faces of the BOP CFC-ll clathrates were seen to be very flat with little 
variation in surface topography; all of the topographical features were 100nm or less in height 
(figs. 3.8 B, 3.8 C). On the main face of the crystal, small spherical indents could be seen in the 
topographic image, and these features showed a difference in phase. These indents were 
consistent across the set of images and did not appear to be artefacts of the imaging technique. 
On the lateral face a series of linear fractures can be seen topographically on an otherwise 
smooth surface. There is little phase difference, and it is likely these are attributable to either 
cracks in the crystal face corresponding with those seen on the SEM images of the BOP CFC-ll 
clathrates (fig. 3.2) or features related to steps in the crystalline surface. The images of the BOP 
IPA clathrate crystals (fig. 3.8 D) showed a consistent topography of irregular nanoscale 
Undulations in the region of SOOnm. Anhydrous BOP showed a similar topographical pattern to 
that of the BOP IPA clathrates, with repeating rising and falling plateaus (fig. 3.8 A). The size of 
these features were however larger than those of the BOP IPA clathrate, with a maximum 
variability of 11lm. The data in table 3.1 shows the calculated average Ra and Rq roughness values 
from the set of AFM images collected for each of the three API materials. From this data it is 
apparent that the anhydrous BOP has by far the roughest surface (Rq 117.6nm), with the 
clathrated samples showing somewhere between a 5-10 times smoother microscale 
topography. The BOP CFC-ll clathrate had the smoothest surface (Rq 12.0nm) in agreement 
With the SEM images obtained (fig 3.2), and the BOP IPA clathrate remained significantly 
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topographically smoother (Rq 29.5nm) than the parent powder, in conjunction with the larger 
more regular crystal shape that was apparent. Both the clathrates also showed significantly less 
variability in surface roughness across images than the anhydrous parent power, as 
demonstrated by the s t a n d a ~ d d deviations about the mean Rq values. 
3.4.2 Characterization of the pressurized metered dose inhaler components 
3.4.2.1 SEM Analysis 
SEM images of the selected pMDI components (FEP coated canister, uncoated canister and 
metering chamber) are shown in figure 3.9. The FEP coated canister (fig. 3.9 A) shows a very 
homogenous microscale surface with few surface artefacts on the surface coating. The layering 
of the FEP coating can be seen as a sweeping effect across the images with some small degree of 
height variability. However, it is worth noting that the fluorinated coating was not always 
continuous across all images and in some cases, a degree of absence was recorded, leading to a 
rougher surface with significant depressions. The uncoated canister (fig. 3.9 B) displayed a 
rougher surface with more consistent topographical variability. Some regions of the canister 
appeared rougher than others with evidence of significant microscale imperfections in the metal 
working. However of the three materials the metering chamber appeared to have the least 
homogeneous surface by SEM analysis (fig. 3.9 C). Multiple micrometre sized holes, scratcheS 
and other surface defects can be seen, probably introduced by the manufacture or finishing 
process of the component. However although more frequent and irregular than the features 
seen on the canister samples, it is difficult to define the depth of these defects given the 
limitations of an SEM image in evaluating three dimensional variability. While these defectS 
were much more common on the metering chamber than the two canister samples, they were 
not uniformly distributed, and while there were areas on the macroscale that showed significant 
surface heterogeneity, there were also others that were much less variable in the extent of their 
topographical features. 
120 
Chapter 3 - Application of the CAB Approach to Inhalation Materials with 'Non-Ideal' Surfaces 
Fig 3.9: SEM images of A) FEP coated pMDI canister 8) Uncoated pMDI canister and C) pMDI stainless 
steel metering chamber 
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3.4.2.2 Atomic Force Microscopy Imaging 
Tapping mode AFM images of the pMDI components are shown in figure 3.10 and the calculated 
Rq and Ra values are given in table 3.2. The Rq and Ra values were ascertained as described above 
from images of Silm x Silm. 
SAMPLE AVERAGE ARITHMETIC MEAN AVERAGE ROOT MEAN 
ROUGHNESS (Ra) (nm±SD) SQUARE ROUGHNESS (Rq) 
(nm±SD) 
FEP Coated Canister 18.1:t 1.3 24.7 tl.33 
Uncoated Canister 29.8:t9.4 40.0:t9.3 
Metering Chamber 15.5 :tS.4 22.8:t8.4 
Table 3.2: Average mean roughness (Ra) and root mean square roughness (Rq) values for pMDI 
components over a S ~ m z z area 
Surprisingly the stainless steel metering chamber reported the smoothest surface of all the 
components across this image size (Rq 22.8nm). The asperities seen on the surface appear to be 
sharper and less consistent in morphology than the features on the canister wall samples (fig. 
3.10 C). However, with only reaching a maximum of 100nm in height they appear less prominent 
than some of the features that occur on the canister samples. The FEP coated canister wall 
shows irregular asperities upon a generally smooth surface (fig. 3.10 A). The reported roughnesS 
values were slightly larger than those seen with the metering chamber (Rq 24.7nm), but 
significantly the standard deviations were much less, showing reduced variability across images. 
Some of these isolated 'islands' of topography reach a maximum of around 300nm in height. 
Both the coated canister and metering chamber reported smoother surfaces across this surface 
area than the uncoated canister (Rq 40.0nm), which shows a more repetitive undulating 
topography with surface features again reaching around 300nm (fig. 3.10 B). 
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Figure 3.10: AFM height and 3D interpretation of (A) FEP Coated Canister, (8) Un-coated Canister and 
(e) Metering Chamber. NOTE vertical scales are NOT identical but as labelled. 
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3.4.3 Cohesive Adhesive Balance of the Beclomethasone APls and the pMOI 
components. 
3.4.3.1 Cohesive and Adhesive Force Measurements 
The average AFM derived Fadh and Fcoh values for the anhydrous BOP, BOP CFC-ll clathrate and 
BOP IPA clathrate tip sets are shown in figure 3.11, 3.12 and 3.13. In each figure the first average 
Fcoh measurement is placed leftmost on the figure. These measurements were made prior to 
adhesive measurements on the inhaler components and represent the force of attraction 
between the functionalized tip and a surface composed of the same API as the tip particle. A 
second average Fcoh measurement taken after the adhesive measurements is shown on the far 
right of the figures. Absolute values of adhesion/cohesion are only of importance when 
considering an individual tip's cross material interactions, and largely irrelevant from tip to tip 
due to the unknown contact geometries. The tip to tip trends within a set are however of 
particular significance in comparison. 
Immediately apparent from these data is the range, and inconsistent nature of the interactive 
forces. The trend of adhesion/cohesion between one tip was rarely mirrored consistently by the 
other tips in the same series, with one tip showing an increase in interactive force from one 
material to another and a subsequent tip showing a decrease. The anhydrous BOP tips (fig. 3.11) 
for example show two separate trends, where on the first BOP and uncoated canister samples 
the three tips increase in force measurement from 1st to 3rd. However, for the coated canister, 
metering chamber and second BOP samples the 1st tips interactions are larger than the 2nd but 
smaller than the 3rd• This infers that there is not a consistent compliance to a ratio of adhesion 
force generation. Overall the metering chamber substrate showed the largest interactive force 
with the anhydrous BOP tips, with the uncoated canister second and the two cohesive 
measurements and the FEP coated canister showing similar interparticulate interactivities. The 
inconsistency in data trend is continued with the BOP CFC-11 clathrate tips (fig. 3.12). Here, 
while the tips show slightly more continuity in rank adhesion forces from tip 1 to tip 3, across 
the CAB substrates, the deviation around the average adhesion forces is very large, as shown bY 
the error bars (as standard deviation). This implicit variability makes it difficult to confirm to the 
rank adhesions with confidence and hints at significant variability around the forces of particle-
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Fig. 3.13 Mean Cohesive and Adhesive Force Values of BOP IPA tips against CAB substrates 
surface contact. In general the absolute forces of adhesion are significantly larger than those 
with the anhydrous BOP tips, in the region of two to four times greater. The metering chamber 
measurements in this BOP CFC-ll tip set evidenced significantly larger Fadh values than the other 
tip materials in comparison to the other sample surfaces especially with tips 2 and 3. 
When considering the BOP IPA (fig. 3.13) tip data, tips 1 and 3 show a consistent force 
relationship, however tip 2 does not conform consistently and the adhesive ratios with the three 
inhaler components are not replicated with the two cohesive measurements. All three inhaler 
components show very similar absolute values of adhesion with the BOP IPA tips, with some 
suggestion that the coated canister was the least adhesive surface. Once more the standard 
deviations around all the data are consistently very large, indicating a massive spread of values 
within the force measurements taken on the sample surfaces by the functionalized tips. 
Critically while comparison of the Fcoh measurements made before and after Fadh measurements 
with the BOP IPA tips, show a reproducible trend of tip to tip cohesion on similar scales, the 
anhydrous BOP and BOP CFC-ll clathrate tips do not mimic this. Instead there is a change in 
rank tip adhesion to the cohesive surface, albeit with large standard deviations that could range 
to redefine this. 
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IPA tips on the FEP coated canister 
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Figure 3.14 shows some selected box plots describing the force data generated from given tip 
sets on given substrate surfaces. These were compiled for all the tip to surface relationships to 
display and analyse the difference between the tip data sets without making an assumption of 
the statistical distribution of the Fadh data. In each plot, the bottom and the top of the boX 
represent the 1st and 3rd quartiles and the band within the box is the median (2nd quartile). The 
dot represents the mean of the data, and the ends of the whiskers represent the minimum and 
maximum force values within the data set. 
Figure 3.14 A shows the representation of the force data from the three anhydrous BOP tips on 
their second set of cohesive measurements (post adhesion measurements). In this plot the 
mean is consistently close to the median for all three tips, and the range of the force data is 
about 10nN for the first two tips and 40nN for the last. Figure 3.14 B shows the force data from 
the BOP CFC-ll tips on their second cohesive measurement. Here there are significant 
differences between both the mean and median of the first two tips and of the quantile 
measures to the range of the data from all three tips. Tip 1 shows that the mean lies above the 
3rd quartile. Figure 3.14 C shows the force data from the BOP IPA tips on their adhesive 
measurements on the coated canister. While tip 1 has a relatively close mean to median 
relationship, tips 2 and 3 do not. There is again a very great dissimilarity in the range of the data 
sets in comparison to the quartile measures. 
Figure 3.15 shows some example cohesive force curves from the functionalized AFM tips. 
Column A shows example force curves of all three tip types that were used to calculate the Fadh 
between the tips and their respective cohesive surface. Column B shows example force curveS 
of all three tip types that were rejected and required to be repeated. The blue line is the tip 
approach while the red is tip retraction. 
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3.4.3.2 CAB Plots 
By plotting the average adhesion values of each tip against the average cohesion values of that 
same tip, a CAB plot can be produced as described earlier. The cohesive values used for the 
plots were an average of the cohesive measurements made both prior to and after inhaler 
component force measurements with an individual tip. CAB plots showing the average Fadh/Ftoh 
of the anhydrous BOP and the BOP clathrates are shown in figures 3.16, 3.17 and 3.18. The 
bisecting line on each plot represents parity between adhesive and cohesive forces, where 
above this line cohesion is dominant (Fcoh > Fadh) and below, adhesion dominates (Fadh > Fcoh)' 
Once the adhesive force values from each tip have been plotted against their cohesive force 
value, the plot points were analysed for a linear fit with respect to a given substrate. Each fit is 
graphically labelled and displayed with the coefficient of determination (R2) and graphical 
equation (CAB ratio / gradient of linear fit) to show firstly how well the linear model fitted the 
data points and secondly what the dependent CAB ratio of that linear regression for tip material 
to surface was. 
Figures 3.16, 3.17 and 3.18 show that there is very little compliance to a linear fit across any of 
the data sets. There is only' one R2 value in excess of 0.7, with the remainder below 0.5. The 
a n ~ y d r o u s s BOP tip series (fig. 3.14) has two tips (2 and 3) that show more cohesive than 
adhesive character on the coated canister but then the other (tip 1) then shows the opposite 
trend (R2 0,41, y=1.31x). Two tips (1 and 2) show more adhesive character than cotiesive on the 
uncoated canister but, the other tip (3) again reverses this trend (R2 0.59, y=0.95x)). Notably in 
this instance tip 1 lies very close to the bisection that represents adhesive and cohesive force 
parity. All three tips do show greater adhesive character than cohesive with respect to the 
metering chamber, but these plots still do not show a good linear relationship and have the 
worst coefficient of determination out of the three APls (R2 0.33, y=0.55x). The CAB plots for the 
BOP CFC-ll tips (figs. 3.17) follow a similar pattern where 2 tips of the three (1 and 2) for both 
the coated (R20,41, y=1.27x) and uncoated (R2 0.59, y=0.95x) canister lie on the adhesive side of 
the intersection but with the 3'd tip lying on cohesive side. The un-coated canister has all three 
tips well across the intersection on the adhesive side and on this occasion the linear fit of theSe 
plot points show a better correlation (R2 0.89, y=0.33x). The BOP IPA tips (fig. 3.18) show the 
least consistency in tip adhesion relationship. Two tips on the coated canister (1 and 3) are 
cohesively dominated, with one (2) that shows more adhesive character (R2 0.27, y=O.86x). TWo 
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Fig 3.18 CAB plot for BOP IPA tips against pMOI components 
tips on the uncoated canister (2 and 3) show adhesive tendency with one again (tip 1) reversing 
this trend (R2 0.14, y=0.14x), and in this instance while two tips (2 and 3) show significant 
adhesive dominance on the metering chamber, one (tip 1) shows an unexpected cohesive 
favourability (R2 0.05, yO.68x). 
3.4.3.3 SEM Characterization of Functionalized Tips 
Figure 3.19 shows SEM images of one of the functionalized tips of each BDP tip material both 
prior to, and after force data acquisition. This was performed to both confirm successful tip 
functionalization and also allow for identification of any obvious changes to tip particle 
morphology that might suggest a critical failure of the contact regime . All 9 functionalized tipS 
were confirmed as having been functionalized successfully. Notably all three particles are very 
large in comparison to the blank tips, especially the BDP CFC-ll clathrate which occupies a large 
area of the DNP-S cantilever. In all cases, while some contamination of the rest of the cantilever 
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Fig 3.19: Low Vacuum SEM images of functionalized tips of A) Anhydrous BOP, B) BOP CFC-ll Clathrate 
and C) BOP IPA Clathrate both prior to (1) and after (2) AFM force curve acquisition 
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chip by particulate matter can be seen, there is was no obvious critical change to the functional 
particle morphology. H o w e ~ e r r two of the tips did pick up contaminant material near the 
functional particle (fig 3.19 A2, C2) during use, and while this does not look to have impacted 
the assumed contact area this cannot be guaranteed. Furthermore on the SEM images of some 
tips the resin used for particle attachment was visible (fig. 3.19 Cl, C2) beneath the functional 
particle. Because this was topographically hidden it was deemed acceptable and unlikely to 
cause any interference in the force data acquisition. These images were typical of the whole set 
of the functionalized tips. 
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3.5 Discussion 
3.5.1 Characterization of Beclomethasone Dipropionate and the Beclomethasone 
Dipropionate Clathrates 
3.5.1.1 SEM and AFM Analysis 
The morphological differences seen between the powder samples in the SEM images (fig. 3.1, 
3.2 and 3.3) were as expected. Typical micronization procedures where larger particles are 
smashed up and broken down, render inherently more cohesive, smaller particles with 
increased surface energies as exemplified by the anhydrous BOP micronized sample (fig. 3.1). 
The AFM images of the anhydrous BOP (fig. 3.8 A) support this view, by showing a rough and 
inconsistent surface, with some areas having roughness values around 10 times in excess of the 
crystalline samples. The BOP CFC-ll clathrate particles {fig. 3.2} were in contrast crystals that 
exhibit a v ~ r y y organized appearance with smooth flat surfaces that are consistent with 
particulate matter that has crystallized into an ordered structure. However, while the BOP CFC-
11 clathrate particles showed consistent shape and surface morphology, they' were very diverse 
in size and in general the particles were much larger than those of the anhydrous BOP and BOP 
IPA clathrate. 
The ordered structure of this sample highlighted the different crystal faces that exist, as shown 
above, which potentially may have a bearing upon the surface energetics that influence 
interparticulate interaction. This is for the reasons described above where different crystal faces 
are known to exhibit different surface energies dependent upon the molecular orientation at 
that crystal face (Hooton et ai, 2008). This ordered crystalline structure is well reflected in the 
AFM data (figs. 3.8 B, 3.8 C) with consistently homogeneous and flat topographies with low 
extracted roughness values (table 3.1). Indeed the CFC clathrate was the flattest of the samples 
by AFM, with an Rq and Ra about half the IPA clathrate. The two faces of the BOP CFC-ll 
clathrate showed small differences, where although both were smooth and equally as flat {Rq 
and Ra data was merged} there appeared differing surface artefacts. The lateral face showed 
some degree of grading and a higher proportion of what appear to be surface fractures. While 
the main face did show a lesser degree of fracturing, it also showed some small, rounded 
depressions. The cracks and fractures were attributed to small degrees of propellant escape in 
synthesis. It is unlikely that they are the result of sputter coating prior to SEM imaging because 
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the same fractures can be seen on the particles that were attached to the AFM tips and imaged 
without sputtering. The depressions however are currently unexplained but presumably reflect 
defects in the crystalline structure. These features were not considered Significant, as the 
apparent integrity of the particles was upheld and the DSC traces that followed showed a 
suitable consistency. 
The BDP IPA clathrate p'articles show less apparent order than the BDP CFC-ll clathrate 
particles. Although the SEM images of the BDP IPA clathrates (fig. 3.3) show plate-like crystals 
. with flat surfaces, these particles show less reproducibility in particle shape. Particle size does 
however, seem more consistent than the BDP CFC-11 clathrate and although the particles are 
morphologically different from the micronized precursor they are not excessively larger. The 
AFM images (fig. 3.8 D) suggest that the IPA clathrate has a surface with features between the 
micronized BDP and the BDP CFC-l1 clathrate. There is an obvious decrease in height variation 
compared to the precursor, but unlike the CFC clathrate, there is still some ridging and 
particulate heterogeneity. Importantly, however the SEM images distinguished the size 
difference between the CFC clathrate and the IPA clathrate, where on a 5 ~ m m x 5 ~ m m image we 
are almost certainly on the face of a single CFC clathrate, whilst with the IPA clathrate and the 
anhydrous BDP the particle size range falls into this resolution, and it is not possible to rule out a 
multi-particle image of both- which would lead to an increase in the estimation of surface 
roughness. However the roughness ranking of the API powders are consistent with what would 
be expected from the SEM images. 
Notably the Rq values established for all the API powders are significantly larger than those of 
the model substrates used in previous CAB studies ("'lnm Rq) (Hooton et ai, 2006, Jones et ai/ 
2008a etc.). All the powders have to be used as a cohesive surface for a CAB and therefore their 
own surface roughnesses across particle contact areas are important. The BDP CFC-ll clathrate 
was the least rough of the substrates, but remained in the region of lOx rougher than the 
recrystallized crystals manufactured for use in model systems. The anhydrous BDP is in the order 
of 100x rougher than an ideal substrate and the .IPA clathrate 20x so. It could be expected 
therefore that the CFC-ll clathrate would show the most promise at providing a consistent 
cohesive surface at the very least, and that the anhydrous BDP is the least likely powder 
substrate to show microscale parity in contact geometry. 
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3.5.1.2 XRPO and OSC 
The observed XRPO traces shown in figure 3.4 help prove the synthesis of the BOP CFC-ll 
clathrate, and rule out the presence of other polymorphs. The expected diffraction peaks 
calculated from the single crystal structure at 2 theta values of 7.2,8.5,9.6, 11.2, 13.8, 16.8 and 
18.5" can be distinguished. There is therefore an appropriate correspondence to the calculated 
diffractogram of the clathrate, distinguishing the BOP CFC-11 clathrate from other BOP 
polymorphs. The intensities are lower and the peaks are broader in the observed sample, but 
this is not unexpected, due to the potential for some disorder in the crystal structure to exist as 
introduced in the process of synthesis, handling, sample preparation and presentation. Any 
phYSical impurity, can lead to a broadening in diffractogram peaks and it is important to note 
that the CFC-11 within the host molecules, is not accounted for in the calculated single crystal 
structure. The existence of the propellant in the molecular structure elicits the broad peaks after 
18.5" 2 theta as the guest molecule shows significant disorder in differing orientations within the 
host BOP. Hence figure 3.4 suggests a sample with good phase purity. This data was therefore 
accepted in proving the BOP CFC-11 clathrate synthesis. The process could not be repeated for 
the BOP IPA clathrate because the structure has not been solved and therefore no reference 
exists. However an XRPO diffractogram was compiled (fig 3.5) and the peaks were similar in 
nature to the CFC-ll clathrate up to 18.5" 2 theta with small differences beyond. The OSC 
traces performed also go some way into proving this was a clathrated structure as described 
below. 
The OSC traces obtained in figure 3.6 prove several key points. All the samples show a consistent 
endotherm that corresponds to the melting point of BOP at around 213'C (Vervaet, Byron, 
1999). The thermograms for the BOP CFC-l1 clathrate and the BOP IPA clathrates show 
energetic events not present in the anhydrous BOP sample. Distinct exotherms around 91'C are 
fOllowed rapidly by endotherms at around 95'C in the BOP CFC-11 clathrate sample. The BOP 
IPA clathrate samples also show a significant broad endotherm prior to melting at around 142'C, 
although no exothermic event can be distinguished prior to thiS. It is proposed that these events 
relate to a solid state rearrangement of the clathrates, or rather declathration, where the 
propellant is released as the caged structure changes (Bouhroum et ai, 2009). At a certain 
temperature the molecular structure of the clathrate changes in response to the thermally 
induced increased molecular freedom. The loss of the typical caged structure is accompanied by 
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a release of the en caged propellant. The loss of the propellant corresponds to the exothermic 
event, whilst the solid state rearrangement is endothermic. Considering the BOP CFC-ll 
clathrate samples, both such events can be seen, although interestingly the exotherm precedes 
the endotherm. This suggests that the increasing molecular mobility of the CFC-ll with 
temperature, reaches a point where the molecules can simply escape clathration, and that this 
loss of the encaged molecules leads to a collapse of the molecular structure of the BOP and 
subsequent re-arrangement. However, the BOP IPA clathrate thermograms do not evidence 
such an exotherm prior to a 'rearrangement endotherm'. This may be related to the fact that 
propellant release and solid state rearrangement will occur almost simultaneously, and that if 
the critical temperature at which declathration occurs is higher (as it appears in the BOP IPA 
clathrate) then the process may be more instantaneous and the endothermic transition will 
mask the propellant release. Alternatively, the OSC traces for the IPA clathrate show that the 
rearrangement endotherm is 'much broader than that of the CFC clathrate, and may reflect a 
more complicated or drawn out change in chemistry. What is however clear from the cyclic 05C 
traces of the clathrated samples (figs. 3.7 A and B), is that these processes are irreversible. ThiS 
is indicative of a non-reversing phase transition that supports the notion of a solid state 
rearrangement and the loss of propellant. 
3.5.2 Characterization of the pMDI Components 
The SEM and AFM imaging of the pMOI components show significant differences between the 
three selected inhaler component surfaces. The effect of FEP coating of the canister wall can be 
seen quite clearly on SEM and AFM imaging. The SEM image (fig. 3.9 A) shows that on the 
microscale the FEP coat gives a very smooth surface, albeit with a layering effect that induceS 
some small ridges across the surface. This homogeneity of the surface, coupled with the 
chemistry of the coating itself would be expected to significantly reduce interactions between 
the formulation and the canister wall, and provide a surface most capable of conforming to a 
CAB relationship. Critically however, the fact that the coating is not complete in some areaS 
leads to a prospective duality in the reactive nature of the canister wall, as well as potentially 
inducing inconsistent tip surface contacts that would disturb a CAB. The AFM images (fig. 3.10 
A) further suggested that while the coating appears to render large areas of flat and 
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homogeneous surface, there exist several induced surface asperities. These may possibly be 
explained as excessive deposits of coating, and in some cases these were very significant in 
scale, reaching in the region of 300nm above the relative surface structure. Most were also 
quite broad and contrasted with the sharper asperities seen on the metering chamber (fig. 3.10 
C), but by virtue of inducing an increased level of surface roughness, would still be expected to 
alter the geometry of any particle contact at those points and increase the range of interaction 
scale across the surface. 
The uncoated canister would be expected to offer more variability ininterparticulate 
interactivity and contact geometry. This is because the surface was seen to possess many more 
obvious surface imperfections by SEM and AFM. The topographical variation by surface rutting, 
scratching and folding is very evident and although the AFM measurements (fig. 3.10 B) of these 
features suggest that they are of a similar size to those features on the coated canister they are 
'much more frequent. SEM images of the metering chamber seemed to suggest it was the 
roughest surface with a multitude of topographical features and significant surface 
heterogeneity (fig. 3.9 C). However the smaller scale AFM images (fig. 3.10 C) are not 
convergent with the SEM images collected over a larger area. The AFM images appear to 
suggest that the surface morphology and topography at the microscale shows significantly 
different consistency than that on the macroscale, and this is borne out by the AFM derived 
roughness values seen in table 3.2. 
These values reflect this unexpected observation by suggesting the metering chamber is of a 
similar roughness (Rq) to the coated canister wall. The larger deviations around the Rq and Ra of 
the metering chamber correspond to a lack of consistency within the surface features, but this is 
still surprisingly low considering the SEM images. The uncoated canister is in the region of 1.5 to 
2 times rougher than both the other pMDI components and would therefore seem to be the 
least suitable surface substrate for CAB assessment. The metering chamber, despite the low Rq 
assessment would still be expected to conform less well to a CAB balance than the coated 
canister because of the microscale inconsistency that would deter an as consistent surface 
contact model. The Rq values calculated for all three pMDI components were in excess of the 
ideal substrates used in previous CAB studies by some distance. Even the coated canister 
showed an Rq of 20x larger than the lnm standard. Therefore, combined with the roughness 
measurement of the powder samples it would suggest that a CAB balance would be severely 
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stretched to provide a useful model on these 'non-ideal' materials, but that if any relationships 
were to hold true, the balance between the BOP CFC-11 clathrate and coated canister would 
theoretically be the most likely. 
3.5.3 The Cohesive Adhesive Balance of the BOP APls and pMOI Components 
The force data that was acquired with the functionalized tips was very diverse and variable. As 
established earlier, because each individual tip presents a different and uncharacterized contact 
regime, even with a flat surface, the absolute adhesion values cannot be compared directly 
between tips and powder samples. However the different tips should elicit the same 
proportionality of adhesive response from surface to surface, if the contact geometry for a 
normalizing cohesive measurement is the same as for an adhesive measurement. This is 
because with reproducible interparticulate forces in a controlled environment, the only 
variation in interaction will be the contact area. Assuming flat substrates, this variation is limited 
to the topography of the individual tip, and the contact geometrics of that topography would be 
the same across all the substrates. Therefore any increase in adhesion from surface to surface, 
should be proportionally mirrored by each tip the same series. However from the average force 
data acquired in figures 3.11, 3.12 and 3.13 it can be seen that this is obviously not so in these 
data sets, and that in all three tip types, several samples have very dissimilar tip to tip 
proportionalities. The CAB plots (figs.3.16, 3.17 and 3.18) reflect this same variability in results 
as they are simply a graphical representation of the ratio of the adhesive forces to the cohesive. 
With tip to tip values varying disproportionately from substrate to substrate, there is little 
linearity in any of the tip plots as highlighted by the consistently low R2 values and wide point 
scatter. If the balance was to have held true for these particulate and component samples then 
some suggestion of a linear fit would have been the consequence of a close to proportiOnal 
movement in adhesion from tip to tip with cohesion. This immediately suggests a failure of anY 
consistency in contact area for tip material contact. This is not totally unexpected but provides a 
level of quantification to the level of roughness that cannot be accommodated in the CAS 
analysis approach.Such a failure could be a sign that the functional tip has been changed over 
time and the effective contact area differed, resulting in adhesion force differences. The SErJI 
images before and after force data acquisition suggest there were no obviously critical 
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differences in the tip morphologies, although as the SEM is limited to a 20 microscale 
assessment it is unclear whether the actual nanoscale point of contact on the functional tips was 
subject to wear or collapse etc. There is also the impact on AFM force measurements of 
technical inaccuracies. 
This is plausible when we consider the large relative size of the functional particles on the 
cantilevers. The assumption that the cantilever can function correctly under the weight and 
dynamics of functionalization is not as yet known. Indeed with the BOP CFC-ll clathrate in 
particular the ONP-S cantilever is dwarfed by the particle and on several occasions, deflection 
and hysteresis could be observed on the AFM outside of surface to surface contact. Figure 3.15 
BOP CFC shows two force curves (A and B) that were recorded using a BOP CFC-ll functionalised 
tip. BOP CFC A was a useable trace that shows a large but analysable adhesion. Even in this 
instance however the tip approach is not smooth, with some undulation that may reflect either 
some scattered laser light hitting the photodiode, or cantilever flex under the weight of the 
functional particle. This has the effect that the deflection signal from the AFM that defines the 
adhesion of the tip to surface is subject to large errors based in the cantilever's modified 
behaviour. The difficulty in recording a force curve with such functionalized tips was further 
typified by the high output of unusable traces such as fig. 3.15 BOP CFC B. The adhesion in this 
instance was so big as to prevent the full and proper movement of the tip through Its approach 
and retract cycle. Here the particle tip appears to have made a massive jump in and remained 
'stuck' to the surface for vast majority of the remaining tip motion. The large nature of these 
particulate tips means that the effective contact area of the tip is increased significantly beyond 
that of a bare tip. Although this causes no problems theoretically, it does have the significance' 
of leading to such large adhesions that they have the potential to exceed the capability of the 
cantilever to quantify completely, or as above, prevent an entire force curve from completing. 
Indeed in several cases such as fig. 3.15 BOP CFC B, the adhesions were so large that they 
exceeded maximal cantilever deflection (that can be sensed by the AFM photodetector), which 
forced the analysis (where possible at all) to be based upon an extrapolation of the force curve 
recorded. This adds error into the assessment of adhesion and might help further explain the 
disparity of the force results from this model. As a consequence there was only a relatively low 
number of force curves collected for each tip on each surface. By limiting the number of curves 
used, the longevity of each tip was preserved, but as a consequence the data collected was 
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more likely to suffer from anomalous results, which may reflect some of the more obscure 
values seen. 
However it is more than likely that the largest influence on the force data is the combined effect 
of the roughness of the substrates. The values collected by the AFM suggested that the 
materials ranged from 10 to 100 times rougher than the CAB standard of lnm Rq, and that the 
influence of asperities or depressions may well be significant even on this scale. Figure 3.20 
shows particle surface contacts on a smooth and rough surface. A particle contacting a smooth 
surface has much more accurately calculable and reproducible contact geometry. A particle 
contacting on a rough surface however has a multitude of differing contact regimes dependent 
upon the site of interaction (Rabinovich et ai, 2000a, Rabinovich et ai, 2000b). Indeed multiple 
asperities smaller than the particle may reduce the contact area and the adhesion force, while a 
variety of asperities larger or of a given orientation can serve to induce a variety of increased 
contact areas (Beach et ai, 2001). This situation is complicated further when we introduce the 
concept of a non-spherical tip particle; where the geometric possibilities widen. Even with the 
smoothest cohesive and adhesive surfaces (the BDP CFC-ll clathrate and the coated canister 
wall) very variable and inconsistent data was recorded. This would seem to indicate that even 
nanoscale roughness in the region of 10-20nm (Rq) has led to s i g n i f i c a ~ t t alterations in contact 
geometries, capable of disrupting the CAB process beyond a workable limit. However there is a 
possibility, specifically in this case, that the large functional tip plays a significant role in this 
perturbation. 
Fig 3.20 Hypothetical Spherical Particle Contact on A) Smooth and B) Rough surfaces 
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The fact the CFC-ll clathrate particle attachments were in the region of 20j.J.m to 60j.J.m and 
relatively smooth, means that the potential contact area was far beyond a 5j.J.m square area. 
Combining the nanoscale roughness measured by AFM, the macroscale topographical variability 
seen on SEM and such large tip surface areas, this adds up to an unavoidably significant amount 
of surface to surface contact heterogeneity, even with low local Rq values. This may account for 
the significantly larger force values obtained with the BOP CFC-ll clathrate tips and the large 
degree of force variability seen. With the suspect contact mechanics of the functionalized tip, it 
would appear that the practical nature of the CFC clathrate as a functional tip may be a very 
limiting feature. 
However fig. 3.15 BOP B and fig. 3.15 BOP IPA B also show two other rejected force curves from 
the other two tip materials where there was evidence of multiple points of adhesion and pull off 
points that compromised the Fadh assessment. The existence of these, would inherently suggest 
that a consistent adhesive and cohesive surface area was impossible, unless the same contacts 
were seen on all the force measurements with that tip. But as fig 3.15 BOP A and fig 3.15 fig BOP 
IPA A show they were not. The most likely explanation for the inconsistent occurrence of these 
traces is therefore the combination of tip particle and substrate roughness leading to highly 
variable contact regimes, with some multiple point contacts, depending on localisation. The very 
inability of the cohesive measurements prior to, and after adhesive force measurement, to 
produce consistent results, is particularly indicative of the challenge of applying< a standard CAB 
approach to non-ideal materials. 
Figure 3.14 shows some example box plots of the Fadh data from the three tip types on given 
substrates. These plots were used to make a non-parametric assessment of the force data. In so 
doing the mean and median of the data .could be compared, and the key' quantile values of 
these data sets with respect to the range of the data could be analysed. Principally, on a 
crystalline smooth surface, force distributions (given a consistent contact geometry) should 
appear Gaussian. In such instances it would be expected that the mean and median averages 
were the same. The further that parity is parted from, the further away from a Gaussian 
distribution the data will have moved. The further away from a Gaussian distribution the force 
data is, it would suggest a more and more Inconsistent contact regime. As figure 3.14 A shows, 
the set of anhydrous BOP tips produced a box plot of reasonable consistency on their second 
cohesive measurements. As described above there was no expectation that absolute Fadh should 
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be similar due to the expected differences in contact geometries between tips, but the mean 
and median averages were relatively close and the 1st and 3rd quartiles showed a similar 
relationship to the extremes of the data (with the exception of tip 3). From this we could infer 
that these tips had a reasonable reproducible contact regime and that a close to Gaussian 
distribution of the adhesive forces was complied. 
However as figure 3.14 Band 3.14 C show, this was not the case with other tip to substrate setS. 
The BOP CFC-ll tips second cohesive data set (fig. 3.14 B) shows that the first tip had a massive 
disparity between the median and mean average Fadh. In fact due to the huge range generated 
by the Fadh point extremes, the mean was dragged above the 3rd quartile. The 2nd tip also shows 
quite a difference from the 2nd quartile to the mean, while the 3rd tip is somewhat closer. The 
BOP IPA tip example (fig. 3.14 C) again shows a large variation, tip to tip, in the coherence of the 
statistical descriptors. This was common to many of the other tip to surface sets. What this 
further describes is that the contact regimes of the individual tips were not just inconsistent 
from substrate to substrate, but also between measurements on the same surface. The disparity 
of the mean from the median in many of the tip to surface cases renders the mean as a largelY 
invalid descriptor in these instances. However as already identified, the impact of tip and 
substrate roughness was so extreme as to visibly render the CAB data uncorrelated. 
Yet, despite the challenged nature of the CAB data, and the lack of many linear regressions with 
good fits to the tip data, it is still possible to suggest some basic underlying trends. From these 
trends there are still some prospective conclusions that can be drawn about the interacting tip 
materials and inhaler surface components. Firstly from the data collected the relative affinitY of . 
each tip material for the inhaler components can be described as indicated by the data spread 
from the CAB plots (fig. 3.16, 3.17 and 3.18): 
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Anhydrous BDP tips: 
Stainless steel metering chamber> Uncoated aluminium canister> FEP coated aluminium 
canister 
BDP CFC-ll tips: 
Stainless steel metering chamber> Uncoated aluminium canister> FEP coated aluminium 
canister 
BOP IPA tips: 
Uncoated aluminium canister> Stainless steel metering chamber> FEP coated aluminium 
canister 
Despite the ~ a r i a b i l i t y y of these data, and the difficulty therein of drawing firm conclusions from 
them, these trends were much as expected prior to the study. Consistently across all three tip 
materials the FEP coated canister seemed to be the least adhesive surface, with most plot values 
for all tip types lying on or above the CAB plot intersection (I.e. Fcoh > Fadh). This would infer that 
the powders were more interactive with themselves than the coating, which would be a 
Significant benefit in an inhaled formulation and fits to the manufacturer's purpose. 
Furthermore the implied CAB ratios of 1.31, 1.27 and 0.86 with the anhydrous BDP, BOP CFC-11 
and BDP IPA tips respectively were consistently higher than for the same tip sets on the other 
CAB substrates. Equally there is some evidence that the metering chamber was the most 
adhesive component with respect to all the powders, as virtually all the plot values lie well 
below the intersection (Fadh > Fcoh) and for both the anhydrous BOP and BDP CFC-ll tip sets, 
linear fitting gave a significantly more adhesive CAB than for the fits for the coated and 
uncoated canisters (CAB ratios of 0.55 and 0.36 respectively). The CAB ratio extracted for the 
BOP IPA tip set on the metering chamber was also 0.68, although this was a less adhesive 
balance than with the uncoated canister in this instance. Importantly, the only good linear fit 
seen between a tip set, was that between the BOP CFC-ll tips on the metering chamber (fig. 
3.17). Here the three tips showed a linear regression with a coefficient of determination of 0.89 
and a CAB ratio of 0.33. This could be said to be a more confident indicator that the BOP CFC-ll 
tips had a very adhesively dominated relationship with the metering chamber and would be 
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likely to preferentially adhere to this surface in-device. However, the lack of consistency across 
the other tip sets renders this definition slightly obsolete, as there is no confident comparator. 
This suggestion of an adhesive force balance may reflect a more adhesive chemical interaction 
between the metering chamber surface and the tip materials. Yet it is worth noting that using Rq 
roughness assessments can be somewhat misleading. This is because surfaces of very different 
topographies may measure close to the same Rq as all that is reported Is the variability of height, 
around the mean height of a sample (I.e. the Rq of a flat surface with many depressions can 
equal a flat surface with many peaks). In this respect the similar Rq values calculated for the 
metering chamber and the BOP CFC-ll clathrate may have disguised the potential for each 
surface to generate consistent surface contact geometries, or as already highlighted simply been 
too small In scale to properly predict the tip particle surface contact regimes. Therefore it would 
seem that in agreement with visual characterization the metering chamber appears to have 
been the most variable of the substrates, with inconsistent surface topography leading to high 
variability in contact geometry and therefore Fadh• 
The uncoated canister is the most ambiguous surface and little can as yet be suggested about 
the data plots for this material. The anhydrous BOP tips and BOP CFC-ll tips produced CAB 
ratios of 0.92 and 0.95 (fig 3.16,3.17), very close to the centre line of 1 (Fcoh = Fadh). Whilst thiS 
might have suggested a generally neutral or slight adhesive preference for these powders, the 
R2 value of the anhydrous tip regression was 0.59, suggesting only a weak fit, and for the BOP, 
CFC-ll tip regression -0.8, which infers no linear trend at all. Furthermore the BOP IPA tips (fig 
3.18) show one tip that sits just above this intersection again, but then has two tips registering 
very adhesive values, that lead to a CAB ratio 0.62 and an R2 value of 0.14. As such It is verY 
difficult to draw any conclusions about this tip material. 
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3.6 Conclusion 
It is apparent that the CAB approach, whilst offering a unique assessment of interparticulate 
adhesion in model formulations cannot be easily applied to 'non-ideal' materials. This is due to 
inherent surface topographies, even on small spatial scales, that render dissimilarities in 
cohesive and adhesive surface geometries that give rise to a collapse of the model. Whilst flat 
surfaces were hypothetically required to apply the model, to what extent this could be 
circumvented to reflect real pharmaceutical powders and device components was unexplored. It 
would appear however that with respect to the materials chosen in this study, the inherent 
surface roughnesses and large functional tip particles combined to exceed the limits of the 
cohesive adhesive balance approach and while to a limited degree expected trends could be 
identified, these remained statistically unproven. Certainly clathrated BDP particles, while 
offering relatively smooth surfaces, are not viable to work in a CAB study. Despite the reduced 
surface roughnesses, the large particle sizes formed in synthesis exaggerate particle contact 
regimes and serve to introduce critical variability in contact area genesis. Furthermore such 
particle sizes would seem to prove too large and inflexible to give accurate and sensitive tip 
. functionality, with negative consequences upon AFM cantilever function. Hence while these 
molecular entities may be of interest and show lower surface energies than other polymorphs 
(Bouhroum et ai, 2009), the CAB approach is not suited to qualifying or quantifying their 
interaction with pMDI components. 
It could be suggested that despite the collapse of the CAB study with the materials investigated 
here, there is evidence to show that the FEP coated canister is effective at reducing 
interparticulate interactions with APls. It may shift a marginally adhesively dominated 
relationship between the un-coated canister and APls to a cohesively dominated relationship. 
This would of course be of large benefit in pMDI inhalers in avoiding dose loss to the inhaler 
housing. However due to the variable nature of the data collected and the problems outlined 
above, particularly with respect to the uncoated canister, this suggestion cannot be confirmed. 
Further work to establish whether the benchmark 1nm Rq marker used in previous studies is the 
maximal limit is appropriate and on-going alongside other refinements of the limits of a CAB 
approach and how it can be linked to other studies of formulation assessment. It remains 
unclear whether the CAB approach can be applied to 'real' materials In their entirety but it does 
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seem that such an approach may only work with very strict morphological controls of both tipS 
and surface, or with some adaptation to the process yet to be developed. 
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4.0 Application of the CAB approach to, and Characterization 
of Semi-Model Inhalation Substrates 
4.1 General Introduction 
4.1.1 Semi-model Substrates for CAB studies 
Chapter 3 showed that the surface roughness constraints of the CAB approach are not 
sufficiently flexible to be extrapolated to unrefined API or device surfaces. Whilst a pure CAB 
was not possible without smooth crystalline surfaces, it was unknown as to whether a rough 
force balance characterisation could be performed that might better describe the materials 
used in real inhalation formulations. The general shortcomings of the CAB performed using the 
materials described in chapter 3 were indicative that substrate roughness and large functional 
particle sizes, stretched the model beyond its workable limits as defined by the contact region. 
However the concerns described relating to the viability of a pure CAB study in describing real 
formulation character still remain. It is therefore of interest as to whether an approach 
somewhere in the middle ground between these two extremes (Le. crystal surfaces and 
micronized particulates) could bridge this gap. As such, if better considered functional particles 
and flatter and more consistent (topographically) CAB surfaces were able to yield a simple 
description of adhesive balance character, for a given API combination, this may still prove 
useful in relating to further 'in-vitro' indicators of real formulation performance. Any links could 
then be potentially extrapolated to provide the basis of a quick and simple screening or 
characterization tool. 
4.1.2 Modification of CAB materials 
In modifying the failed CAB technique application to raw surfaces from chapter 3, there is a 
desire to account for the two identified critical factors. Firstly the particulate tips should be of a 
size conducive to controlled cantilever contact mechanics. They should generate particle to 
particle contact on as small a scale as possible, (ideally one to one) to reduce topographical 
variability being exaggerated. Secondly CAB surfaces should be made to be as topographicallY 
smooth as possible so as to reduce unavoidable differences in contact geometries. It is alSO 
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important to determine whether any alterations to the CAB materials in achieving these effects 
occur without significantly compromising the physicochemical makeup of the material form I.e. 
the Inducement of polymorphism etc. Otherwise the distinction between a 'real' surface and a 
'model' surface is reduced. This therefore dictates that the surface chemistry should not be 
changed, surface contamination should be avoided and environment specific behaviours 
eliminated. This therefore limits the approaches that can be used to better 'idea lise' the real 
material surfaces, but protects the validity of so doing so. In this chapter the investigatory 
approach adopted was to compress the free powder of a range of inhalation APls into a powder 
disc. In so doing to attempt to generate a semi-model substrate with improved topographical 
character and investigate the process as a means of generating an API surface that is better 
suited for a CAB experiment than the raw powder yet without needing a recrystallization 
process. This chapter therefore proceeds by looking at the effect of such compression on API 
surface roughness, whether this will allow a more consistent evaluation by AFM methodology 
and more specifically, a fundamental CAB assessment of two APls. 
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4.2 Chapter Aims and Objectives 
4.2.1 Chapter Aim 
The aim of this chapter was to characterize and investigate the use of 'semi-model' processed 
APIs as a substrate for AFM investigations and in particular as a means to perform a CAB studY 
between designated combinations of inhalation APls. In so doing to examine the functionality of 
a compromise between 'model' crystalline surfaces and the 'non-ideal' formulation materials in 
providing an assessment of the force balance between two APls. 
4.2.2 Chapter Objectives 
The objectives of this chapter were as follows: 
To examine the impact of API powder compression upon the ease of application to AFM 
based imaging and force based investigations. 
To determine the effect of API compression in reducing API surface roughness. 
To determine the effect of API compression upon surface specific morphologies, 
topographies and physicochemstry. 
To attempt to extract a rough force balance between combinations of compressed APIS 
using a modified CAB methodology. 
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4.3 Materials and Methods 
4.3.1 Materials 
4.3.1.1 Active Pharmaceutical Ingredients 
Beclomethasone dipropionate (BOP), salbutamol sulphate (55), budesonide (BUD), salmeterol 
xinafoate (SX) and fluticasone propionate (FP) were chosen for investigation due to their 
prominence of use within inhaler formulations in modern medicine, and both the subtle and 
significant chemical differences between the APls within their classes, and between their classes 
respectively. The micronized powders were all provided by 3M Healthcare (Loughborough, UK). 
,All other reagents and accessories were provided by Sigma Aldrich Company Ltd (Gillingham, 
UK). 
4.3.2 Methods 
4.3.2.1 API Powder Compression 
The API powders were compressed using a manual hydraulic Specac IR press model 15011 
(Specac Ltd., Kent, UK) to provide significantly smoother API surfaces for CAB experimentation 
while still retaining strong physicochemical similarities with the parent free powder. Sufficient 
powder to form a solid compress was filled onto a stainless steel pellet fitted within a 13mm 
cylindrical IR die. This was sealed off with a second steel pellet after minor damping of the 
powder and removal of any excesses and spillage. The assembly was then attached to a base 
unit with an air outlet feeding from the die. The entire cast was loaded into the press housing, 
where a metal punch was loaded into the cast column and manually lowered onto the topmost 
pellet. By using an adjustable upper bolster on the punch, maximum manual compression was 
applied, before a vacuum pump was attached to the air outlet at the bottom of the cast. The 
vacuum pump was then activated and the desired pressure on the system was induced via a 
manual pumping process. The API discs produced were formed using a 10 ton pressure 
application for two minutes. The discs were carefully removed from the die and placed Into a 
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desiccator until required for use. The discs were mounted to a double sided sticky carbon stub 
attached to an SPM specimen disc before SEM or AFM imaging and force interrogation. 
4.3.2.2 SEM Imaging 
SEM images of the morphology and topography of the powdered and compressed APls were 
collected by a JEOL JSM-6060LV scanning electron microscope (JEOL Ltd, Tokyo, Japan) at 
various magnifications under vacuum. Powder samples were sprinkled directly onto a double 
sided sticky carbon stub mounted on an SEM sample holder before being compressed lightly 
with a sterile glass coverslip and nitrogen gassed to remove excess deposits that might detach in 
the sample chamber. Compressed powder discs were mounted directly onto the carbon stubs. 
All API material samples were sputter coated in gold using a Balzers Benchtop Sputter Coater 
SCD 030 in an argon atmosphere (50Pa) at 30 mA for 4 minutes before SEM imaging took place. 
The functionalized AFM cantilevers were also imaged by SEM prior to force b a l a n ~ e e
determination in order to confirm the functionalization process and examine the attached 
particulates. The tips were placed on a sliver of silica gel attached to a carbon stub and were not 
sputter coated to allow their use after imaging. Subsequently low vacuum mode was used to 
allow SEM images of these cantilevers without charging. 
4.3.2.3 Differential Scanning Calorimetry 
A TA Instruments DSC 2920 differential scanning calorimeter (TA Instruments, Delaware, US) 
was used to perform all DSC work. DSC was used to compare the pre- and post- compressed API 
powders in order to identify any obvious differences in physical transition that might suggest a 
significant impact to the physicochemical state of the APls by the compressive force used in the 
powder compression process. Accurately weighed samples of 'about 6 mg were sealed in 
aluminium hermetic pans, equilibrated at O°C, kept isothermal for 3 minutes and then heated at 
lOOC per minute under nitrogen to just above the reference melting points of each of the APIS 
(250·C for BOP and SS, 350·C for FP and 160°C for SX). Disc samples were collected and analysed 
after deliberate fragmentation of compressed API discs. Thermograms produced were analysed 
using TA universal analysis -NT software (TA Instruments, Delaware, US). 
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4.3.2.4 AFM Imaging and Roughness Measurements 
AFM images were acquired in a tapping mode operation with TAP300 (BrukerNano, Coventry, 
UK) tips using a Dimension 3000 AFM (BrukerNano, Coventry, UK). Each tip was loaded into the 
tip holder and then optically aligned, before the resonant frequency was determined using the 
operating software. Height and phase images were then collected using the calibrated resonant 
frequency over spatial distances of 51lm x' 5 11m and 10llm x 10llm at between 1.5 - 2Hz for 
topographical and morphological visual characterization and surface roughness comparison 
between APls and the pre- and post-compressed powder forms. 5 images were collected at both 
scan sizes across the same API samples (powder or compress) with a minimum of 50llm spatial 
difference in either x or y. Images were flattened and noise reduced before presentation using 
Nanoscope 7.3 (BrukerNano, Coventry, UK). Roughness measurements were made using the 
same software but prior to any image processing so as to avoid any bias to the raw data. The 
roughness measures used were the root mean square roughness (Rq) and the arithmetic mean 
roughness (Ra) alongside the maximum surface feature height (Rmax) which was included to 
identify the extent of idiosyncratic feature occurrence and variability, even if unrepresentative 
of the bulk of the surface topography. The derivation of the former roughness parameters was 
discussed in chapter 3, while the Rmax represents the maximum height deviation from the 
average surface level across a given surface area. 
4.3.2.5 AFM Work of Adhesion and Surface Energy Measurement 
Surface energy measurements were carried out on the compressed API pellets using three 
silicon nitride DNP-S (short, thick) tips (BrukerNano, Coventry, UK). These tips were chosen due 
to their low spring constants and therefore high sensitivity to adhesion forces. The force of 
adhesion (Fadh) between each tip and the substrates was measured by collecting 2S force curves 
on each material after deflection sensitivity calibration on a non-deforming silicon wafer, and 
prior to tip self-Imaging on a TGT-l tip grating (NT-MDT, Moscow, Russia). The Fadhand tip radii 
were then calculated using Nanoscope 7.3 (BrukerNano, Coventry, UK) software using the force 
curves and tip images obtained. Using the following equation it was then possible to calculate 
the work of adhesion (W A): 
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W 2Fadh 
A 31rR 
. (4.1) 
Where R is the radiui of the contacting tip. (This equation assumes the Johnson-Kendall-Roberts 
model of contact). The surface free energy (VI) of the API substrate could then be calculated 
using the following relationship: 
(4.2) 
Where Vz is the surface free energy of the silicon tip, assumed to be a referen"ce 42mJ mo2 (James 
et ai, 2008). 
4.3.2.6 AFM Tip Functionalization 
Contact mode DNP-S (short, thick) tips (BrukerNano, Coventry, UK) were used for 
functionalization by the same practical method as indicated in chapter 3. However in thiS 
instance they were functionalized using a Multimode AFM with a Nanoscope V controller and 
Nanoscope version 8.10 software (BrukerNano, Coventry, UK). The spring constant of each tiP 
was determined by the AFM software using a thermal noise method (Hutter, Bechhoefer, 1993). 
Ten functionalized tips were prepared in total,S with micronized (anhydrous) beclomethasone 
dipropionate and 5 with salbutamol sulphate. An epoxy resin (loctite, Henkel ltd, Hatfield, UK) 
was applied to a silica disk and placed onto the AFM stage. A sacrificial AFM tip was used to 
draw thin lines of the adhesive from bulk several times until a very thin strand of adhesive was 
accessible. The blank cantilevers were placed in the tip holder, optically aligned to allow their 
spring constant to be calculated and then manually lowered on to these glue strands until 
contact was observed via laser deflection or visually, before removal. The resin substrate was 
then removed and replaced with the appropriate powder sample. The powder samples were 
sprinkled onto double sided sticky carbon stubs mounted on an SPM specimen, and blown doWn 
with a nitrogen tap to remove any excess powder. Using the AFM microscope small individual 
powder particles or agglomerates were resolved, identified and aligned with the position of the 
tip. The cantilever was then lowered manually onto the powder particles for attachment and 
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then removed. Great care was taken to identify small and isolated particulates to minimize the 
chance of multiple uptake or excessively large functional masses. The functionalized tips were 
left to dry for 24 hours. Successful tip functionalization was confirmed by low vacuum SEM 
imaging as described above. 
4.3.2.7 Cohesive Adhesive Balance Measurements 
AFM based CAB force measurements were carried out using an EnviroScope AFM (BrukerNano, 
Coventry, UK) with a NanoScope lila Controller according to largely the same methodology as 
described in chapter 3. In this instance 100 force measurements were taken by each 
functionalized tip on both the adhesive and cohesive surfaces and both the powder compress 
surfaces were given positive and negative ion bombardment via a antistatic gun (Milty Zerostat 
3, Fisher Scientific, Loughborough, UK) to eliminate electrostatic build up as a consequence of 
the c o m p r e ~ s i o n n process. Force measurements were performed after automatic raster of the 
sample relative to the tip, by steps of llJ,m in the x and y direction after each individual 
measurement. This was to examine the adhesive force spread across a larger area of the 
substrates and avoid any bias to anomalous regions of topography or contamination etc. 
Humidity was again kept as close to 0% RH as possible to minimize capillary interaction, with no 
rises above 5% during operation tolerated. Once the Fadh and Fcoh had been extracted from the 
force curves these values were averaged and then plotted against each other on a tip by tip 
basis to generate a CAB plot for each API tip type. Linear fitting was then applied to each tip set 
to attempt to identify any trend appreciable as a CAB. 
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4.4 Results 
4.4.1 AFM Derived Surface Free Energy Determination of Compressed APls 
Figure 4.1 shows the AFM calculated average surface free energies (y) of the inhalation APls 
beclomethasone dipropionate (BOP), salmeterol xinafoate (5X), salbutamol sulphate (55), 
fluticasone propionate (FP) and budesonide (BUD) after compression in an IR press. Table 4.1 
breaks down these results to the force of adhesion (Fadh), work of adhesion (WA) and surface 
free energy of the APls as ascertained by each of the individual AFM tips. Figure 4.1 shows that 
of all the APls investigated 55 showed the greatest surface free energy. with an average 
45.3mJ/m-2 (± 5.7). The other betaz-agonist 5X, averaged 37.1mJ/m-2 (± 3.9), but was superseded 
by BOP with an average surface energy of 39.2mJ/m2 (± 2.9). Both these APls did however shoW 
greater consistency between the three tip measurements than 55, with smaller standard 
deviations. The two remaining corticosteroids FP and BUD showed reduced average surface 
energies at 27.7mJ/m-2 (± 6.6) and 29.9mJ/m-2 (± 8.3) respectively'. Notably both these APIS 
showed large inconsistencies in measurement, and BUD in particular showed a significantly 
exaggerated standard deviation in calculated W A and surface energy between the AFM tipS, 
predominantly between the first and remaining two (table 4.1). 
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Figure 4.1: Average surface energies of compressed Beclomethasone Oipropionate (BOP), Salmeterol Xinafoate 
(SX), Salbutamol Sulphate (55), Fluticasone Propionate (FP) and Budesonide ( B U ~ ) ) as determined by AFM 
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API 
BOP 
SX 
S5 
FP 
BUD 
Tip 
Tip 1 
Tip2 
Tip3 
Tip 1 
Tip2 
Tip3 
Tip 1 
Tip2 
Tip3 
Tip 1 
Tip2 
Tip3 
Tip 1 
Tip2 
Tip3 
Force of Work of 
Adhesion (Fadh) Adhesion (W A) 
nN mJ m-z 
33.9(±15.2) 
116.0(±37.2) 
41.8(±8.4)' 
31.9(±12.4) 
124.9(±33.2) 
37.9(±7.2) 
33.4(±7.1) 
137.7(±14.2) 
44.2(±6.4) 
31. 7(±lS.8) 
94.4(±39.8) 
31.9(±6.8) 
18.8(±7.97) 
102.5(±42.2) , 
32.7(±9.12) 
82.4 
77.6 
83.4 
77.5 
83.5 
75.7 
81.20 
92.06 
88.24 
77.0 
63.1 
63.6 
45.6 
68.6 
65.3 
Surface 
Energy 
(V) mJ m-z 
40.4 
35.9 
41.4 
35.8 
41.5 
34.1 
39.2 
50.5 
46.4 
35.3 
23.7 
24.1 
12.4 
28.0 
25.4 
, -
Table 4.1: The force of adhesion, work of adhesion and surface energy of inhalation APls as determined 
byAFM 
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4.4.2 Differential Scanning Calorimetry Analysis on the Effects of API Compression 
Figure 4.2 shows the overlay of three individual differential scanning thermograms of the pre-
compressed API powders BDP, 55, FP and 5X. The three BDP samples all showed a consistent 
melting point at around 212°C. Crucially no other thermodynamic event was seen on the 
thermograms for any of the samples that might suggest polymorphic impurities such as the 
common hydrate formation. The three 55 samples were also consistent showing a broad melting 
point endotherm beginning at around 190.98°C. The three 5X samples all showed a large 
endotherm at ar'ound 123°C and a subsequent smaller endotherm at 139°C. The FP samples 
were the least consistent, but still all evidenced a single melting point endotherm at about 
290°C. 
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Figure 4.2: Differential scanning calorimetry thermograms of the pre-compressed powders of Beclomethasone 
Dipropionate (BOP), Salbutamol sulphate (55), Fluticasone Propionate (FP) and 5almeterol Xinafoate (5X) 
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Figure 4.3 shows the thermograms of the same four APls after compression by IR press use. The 
figure shows that the three BDP samples had almost identical melting endotherms at about 
209°( again with no other obvious events in the rest of the trace. The SS samples showed a 
single but very broad melting endotherm maximizing at around 202°( , but beginning nearer 
180°C. The FP samples showed a repetitive melting endotherm at 296°(, with no other 
thermodynamic transitions. The SX samples all showed the two endotherms as described pre-
compression with a larger transition at 124°( and a smaller endotherm at 138°C. 
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Figure 4.3: Differential scanning calorimetry thermograms of the compressed powders of 
Beclomethasone Dipropionate (BOP), Salbutamol Sulphate (55), Fluticasone Propionate (FP) and 
Salmeterol Xinafoate (SX) 
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Figure 4.4 shows the two sets of thermograms overlaid for comparison . The pre-compressed API 
powder traces are in blue with the post-compressed disc samples in red . The figure shows that 
while the size of the endothermic transitions witnessed do appear to change between the 
sample sets, particularly with regards the two beta2-agonists, none of the samples show any 
significant deviation in the onset of the transitions observed or any developed or unique 
transitions corresponding to O(le set and not the other. 
" 
BOP SS 
~ , ,
i' [ 
~ ~ I -10 
I . , 
,. 
' 00 
T ~ l u u ( ' C J J
,so · " : t - - - - . - - . . - - - - - - , J ; ; " o o ~ - _ ; r ; _ - ~ : _ _ ~ _ _ _ _
Temper.::lIure toq 
sx FP 1 f f ~ ~
, _f\,.U.D5I(IOOI 
• _ f W.osoa lll i 
_ nU. OSoOooI 
_ n n _ ~ o l o o ' '
_ I'W . PWOlOllI 
_fW.I'WOlOOI 
T ~ r r ( ' C ) )
- - " " ~ I I- ........ "" - ....... "', -  
- --'" 
---"" 
0 20 .. .. .. 
'00 ". 
, .. 
T ~ k k ( ' C ) )
Figure 4.4: Comparison of the differential scanning calorimetry thermograms of the pre-compressed 
and post compressed powders of Beclomethasone Oipropionate (BOP), Salbutamol Sulphate (SS), 
Fluticasone Propionate (FP) and Salmeterol Xinafoate (SX) 
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4.4.3 The Cohesive Adhesive Balance of Salbutamol Sulphate and Beclomethasone 
Dipropionate using Compressed Powder Substrates 
4.4.3.1 SEM and AFM Topographical Analysis 
Figure 4.4A shows representative 5EM Images of the pre-compressed S5 and BOP powders at 
two magnifications. The micronized salbutamol sulphate powder appears to show an irregular 
plate-like particulate structure at larger magnifications (fig 4.4A 55 B), with individual particle 
sizes varying from less than a micron up to several microns. Some of these particles can be seen 
to be co-associated with surrounding particles into larger particulate agglomerates several 
microns in diameter. Over larger areas (fig 4.4A S5 A) these agglomerated masses can also be 
differentiated, and the variation in agglomerate size can also be discerned as progressing from 
submicron up to 5 or 10 Ilm in diameter. The surface of the powder is therefore inherently 
'rough' with irregularly shaped particle agglomerates stacked and localized to generate a surface 
with macroscale variability in topographic profile. The BOP powder (fig 4.4A BOP B) shows a 
distinctly different particulate morphology, with more spherical and smooth micronized 
particles ranging in size from less than 0.51lm and less frequently up to around 41lm in diameter. 
These spherical particles are however again arranged into agglomerates, with the smaller 
particles distinctly visible within coherent larger particulate bodies fn generating irregularlY 
arranged composites that overlay each other. Over larger areas (fig 4.4A BOP A) the SEM images 
give the impression of significant topographical variability with appreciable depressions and 
elevations caused by wide spread irregularly coordinated agglomerate stacking. 
Figure 4.5 shows representative 5EM images of the post-compressed 55 and BOP powder discS. 
The 55 surface post compression shows a very smooth topography (fig 4.5 SS A) that is scored 
with various impression marks and the occasional particulate debris. At higher magnification (fig 
4.5 S5 B) it can be identified that the distinction of individual particulates or agglomerate masses 
is lost and the s u r f ~ c e e shows a softly undulating but homogenous nature, with the occasional 
depression or debris based feature. The BOP compress shows a macroscale (fig 4:5 BOP A) 
surface that appears generally topographically smooth, but with a wide spread 'paving' effect, 
where a distinct repetitive micro-scale pattern can be seen to cover the majority of the surface. 
Notably the disc surfaces are littered irregularly with particulate debris, some of which are 25 to 
SOllm in diameter. At further magnification (fig 4.5 BOP B) the compressed BOP samples can be 
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A B 
Figure 4.4A: SEM images of Salbutamol Sulphate (55) and Bedomethasone Oipropionate (BOP) micronized powders 
before compression at A) 550x magnification and B) 8,OOOx magnification. Scaled as indicated. 
seen to consist of still quite well defined particulate associations, with 'squashed' agglomerates 
and particulate matter of varying sizes interlocking and overlaying to give rise to the paving 
effect observed at lower magnifications across the majority of the compress surface. These 
agglomerates show a small degree of topographical variability, with some protruding from the 
mean surface into mounds or as distinct particulate extrusions. The particle and agglomerate 
sizes appear consistent with the pre-compressed powder, although the quantity of larger 
particulate associations seems to have increased under compression. The spherical or rounded 
particle shape is maintained, and the surface topography reflects this with repetitive spherical 
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Figure 4.5: SEM images of Salbutamol Sulphate (55) and Beclomethasone Oipropionate (BOP) powders after 
compression at A) 250x magnification and B) 2,OOOx magnification. Scaled as indicated. 
arrangements. Figures 4.6 and 4.7 show tapping mode AFM topographic images powders at a 
Sllm x Sllm, and lOllm x lOllm scan size of the pre- and post-compressed BDP and SS 
respectively. The pre-compressed 55 powder shows an irregularly shaped particulate 
arrangement. There is a predominance of larger (2-Sllm diameter) particles, but there are soll1e 
smaller particles (O.S-lllm diameter) observed, frequently in the spaces associated with these 
larger interlocking 'plate' type particles. When the 55 powder is compressed the subsequent 
AFM images show a surface with a significant reduction in topographical features. The SIlIl1 )( 
Sllm scan size (fig 4.7 55 A) shows that some degree of individual particle character can be 
identified, albeit on a sub-micron scale, along with some small surface cracks. There are nO 
evident larger particulate masses, although some of the surface cracks appear to define larger 
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A B 
Figure 4.6: Example tapping mode AFM images of Beclomethasone Oipropionate (BOP) and Salbutamol 
Sulphate (SS) pre compression at 5 ~ m m x 5 ~ m m (A) and 1 0 ~ m m x 1 0 ~ m m (B) scan sizes. 
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A B 
Figure 4.7: Representative tapping mode AFM images of Beclomethasone Oipropionate (BOP) and 
Salbutamol Sulphate (55) after compression at Slim x Slim (A) and lOllm x lOllm (B) scan sizes. 
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plate like subsections of the API surface. At this scale and more prominently over the 10J,.lm x 
10J,.lm scan size images, the surface appears to be largely topographically homogeneous apart 
from some areas of material bunching (Le. into small peaks of between S-SOJ,.lm) or areas with 
small surface cracks. The surface of the 55 compresses also appears to have a unidirectional 
surface specific sweeping pattern across larger areas. The BOP powder prior to compression 
shows an arrangement of more rounded particles, varying in size from O.2SJ,.lm up to 2J,.lm (fig 
4.6 BOP A). These particles appear to be co-associated into groups or agglomerates, better 
defined in the larger scan size (fig 4.6 BOP B). These collections of smaller particles overlay into 
broader topographical features, that generate rises and falls in the powder surface. After 
compression the BOP (fig 4.7 BOP A) shows a smoothened sub-micron particle littered surface 
with significant larger particle fragments (1-4J,.lm) spread across this underlay. The sub-micron 
particles are visible as co-associated rounded elements forming the broader surface structure. 
When the larger scan size is viewed (fig 4.7 BOP B) this can be seen to be consistent across a 
larger area, with little co-ordination of the large particle protrusions from a lightly undulating 
background surface topography. The protruding particles from the BOP surface appear to be in 
the region of 30-40nm proud of the general surface structure. 
4.4.3.2 AFM Derived Roughness Measurements 
Table 4.2 and table 4.3 show the calculated root mean square (Rq), arithmetic mean (Ra) and 
maximum feature height (Rmax) of the BOP and 55 pre-compressed powders and their 
corresponding powder compresses across the SJ,.lm x SJ,.lm and 10J,.lm x 10J,.lm scan sizes 
respectively. For each sample 5 tapping mode images were collected and while tables 4.2 and 
4.3 show the breakdown of the Individual image analysis, figure 4.8 shows the collated data in 
terms of the Rq average for each sample· type. As table 4.2 documents, when considering the 
5J,.lm x 5J,.lm scan size images, the BOP pre-compressed powder returned an average Rq of 
352nm, and an average Ra of 282nm. The Rmax values for the images analysed ranged from 
lS8Snm up to 2718nm. In comparison the BOP powder compress showed an average Rq of 
2S.4nm and Ra of lS.0nm with Rmax values ranging from 170nm to 430nm. The 55 powder pre-
compression showed an average Rq of 230nm and Ra of 182nm with Rmax values starting at 
1278nm and peaking at 2257 while its powder compress averaged an Rq of 1l.8nm an Ra of 
9.4nm. When the 10J,.lm x 10J,.lm scan size is considered, table 4.3 shows that the BOP powder 
averaged an Rq of 541nm, with an average Ra of 433nm and Rmax values ranging from 2982nm to 
171 
Chapter 4 - Application of the CAB approach to, and Characterization of 'Semi-Model' Inhalation 
Substrates 
API AFM Root Mean Square Arithmetic Mean RMaxlmum 
Image Roughness (Rq) nm Roughness (Ral nm (Rmaxl nm 
Number 
BOP 1 394 313 2702 
Powder 2 351 280 2373 
3 411 340 2122 
4 244 197 1585 
5 360 278 2718 
Average 352 282 2300 
BOP 1 19.9 12.1 253 
Disc 2 20.0 13.7 184 
3 17.5 12.3 170 
4 38.2 19.8 430 
5 31.3 16.9 384 
Average 25.4 15.0 284 
SS 1 270 210 2257 
Powder 2 251 201 1442 
3 202 160 1278 
4 207 164 1372 
5 218 177 1419 
Average 230 182 1557 
S5 1 13.1 10.3 124 
Disc 2 11.3 9.1 87.2 
3 13.8 11.2 99.2 
4 10.5 8.2 86.2 
5 10.4 8.0 99.4 
Average 11.8 9.4 99.2 
-Table 4.2: SlJm x 5IJm tapping mode Image Rq, R. and Rmax Roughness analysis of Beclomethasone 
Olpropionate (BOP) and 5albutamol 5ulphate (55) powders b e f o r ~ ~ and after compression 
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. API AFM Image Root Mean Square Arithmetic Mean RMaximum 
Number Roughness (Rq) nm Roughness (R.) nm (Rma.) nm 
BOP 1 525 421 3837 
Powder 2 438 349 2982 
3 432 344 3042 
4 565 459 3740 
5 743 594 4532 
Average 541 433 3627 
BOP 1 10.2 6.55 209 
Disc 2 17.9 13.6 179 
3 15.3 10.1 308 
4 15.2 10.1 284 
5 19.5 14.7 324 
Average 15.6 11.0 261 
S5 1 455 367 3023 
Powder 2 671 523 4672 
3 398 313 2954 
4 581 476 4210 
5 486 380 3134 
Average 518 412 3599 
55 1 19.8 15.6 258 
Disc 2 17.6 13.8 158 
3 18.7 13.8 143 
4 16.2 13.0 96 
5 14.4 11.4 109 
Average 17.3 U.S 153 
Table 4.3: 10IJ.mx10IJ.m tapping mode Image Rql R. and Rm •• roughness analysis of Beclomethasone 
Dipropionate (BDP) and Salbutamol Sulphate (55) powders before and after compression 
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Figure 4.8: Comparison of the average root mean square roughness of Beclomethasone Oipropionate 
(BOP) and Salbutamol Sulphate (55) powders pre- and post-compression as derived from Sl1mxSl1m and 
lOl1mxlOl1m tapping mode AFM images 
4532nm . The compressed beclomethasone in comparison showed an average Rq of 15.6nm and 
Ra of 11.0 with Rmax values ranging from 179nm to 324nm. The salbutamol powder across th is 
scan size had an average Rq of 518nm and an average Ra of 412nm, with Rmax values from 
2954nm to 4672nm. The 55 compress however returned an average Rq of 17.3nm, with an 
average Ra of 13.5nm and Rmax values st arting at 96nm and topping at 258nm . Figure 4.8 displays 
t he average Rq values for both the compressed and un-compressed API samples at both sca n 
sizes for comparison . Notably the 55 roughness values are lower than the BDP samples for all 
but t he 10llm x 10llm compressed disc topography sca ns. There is approximately a 14x decrease 
in surface roughness by Rq between the BDP samples at 51lm x 51lm, increased to a 34x decrease 
when considering the same samples at 10Ilm x 101lm. The 55 powder compress shows a 19)( 
decrease in surface roughness by Rq over SlIm x 51lm, with a 30x decrease across the 10llm )( 
l Ollm images. Importa ntly, the un-compressed samples also showed significant ly more 
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Figure 4.9: Example SEM images of functionalised AFM tips with Beclomethasone Oipropionate (BOP), 
and Salbutamol Sulphate (55) particulates. Magnification as stated. 
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variability (as standard deviation) of their roughness measurements, exaggerated when the scan 
size was increased. 
4.4.3.3 SEM Imaging of Functlonallzed AFM tips 
Figure 4.9 shows two example 5EM images of the functionalised ONP-5 cantilevers prior to CAB 
based force probing. SEM was used to ratify that successful functionalization had occurred. 
Figure 4.9 shows representative images of both a BOP functionalised and 55 functionalised tip. 
Three tips from the original functionalization procedure (2 BOP and 1 55) were found to have 
been either unsuccessfully functionalised or inappropriately contaminated with excess API or 
adhesive. These tips were therefore discarded and replacements created; further 5EM imaging 
confirmed that all subsequent tips had been functionalised successfully. These tips were then 
used for force curve genesis on the API powder compresses. As figure 4.9 shows, small 
particulate attachment could be confirmed visually for both APls. In all instances particle 
agglomerates were seen to be the functionalising body rather than an individual particle. As the 
BOP example shows (fig 4.9 BOP) areas of bare adhesive could sometimes be identified in some 
5EM images, although this was only considered problematic if the imaging suggested significant 
functional particle coverage. As the 55 tip also indicates (fig 4.9 55) there was also often 
additional particle debris introduced to the rest of the cantilever in the attachment procesS, 
though this was considered acceptable as long as it did not interfere with the prominent particle 
or offer potentially multiple contact sites. 
4.4.3.4 Cohesive Adhesive Balance using Powder Compress Substrates 
Figures 4.10 and 4.11 show the resultant CAB plots based on the average adhesion and cohesion 
force AFM data from 100 force measurements using five BOP functionalised tips and SS 
functionalised tips respectively. Figure 4.10 indicates that all five BDP tips registered 
adhesion/cohesion plots below the xy intersect. The five tips could be described by a linear fit 
with a y = 0.35 x gradient and an R2 value of 0.57. Conversely the five salbutamol tips (fig 4.11) 
all lay above the xy intersect with a linear fit that reads a y = 1.69 x gradient and a 0.57 R2 value. 
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Figure 4.12 shows example cohesive and adhesive force curves obtained with the same 55 and 
BOP functionalised tips respectively. The blue trace is the extension curve and the red line the 
retraction. The example BOP traces show a smaller adhesion by cohesive (BOP-BOP) 
. measurement than by adhesive measurement on a $5 surface. Conversely the 55 traces show a 
larger adhesion on cohesive measurement (55-55) than on adhesive measurement on a BDP 
surface. 
Figures 4.13 and 4.14 show the box plots of the 55 and BOP functionalised t i ~ ~ force data on both 
the cohesive and adhesive surfaces. The bottom of the boxes represent the 1st quartile, the top 
of the boxes the 3rd quartile and the line inside the box the median (2nd quartile). The dots 
represent the mean, and the ends of the whiskers represent the maximum and minimum Fadh 
recorded. Fig 4.13 shows that both the adhesive and cohesive data sets from the 55 tips showed 
good consistency between the mean and median with only a couple of small discrepancies (tip 4 
cohesive data, and tip 3 adhesive data). The ranges of the tip data sets are variable with some 
showing evidence of extreme minimums or maximums that dwarf the quantile measures. Fig 
4.14 shows that the same is true of the BOP. tips force data, with a generally tight agreement of 
the mean to the median, especially within the adhesion data on the 55 substrate. Tips 1 and 2 
within the cohesive data show the largest disparity. The range of each tip substrate data set is 
more consistent, but there remains evidence of outlying maxima and/or minima that have 
biased the mean, such as with tip 1. 
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Figure 4.12: Example A) cohesive and B) adhesive force curves using the same BecJomethasone 
Oipropionate (BOP) and (55) functionalised tips respectively 
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4.4.4 The Cohesive Adhesive Balance of Salmeterol Xinafoate and Fluticasone 
Propionate using Compressed Powder Substrates 
4.4.4.1 SEM and AFM Topographical Analysis 
Figures 4.15 and 4.16 show the SEM images of the SX and FP powders pre- and post-
compression respectively. The un-compressed SX powder (fig 4.15 SX B) shows an irregular 
elliptical, or shard-like particulate morphology. Particles are generally long and thin with a size 
range from 1-51lm in length and 1-21lm in width. These particles can be seen over larger areas to 
have clustered into irregularly shaped and accumulated agglomerates (fig 4.15 SX A) creating a 
heterogeneous surface topography. The FP powder shows (fig 4.15 FP B) shows more consistent 
particle morphology. 
Figure 4.1S: SEM images of Salmeterol Xinafoate (SX) and Fluticasone Propionate (FP) micronized 
powders before compression at A) SOOx magnification and B) 3,SOOx magnification. Scaled as indicated. 
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Particles are generally spherical but rough and nodular. They have a particle size range of 
between 1-211m in diameter, and can be seen (fig 4.15 FP A) to aggregate to some extent over 
larger areas into peaks and troughs of particle coverage. Again the surface can be seen to be 
rough and tumultuous, with particle overlay leading to elevations and depressions in 
topography. The compressed SX powder (fig 4.16 SX 8) shows a distinct flattening of 
topographical features. Individual particle character is largely lost, giving a broadly 
homogeneous and optically smoothened surface. Some small undulation seen at larger 
magnifications hints at compressed particle overlay. Over both larger areas (fig 4.16 SX A) and 
with increased magnification to smaller areas (fig 4.16 SX 8) distinct surface disruption can be 
seen, with unidirectional surface demarcation as surface ridging or surface depression stretching 
across images. 
A B 
Figure 4.16: SEM Images of Salmeterol Xinafoate (SX) and Flutlcasone Propionate (FP) micronized 
powders after compression at A) SOOx magnification and B) 4000-S000x magnification. Scaled as 
indicated. 
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These features run consistently across all images, dissecting the otherwise planar powder ~ e d . .
Some surface debris can also be seen to be scattered inconsistently across the surface. The 
compressed FP (fig. 4.16 FP A) powder shows a largely homogenous surface, with repetitive 
unidirectional ridging inter-dispersed with occasional areas of surface fracture or collapse (fig 
4.16 FX A). Here surface cracks ranging from the nanoscale up to several microns can be 
identified and at some points the surface layers can be seen to have separated entirely. Some 
have either inverted or risen over each other. At larger magnifications (fig 4.16 FX B) the powder 
compact can be seen to have an irregularly patterned surface with some distinction of original 
particle morphology. Some minor surface protrusion can be seen, with the occasional 
depression or surface crack . 
. Figure 4.17 shows the associated tapping mode AFM images of the compressed SX and FP 
powders over a SjJ.m x SjJ.m (fig 4.17 A) and a 10jJ.m x 10jJ.m (fig 4.17 B) surface area. Both 
powder compresses show identifiable individual particle definition, in particular over the smaller 
surface area. The SX images (fig 4.17 SX A, B) seem to show a mildly undulating surface with 
unidirectional tracking. Over the larger scan size, whilst there does a p p ~ a r r frequent particulate 
protrusion, these are of a small scale «ljJ.m diameter), maximising at 60nm proud and 
consistently far below this. In general the topography appears widely homogenous. The FP 
compress (fig 4.17 FP A, B) shows frequent individual particle protrusion from the surface bed. 
The protrusions regularly extend up to 80nm from the surface, are between 1jJ.m-3jJ.m in 
diameter, occur at irregular angles and show extensive coverage over the larger scan sizes. The 
topography of the FP compact therefore appears more heterogeneous than the SX compact. 
Figure 4.18 presents the average root mean square roughness analYSis of the FP and SS powder 
compacts as derived from the collected tapping mode AFM images. The FP powder compact 
averaged an Rq of 20.0nm over the SjJ.m x SjJ.m images and 23.6nm over 10jJ.m x lOjJ.m images . 
. 
The SX powder compact averaged an Rqof 13.9nm over the SJ,lm x SJ,lm scans and 17.4nm over 
the 10jJ.m x 10jJ.m scans. The image to image roughness deviation was greatest across the 
smaller scan size images than the larger. 
184 
Chapter 4 - Application of the CAB approach to, and Characterization of 'Semi-Model' Inhalation 
Substrates 
A B 
59.5nm 59.2nm 
. ... ; , , /' ,'" \ . .. ~ ~ . t 
 
. ~ S S · ·
• 
- ~ , . .
~ ~
~ ~ ~ ~ , . 
~ ~ ~ .. k.. \ f:'t 
• 
• .; 
~ ~ , ~ ~ ~
I .-
/. ~ . .
# 
.. 1 
, ~ ~ ~ f f
, 
... 
,.'i i .. 
~ ~ .. • 
," 
f? 
" 
\ 
,'" ~ ~ . r ol " 
~ ~
I 
, , 
.. J. • 
" 
4 ~ ' ' .. 
.. 
~ ~
\ >I " 
\ 
~ ~ , 
..... • 
" 
f 
,.,,. 
.. 
' ~ ~
(l ,. 
, 
:. ., of - ""-
, fI" • 
. 
---
'/lit. ~ ~ , 
., 
97,1 rvn 75.9nm 
.., 
.. 
, 
- ~ , , ~ ~ 'J) F:P /' • i i ,. 
4' 
,... 
" 
.. 
~ ~p . 
" 
" ~ ~
"" , ~ . . /. "" ,
~ ~ . ~ ~
~ ~ .... , ~ ~ .. 
/ 'II, ...... 
,1 
. 
''-:., " --r' 
· , ~ _ , f l . , ,
~ ~
~ ~
. 
.." 
...... 
.... ... /" .. ~ ~.. '- ' . 
...... 
"-
-
, A ~ ~ . , ,
...... ,-. /. 
,57.anm 
Figure 4.17: Representat ive t apping mode AFM images of Salmet erol Xinafoate (SX) and Fluticasone 
Propionate (FP) after compression at 51lm x 51lm (A) and lOllm x lOllm (8) scan sizes. 
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Figure 4.18: Average Root Mean Square Roughness Analysis of Fluticasone Propionate (FP) and 
Salmeterol Xinafoate (SX) Powder Compacts at S ~ m x S ~ m m and 1 O ~ m x 1 0 ~ m m scan sizes. 
4.4.4.2 SEM Imaging of Functionalized AFM tips 
Figure 4.19 shows example SEM images of functionalised SX and FP DNP-S AFM tips. All ten AFM 
tips were seen to have been functionalised successfully on the first attempt. In all cases 
functional particle masses could be identified at the tip site. Often these were multi particle 
agglomerates. In some images (fig 4.19 SX B) multiple particle attachment masses could be seen. 
These tips were assessed with further imaging and it was decided in all cases that multiple point 
adhesion was highly unlikely, and that the tips could be used for the subsequent force balance. 
In a couple of instances excess bare adhesive could also be identified. Again following further 
functional particle assessment it was deemed that this would not contaminate the particle 
surface interaction in any way. 
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A B 
Figure 4.19: Example SEM images of functlonalised AFM tips with Salmeterol Xinafoate (SX A B), and 
Fluticasone Propionate (FP A B) particulates at various magnifications. 
4.4.4.3 Cohesive Adhesive Balance using Powder Compress Substrates 
Figure 4.20 shows example force curves using the same functionalised FP and SX tips on both 
cohesion and adhesion substrates. The blue line is representative of tip extension and the red 
line is tip retraction. The FP tip can be seen to have a larger adhesion on the SX substrate 
(adhesive measurement) than on the FP substrate (cohesive measurement). The SX tip shows 
the reverse with a larger adhesion on the cohesive SX measurement over that on the FP surface. 
Figures 4.21 and 4.22 show the CAB plots established from the Fadh derived from 100 force 
curves using the FP tips and SX tips respectively on the compacted powder surfaces of adhesion 
and cohesion. Figure 4.17 shows that the FP tips' plot points all lie on the adhesive side ofthe xy 
intersect, with a linear fit giving a coefficient of determination of 0.81. The gradient of this linear 
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fit (or CAB ratio) is 0.63. The SX tips force balance plot points (fig 4.21) all lie just above the xy 
intersect, with two tip values lying almost on the intersect itself. A linear fit of these points gives 
a coefficient of determination of 0.97 with a CAB ratio of 1.05. 
Figures 4.23 and 4.24 show box plots for the cohesive and adhesive force data of the SX and FP 
tips. The box plots are constructed as identified above in section 4.4.2.4 for the SS and BOP 
plots. Both figures show some small disparities between the mean and median within some tip 
surface data, most particularly with the SX tips 1, 2 and 4 cohesive data, the FX tip 2 cohesive 
and adhesive data and the FX tip 4 adhesive data. Each of these tip substrate sets show large 
maxima or minima Fadh values (as whiskers) that appear to have skewed the mean some . 
distance either above or below the median. However the other tips seem to have a generallY 
strong agreement of both averages and smaller and more balanced force extremes. 
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Figure 4.20: Example A) cohesive and 8) adhesive force curves using the same Fluticasone Propionate 
(FP) and Salmeterol Xinafoate (SX) functionalized tips respectively 
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Figure 4.22: CAB plot for Salmeterol Xinafoate (SX) tips with Fluticasone Propionate (FP) 
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Figure 4.23: Box plots of the force of adhesion measurements of Salmeterol Xinafoate tips on a A) 
Salmeterol Xinafoate substrate and B) Fluticasone Propionate substrate 
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Figure 4.24: Box plots of the force of adhesion measurements of Fluticasone Propionate tips on a A) 
Fluticasone Propionate substrate and B) Salmeterol Xinafoate substrate 
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4.5 Discussion 
4.5.1 Characterizing the API Power Compresses 
4.5.1.1 Surface Energy Analysis and Differential Scanning Calorimetry 
The compression of the API powders into powder pellets was largely a success in providing 
coherent substrates intended for further AFM based work. All of the APls produced succinct and 
structurally solid powder 13mm discs after compression in the IR press with the exception of 
BUD. This API consistently produced a structurally unstable, fractured compress easily disrupted 
with minimum handling. Both the other corticosteroids, BDP and FP did produce useable pellets 
although it is worth noting that these were both significantly more friable than the two beta2-
agonists, which themselves produced distinctly homogeneous and structurally stable powder 
discs. Once these discs had been manufactured the next step was to investigate whether the 
compression process itself had induced any obvious changes in the physicochemical state of the 
APls, and through an investigation into the surface free energy of the resultant powder discs, 
determine both their suitability for force based AFM work and an appreciation of their rank 
interactivity . 
As table 4.1 and figure 4.1 illustrate, the rank order of surface free energy as determined by 
AFM ran as follows: 
55 > BOP> 5X > FP > BUD 
The values for the surface free energy levels observed were broadly similar to those extracted 
by other AFM based surface free energy experiments (James et aI, 2008, Bouhroum et ai, 2009 
etc.) with the exception of the FP and BUD samples. Both theses samples recorded lower 
surface free energies than previously documented, (although it is worth noting significant 
variability in the recorded values). These two substrates were the most difficult samples to 
generate force data from with quite visible and tactile degeneration of the compress surfaces. 
Most specifically the BUD sample as a compact, was very fragile and fell apart readily. This led to 
a great deal of difficulty in identifying appropriate regions upon which to make force 
measurements, and as a consequence of the poorly homogeneous surface s t r ~ c t u r e e led to 
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several force curves of unusable nature. The degree of surface heterogeneity is most probably 
why the budesonide sample showed the greatest standard deviation within the three AFM tips 
employed (fig 4.1, table 4.1). Because of the difficulty using the BUD compress it was decided 
that this API would not be put to further use within further CAB based experimentation. FP, 
although generating a fragile compact was still proven capable of standing up to handling and 
force based experimentation albeit with a persistent degree of variability between and within 
the individual AFM tips. The three other powder discs were much more versatile and the beta2-
agonists in particular generated apparently topographically smooth and stable compacts. The 
BOP compact was not quite as stable as the SS and SX samples, and appeared less homogeneoUS 
topographically, with some areas of surface splintering and protrusion. It was of interest that 
the corticosteroid should have a calculated surface free energy between the two betaragonists 
as it was expected that the two distinct chemistries of the different API classes would generate a 
class specific divide. It is however possible that the BOP sample showed a greater surface free 
energy than the SX compress due to increased variability in adhesion forces arising from a less 
consistent topographical surface. While figure 4.1 shows that the BOP samples showed the least 
variance between the AFM tips, when considering table 4.1 the adhesion force data for BOP had 
a larger deviation than the SS and SX. This may infer increased surface roughness, leading to a 
greater variability in contact regimes between probe to surface contacts. Notably the S5 
substrate showed the greatest consistency within each tip's adhesive force data measurements, 
but a greater degree of deviation between the tips than both the SX and BOP compress samples. 
This may reflect both a short range homogeneity and lack of surface roughness of the 
salbutamol sample but with wider topographical heterogeneity. 
From figures 4.2, 4.3 and 4.4 we can compare the basic thermodynamic assessment of the API 
powders before and after compression. As indicated BUD was not used due to the failure of the 
API to produce a workable powder compact. However the other four APls were analysed by 05C 
to identify any induced thermodynamic events in the compressed sample, or changes to the 
extent or occurrence of previously identified transitions. What can be seen, especially in figure 
4.4, is that for all the samples, there was no obvious induction of any new phase transitions, or 
displacement of the existing (primarily melting) endotherms. Whilst this suggests that the APIS 
had not been significantly contaminated or undergone radical polymorphic changes it is worth 
noting that the OSC runs for these samples would not be expected to pick up very subtle 
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alterations to API physicochemical states such as crystallization behaviours etc. without further 
methodology refinement. In particular any surface changes which may be insignificant in terms 
of percentage mass (and hence undetected by osq may have a significant impact on AFM based 
measurements. What was evident however was that there were some changes to the behaviour 
of the compressed APls. SX showed consistent thermograms prior to compression with a large 
endotherm at around 124°C and a second smaller endotherm at 138°C. Very obviously after 
compression the first endotherm had reduced relative to the second. These endotherms can be 
associated with the melting of two polymorphs of the beta2-agonist, the stable form I (124°q 
and the meta-stable form II (138°q (Tong et ai, 2001, Beach et ai, 1999). Subsequently it can be 
concluded that the compression process may have changed the polymorphic balance of SX, with 
more form II being formed. This is important as it suggests the compression process has affected 
the API, and may have led to different m o l e c u l ~ r r orientations which could impact a CAB. This 
will warrant further investigation, such as the use of techniques such as FT-IR or confocal Raman 
so as to ascertain the extent and location of any polymorphic change which was beyond the 
scope of this current work. 
4.5.1.2 SEM and AFM Roughness Analysis of Beclomethasone Dlproplonate and Salbutamol 
Sulphate Powder Compacts 
From the surface energy data and the OSC thermograms collected it was decided to further 
analyse the SS and BOP by SEM and AFM. While these two APls would not be considered in a 
real formulation together due to their different clinical frequencies of use and speed of 
respective physiological effects, they proved to be the two highest surface energy APls, which 
would give them the greatest chance of developing significant forces of adhesion and cohesion 
that could be identified within a CAB model (adapted to rougher surfaces). More fundamentally 
they are APls from two different drug classes with distinctly different chemistries between 
Which it would be of interest to explore in a force balance approach. 
As the data in figure 4.4A and figure 4.6 shows, both powders had very distinctive morphologies 
prior to compression. The AFM and SEM images were in agreement that the SS powder presents 
as a series of irregular plate-like particulates that co-associate to some extent. The particle size 
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was in the region of 2-5jlm in diameter, however some smaller particulates can be seen 
especially by SEM (fig. 4.4A). The existence of several even larger agglomerated particle masses 
on the scale of 5-10jlm can also be Identified. The BOP powder showed a very different 
morphology, with both the SEM and AFM images showing much more spherical particles, 
generally smaller (""O.5-1jlm in diameter) than the SS particles with some larger exceptions. 
Quite evidently however these smaller particles are broadly all a g g r e g a t ~ d d into larger and 
irregularly spread agglomerates that span across the powder bed. From the SEM images (fig 
4.4A BOP, SAL A) it can be seen that the BOP powder looks rougher than the SS powder, with 
more topographical variability as the irregular agglomerates stack to generate frequent particle 
protrusions and crevices between the aggregates. The SS powder bed looks smoother in 
comparison but in a similar fashion there are some obvious topographical features developed bY 
the arrangement of the larger particles and smaller particles associated with these into 
aggregate mounds and depressions between them. This suggests both powder beds are 
inherently much rougher than the target sub to low nanometre constraints of a pure CAB study, 
and the AFM imaging bears this out (fig. 4.6). 
Crucially tables 4.2 and 4.3 define the roughness of these powders and show that they are both 
too rough for use as a CAB substrate, with roughness values in excess of the failed CAS 
substrates in chapter 3. It was considered important to look at two scan sizes for the roughneSS 
calculations, as the roughness parameters defined and used in tables 4.2 and 4.3 are specific to 
the surface area to which they refer and significantly, powder surfaces will often not be uniforrn, 
i.e. topographical variability will usually increase over larger surface areas. So while a 5jlrn )( 
5jlm scan area may better represent the locale where a single particle contact may occur, the 
10jlm x 10jlm scan size gives a better idea of how consistent that surface character is. This is a 
particularly significant consideration when there is an intention to perform force based 
measurements across a surface, as such force based surface characterization is much rnore 
representative of that material if wider areas are sampled. The surface roughness values of the 
SS powder across both scan sizes were 230 nm Rq over 5jlm x 5jlm and 530nm Rq over 10jlrn )( 
10jlm. The BOP powder had an average Rq over Sjlm x Sjlm of 3S2nm and over 10jlm x 10jlrn of 
541nm. Significantly this data backed up the visual appreciation that the BOP powder waS 
rougher than the SS at both scan sizes, however interestingly, the BOP powder had not 
increased in roughness (54% increase) to the same extent as the SS powder (130% increase) .. 
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This is perhaps explained by the average Rmax values of both powders, where the increase 
between the two scan sizes for BOP was from 2300 nm to 3627nm, where SS was from 1557nm 
to 3599n.m. This suggests that smaller particle agglomerates of the BOP powder generate larger 
surface topographical variability at smaller scales, but that the larger particles of S5 will orient 
and render more significant. roughness over larger areas, as irregular large particulate 
agglomerates protrude from the surface or generate surface depressions. 
After compression the 5EM images (fig 4.5) show the· dramatic changes to the API surface 
morphologies and consequent topographies. The 55 compress shows an almost complete loss of 
individual particle definition at higher magnifications (fig 4.5 S5 B). The surface now appears 
consistently mildly undulating with some very small irregular depressions. The macroscale 
surface (fig 4.5 55 A) appears flat and homogeneous apart from some d i s t i ~ c t t surface defects 
such as scoring and the occasional fragment contaminant. The scoring marks are likely the result 
of surface defects of the stainless steel IR die pellets that compress the powders, causing an 
imprint to be generated on the powder compact. The fragments are also probably the result of 
some surface destruction in the compress removal or handling process. Both these surface 
features are not consistent in their coverage of the powder compact. 50me areas suffer heavy 
incidence while others remain largely homogenous and topographically consistent. The 
beclomethasone compact still shows some Individual particle character (fig 4.5 BOP B) in the 
SEM images, as it appears the small spherical particles have been compacted as multi-
component agglomerates into each other. The surface appears significantly smoother, but the 
compressed particle agglomerates create a 'paving' pattern with some degree of protrusion 
shown by the electron micrograph. Over the larger areas (fig 4.5 BOP A) this paving effect can 
still be seen, and in similar fashion to the S5 powder disc, there Is evidence of some surface 
scratches and fractured powder debris inconsistently spread across the surface. This debris 
appears more regularly on the BOP Images, suggesting the more friable powder was more 
susceptible to damage on production and handling than the 55. 
The AFM images (fig 4.7) again are largely consistent with the SEM images with respect to the 
compacted discs. The SS disc shows evidence of some individual particle, or Individual 
agglomerate character at the smaller scan size. Here some surface cracks and powder 
demarcations suggest the overlap of the original particulate matter. These are not significant in 
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scale, often only a few nanometres in width and one or two micron in length at most. However 
when looking at the larger scan size, these features are much less discernible and the surface 
appears very homogenous, scattered irregularly with small peaks and surface folds. The vast 
majority of the surface appears to bear a unidirectional sweeping pattern, which again is most 
likely the imprint of the stainless steel pellet used to compress the APls. The AFM images of the 
BOP pellet highlight the paving effect of the compressed particles seen in the SEM images. 
Notably, while the height differential is actually quite small (lOs of microns) the AFM images at 
both scan sizes define the surface as a compacted multiparticulate background with frequently 
dispersed larger particle protrusions. This spread is best seen at the larger scan size and 
contrasts distinctly from the SS disc on which larger images make it less obvious to define 
individual particle situation. 
From both the SEM and AFM images of the two compacts it is evident that a significant 
reduction in surface roughness was achieved, and this is most obviously proven in tables 4.2 and 
4.3 and figure 4.8. Figure 4.8 shows most graphically the extent of the surface roughnesS 
decrease between the free powders and their associated compacts, with close to a 14x and 19x 
reduction in average Rq at t h ~ ~ Slolm x Slolm scan size for beclomethasone and salbutamol 
respectively, and a 34x and 30x decrease in average Rq at lOllm x 10llm:The average roughnesS 
values (Rq) for both compacts across both scan sizes are much closer to the target roughnesS 
values that would a l l o ~ ~ a semi-model CAB to be performed (2S.4nm and lS.6nm for BOP and 
11.8nm and 17.3nm). As expected an increase in topographical consistency of the powder 
compacts is related to a reduction in the standard deviation about the roughness measurements 
made on the samples. The inherently rough and irregular powder sample AFM images 
, . 
individually show a range of Rq values and maximum topographical features, while the powder 
compact images are significantly more consistent with less variation from location to location in 
terms of absolute Rq or Rmax. Despite this significant improvement it should still be borne in mind 
that this represents a lOx-20x greater roughness than a single crystal face. The only unexpected 
result from the roughness analysis is the lower average Rq for the BOP compact across the larger 
scan size than the smaller scan size. This may simply be related to the increased deviation about 
the BOP Slolm x Slolm measurements, with two slightly raised Rq values skewing the data. What 
can also be seen is that the S5 compacts were smoother than the BOP compacts over the lower 
scan size and that this was reversed over the larger areas. 
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Certainly the compression process can be seen to have dramatically reduced the surface 
roughness of both the APls, generating substrates which would be much more suitable for a 
force balance experiment. The surface morphology of both has also been altered, significantly 
more so with the betaragonist than the corticosteroid. This has facilitated the topographical 
normalization but it is unclear as to whether subtle surface specific physicochemical changes 
have occurred which would affect the validity offorce measurements. 
4.5.2 The Cohesive Adhesive Balance of Salbutamol Sulphate and Beclomethasone 
Dipropionate using Semi-Model Substrates 
4.5.2.1 AFM Tip Functlonallzatlon 
The AFM tip functionalization process was carried out with great care to generate only small 
, 
functional tips. This was in an attempt to reduce the size of the contact regime in the force 
balance and avoid the impact that such large functional particles (such as the clathrates In 
chapter 3) had in multiplying the effect of substrate roughness. In this fashion, with particular 
care to use only minimal volumes of adhesive and attach only individual particles (or particle 
agglomerates) the AFM. tips were all c h a r a c t e r i z e ~ . . by SEM. to confirm successful 
functionalization (fig 4.9). From the SEM images obtained it was possible to see that all the 
functional particulates were attached to the AFM tip, with no critical contaminants on the rest 
of the cantilever. On two occasions excluding the rejected tip (e.g. fig 4.9 SOP) multiple 
particulates were seen on the same tip, however it was obvious from both images that because 
of the morphological difference in the particles, only one would make surface contact as the 
functional particle and hence these tips were accepted. This differed from the rejected tip 
where multiple particles presented quite possibly multiple sites of surface contact. On a couple 
of tips there was also concern about larger amounts of adhesive being present than intended. 
However as the functional particulates were not seen to be coated in the adhesive, it was 
assumed this would not be a practical issue upon force measurement. 
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4.5.2.2 The Cohesive Adhesive Balance 
Figure 4.10 shows the CAB plot representing the force data for the BOP functionalized probes. 
Significantly it can be seen that all the plot points lie on the adhesive side of the xy intersect. 
Furthermore, these plot points all appear to be well correlated, and indeed a linear fit gives a 
CAB ratio of 0.35, with an R2 value of 0.57. Figure 4.11 shows the CAB plot for the SS 
functionalized tips. Conversely in this instance all the probes return force results that lie above 
the xy intersect, or in the cohesive domain. These plots again appear reasonably well correlated 
with perhaps one exception (154,355), and a linear fit models a CAB ratio of 1.69 with a 
coefficient of determination again of 0.57. 
These results are significant in a multitude of ways. Firstly the very co-association of all the plot 
points in both figures 4.10 and 4.11 onto one side of the CAB plot is strong evidence for a 
general classification of the two materials into a force balance descriptor. This would suggest 
that the BOP tips induced a greater adhesive force with the SS substrate than the cohesive force 
from the BOP substrate, and that the SS tips interacted to a greater extent with the cohesive 
substrate than the adhesive substrate. In essence this reflects that SS is more interactive with 
itself than BOP but that BOP is more interactive with 55 than itself. This could be considered an 
expected trend, as it is consistent with the surface energy measurements made in figure 4.1. 
Here the API with the higher surface energy measurement dominates the force balance with 
respect to the API with a lower recorded surface energy. However the realization of this 
relationship as a quantifiable force balance could be of huge significance if these two APls were 
co-formulated, as this relationship may lead to an influence on a multitude of parameters, from 
solubility issues, to aerodynamic particle genesis and the reSUlting deposition profile. 
Furthermore the reasonable linear correlation of the data points, would support confidence in 
the balance data. 
Figure 4.12 shows some example force curves from both a SS and BOP tip on a cohesive and 
adhesive surface respectively. The consistency seen with the force curves in this instance was far 
superior to that seen in the previous chapter and there was no rejected force curves due to 
technical failings. The example adhesions seen in figure 4.12 were representative of the data as 
a whole and support the inference of the CAB plots that BOP has a larger force of adhesion with 
5S than it does with itself and vice versa. 
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Figures 4.13 and 4.14 go further towards supporting the significant improvement in surface 
contact area consistency. The box plots of the two tip materials show a generally good 
compliance of the mean to the median average of the tip-surface data. This is important as it 
suggests a broadly Gaussian distribution of the force data that would be the expected 
distribution on a molecularly smooth surface. While there are some slight discrepancies, such as 
the 55 tip 4 adhesive data the 55 tip 3 cohesive data (fig 4.13) and the BDP tip 1 and 2 cohesive 
data, these have been caused by some extreme outliers. The existence of such outliers may be 
. 
attributed to the remaining surface and tip roughness combinations causing more discreet but 
still palpable alterations to F.adh genesis. However in comparison to the pure material runs in 
chapter 3 the compliance of the two averages and the visibly more symmetrical statistical 
arrangements ofthese box plots serves to confirm that compression of the substrates, and small 
particle tip functionalization had a significantly positive impact on contact regime consistency. 
Furthermore in this instance these plots validate to the most part the use of the mean as the 
data descriptor within the CAB plots. 
Hence, it can be suggested in light of the range of data above that the compression of the APls 
was sufficient to allow a CAB to function broadly. While topographical variability is obviously still 
an issue, as evidenced with the small spread from a linear fit observed and the statistical 
arrangements shown by the box ~ I o t s s presented, the close to 60% confidence in the CAB ratios 
extracted lends itself to the success of the semi-model substrates as a middle ground for CAB 
assessment. This is again potentially of importance, as if we determine the semi-model 
substrates are better characteristic of the 'in-situ' APls then such a CAB may better define the 
relationship of the real materials or offer a less work intensive means to assess this force 
balance . 
. There is a significant improvement in terms of a correlation over the previous results and 
. . 
suggests that the semi-model substrates and smaller functional tips have sufficiently reduced 
the geometric variability in the contact regime to allow the broad application of a CAB approach. 
While a pure CAB remains impossible with such materials, the improved confidence in such 
correlation is adventitious in providing a quantification of the balance. This was beyond the 
expected classification of the API force balance simply into an adhesive or cohesive domination 
and allows for a direct comparison with future force balances. 
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4.5.3 The Cohesive Adhesive Balance of Salmeterol Xinafoate and Fluticasone 
Propionate using Semi-Model Substrates 
4.5.3.1 SEM and AFM Characterization of the Powder Compacts 
Having seen that a force balance was successfully carried out using BOP and SS powder 
compacts, it was decided to investigate whether another force balance could be established 
with a second combination of APls using the same modified substrate approach. The second 
combination of APls chosen was that of SX and FP. These two were another combination of a 
betaragonist and corticosteroid, but with subtly different chemistries. Furthermore this 
combination has widespread clinical use, as both a OPI and pMOI formulation for the treatment 
of asthma and other inflammatory respiratory diseases (Seretide 4D Inhalers). In this instance 
therefore the combination of APls is a more realistic one than that experimented with using BOP 
and SS and still presents an interesting combination of chemistries. While the success of the 
compression process in reducing powder roughness and increasing surface suitability had 
already been proven and characterized using the BOP and 55 data, it was still considered 
important to broadly characterize the 5X and FP powders using imaging techniques to account 
for any variation in effect the individual APls might show as a result of their unique chemistries. 
Before compression figure 4.15 shows the particle morphologies of the two APls as seen by SEM 
imaging. The 5X and FP powders show different particle shapes and sizes. The FP particles are 
significantly more spherical, with nodular rough surfaces. At larger magnifications (fig 4.15 FP B) 
these particles show a strong tendency to cluster into agglomerates. They are smaller in length 
than the 5X particles in general but broader. The SX powder (fig 4.15 5X B) shows more irregular 
particle morphology with more elliptical, long, thin and smoother particle characteristics. These 
appear to have agglomerated less consistently at higher magnifications over smaller areas. 
However, lower magnification (fig 4.15 5X A) images show agglomerate development, with 
distinct particle bodies creating an irregular surface by particle clustering and overlay. BY 
contrast the 5EM images of the compressed powders show significant topographical smoothing. 
The FP powder compact (Figure 4.16 FX) now shows a much more consistent topography. 
Individual particle character has been generally reduced, although some definition of the 
individual particles can still be seen as a pattern of slight protrusions away from the average 
surface, and demarcations of particle outlines. The 5X compact similarly shows some small signS 
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of individual particle character (fig. 4.16 SX B) at higher magnifications, although not so 
pronounced as with the FP disc. Over larger areas at lower magnifications (fig. 4.16 FP SX A) 
both discs show no distinctive pattern to identify the original particulate localization. Both show 
significant smoothing with large areas of a consistent surface. However both discs also show 
surface features consistent with the SS and BDP samples, in the unidirectional track marks 
across the images. Again these are likely to be the impression left by the die casting process. In 
SX's case these are less obvious, but where visible show significant topographical impact, 
leading to bunching of the API material and small pieces of surface debris in secluded areas. The 
FP disc shows far more consistency of these imprints, with many leading to small surface cracks 
and some to entire fissures. 
The AFM images of the powder compacts support the impressions given by the SEM image 
assessment (fig. 4.17). Both the FP and SX discs show a spread of particles protruding from the 
surface, but these are more significant in terms of scale and frequency on the FP disc. Both 
samples seem to evidence the same undulation of the surface as the probable consequence of 
the press imprint, but the SX disc looks broadly more homogenous, with the FP surface less 
consistent with far more irregular associations of prominent particles. The roughness analysis of 
the compacted API powders performed on the AFM images is shown in figure 4.18. A 
comparison with the free powder was not done, as it was not considered necessary to further 
characterize the scale of roughness reduction, as the flattening process was plainly evident from 
the SEM images collected. Importantly though, figure 4.15 highlights that the compaction 
process has generated surfaces with similar a roughness to the two previous APls. This 
suggested that these powder compacts were suitable for use as CAB substrates. The SX compact 
can be seen to give a smoother average Rq than the FP compact over both scan sizes (13.9nm Rq 
at 5 x 5 and 17.4nm ~ q q at 10 x 10 compared to 20.0nm Rq 5 Ilm x 5 Ilm 23.6nm Rq 10 Ilm x 
10Ilm). This again shows the beta2-agonist as smoother on compression than the corticosteroid. 
This may suggest, in line with some of the features seen optically and the general handling of 
the compacts, that the corticosteroid surfaces are more fragile, and fracture prone, less flexible 
to the compression process. However the increase in roughness from small scan area to larger 
presents a bigger percentage increase by Rq with respect to the SX powder (25%) than the FP 
powder (18%). This in turn may indicate the FP powder has a more consistent topography over 
larger areas than SX powder. However, from the SEM images analysed the FP disc can be seen 
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to be subject to several surface collapses (cracks, inversions etc.) that will not be factored into 
the AFM data on these scan sizes and by scan area selection. 
4.5.3.2 AFM Tip Functionalization 
The 5EM images of 5X and FP tip functionalization (fig 4.19) were consistent with those seen 
with the BOP and 55 tips. In this instance no tips were seen to have failed the functionalization 
process or were rejected. There were similar issues regarding multiple particulate attachments, 
and some excess areas of adhesive, but these were again investigated with further imaging and 
accepted as non-critical. In general the FP particle attachments were larger than the 5X 
attachments, but all were of a significantly decreased particle size to the failed functional 
particles in chapter 3. 
4.5.3.3 The Cohesive Adhesive Balance 
The CAB of 5X and FP using the powder compacts further proved that the semi-model substrates 
could be utilized successfully in describing the force balance of a combination of APls. For both 
API tip types a strong linear relationship between all the tip plot points could be seen. This 
suggests that proportionality was broadly maintained between Fadh and Fcoh from tip to tip. The 
implications of such are that the contact geometry between the tips and the cohesive and 
adhesive surface was not changing critically so as to bias the basal chemical forces. In this 
instance the confidence in the fit was compounded by coefficients of determination that were 
even stronger than those with the 55 and BOP powders, (0.81 for FP tips and 0.97 for 5X tips). 
This supports the success of the compaction process in providing substrates suitable for use 
with a CAB approach in defining a broad force balance of two APls. The FP tips (fig. 4.21) all lie in 
the adhesive domain of the CAB plot, and when fitted linearly generate a CAB ratio· of 0.63. ThiS 
therefore infers that FP has a stronger force of adhesive interaction with 5X than the force of 
auto-adhesion. Conversely the 5X tips (fig 4.22) all plot force points just above and very close to 
the xy intersect where Fadh = Fcoh' The gradient of the linear fit of these points gives a CAB ratio 
of 1.08. This would therefore indicate that 5X has a very slight cohesive tendency i.e. it 
undergoes larger interactive forces when contacting itself than when contacting FX. However, 
this CAB ratio is only just above the cohesion/adhesion parity, and therefore this balance may 
204 
Chapter 4 - Application of the CAB approach to, and Characterization of 'Semi-Model' Inhalation 
Substrates 
reflect that SX largely interacts on a similar scale with both itself and FP and has a neutral force 
balance. When this balance is compared to the one performed between 55 and BOP the same 
broad trend can be seen, i.e. that the betaragonist has a cohesively dominated relationship 
with the corticosteroid and the corticosteroid an adhesively dominated relationship with the 
betaragonist. However with the SX FP force balance this is far less pronounced. Visually both 
the FP and 5X balances lie closer to the xy intersect than the 55 BOP balances. The CAB ratios for 
the two beta2-agonists are 1.69 and 1.08 for 55 and SX while for the two corticosteroids are 0.57 
and 0.63 for BOP and FP respectively. Broadly the force balances sit according to what might be 
expected in line with the surface energy assessment of the APls. However interestingly, the 
implied difference between SX and FP in surface free energy (37.1 mJ/m2 to 27.7 mJ/m2) was 
very similar to that between 55 and BOP (45.3 mJ/m2 27.7 mJ/m2). This would have suggested 
that based on a pure surface free energy basis, both balances would have shown similar 
cohesive and adhesive separations. It is possible that the deviation around the surface energy 
measurements on the FP compact hide the fact that it was closer to 5X in surface free energy 
than the average suggested. 
The example force curves in figure 4.20 were representative of the bulk of the force curves 
collected with all the functional tips used. Consistency was high and there were no rejected 
curves as a result of unusable traces. Again, as expected the general appearance of the curves IS 
consistent with the CAB balance constructed from the mean of the data, showing larger 
adhesions between 5X tips and 5X than between SX tips and FP and the reverse with the FP tips. 
The box plots in figures 4.23 and 4.24 show a similar analysis to that of the 55 BOP data. Broadly 
the mean and median of the tip-substrate datasets are roughly consistent, with some 
discrepancies arising where particularly large outliers appear to have pulled the mean away 
from the 2nd quartile. The fig 4.24 FP tip 2 cohesive and adhesive data is a good example of this, 
as is the FP tip 4 adhesive data and the fig 4.23 SX tip 1 cohesive data. In these examples it is 
reasonable to presume that this is still related to the roughness of the compressed substrates. 
Some variability in tip-surface contact geometries still occurs because the compressed 
substrates are not molecularly smooth. In some instances this is still generating contacts that 
are not equivalent in area, which leads to the genesis of exaggerated or suppressed Fadhs that 
stretch the data, and move away from the pure Gaussian distribution desired. Yet the SX 
adhesive tip data and most of the remaining tip-surface data shows a very good consistency of 
the mean to the median with balanced quartiles and whiskers. This infers a far more consistent 
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contact regime than with the pure materials tria lied in chapter 3, which in turn gives rise to the 
far better correlations between the plot points in the CAB balance. That a linear regression of 
these points gives acceptable coefficients of determination is further support that the trends 
identified are not artificial. As with the SS BDP data, the box plots in figs 4.23 and 4.24 were 
assumed to provide suitable confirmation that the mean was a reasonable descriptor of the data 
for use in the CAB plots and that these CAB ratios were not overly biased by anomalous data. 
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4.6 Conclusions. 
It has been shown that the compression of API powders for use as AFM substrates has been not 
only successful in allowing a series of investigations by AFM, including both imaging and force 
probing, but also (in conjunction with the considered selection of smaller functional particle 
probes) in allowing a broad CAB approach to be applied with success to two combinations of 
common APls .. The compression process has been shown to induce several changes in' API 
morphology, topography and to an unknown extent the physicochemical makeup of the APls. 
Some of these. alterations are beneficial. Surface roughness of salbutamol sulphate and 
beclomethasone dipropionate powders have been reduced 15x to 30x fold depending upon the 
scan area considered, consistent with an obvious reduction in prominent particulate matter and 
surface smoothing. This has operationally facilitated conventional AFM measurements and 
allowed for the CAB approach to be applied without the model constraints being exceeded due 
to surface roughness induced contact regime alteration. The use of the compacts was further 
supported by the success of fluticasone propionate and salmeterol xinafoate compacts to 
perform further CAB analysis. Interestingly a slightly different force balance was identified that 
offers an interesting comparison to that of the salbutamol and beclomethasone. 
However there are concerns raised that the induction of thermodynamic alteration as seen by 
DSC, such as the potential polymorphic shift between the ratio of salmeterol xinafoate form I 
and form II is an indicator that the solid state structure of the API maybe affected and hence 
should be taken into account in future measurements. This perhaps defeats to some extent the 
purpose of finding a middle ground between the excessively rough 'as received' micronized 
powder particles and the recrystallized API surfaces in establishing a force balance. However the 
other APls do not show any obvious changes to, additional or omitted thermodynamic events 
that might suggest critical changes to phase behaviour (Although this must be tempered by the 
inability to assess crystallinity or other succinct changes in physiochemical form). The , 
appearance, in particular of salbutamol sulphate, post-compression may infer a recrystallization 
process has occurred under pressure. This again would detract from the aims of producing a 
semi-model substrate. Further investigation and characterization of the precise impact of the 
compression procedure would be advisable but this is limited by the exact demands of certain 
technical procedures and more problematically sample availability. However despite this the 
excellent success of these modified substrates in generating CAB plots with significantly 
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improved linear force plot correlations, has allowed a rough quantification of the force balance 
in both a salbutamol / beclomethasone and salmeterol / fluticasone system. The distinct division 
between the pairing of the adhesively dominated beclomethasone and cohesively dominated 
salbutamol as well as the near neutral balanced salmeterol and adhesively dominated 
fluticasone offers an opportunity to investigate differing force balances and their association 
with formulation performance indicators. 
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5.0 The Cohesive Adhesive Balance of Inhalation Formulations 
and their 'in-vitro' Deposition Performance 
S.l General Introduction 
5.1.1 Associating Force Balances to 'in-vitro' Deposition Performance 
Chapter 4 showed that using a compressed API surface it is possible to perform a descriptive 
CAB experiment between combinations of APls. Whilst the exact effects of the compression 
process upon' the physicochemical nature of the APls requires further investigation, there was 
success in identifying a rough force balance between two sets of inhalation APls, which was not 
achievable with raw materials. This offers an opportunity to investigate the links between the 
force balance of the primary components of an inhalation system and the performance 
attributes of that system. When considering inhalation formulations one of the principal 
attributes a device and formulation combination must achieve is a suitable deposition profile. As 
chapter 1 indicated, for an API to elicit a physiological effect it needs to reach the appropriate 
target site. This not only requires a particle size of between 1 and Sllm, but also a subsequently 
suitable aerodynamic particle character. One of the means to measure the aerodynamic particle 
size ofa formulation is to use an Andersen Cascade Impactor (ACI). This device acts loosely as an 
'in-vitro' model of the airways, and its complete description and fundamental principals are 
explained in chapter 2. In basic terms the ACI is a series of calibrated gratings of reducing nozzle 
size which, with a calibrated air through flow, can be used to separate out incumbent airborne 
particulates onto collection plates below each grating. The gratings are also attached to pre-
grating components that link the pMDI or DPI to the ACI stack, and roughly mimic the upper 
airways. The collection plates and the surfaces of the attaching components can then be 
analysed for quantifiable assessment of particulate deposition. The proportion of deposition 
throughout the stack can be used as an assessment and measure of the aerodynamic particle 
sizing of a formulation. Ultimately the effective aerodynamic particle size is derived from many 
complex variables, and this is even more complicated in a pMDI system with the use of a volatile 
propellant. Nevertheless the fundamental driving force is the interparticulate or inter-surface 
interactivity of the formulation components. Thus it is highly likely that differing force balances 
between the primary components will result in alterations to the aerodynamic particle sizing 
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achieved. While it is overly simplistic to factor out the influence of solvent forces derived from 
API suspension in the propellant, being able to associate the force balance between two key 
components to given changes in deposition profile could prove invaluable in the assessment of 
current and prospective formulations. This chapter will therefore centre on performing 'in-vitro' 
deposition assessments of two API combinations using and Andersen Cascade Impactor, in an 
attempt to link changes in the profiles obtained to the CAB of the systems already performed. 
S.2 Chapter Aims and Objectives 
5.2.1 Chapter Aim 
The aim of this chapter was to investigate the 'in-vitro' deposition performance of two binary 
pMDI formulations in HFA134a, namely salbutamol sulphate with beclomethasone dipropionate 
I 
and salmeterol xinafoate withfluticasone propionate. In so doing to attempt to identify whether 
a basic API system CAB could be associated with beneficial or disadvantageous changes to the 
deposition character of the individual components of a propellant based inhalation system. 
5.2.2 Chapter Objectives 
The chapter objectives were as follows: 
To investigate the 'in-vitro' deposition performance of the two binary systems in 
comparison to the deposition performance of the individual APls. 
To establish any link between the CAB balance of the API combinations and their 
deposition performance. 
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5.3 Materials and Methods 
5.3.1 Materials 
-
Beclomethasone dipropionate (BOP), salbutamol sulphate (55), salmeterol xinafoate (5X) and 
fluticasone propionate (FP) were chosen for investigation in this chapter. BOP and 55 were 
chosen to be used as a combination as a result of the CAB performed between the two APls in 
chapter 4. This identified a clear force balance. BOP showing a strong adhesively dominated 
relationship with the beta2-agonist and the 55 showing a strong cohesively dominated 
relationship with the corticosteroid in return. Fluticasone and 5almeterol were chosen as 
comparators to be investigated due to both the clinical prominence of this combination within 
both OPI and pMOI inhaler formulations (5eretide(lIl), and also as another combination of the 
same two drug classes with subtly different chemistries. The force balance between these tWO 
APls showed FP with a mildly adhesive force domination with 5X and that 5X showed a marginal 
cohesive, if not neutral force relationship with FP in return. The micronized powders were all 
provided by 3M Healthcare (loughborough, UK). A Ventolin® inhaler (containing salbutarnol 
sulphate lOOllg per actuation in HFA134a) was also provided by 3M Healthcare ltd 
(loughborough, UK) to run as a comparator to the salbutamol containing formulations. All pMOI 
components and accessories for manufacture were provided by 3M Healthcare Ltd 
(loughborough, UK) unless otherwise stated. All other reagents and accessories were provided 
by Sigma Aldrich Company ltd (Gillingham, UK). 
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5.3.2 Methods 
5.3.2.1 Formulation of pMDI canisters 
The pMDI formulations manufactured in this chapter were as follows: 
SS 100: 
BOP 100: 
SS BOP 50: 
SS BOP 100: 
FP 100: 
SX 100: 
SXFP 50: 
SX FP 100: 
Salbutamol Sulphate 0.16Sg, HFA134a 99.83g 
Beclomethasone Oipropionate 0.16Sg, HFAl34a 99.83g 
Beclomethasone Oipropionate 0.0825g, Salbutamol Sulphate 0.0825g, HFA134a 99.83g 
Beclomethasone Oipropionate 0.165g, Salbutamol Sulphate 0.165 g, HFA134a 99.67g 
Fluticasone Propionate 0.165g, HFA134a 99.83g 
Salmeterol Xinafoate 0.165g, HFA134a 99.83g 
Fluticasone Propionate 0.0825g, Salmeterol Xinafoate 0.0825g, HFA134a 99.83g 
Fluticasone Propionate 0.165g, Salmeterol Xinafoate 0.165g, HFA134a 99.67g 
In addition to the formulations manufactured above, a Ventolin® inhaler (salbutamol sulphate 
lOOllg per metered dose provided by 3M Healthcare Ltd, Loughbourogh, UK) was used as a 
comparator to the 55 100 formulation to identify any obvious differences in deposition profile 
that might indicate critical formulation issues with the in-house pM Dis. 
The above manufactured pMDI target systems were based on a HFA 134a density of 1.206g/ml 
and a SOIlI metering valve. Each formulation was then designed to deliver the following masses 
of API per metered dose: 
SS 100: 
BOP 100: 
SSBOP50: 
SSBOP 100: 
Salbutamol Sulphate l00f.lB 
Beclomethasone Olpropionate l00f.lB 
Beclomethasone Dipropionate SOf.lB, Salbutamol Sulphate 50f.lB 
Beclomethasone Oiproplonate 100f.lB, Salbutamol Sulphate l00f.lB 
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FP 100: 
SX 100: 
SX FP 50: 
SX FP 100: 
Fluticasone Propionate 100j.lg 
Salmeterol Xinafoate 100j.lg 
Fluticasone Propionate 501J.8, Salmeterol Xinafoate SOj.lg 
Fluticasone Propionate 100j.lg, Salmeterol Xinafoate 100j.lg 
For each system a bulk unit was prepared in a Trimline can (1 inch neck) by adding the required 
amount of API or mixture of APls to the can. The can was then sealed and the required quantitY 
of HFA 134a (DuPont, Steven age, UK) was then injected through the 1 inch non-metering valve 
from a donor can using a PTFE transfer button, to the target weight. Each Trimline can was then 
sonicated in an ultrasonic water bath for 3 minutes to effect dispersion of the micronized 
powder. The cans were then chilled in a cryobath to -60°C to maintain the liquidity of the 
propellant without pressurization and a then a hole was punched with a nail at a point just 
beneath the valve crimp. To form a spout, a polythene Pasteur pipette was then pushed into the 
hole and then clipped off around 1cm away from the can. The chilled contents from the Trimline 
can were then sequentially decanted via the formed spout into 16ml FEP coated pMDI canisterS 
(3M Healthcare Ltd, Loughborough, UK) which were immediately crimped with Bespak BK357 
SOmcl metering valves. This generated a total of 6 MOl units per system. All units were then 
water bath tested for leaks at 40°C. 
The formulated masses of SX and FP used in the formulations above are not representative of 
those in clinical use. 5X and FP systems are usually dosed at a constant dose of 2Sj..lg per 
actuation of 5X with a variable dose between SOj..lg to 2S0j..lg of FP per actuation. 55 and BOP are 
not clinically used together due to the predominant use of 5S as an 'as required' reliever, and 
BOP as a regular prophylactic. However usual doses of S5 and BOP are in the region of 100j..lg per 
metered dose. The masses chosen in this chapter were used to allow an appropriate assessment 
of the force balance of the system. By mass matching this removes mass variance as a variable 
for deposition effects. Both combinations of APls were produced as a SOj..lg per actuation (SOj..lS 
API 1 and SOj..lg API 2) formulation and as a 100j..lg per actuation (100j..lg API 1 and 100j..lg API 2) 
formulation. By delivering SOj..lg of each API this meant that a total API delivery of 100j..lg was 
maintained, and could be compared both with the individual API formulations for consistenCY 
but also to the doubled mass formulation to examine mass based effects. No other excipients 
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were used in the formulation process, so as to rule out their impact on the surface interactions 
of the APls under consideration . The formulations were therefore tested within a maximum of 
two weeks of manufacture to reduce the potential for degradation or instability issues. 
5.3.2.2 Andersen Cascade Impaction 
An eight stage Andersen Cascade Impactor (3M Healthcare Ltd, Loughborough, UK) was used for 
aerodynamic particle sizing and deposition profiling of the formulated aerosols. A schematic of 
the apparatus is given below in figure 5.1 
Pa rti cle Size 
Plate 0 - 9.0-10 Jlm 
Plate 1 - 5.8-9.0 Jlm 
Plate 2 - 4.7-5.8 11m 
. Plate 3 - 3.3-4.7 Jlm 
Plate II - 2.1 -3.3 Jlm 
Plate 5 - 1.1 -2.1 Jlm 
late 6 - 0.65-1.1 Jl m 
I te 7 - 0.43-0.6 Jlm 
A ctu ato r Coupler 
Unit and Actu ator 
USP 24 Throat 
Collar 
Jetj Stag e 0 
late 0 
St ge 1 
late 1 
St ge 2 
PI te 2 
St ge 3 
I te 3 
St ge 4 -
St ge 7 
c: ::::::> I t 7 
Va cuum 
Source 
Air low Ef-.:a::a:::::ii!:!::!!:;i ..... ~ - 1 . . J J ilter Stage 
+- 28.3 I m i i ~ ~ "":I 
Figure 5.1: Schematic of an Andersen Cascade Impactor and associated particle size separation (3M 
Healthcare Ltd) 
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The ACI stack was assembled with all stages plated as shown, with silicone O-rings around each 
stage and Whatman grade 934-AH glass microfiber filter paper (Sigma Aldrich Ltd, Gillingham, 
UK) cut to size and fitted into the filter stage. A vacuum pump was used to draw airflow through 
the ACI stack at 28.3 I/min as per European Pharmacopeia standards for pMDI assessment 
(European Pharmacopeia, 2012). Airflow was calibrated by a DFM 200 flow meter (CopleY 
Scientific, Nottingham, UK) attached via a mouthpiece adaptor, with a tolerance of ±O.S I/min. 
After airflow had been adjusted as necessary, formulation canisters were loaded into clean 
actuators. As per the ACI/HPLC methods described below these formulations were then pre-
processed (waste firing, weight records etc.) as appropriate. After pre-processing, the canisters 
were dried and replaced into a fresh actuator. The formulations were shaken .for the durations 
specified in the methods below ~ n d d then actuated via an actuator coupler into the ACI stack. 
After a given number of repeat actuations, the vacuum pump was switched off, and the ACI 
stack disassembled. The ACI stages were each rinsed with given quantities of the sample 
diluents detailed below, and samples of the rinsing were taken and placed in HPLC autosampler 
vials for HPLC quantitative analysis. The ACI components were then washed thoroughly with 
water and methanol before drying prior to reassembly for further runs. 
5.3.2.3 High Performance Liquid Chromatography Analysis 
HPLC analysis was carried out using a HP Agilent 1100 HPLC with Agilent Chemstation software 
(Agilent Technologies Ltd, Stockport, UK). The HPLC was equipped with an autosampler, uV 
detector and electronic integrator. All work was carried out according to the assay protOCOls 
detailed below. 
5.3.2.4 Salbutamol Sulphate ACI Assay 
The SS assay was performed using a reverse phase methodology. A Supelco LC-18, 4.6 x 150mm, 
SlJ.m particle size column (Sigma Aldrich Ltd, Gillingham UK) was used. Samples were injected at 
a volume of 401J.I, run for 6 minutes at 2.0ml/min, 40·C with UV detection at 22S nm. Two blanks 
and two reference samples were run before and after each sample set for system evaluation 
and calibration. The mobile phase was a mixture of 45% HPLC methanol: 55% triethylamine 
phosphate buffer with sodium dodecyl sulfate (pH 2.5). The triethylamine solution was prepared 
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by dissolving 1.442g sodium dodecyl sulfate into 980ml of HPLC grade water, then adding 6.8ml 
of phosphoric acid. The pH of the resulting solution was then adjusted to 2.5 with triethylamine 
( .... 11ml) and degassed for an hour. This generated a final buffer composition of 100 mM 
triethylamine phosphate with 5 mM sodium dodecyl sulphate. A binary solvent input was used 
on operation to obtain the requisite mobile phase constitution 
The ACI stage sample diluent used was a mixture of 45% HPLC grade methanol: 55% 0.1% 
phosphoric acid (v/v). This was prepared by mixing 1ml phosphoric acid with 1000mi HPLC grade 
water, then combining 550ml of the resultant solution with' 450ml methanol. 55 reference 
standards were produced in duplicate. 43mg of 55 was accurately weighed into a 100mi 
volumetric flask. This was dissolved into approximately 50ml of sample diluent, before 
sonication. After cooling the flask was diluted to volume with sample diluent. 2ml of the 
resultant solution was pipetted into a 200ml volumetric flask, diluted to volume and mixed well. 
25ml of this solution was pi petted into a 50ml volumetric flask before dilution to volume and 
mi'xing. This gave a 55 reference solution of approximately 2J,1g/ml (lOOllgj50ml). 
Each 55 formulation was actuated to waste four times after 10 seconds of appropriate shaking. 
The valve and valve stem were then cleaned with 10ml of water and 10ml of methanol before 
drying with a nitrogen tap. The canisters were then accurately weighed before returning to a 
new actuator. The ACI was operated at a standard 28.31/min flow rate. The 55 containing 
formulations were shaken appropriately for 10 seconds before coupling to the ACI via the 
mouthpiece adaptor, and actuation before 2 seconds from the end of shaking. The actuated unit 
was left for 30 seconds attached to the adaptor before removal and the process was repeated. 
Each device was actuated a total of five times into the ACI stack. After the final actuation the ACI 
stack was left running with the device attached at the mouthpiece for 30 seconds before the 
vacuum pump was shut down. The ACI was then disassembled into its constituent pieces which 
were all placed into sterile plastic bags pre-filled with given volumes of sample diluent. The 
volumes of sample diluents used were as follows: 
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-Component I Plate Rinse I Diluent (ml) 
Valve Stem* 10 
Actuator 50 
-Throat and Coupler 50 
-jet, Plate 0 - Plate 3 10 
Plate 4 - Plate 5 50 
Plate 6 - Plate 7 10 
-Filter 10 
Table 5.1 Salbutamol sulphate Atl stage diluent rinse volumes 
After each component was placed into the bag, these were sealed and the pieces were agitated 
in the diluent using manual shaking for a minimum of 90 seconds. Each component was then 
rinsed down with the diluent volume using a disposable syringe before the further mixing to 
ensure homogeneity. Approximately 2ml of the diluent was then pipetted into a HPLC 
autosample vial. Notably the valve stem was an exception to this technique. It was not placed 
into a plastic bag but rather washed down inside and out with the 10ml of allocated diluent 
using a Sml syringe and a needle into a clean beaker. The rinsing was mixed and then 
approximately 2ml was pi petted in a HPLC autosampler vial. The filter sample was first passed 
through a 0.451lm PTFE syringe filter to prevent any fibers from the filter paper itself 
contaminating the HPLC sample. The canister was then cleaned with water and methanol before 
drying and the recording of an accurate post run weight. 
The API peaks from the HPlC chromatograms for were then integrated using the chemstation 
software to ascertain the area counts for quantification. The deposition mass on each stage was 
then calculated based on the calibration factors acquired from the standard solutions using the 
following equation: 
ss = Asam X W X ..!...- X V sam X 2/200 X 25/50 X ~ ~ (5.1) 
Mass Astd std 100 100 1 1 5 
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Where SSMass is the mass of SS per actuation, Asam is the area counts of the sample SS peak, 
Astd is the (average) area counts of the SS peak in the SS standard, Wstd is the weight of the 
reference standard, P is the purity of the SS (%), Vsam is the volume of sample diluent used for 
the relevant sample stage, 2/200 and 2S/S0 represent the 5S reference sample dilutions and S 
represents the number of actuations. 
The mass of SS deposited on each component was then expressed as a percentage of the total 
recovered mass for deposition analysis. The mass of SS deposited on plate 3 to plate 7 was 
summed as the fine particle dose (FPO). This represents an aerodynamic particle size of <SI-lm 
and is considered the target area for primary effect. The FPO can be expressed as a proportion 
of the total mass recovered of SS as the fine particle fraction (FPF). The mass median 
aerodynamic particle size (MMAO) for the formulation (the diameter at which SO% of the 
particles recovered by mass are larger and SO% are smaller) was then calculated from the ACI 
stack mass distribution using MMAOcalculator (www.mmadcalculator.com.2013}.This 
calculation uses the calibrated nozzle sizes of the ACI in conjunction with the mass distribution 
, 
of the formulation to plot cumulative masses versus aerodynamic diameters and statistically 
identify the median diameter. The geometric standard deviation (GSO) is then calculated in 
conjunction as a measure of the spread of the aerodynamic particle size distribution. 
Importantly both values apply with restriction to the calibrated ACI stack and do not account for 
mass lost to any un-calibrated pre-stack components (valve, actuator, throat etc.). 
5.3.2.5 Beclomethasone Dipropionate ACI Assay 
The BOP assay could not be performed from the same samples as the SS analysis due to the 
difficulty finding a method to separate the two APls from each other in an adequately accurate, 
and time conservative manor. As such all the BOP assays were performed on separate runs, 
which was a limitation to a direct comparison of deposition performance. A Supelco LC-18, 4.6 x 
lS0mm, SI-lm particle size column (Sigma Aldrich Ltd, Gillingham UK) was used to run 201-l1 
aliquots of the samples. These were run at a 2.0ml/min flow rate, at GOoC for 12 minutes with 
UV detection at 238nm. The mobile phase was a mixture of 55% HPLC grade acetonitrile: 45% 
HPLC grade water. This was achieved using a binary solvent input. Standard solutions of BOP 
were produced in duplicate. SOmg of BOP (anhydrous) was accurately weighed into a 100m I 
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volumetric flask, dissolved in approximately 50ml of acetonitrile with sonication. After cooling 
the solution was diluted to volume. 2ml of this solution was pi petted into a 200ml volumetric 
flask which was diluted to volume with acetonitrile to give a standard solution of 5llg/ml BOP. 
Acetonitrile was used as the sample diluent. ACI operation parameters, sample diluent volumes 
and HPLC quantification was carried out in identical fashion to that described for SS in 5.3.1.4. 
The mass of BOP per stage was then expressed as a percentage of the total weight recovered for 
analysis, and the FPO and FPF of each BOP containing formulation documented. 
5.3.2.6 Salmeterol Xinafoate and Fluticasone Propionate ACI Assay 
An ACt assay for sx and FP was used that allowed for both APts to be separated and detected 
using the same HPLC methodology. An ACE 5 C18, 75 x 4.6mm 51lm particle size HPLC column 
'was used for analysis. Samples were run for 8 minutes (15 for jet stage and filter) isocratically at 
40·C with a flow rate of loOml/min. Injection volumes of 20111 were used from each sample and 
the detector was set to record UV absorbance at 228nm. The mobile phase for this assay was a 
mixture of 63% HPLC grade methanol: 37% ammonium acetate Solution (0.6% w/v): 0.05% 
trifluoroacetic acid (TFA). This was prepared by first ,accurately weighing 6g of ammonium 
acetate, and dissolving in 1000mL of HPLC grade water. 370ml of this resultant 0.6% w/v 
solution was then mixed with 630mL of HPLC grade methanol and O.5ml of TFA to generate the 
mobile phase. Sample diluent for the ACt stage dissolution was prepared as a m i x t ~ r e e of 85% 
HPLC grade methanol: 15% ammonium acetate solution, produced by mixing 850ml of methanol 
with 150ml of the 0.6% ammonium acetate solution. 
SX and FP standards were prepared in duplicate. 30mg of FP was accurately weighed into a 
100m I volumetric flask. About 50mL of HPLC grade methanol was added, and the contents were 
sonicated until the API had completely dissolved. After the solution had cooled to room 
temperature, the flask .was diluted to volume with methanol and mixed well giving a FP 
concentration of approximately 300Il8/ml. 30mg of SX was accurately weighed into a 200ml 
volumetric flask. Approximately 100ml of HPLC grade methanol was added and the contents 
sonicated to complete dissolution. After equilibration to room temperature the flask was diluted 
to volume with further methanol and mixed well giving an SX concentration of 1 5 0 ~ m l l
(1031l81ml salmeterol base). Using volumetric pipettes, 4ml of the fluticasone stock and 3ml of 
the salmeterol stock was measured into a 100m I volumetric flask. This was diluted to volume 
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with sample diluents and mixed well giving a standard solution with an FP concentration of 
12llg/ml and an 5X concentration of 4.5Ilg/ml (3.11lg/ml salmeterol base). ACI operation was 
identical to that as described fro 55 in 5.3.1.4 with the exception that 6 total actuations were 
used per formulation and that the following volumes of sample diluent were used for the 
relevant stages: 
Component / Plate Rinse / Diluent (ml) 
Valve 5tem* 10 
Actuator 20 
Throat and Coupler 50 
Jet, Plate 0 - Plate 2 10 
Plate 3 - Plate 4 20 
Plate 5-Plate 7 10 
Filter 10 
Table S.2 Salmeterol xmafoate and flutlcasone propionate ACI stage diluent rinse volumes 
An example chromatogram of a 5X FP sample solution is presented below in figure 5.1A showing 
the expected elution times and peak occurrences of the two APls : 
L"X..nIPLE CHROMATOGRnI OF SAl\IPLE SOLlmON 
0. e 
0. 6 § 
o.G14· I 
0.012 
0..0111-
~ 0 . ! D I I
o.!Il6 l5 ~ ~
0.0C4 
, 
0.002 
0._ 1 
.0-
A ) \ 
I> <l L> 
" 
0.Il0 0.50 IDe 1..50 2.00 2.50 30.0. 3.50 4.00 4.50 5.Q] 5..50. 6.00 6Sl 7.00 7SJ 8DO 
!.h.I!, 
Figure S.IA: Example chromatogram of salmeterol xinafoate and fluticasone propionate sample 
solution (3M Healthcare ltd). 
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The API peaks were again integrated using the chemstation software to ascertain the area 
counts and the amount of each of the components was calculated based on the calibration 
factors acquired from the standard solutions. The SX calibration (Bsx) standard was calculated 
as follows: 
B A [(WstdXPXO.6883) 3ml ] sx = rea d -:- X --st 200mi 200mi (5.2) 
Where Areastd is the average peak area of the salmeterol peaks from quantification standards, 
Wstd is the weight of SX used, P is the purity of the SX (1 for completely pure material), and 
0.6883 is the molecular weight c o ~ v e r s i o n n from salmeterol xinafoate to salmeterol base. The 
remaining volumes represent the dilutions of the reference in production as described above. 
The calibration factor for FP (B FP) was calculated as follows: 
B = Ar ..:.. [(Wstd XP) X 3ml] 
FP eastd' lOOmi 200mi (5.3) 
Where Areastd is the average peak area of the fluticasone peaks from the quantification 
standards, W std is the weight of FP used and P is the purity of the FP (1 for completely pure 
material). 
The concentration of SX and FP found on the valve stem, actuator, throat and couplet, jet stage, 
plates 0-7 and the filter could be calculated as follows: 
Concentration (p.g/ml) = Areasam X 1000 
BSX/BFP 
(5.4) 
Where Areasam is the peak area of the sample peak of interest, and the x 1000 reflects the 
conversion from mg to Ilg. The amount (ll8Iactuation) of FP and SX on each component waS 
calculated as follows: 
Amount (pg/act) = Areasam X Dilution X 1000 (5.5) 
Bsx/BFP 6 
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Where Dilution is the volume of sample diluent used to rinse each stage respectively, 6 is the 
number of actuations per sample run and xlOOO is the conversion from mg to ~ g . . In this fashion 
the amount of SX and FP deposited on each component could be calculated. The quantity of SX 
and FP deposited on plate 3 to plate 7 was summed as the fine particle dose (FPO). This 
represents an aerodynamic particle diameter of < 5 ~ m m and is considered the target area for 
primary effect. The FPO as a proportion of the total dose mass recovered is the fine particle 
fraction (FPF). The FPO may also be described as a proportion of the total expected dose 
delivered (Le. 6 x 1 0 0 ~ g g FP = 6 0 0 ~ ) . .
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5.4 Results and Discussion 
5.4.1 Deposition of the Solo and Co-Formulated Salbutamol Sulphate and 
Beclomethasone Oipropionate 
5.4.1.1 Deposition Performance of Salbutamol Sulphate 
Figures 5.2, 5.3, 5.4 and 5.5 show the individual stage by stage deposition of 55 in a Ventolin® 
100, 55 100, 55 BOP 50 and 55 with BOP 100 pMOI formulations respectively. These deposition 
profiles are expressed as percentages of the total collected dose of the respective APls derived 
from the HPLC assay of the solvent wash offs of the ACI stack stages. Figure 5.6 shows all these 
deposition profiles for 55 in combination for comparison. It can be seen that in all the SS 
formulation assays, there was a consistent general trend of deposition. High level deposition on 
the pre-ACI stages can be seen, most particularly the actuator and throat, where there was a 
consistent 50-60% of collected dose found in combination across all the salbutamol assays. 
There was then a subsequent decrease in deposition across the early stages of the ACI Uet stage 
to plate 1} before a subsequent increase to a 'second peak' starting at plate 2 and maximizing at 
plate 4, followed by a variable drop off in deposition to plates 5 and 6, with very little recovered 
mass on plate 7 or at the filter. Plate 4 was consistently the ACI plate with the most deposited 
material across all the formulations (16% Ventolin-, 13% 55 100,13% 55 BOP 50 and 13% 55 'BOP 
l00) with plate 5 consistently the next highest, followed by plate 3. This suggests that for all the 
formulations there were two significant areas of salbutamol deposition. Primarily this was the 
pre-stack surfaces, suggesting a high proportion of the emitted dose would be lost to the device 
or with respect to 'in-vivo' correspondence would be swallowed. However the second peak in 
deposition is in the respiratory target range or rather on the fine particle plates. These plateS 
from plate 3 down to the filter represent an aerodynamic particle size of <SJ,1m, which is 
considered the ideal particle size range to reach the target airways and illicit the intended 
physiological responses. 
Critically, however, it can be seen that the general trend in 55 deposition is the same for all the 
formulations, with some distinct changes in the exact pattern. The salbutamol only formulationS 
(Ventolin- and S5 100) shows a higher percentage deposition on the fine particle plates than the 
formulations co-formulated with BOP. This is coincident with what appears to be less 
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Figure 5.2: Percentage deposition profile across an Andersen Cascade Impactor of total collected dose 
of salbutamol sulphate from a V e n t o l i i ~ ~ pMDI formulation. 
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Figure 5.3: Percentage deposition profile across an Andersen Cascade Impactor of total collected dose 
of salbutamol sulphate from a salbutamol sulphate lOOl1g / actuation pMDI formulation. 
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Figure 5.4: Percentage deposition profile from an Andersen Cascade Impactor of total collected 
salbutamol sulphate from a salbutamol sulphate and bedomethasone dipropionate 5 0 ~ g g / actuation 
pMDI formulation. 
40 
35 
30 
25 
20 
15 
10 
SALBUTAMOLSULPHATE (+ BECLOMETHASONE DIPROPIONATE + HFA134a) 
1 0 0 ~ g g / ACTUATION ACI DEPOSITION PROFILE 
-
II 
- -
VALVE ACTUATOR niROAT JET STAGE 
ACI STAGE 
-fiLTER 
Figure 5.5: Percentage ACI deposition profile of total collected salbutamol sulphate from a salbutamol 
sulphate and bedomethasone dipropionate 1 0 0 ~ g g / actuation pMDI formulation. 
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Figure 5.6: Percentage ACI deposition profiles of total collected dose of salbutamol sulphate from all 
formulations 
Formulation Average Total Expelled FPDSS FPF FPF MMAD GSD 
(55 Weight/ Weight 55/ Dose 55 (jlg) Collected Expected (jlm) (jlm) 
Actuation) Actuation Recovered Dose 55 Dose 55 
(jlg) (%) (%) (%) 
Ventolin " 106.94 106.9 37.89 35.4 37.9 2.49 1.56 
lOOllg 
SS 100 112.91 112.9 39.22 34.7 39.2 2.80 1.82 
SS + BOP SO 63.31 126.6 18.56 29.3 40.7 2.86 1.82 
SS + BOP 90.43 90.4 23.00 25.4 23.0 3.02 1.59 
100 
.. Table 5.3: Salbutamol sulphate deposition indicators from ACI! HPLC data across all formulations 
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percentage deposition on the earlier stages, including the actuator and throat as well as the 
early ACI stack stages. 
Table 5.3 highlights these differences further. It shows the critical indicators for each of these 
formulations with respect to SS deposition. These indicators include the total weight per 
actuation recovered, the percentage of this weight with respect to the total expected weight per 
actuation, the fine particle fraction (FPF) of the recovered dose per actuation (the weight of API 
reaching plate 3 or lower «5Ilm) as a percentage of the total mass of recovered API) and the 
fine particle fraction of the expected dose per actuation (fine particle dose as a percentage of 
the expected mass of actuated material). In addition the mass median aerodynamic particle 
diameter (MMAO) and geometric standard deviation (GSO) of each formulation are shown as 
calculated. 
The table shows that for every actuation, 37.89 Ilg of SS in the Ventolin ill pMOI reached the fine 
particle plates, compared to 39.221lg of SS from the SS lOOllg formulation, 18.561lg from the SS 
BOP 50 formulation and 23.001J.g of SS from the SS BOP 100 formulation. When the total masses 
of SS recovered are used to normalize these values we can see that the fine particle fractions 
show a subsidence from the SS only formulations upon the addition of BOP. The Ventolin ill and 
SS 100 formulations have similar FPFs (collected dose) of 35.4% and 34.7% each while the SS 
BOP 50 shows a reduction in FPF to 29.3%, and the SS BOP 100 formulation has the worst FPF, 
with 25.4%. This reduction in FPF is also mirrored by a gradual increase in MMAO. The S100 
formulation reported a MMAO of 2.80Ilm, which increases to 2.861lm with the SS BOP 50 
formulation and then 3.021lm with the S5 BOP 100 run. This suggests that the aerodynamiC 
particle size distribution is becoming more biased towards larger particulates upon the co' 
formulation of S5 with BOP. In effect this is indicative of a reduction in the frequency of smaller, 
more penetrative particle bodies and an increase in those with larger aerodynamic diameter. 
This is evidenced by the concurrent change in proportional deposition up the ACI plates. 
Interestingly the Ventolin ill formulation had a MMAO of 2.491lm despite similar FPFs, which 
highlights the comparable increase in proportional mass reaching plates 4 and 5 over plate 3. 
The spread of the aerodynamic diameters as GSO was relatively quite similar across the 
formulations. 
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This data combined therefore seems to suggest that there is a negative impact on the 
deposition performance of SS by the addition of BOP. 5uch an effect on deposition may indicate 
an alteration to the 55 aerodynamic particle formation by its interaction with the BOP particles 
either in formulation or on actuation. This negative effect on 55 deposition may also be 
exaggerated with an increase in expelled total particle mass, as shown by the largest MMAO of 
3.02Jlm and lowest FPF of 25.4% with the 55 BOP 100 formulation. If we consider the average 
weight per actuation of each of the formulations we can see that the Ventoline , 55 100 and 55 
BOP 50 formulations all led to a greater than expected recovery of material. This was most 
significant with the 55 BOP 50 formulation where 127% of the expected dose was recovered (i.e. 
127Jlg for every expected 100Jlg). The 55 BOP 100 formulation however shows a 10% under-
recovery of the expected mass. 5mall differences in the total recovered dose to that expected 
from pMOI inhalers are often experienced, as the pMOI valve b a s ~ d d means of dose measuring 
relies on precision engineering with small tolerances. In conjunction with the imprecise 
distribution of the suspended API within the HFA134a this can lead to over or under dosing . 
. Greater than 15% deviations' are generally considered critical, and would suggest some 
experimental failure. It is therefore clear that if we use the FPF of the expected total dose per 
actuation, this over- and under-recovery skews the trend in FPF effect. Therefore the FPF of the 
recovered dose appears a better measure; however it should be borne in mind that this is in 
turn slightly misleading as it implies a pattern of deposition without accounting for mass that 
may have been lost outside of the measureable system (Le. device retention) or simply in the 
process of h a n d ~ i n g . .
5.4.1.2 Deposition Performance of Beclomethasone Dipropionate 
Figures 5.7, 5.8 and 5.9 show the individual stage by stage deposition of BOP in a BOP 100, 55 
BOP 50 and 55 BOP 100 pMOI formulations respectively. Figure 5.10 shows these deposition 
profiles in combination for comparison while table 5.4 shows the deposition indicators for the 
BOP recovered from the formulations. What is immediately noticeable from the individual 
graphs and in combination, is a significantly poorer fine particle performance with respect to the 
salbutamol assays. There is a significant deposition of again 50-60% recovered BOP dose on the 
actuator and throat, and while there is on all three formulation assays a small increase in 
percentage deposition over plates 3, 4 and 5 this is not on the same scale as the 55 assays. The 
dominant fine particle plate in each of the individual formulations varies, with plate 3 (8%) 
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Figure 5.7: Percentage ACI deposition profile of total collected beclomethasone dipropionate from a 
beclomethasone lOOllg I actuation pMDI formulation. 
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Figure 5.8: Percentage ACI deposition profile of total collected beclomethasone dipropionate from a 
salbutamol sulphate and beclomethasone sOllg I actuation pMDI formulation. 
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Figure 5.9: Percentage ACI deposition profile of total collected beclomethasone dipropionate from a 
salbutamol sulphate and beclomethasone 100llg / actuation pMDI formulation. 
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Figure 5.10: Percentage ACI deposition profiles of total collected dose of beclomethasone dipropionate 
from all formulations 
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Formulation Average Total Expelled FPO BOP FPF FPF MMAO 
(BOP Weight / Weight BOP Dose BOP (Ilg) Collected Expected (Ilm) 
Actuation) / Actuation Recovered Dose BOP Dose BOP 
(Ilg) (%) (%) (%) 
BOP IOOllg 65.29 65 13.17 20.2 13.2 3.82 
55 + BOP 33.23 66 7.48 22.5 15.0 2.67 
50llg 
55 + BOP 52.01 52 10.35 20.0 10.4 3.76 
100llg 
GSO 
(Ilm) 
1.75 
1.94 
2.68 
.. Table 5.4: Beclomethasone dlproplonate depOSition indicators from ACI / HPLC data across all 
formulations 
having the highest percentage deposition in the BOP 100 formulation, plate 5 (9%) in the 55 BDP 
50 formulation and plate 4 (7%) in the 55 BDP 100 formulation . 
More interestingly however, when table 5.4 is considered it is seen that the BOP 100 
formulation shows only a 65% total recovery from the deposition profile, while the 55 BDP 50 
and the 55 BDP 100 formulations show 66% and 52% total dose recovery respectively. These 
results are of significance as they imply that there is almost half the expected mass of BDP 
unaccounted for in the ACI HPLC samples. It also renders the deposition profiles less valid as 
they do not take account for the missing BDP. It is possible that the missing mass of BDP may be 
the result of device retention or instability in formulation but this requires further work to 
establish. Because of this consistent mass loss there were no further repeats performed of the 
BOP or 55 assays, in lieu of further investigation (chapter 6). From the mass of BDP that was 
detected in the assay, we can infer little with confidence because of such significant 
unaccounted mass. However if we look at the FPF performance of the BDP recovered, we can 
see that all three formulations generated similar values. The BDP 100 formulation, the 55 BDP 
50 formulation and the 55 BDP 100 formulation recording 20.2%, 22.5% and 20.0% FPFs 
respectively. This suggests that despite the inconsistency of the dominant fine particle plate 
there were similar percentage masses reaching the target respiratory zone. Notably, these 
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percentages are significantly lower than those of the 55 (25%-35%) formulations. It could be 
suggested that the addition of 55 has not had a significant impact on deposition performance, 
and by the fact that huge mass deficits were seen with the BOP only formulation too, it would 
imply the critical failing is not related to instability of the BOP due to SS. The fact that the 
greatest unaccounted mass of BOP comes from the SS BOP 100 formulation may suggest that 
the increased mass of the system has exaggerated the issue, but the fact that the FPF of the 
accounted mass is equivocal to that of the other two formulations also infers that there is no 
mass induced effect upon BOP aerodynamic particle performance, but rather a core stability 
issue. 
The MMAO and GSO data for the BOP formulations is misleading in this instance. Because the 
calculation can only be based on particle mass within the calibrated ACI stack, the values 
reported ignore mass lost to pre-stack stages. Therefore although the BOP 100, 55 BOP 50 and 
5S BOP 100 reported MMAOs of 3.82, 2.67 and 3 . 7 6 ~ m m respectively, the fact that the total 
recovered dose and FPO values are so small means that these have little quantitative or 
, 
qualitative use. As such a significant mass appears to have been lost outside of the measureable 
system, much less the pre-stack stages (also not accounted for by the MMAO and GSO 
calculation), these reporters are largely irrelevant in this case. 
5.4.1.3 The Deposition Performance of Salbutamol Sulphate and Beclomethasone 
Dipropionate 
The data acquired from the salbutamol and beclomethasone assays is difficult to link to the CAB 
data acquired previously. Evidently from the loss of BOP mass from all of the BOP ACI assays 
there appears to be a performance issue aside from the impact of co-formulation on deposition. 
It is likely that there may be a stability issue of the BOP in HFA134a alone, or that the separate 
HPLC method utilised for BOP may have given rise to an operational failure that has excluded 
the BOP data from a useful comparison. In any case the necessity to use separate ACI runs, with 
separate solvent collections and HPLC runs was not ideal, as it means that for each co-
formulation run it is impossible to directly compare the effect of one API to another. An indirect 
comparison is all that is capable in this fashion. But even this is compromised by the inexplicable 
BOP mass recovery. What can be seen from the data returned was that 55 appeared to show a 
decrease in FPF performance when co-formulated with BOP. This might have suggested that the 
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cohesively dominated salbutamol suffered a reduced capacity to develop the same aerodynamiC 
character in the presence of the adhesive dominated BOP. However it is difficult to do so in 
confidence without knowing if the co-formulated BOP was stable enough in the suspension to 
be actuated and played a part in the aerosolization process. From what BOP mass was recovered 
there was little suggestion of a change in overall FPF and certainly no confidence in the MMAO 
descriptors. Oespite this, figure 5.10 did suggest that co-formulation may have shifted 
deposition further down the ACI stack; more deposition on plates 4 and 5, and less on plates 0 
to 3. The FPF of the BOP formulations was around the 20% mark for all the formulations, 
comparing unfavourably with the SS FPFs ranging from 25%-35%. This shows that BOP suffers a 
worse aerodynamic deposition profile, however as it suffers a critical loss in overall mass, this is 
of little value, as the low percentage may be directly related to the critical formulation failure 
rather than the aerodynamic character of BOP. 
5.4.2 Deposition of the Solo and Co-Formulated 5almeterol Xinafoate and Fluticasone 
Propionate 
5.4.2.1 Deposition Performance of Salmeterol Xinafoate 
Figures 5.11, 5.12 and 5.13 show the average (3 runs) individual stage by stage deposition of SX 
in a SX 100 formulation, 5X with FP 50 formulation and SX with FP 100 pMOI formulation 
respectively. Figure 5.14 shows these deposition profiles in combination for comparison while 
table 5.5 shows the deposition indicators for the 5X recovered from all the formulations. 
Considering the individual formulation runs and figure 5.14 for illustration, it can be seen that all 
the 5X assays show similar characteristic fingerprinting to the S5 and BOP deposition profiles. AS 
seen with the 55 and BOP assays all 5X formulations show a large proportion of deposition 
across the pre-stack surfaces. Both the 5X lOOIlS and SX FP 50llS formulations show the most 
deposition on the actuator (25.8% and 27.6%), while the SX FP l 0 0 ~ g g formulation shows the 
most deposition on the throat (27.3%). In combination all the formulations show in the region of 
45% total deposition across the valve, actuator and throat sections. However all the 
formulations also show significant deposition across the fine particle plates. More specifically 
plates 3 to plate 6 show high percentage 5X depOSitions, with plate 4 consistently the best 
deposited (25.1% SX 100, 21.9% SX FP 50 and 14.5% 5X FP 100). In both the SX 100 and SX FP 50 
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assays the deposition on plate 4 was actually the second most weighted behind the actuator, 
with plate 4 on the SX FP 100 assay falling to third behind the throat piece and actuator. This 
suggests a high proportionate level of the SX in formulations reaching the target respiratory 
zone. What figure 5.13 and the individual deposition profiles also suggest however is a decrease 
in the proportional mass of ~ X X reaching the fine particle plates, with the addition of the FP to 
the formulation. The percentage of SX reaching plates 4 and 5 are the most obvious indicators. 
Plate 4 deposition decreasing by 3.2% between the SX only and SX FP 50 formulations, and 
showing a drop of 10.6% when additional mass is added to the system. Plate 5 shows a 5.2% 
drop in deposition between the SX 100 and SX FP 50 formulations, and a drop of 8.92% between 
the SX 100 and SX FP 100 formulations. Visually the ratio of the 'second' peak in the deposition 
pattern, in relation to that on the pre-stack stages, obviously decreases as the formulations are 
moved through. This seems to infer that the co-formulation of the two APls has had a negative 
impact on the aerodynamic deposition of the betaragonist. It can also be evidenced that the 
two formulations containing both APls, showed the greatest variation about deposition 
performance across the three ACI runs. This decrease in reproducibility may suggest an increase 
in complexity of the interparticulate interactions occurring, and the additional variables that an 
extra component induces to aerodynamic particle definition. The variability within the SX FP 100 
system may reflect the increase in total (both APls) mass per actuation having a direct impact on 
dose reproducibility and aerodynamic character. 
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Figure 5.11: Percentage deposition profile across an Andersen Cascade Impactor of total collected 
salmeterol xinafoate from a salmeteroll00llg / actuation pMDI formulation . 
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Figure 5.12: Percentage deposition profile across an Andersen Cascade Impactor of total collected 
salmeterol xinafoate from a salmeterol and fluticasone propionate sOllg / actuation pMDI formulation . 
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Figure 5.13: Percentage deposition profile across an Andersen Cascade Impactor of total collected 
salmeterol xinafoate from a salmeterol and fluticasone propionate lOOl!g / actuation pMDI 
formulation. 
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Figure 5.14: Percentage deposition profile across an Andersen Cascade Impactor of total collected 
salmeterol xinafoate from all pMDI formulations. 
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Formulation Average Total Expelled FPDSX FPF FPF MMAD 
(SX Weight/ WeightSX/ Dose SX (Ilg) Collected Expected (11m) 
Actuation) Actuation Recovered Dose SX Dose SX 
(Ilg) (%) (%) (%) 
55100llg 80.45 80.5 32.77 48.9 32.8 2.46 
55 + FP 50llg 41.97 83.9 15.29 43.7 30.6 2.63 
55 + FP 100llg 94.44 94.4 31.82 37.1 31.8 3.09 
GSD 
(11m) 
1.46 
1.49 
1.69 
.. Table 5.5: 5almeterol xlnafoate deposition indicators from ACI / HPLC data across all formulations 
-
-
Table 5.5 shows further that the total mass of the collected SX reaching plate 3 or below was 
consistently higher as a proportion than the masses of both the SS and BOP previously 
examined . This is reflected with FPFs of 48.9%,43.7% and 37.1% for the SX 100, SX FP 50 and sX 
FP 100 formulations respectively. This suggests that between a third to a quarter of the SX in an 
actuation across the formulations is reaching the target fine particle plates. Evidently the 
difference between the formulations can still be seen to be prominent, with an average 5.2% 
reduction in FPF between the SX 100 and SX FP 50 formulations, and a difference of 11.8% 
between the SX 100 and SX FP 100 formulations. Of further interest is the gradual increase in 
MMAO from the SX 100 formulation ( 2 . 4 6 ~ m ) ) to the SX FP 50 ( 2 . 6 3 ~ m ) ) and then SX FP 100 
( ( . 0 9 ~ m ) , , and the tentative increase in accompanying GSO (1.46, 1.49 and 1 . 6 9 ~ m ) . . This is 
further indicative that the aerodynamic particle diameter distribution is shifting in a negative 
fashion towards a larger bias by larger particulates, and that the spread of the distribution is 
growing. This would infer a proportional increase in larger particulates upon the co-formulation 
of SX with FP and then with additional mass in the system. This leads to less desirable 
aerodynamic deposition character and decreased consistency in particulate size ex-canister. In 
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combination these descriptors support the suggestion that the aerodynamic deposition 
performance of SX is adversely affected by co-formulation with FP. The significantly worse 
performance drop in terms of FPF and MMAD with the SX FP 100 formulation may again also 
infer that aerodynamic character is particularly affected with the additional particle mass 
present per actuation. This decrease in FPF is offset by a coincident increase in particle 
deposition in the throat and over the earlier stages Get stage, plate a and plate 1) as seen in 
figure 5.13 and 5.14. 
5.4.2.2 Deposition Performance of Fluticasone Propionate 
Figures 5.15, 5.16 and 5.17 show the average (3 runs) individual stage by stage deposition of FP 
in a FP 100llg (per actuation) formulation, SX with FP 50llg formulation and SX with FP 100llg 
pMDI formulation respectively. Figure 5.18 shows these deposition profiles in combination for 
comparison while table 5.6 shows the depOSition indicators for the FP recovered from all the 
formulations. Once more a similar general fingerprint of a deposition profile is seen across all 
, 
three formulations. As the individual profiles show, there is a consistent 53-56% deposition of FP 
across the pMDI valve, actuator and throat piece. In all three formulations the deposition on the 
throat piece is the most significant 27%, 27% and 28% respectively, although the actuator 
follows closely (23%, 26% and 25%). The fine particle plates do see a second peak of deposition, 
but in this instance it is plate 3 that caps this fine particle deposition trend. Plate 3 consistently 
shows the most proportional deposition of FP with 12% on the FP 100 profile, 13% on the SX FP 
50 profile and 15% on the SX FP 100 profile. Compared to the SX profiles there is obviously an 
increased proportion of the collected dose depositing on jet stage through to plate 2, especially 
from the solo API formulation. Figure 5.14 further suggests that the FP 100 formulation 
performs the worst of the three in terms of target deposition. Here is an obvious decrease in 
percentage deposition on the fine particle plates to go with the increase in deposition on the 
earlier plates. Further evident from all the depOSition profiles is the large variability about each 
average, particularly exaggerated in the case of the FP 100 formulation. This variability is 
decreased in the SX FP 50 formulation, and decreases further again with the SX FP 100 
formulation. The deposition profiles of each of the formulations therefore seem to suggest that 
the co-formulation of the SX with FP, improves the fine particle performance of FP. The doubling 
of the mass of both SX and FP in the SX FP 100 formulation further improves the deposition 
performance of FP and even seems to show greater consistency in deposition. 
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Figure 5.15: Percentage deposition profile across an Andersen Cascade Impactor of total collected 
fluticasone propionate from a fluticasone 100jlg / actuation pMDI formulation. 
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Figure 5.16: Percentage depo.sition profile across an Andersen Cascade Impactor of total collected 
fluticasone propionate from a fluticasone and salmeterol xinafoate 50jlg / actuation pMDI formulation. 
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Figure 5.18: Percentage deposition profile across an Andersen Cascade Impactor of total collected 
fluticasone propionate from all pMDI formulations. 
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Formulation Average Total Expelled FPD FP FPF FPF MMAD 
(FP Weight / Weight FP / Dose FP (Ilg) Collected Expected (Ilm) 
Actuation) Actuation Recovered Dose FP Dose FP 
(Ilg) (%) (%) (%) 
FP lOOllg 93.86 93.9 26.65 28.5 26.7 4.08 
SS + FP 50llg 42.84 85.7 13.40 31.4 26.8 3.48 
SS + FP lOOllg 89.81 89.8 30.26 33.7 30.3 3.79 
GSD 
(Ilm) 
2.09 
1.48 
1.46 
.. Table 5.6: Salmeterol xlnafoate deposition indicators from ACI / HPlC data across all formulations 
-
-
-
This inference is further supported by table 5.6, which shows that the FPF performance of FP 
across the three formulations goes from 28.5% with the FP 100 formulation, to 31.4% with the 
SX FP 50 formulation and 31.8% with the SX FP 100 formulation . There can be seen an increase 
of 3.5% from the SX FP 50 formulation to the SX FP 100 formulation. And the SX FP 50 
formulation has itself a 2.9% increase in FPF over the FP 100 formulation . These figures validate 
figure 5.18's suggestion of an increase in FPF when SX is added to the formulation. Notably all 
the recovered masses of FP from all the formulations were of an acceptable quantity (85-115%)· 
There is some suggestion that the co-formulation of the two APls appears to have reduced the 
mass of FP recovered, however the decrease from the FP100 formulation to the SX FP 50 
formulation is not worsened further to the SX FP 100 formulation, which may infer that the 
difference was simply in operational variability. 
The MMAD values of the formulation runs move from 4.081lm with the FP 100 formulation, to 
3.481lm with the FP SX 50 formulation and then to 3.791lm with the SX FP 100 formulation . ThiS 
decrease from the mono-FP to the combination formulations, again emphasizes an 
improvement in deposition performance (smaller aerodynamic particle diameters) . The increase 
in MMAD from the SX FP 50 formulation to the SX FP 100 formulation, may however evidence 
that despite the direct improvement in deposition performance on FP by co-formulation, that an 
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increase in total system mass remains detrimental as seen in the SX assay. The GSD values for 
the combination formulations are roughly equivocal, and both are smaller than that for the FP 
100 formulation, which again suggests more consistent aerodynamic particle sizing on co-
formulation. 
5.4.2.3 The Deposition Performance of Salmeterol Xinafoate and Fluticasone Propionate 
The data presented above highlights a very interesting trend. The suggestion is that the fine 
particle deposition performance of SX is reduced by the co-formulation with FX. There is an 
obvious decrease in FPF, and concurrent rise in MMAD and GSD. This would imply that the 
addition of the corticosteroid causes the SX particles to have reduced aerodynamic character 
upon actuation from the pMDI canister. Conversely however the FP data highlights that the co-
formulation of FP with SX seems to have improved the deposition performance of the 
corticosteroid. This thereby infers an improvement in aerodynamic particle character, (seen by 
, 
increasing FPFs and decreasing MMAD/GSD values) upon actuation in the presence of the betar 
agonist. This data is particularly persuasive as the deposition profiles for both the APls were 
extracted from the same ACI wash off samples and the same HPLC runs, as allowed by the joint 
HPLC method. This means that there is much less scope for bias induced by method 
inefficiencies, or operational anomalies. 
As chapter 4 defined, the SX FP force balance is characterised by FP having an adhesively 
dominated relationship with SX, and SX having a slight cohesively dominated or neutral 
relationship with FX. One explanation of the results of the deposition study is that by co-
formulating FP with SX, FP undergoes an increase in particle clustering aggregation as a 
consequence of increased interparticulate adhesive forces with SX particulates. This may in turn 
lead to larger particle agglomerates that on actuation, in the subsequent airstream, are subject 
to increased drag forces, causing improved particle dispersion and deagglomeration. Such a 
theory was discussed principally with respect to DPI formulations and the intrinsic autoadhesive 
forces of APls (Segat et ai, 2004, Jones et ai, 2008). However it is feasible that such an effect 
may be seen with API mixtures from pMDI formulations. The force balance of a combination of 
two APIS may dictate subtle shifts in aggregation behaviour that alter aerodynamic particle 
character and therefore, aerodynamic drag forces and kinetic energy states. Smaller dispersed 
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particles as a result of larger a g g l ~ m e r a t e s s would then be capable of passing to lower levels of 
the ACI stack. Reversing this however, SX has a slightly cohesive favourability with respect to FP, 
and may see a slight decrease in agglomerate formation, as FP effectively dilutes the particulate 
content. This may reduce aerodynamic particle performance by reducing initial agglomerate 
genesis, resulting in smaller SX based particulates leaving the canister on actuation. These would 
be subject to smaller drag forces, and less likely to be d i s s e m i n ~ t e d . . The persisting agglomerates 
would thereby be of larger aerodynamic diameter and impact further up the ACI stack with a 
concurrent reduction in FFP. 
It is worth noting that despite the trend of improved performance with FP, and decreased 
performance with SX upon co-formulation, SX still maintains a better aerodynamic performance 
across all the formulations. The reported MMAD values indicate a persistent (although 
decreasing) larger median diameter of the FP particulates compared to the SX equivalents. FrorTl 
the mono-API formulations SX is reported with a MMAD of 2.461J,m and FPF of 48.9%, while FP 
has a MMAD of 4.081J,m and FPF of 28.5%. The SX FP 100 formulation gives a MMAD of 3.091lrTl 
and FPF of 37.1%, for SX and a MMAD of 3.791J,m and of 33.7%. FPF for FP. Whilst the gap 
between the two has significantly reduced from the single API formulations, SX still retainS 
better deposition at the fine particle plates than FP. This may suggest that the powder 
morphology has a significant role to play in determining deposition performance. Alternatively it 
may be that as SX had a higher surface free energy (as shown in AFM measurements in chapter 
4) it forms stronger auto-adhesive agglomerates, which again lead to larger agglomerates on 
actuation favouring smaller friction induced particulate cast offs. It is also worth considering 
that in looking for a simple characterization technique, the relationship of each of the APls to 
the HFA134a propellant has been ignored and it cannot be ruled out that the solvent forceS 
involved between the propellant and the individual APls may lead to an impact on deposition 
performance. Hence broad generalizations about the interaction between the APls and their 
deposition performance must be tempered with caution. However, it is clear from the data 
above that there appears to be a significant impact on the deposition profiles of the two APIS 
when co-formulated that may be related to their CAB. 
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5.5 Conclusions 
The deposition analysis by ACI and HPlC in this chapter has identified several points of note. 
Firstly the deposition profiles of salmeterol xinafoate and fluticasone propionate can be seen to 
change in an opposite manor from solo formulation in HFA134a to co-formulation. 5X shows an 
increase in aerodynamic particle diameter with a reduction in fine particle performance when FP 
is co-formulated, while FP shows a decrease in aerodynamic particle diameter and an increase in 
fine particle performance when 5X is co-formulated. This may reflect the CAB balance of the two 
APls influencing aerodynamic particle character. That FP has an adhesively dominated 
relationship with 5X, and that 5X has a mildly cohesive relationship with FP may lead to subtle 
changes in the interparticulate forces in the formulation. This may in turn define the particle 
cluster sizing or constitution that upon actuation results in differing fluidization, and aerosol 
generation mechanics. One proposal is that the FP particles interact more strongly with co-
formulated 5X, generating tighter b ~ u n d , , larger agglomerates that are aerosolized and then 
subject to larger drag forces by virtue of their mass. This frictional force causes the originally 
larger agglomerates to break up into finer particulate bodies that can penetrate further into the 
ACI without inertial impaction. Conversely 5X, will suffer a reduction in interparticulate or 
agglomerate strength and size by virtue of a less energetic contact with FP. This may lead to less 
coherent agglomerates that are aerosolized, therefore subject to reduced drag forces and 
ironically undergoing less particulate breakdown to fine particle bodies. The impact of additional 
mass in the system is unclear. It appears to have reduced the fine particle performance of 5X, 
and slightly improved the fine particle performance of FP. This may reflect a forced increase in 
the extent of agglomerate formation of the two APls if we persist with the theory above, that 
exacerbates the change in deposition trend seen with the mass equivalent formulations. 
Unfortunately however the other combination of APls in salbutamol sulphate and 
beclomethasone was not able to operate as a suitable comparator. The necessity to use 
separate HPlC methods was already a limitation, but the critical mass loss of BOP from the BOP 
assays suggests a stability issue in the formulatio.ns that has compromised the validity of 
assessing the impact of one API on the others deposition performance. From the data available 
it appeared 55 suffered a small reduction in fine particle performance with the co-formulation of 
BOP. The comparison of the bespoke 55 100 pMOI and the commercial Ventoline was largely 
equivocal, suggesting the stability of the 55 in neat HFA134a was good. However the BOP data 
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available can be used to suggest little with confidence. There is some slight indication, in terms 
of plate to plate deposition shifts and fine particle performance, that there is a slight 
improvement with co-formulation with SS. Considering the SX and FP data these trends would 
be expected if we apply the same critical agglomerate philosophy.· However given the 
significantly more polarised CAB ratios of the two API5 (1.69 and 0.35 for 55 and BOP 
respectively compared to 1.05 and 0.63 for 5X and FP) it would be assumed that this would 
exaggerate further the deposition impact seen between 5X and FP. That is to say that we might 
expect 55 deposition to suffer a much more severe drop off in performance on co-formulation 
with BOP, and that BOP would experience significantly improved deposition performance on co-
formulation with SS. However if the BDP in formulation has been retained as a result of 
crystallization, polymorphism etc. this may explain the loss of recovered BDP, and the reduction 
in the deposition effect seen on the 5X. This will be investigated further in chapter 6. 
Consequentially while a successful deposition analysis has been performed using 5X and FP 
formulations, and a link to the CAB of the two APl5 has been put forward, there is no confident 
comparator to determine whether this deposition character can more broadly be linked to the 
fundamental force balances. However the identification of this trend defines this system as one 
of interest for further investigation and may infer a causative link between the APls, as force 
modulators in an agglomerate driven dispersion mechanic. 
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6.0 Investigating the Co-Deposition of Active Pharmaceutical 
Ingredients from HFA134a pMDI systems 
6.1 General Introduction 
6.1.1 Combination Inhalers for the Treatment of Airways Disease 
As described in chapter 1 the use of inhaled long acting betaz-agonists (LABAs) and 
corticosteroids (ICS) is a pillar of respiratory medicine in treating the common airway disorders. 
Depending upon the particular condition, disease severity and presentation these APls may be 
used independently or, as is becoming more frequent, in combination. Their concurrent use 
represents the third step of the British Thoracic Society and Scottish Intercollegiate Guidelines 
Network's asthma management ladder (BTS,SIGN,2011) and is the first line treatment for high 
risk COPD patients as per the Global Initiative for Chronic ,Lung Disease (GOLD, 2011). In 
asthmatics the addition of a long acting beta2-agonist is considered if the use of short a c t i ~ g g
betaz-agonists alone, and then in conjunction with regular inhaled corticosteroids, has failed to 
adequately control asthma symptoms. In COPD treatment, the combination of ICS and LABAs is 
deemed appropriate if the patient is assessed as having severe or greater airflow limitation (by 
spirometric classification, exacerbation risk, and scorings on the modified medical research 
council dyspnoea scale (MMRC) and COPD assessment test (CAT))(GOLD, 2011). 
The common LABAs and ICS used clinically in COPD and asthma management, alongside their 
pharmacological impetus for use, were outlined in chapter 1, and it is widely accepted that 
concurrent use has a significant role to play in more refractory airways disease. In particular a 
significant collection of randomised trials has shown that the addition of LABA therapy to 
asthmatic adults not fully controlled using ICS alone, leads to a reduction in the rate of 
exacerbations requiring oral steroids; from 23% to 15-11% (RR 0.77, 95% CI 0.68 to 0.87 across 
28 studies with 6808 participants), improves lung function and symptoms and modestly 
decreases use of rescue short-acting beta2-agonists (Ducharme et ai, 2010). 
All of the common LABAs and ICS are available as individual DPI and or pMDI inhalers (e.g. 
Serevente (salmeterol), Atimos Modulitee (formoterol), Fllxotidee (fluticasone), Oxls 
Turbohalere (budesonide) etc.) and are frequently prescribed in conjunction with each other. 
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There are also combination pMDI or DPI products available that provide both the LABA and ICS 
within the same formulation. The three most prevalent being Symbicort· (budesonide and 
formoterol), Seretide· (fluticasone and salmeterol) and Fostair· (beclomethasone and 
formoterol). In clinical practice, the combination products are advocated over the individual 
formulations. This is principally due to the fact that it has become clinically accepted that using 
just one inhaler to deliver two APls increases patient compliance and guarantees that the LABA 
can't be taken without the ICS (BTS, SIGN, 2011). However to date it is also accepted that there 
is no significant body of evidence suggesting a difference in pharmacokinetic or 
pharmacodynamic efficacy between the individual inhalers or compound equivalents (BTS, SIGN, 
2011). 
6.1.2 The Co-Deposition of Salmeterol Xinafoate and Fluticasone Propionate 
'A collection of recent research offers evidence that this may not be the case across the board 
with all ICS and LABA combinations. Studies comparing the use of combination salmeterol 
xinafoate (SX) and fluticason'e propionate (FP) DPI inhalers to their individual counterparts have 
been carried out. (Bateman et aI, 1998. Chapman et aI, 1999. Aubier et aI, 1999. Van den Berg et 
at, 2000.). When meta-analyzed, these studies suggested that further to the pharmacological 
synergy of the two API classes, (seen with both individual and combination inhaler types), there 
was a significant improvement again in clinical efficacy with the combination delivery (as FEV1 
and morning PEF over 12 weeks) (Nelson et ai, 2003). 
It has been proposed that the improvement in clinical outcome seen with this combination 
formulation was as a consequence of an increase in local co-deposition of the two APls (Nelson 
et ai, 2003. Barnes, 2002, Theophilus et ai, 2006). As described previously, the synergistic effects 
of LABAs and ICS are rooted in cellular signaling pathways, localized to individual locations 
within the respiratory tract. The rapid promotion of betarreceptor expression by ICS and the 
nuclear translocation of glucocorticoid receptors by LABAs in respiratory smooth muscle tissues 
(Black et ai, 2009) would therefore suggest that the synergy of action is dependent upon having 
both LABAs and ICS working at the same cellular location. Therefore it is possible that the 
degree of co-localization of the APls might correspond directly to a clinical response. As with all 
combination products co-deposition will occur more readily than from two separate inhalers as 
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the inherent natural variation in inspiratory maneuvers is negated, which will otherwise give 
different deposition patterns from breath to breath (Theophilus et ai, 2006). Yet crucially as 
highlighted by other research into different combinations (including budesonide and 
formoterol) and the clinical guidance issued by the BTS and SIGN, this has not manifested as a 
marked improvement in clinical performance with other combination products (Zetterstrom et 
ai, 2001. BTS, SIGN, 2011). Therefore the SX and FP combination may present unique 
. 
formulation characteristics that lead to an advancement in clinical performance. 
6.1.3 Assessing 'in-vitro' Co-Deposition 
As discussed in chapter 4, the CAB of FP and SX shows that FP has an adhesively dominated 
relationship with SX, while SX has a slightly cohesively dominated relationship with FX. This led 
to distinct changes in deposition performance 'in-vitro' (chapter 5). The co-formulation of the 
two APls gave rise to a reduction in fine particle performance of SX, but an improvement in that 
of FP. While a link between the CAB of the two APls and the change to individual deposition 
character could be hypothesised, it remains of interest to see whether there is a link between 
the CAB of the APls and the degree of co-deposition. It is therefore of particular interest 
whether with the application of a range of surface specific imaging techniques, both visual and 
chemical, the extent of co-deposition could be identified 'in-vitro' using an Andersen cascade 
impactor. Several analytical techniques allow the spatial mapping of surfaces, and it is of 
interest as to how well they can define the distribution of a mUlti-component system. 
Furthermore if it were possible to link the deposition association of two components (Le. SX and 
FP) to a force balance as established by a semi-model CAB this would potentially offer significant 
insight into formulation design of prospective formulations. From chapter 5 we are also aware 
that in the attempt to characterize the influence of co-formulation of two other APls, 
salbutamol sulphate (SS) and beclomethasone dipropionate (BOP) there was a critical loss of 
recovered BOP mass. This suggested instability in the BOP HFA134a system. It is of interest 
therefore to see whether supplementary imaging techniques support the data from the HPLC 
assay and show reduced BOP deposition post actuation in comparison to the SS delivered. 
Simultaneously if SS and BOP characterisation suggests any co-ordination between the API mass 
• that has been delivered then this can be used as a rough comparator to the SX and FP system. 
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6.2 Aims and Objectives 
6.2.1 Chapter Aim 
The aim of this chapter was to investigate the use of several surface specific analytical imaging 
techniques in describing the extent and nature of the deposition of APls from binary HFA134a 
pMDI systems. If possible to assess co-deposition behaviour 'in-vitro' and link this to the force 
balances described by prior semi-model CAB experimentation. 
6.2.2 Chapter Objectives 
- To compare the surface specific characterisation of binary combinations of APls from HFA134a 
pMDI suspensions by multiple analytical techniques including SEM, Raman Spectroscopy, ToF-
SIMs and DES!. 
- To describe the extent to which APls from combination inhalers can be seen to co-deposit 'in-
vitro' on Andersen Cascade Impactor plates. 
- To investigate the mass retention of BDP from BDP containing HFA134a pMDI formulations 
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6.3 Materials and Methods 
6.3.1 Materials 
5almeterol xinafoate (5X), fluticasone' propionate (FP), salbutamol sulphate (55) and 
bec/omethasone dipropionate (BOP) were chosen to follow up the work carried out in chapters 
4 and 5. The 5X and FP formulation was of specific interest due to documented research into the 
exaggerated synergy of the two APls by co-deposition. 55 and BOP were investigated further 
with interest in investigating the mass retention of BOP from the self-formulated HFA134a 
canisters. The micronized powders were all provided by 3M Healthcare (Loughborough, UK). All 
other reagents and accessories were sourced from 5igma Aldrich Company Ltd (Gillingham, UK) 
unless specified in the methods. 
6.3.2 Methods 
6.3.2.1 Formulation of pMOI canisters 
The remaining combination formulations of 55 with BOP and 5X with FP produced in chapter 5 
were used for the work described in this chapter. The formulations specifically chosen for this 
co-deposition investigation were the following: 
BDPloo: 
5S BDP 100: 
FP 100: 
SX 100: 
5X FP 50: 
SX FP 100: 
Beclomethasone Dipropionate 1001ol8 
Beclomethasone Dlpropionate 1001-1& Salbutamol Sulphate loolol8 
Fluticasone Propionate 1 0 0 ~ g g
5almeterol Xinafoate loolol8 
Fluticasone Propionate 50Iol8, Salmeterol Xinafoate 5 0 ~ g g
Fluticasone Propionate loolol8, Salmeterol Xlnafoate 1 0 0 ~ g g
The BOP 100 formulation was further investigated in an attempt to identify any physical or 
chemical instability of the API in neat HFA134a that may have led to the critically poor 
deposition performance seen in chapter 5. A high mass combination of 55 and BOP was run 
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through the surface specific mapping techniques described below to identify if the observation 
of low BDP deposition was consistent and attempt to characterize any co-deposition of the API 
mass that was delivered. 
The SX and FP low and high mass combinations were both investigated to examine the ACI 
based deposit structure by a variety of analytical techniques and help determine whether the 
extent of co-deposition could be established. Single API formulations were used as a means for 
proof of concept within some of the techniques. For a full description of the cold fill pMDI 
manufacture see chapter 5 (5.3.2.1). 
6.3.2.2 Andersen Cascade Impaction 
An eight stage Andersen Cascade Impactor (3M Healthcare Ltd, Loughborough, UK) was used for 
aerodynamic particle sizing and deposition profiling of the formulated aerosols. The same 
methodology as applied in ch?pter 5 was broadly utilized to generate ACI plates with the 
designated formulation particle impacts for analysis. For a complete description of the ACI stack 
operating parameters see chapter 5.3.2.2. The only alterations to this methodology were that 
for ToF-SIMS, Raman and DESI work each formulation was only actuated twice per run. As no 
quantification was required, the pMDI canister was not weighed for mass change, and did not 
have the valve cleaned down between waste firing and stack use. The ACI plates were not 
agitated into known volumes of sample diluent but extracted into petri dishes prior to use in the 
respective analytical methods outlined below. 
The samples for SEM imaging were collected by inverting plate 5 of the ACI stack and securing 
several SPM specimen discs with double sided tape to the inverted plate surface below the 
stage nozzles. pMDI actuation was kept to two actuations for the sample production, and in this 
fashion, after the ACI run was complete the SPM discs could be extracted, mounted onto a SEM 
sample holder and gold coated for high vacuum work, without damaging or compromising the 
actual ACI plate. 
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6.3.2.3 SEM Imaging 
SEM images of the morphology and topography of the deposited SX and FP particles on plate 5 
of the ACI from the SX and FP 100 formulation were collected by a JEOl JSM-6060lV scanning 
electron microscope (JEOl ltd, Tokyo, Japan) at various magnifications under vacuum. Samples 
were generated as described above on 13mm SPM specimen discs that were in turn mounted to 
SEM sample holders. The samples were then sputter coated in gold using a Balzers Benchtop 
Sputter Coater SCO 030 in an argon atmosphere (SOPa) at 30 mA for 4 minutes before SEM 
imaging took place in high vacuum mode. Samples were imaged at 90° from the electron gun 
before being tilted to 4S0 from incident, to allow an assessment of deposit height profile to be 
gained. 
6.3.2.4 Raman Spectroscopy 
All Raman spectroscopy was performed using a labRAM HR confocal Raman microscope (Horbia 
Scientific, Kyoto, Japan) equipped with Olympus xl0 or xSO optical lenses (Olympus Microscopy, 
Southend-On-Sea, UK) using a green (S32nm) or near infra-red (78Snm) laser with a 600 
lines/mm grating and a thermoelectrically cooled Synapse CCO detector. Spectrum and 
hyperspectral imaging analysis was performed using labSpec version S (Horiba Scientific, Kyoto, 
Japan). 
The SS BOP formulation was analysed using a xSO objective lens at S32nm. Reference samples of 
the parent powders were first analysed for determination of reference spectra and to trial the 
choice of illumination source. It was determined that the green laser source used was adequate 
for the purpose of distinguishing the APls as shown below. Subsequently the SS BOP formulation 
deposited on plate 4 of an ACI was mapped over a 250llm diameter spherical area using the 
532nm source with 100% filter exposure, 300 Ilm confocal hole size, 1 second exposure time, a 
single spectrum per pixel point and one pixel per 2.51lm in X and Y (2.5Ilm resolution). 
The SX and FP formulations were analysed using a x50 objective lens at 785nm. Attempts to use 
the 532nm laser to capture reference spectra from the API parent powders resulted in 
significant fluorescence from the SX samples that hid the Raman signal and would not suitably 
quench. As fluorescence generally occurs in the near UV to visible region, the use of a NIR laser 
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was trialled. This provided much more stable Raman spectra across both APls with no 
interference from a fluorescent effect. Subsequently the individual API formulations SS lOa, FP 
100 and the SS FP 100 formulation were mapped across a 1 0 0 ~ m m x 1 0 0 ~ m m area, using the 
785nm wavelength with a 75% filter exposure, 3 0 0 ~ m m confocal hole size, 1 second exposure 
time, 1 spectrum per pixel point, and one pixel per l ~ m m in X and Y ( l ~ m m resolution). The 
combination formulations SX FP 50 and SX FP 100 were also mapped with the same parameters 
but across a larger 6 0 0 ~ m m x 8 0 0 ~ m m area, that encompassed an entire API spot for a macroscale 
appreciation of the API distribution. All Raman spectroscopy was performed on plate 4 of each 
formulation ACI run, as this plate was shown to consistently impact high masses of all APls 
(except BDP) while showing a coherent on-plate deposit that would not be so concentrated as 
to hide individual particle layout. 
With respect to the Raman methodology, the following procedures were followed for all work. 
After the selection and activation of the appropriate laser source, the requisite laser filters, 
electronic switches, grating anq detector were also selected. The laser source was allowed to 
reach running temperature and stability. The instrument was then zero calibrated using white 
light, and Raman calibrated using a silicon calibration sample before each session of use or each 
mapping procedure. Powder samples were tapped onto a clean glass microscope slide before 
arrangement and light compaction using a clean glass coverslip. They were then loaded onto the 
microscope slide sample holder on the sample stage. ACI plates were secured directly onto the 
sample stage using double sided tape to avoid movement on sample stage rastering. All samples 
were located optically using a white light source and a xl0 optical lens with manual adjustment 
of the microscope position. If a macroscale image was desired this objective was used to plot 
the mapping grid. For spectral mapping, increased magnification was required and the x50 
objective lens would then be swapped into position. Optical focus was then maximised manually 
using the projected on screen image before a protective shield was placed around the 
microscope (to prevent laser exposure to the user and protect the sample from other light 
sources), and the optical alignment was readjusted to adjust for the slight loss of focus. 
The white light source was then turned off and samples were exposed to the chosen laser 
source. A real time display of live spectra was used to maximise the Raman signal with fine 
movement of the microscope lateral position. Any samples that showed fluorescence (typically 
under the 532nm light source) were given 15 minutes of broad laser exposure across the 
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topographical area to be analysed. This was in an attempt to try and quench any fluorescence 
and improve the Raman signal. A rastering grid with desired geometry and operating 
parameters (as indicated below) was overlaid onto the optical image of the sample for mapping 
experiments to allow selection of an area of interest. In such experiments, an autofocus macro 
was utilised to automatically adjust the stage height with the raster position in maximising 
Raman signal to accommodate topographical variations. 
6.3.2.5 TIme of Flight Secondary Ion Mass Spectrometry and Multivariate Analysis 
Time of Flight Secondary Ion Mass Spectrometry (ToF-SIMS) was carried out using a TOF-SIMS IV 
spectrometer with SurfaceLab 6 software (ION-TOF GmbH, Munster, Germany). All analysis was 
performed with a 25kV Bismuth liquid metal ion gun, utilising beam split and bunched incident 
Bi3+ ions for static SIMS analysis. Serial ACI plates were loaded directly into the TOF-SIMS 
instrument after pMDI ACI operation and secured to a sample stage. Individual deposits were 
located manually using the spectrometer chamber camera, and after the sample chamber was 
allowed to pump down to vacuum, the pre-designated spatial area was raster scanned. Positive 
and negative spectra were collected over an area of 500\lm x 500\lm at 256 x 256 pixels to 
analyse individual API deposits. Sample surfaces were charge compensated with an electron gun 
at 20eV between primary ion bursts. Stage scan functionality was used to control sample raster, 
and all chemical imaging was performed at ambient temperatures. 
Principal Component Analysis (PCA) was undertaken on the subsequent ToF-SIMS data sets using 
PLS_Toolbox version 5.2 (Eigenvector Research, Manson, WA, USA) for Matlab (Mathworks Inc., 
Natick, MA, USA). The PCA images were considered alongside the respective eigenvalues; the 
number of factors to model for using Multivariate Curve Resolution (MCR) was then manually 
determined. The same software was then utilised to carry out the MCR analysis. There was no 
data pre-processing carried out prior to MCR analysis in order that the non-negativity constraint 
(see chapter 2) be upheld. Spectral investigation was subsequently performed on MCR identified 
variates using SurfaceLab 6 software (as above) and in-house techniques using Microsoft Excel 
(Microsoft, Redmond, WA, USA). 
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6.3.2.6 Desorption Electrospray Ionization Mass Spectrometry 
All Desorption Electrospray Ionization Mass Spectrometry (DESI) was carried out using a Prosolia 
Omnispray 20 Ion Source (Indianapolis, IN, USA), on a Thermo Scientific LTQ Velos ion trap mass 
spectrometer (Waltham, MA, USA). The DESI plume was generated from a 70% HPLC Grade 
Methanol: 30% HPLC grade Water mixture. This was run at 60 psi N2 gas and a 2 ~ l / m i n n flow rate 
with a raster speed of 3 0 3 ~ m / s e c . . The DESI spray was aligned 4mm away from the sample 
surface with a 50· spray to surface angle. The mass spectrometer (MS) inlet was at 10· from the 
sample surface, with an approximate Omm distance (almost touching). The spray tip to MS inlet 
distance was 4mm. MS data was collected in positive mode at 4kV cone voltage, 250·C capillary 
temperature, mlz 1 5 0 ~ 2 0 0 0 0 range, 2 microscans, 200ms maximum injection time and automatic 
'I gain control off. Multispectral image composition and analysis was carried out using Biomap 3x 
(Novartis Institutes for Biomedical Research, Basle Switzerland). 
6.3.2.7 Differential Scanning Calorimetry 
A TA Instruments DSC 2920 differential scanning calorimeter (TA Instruments, Delaware, US) 
was used to perform analysis of BOP extracted from the BOP 100 formulation. The BOP was 
extracted from formulation by first cooling the canister in an ice bath with acetone to below the 
boiling point of HFA134a. The canister lid was then punctured with a nail, and the canister was 
allowed to re-equilibrate slowly to room temperature in a fume hood. This led to the 
vaporization and escape of the propellant from the canister, leaving the API. Samples of the 
BOP were subsequently collected by cutting off the canister lid, and extracting the retained 
powder. Accurately weighed samples of about 6 mg were sealed in aluminum hermetic pans, 
equilibrated at O·C, kept isothermal for 3 minutes and then, heated at 10·C per minute under 
nitrogen to 250·C. Samples of the parent anhydrous BOP were also run as a comparator in the 
, same fashion. Thermograms produced were analyzed using TA universal analysis -NT software 
(TA Instruments). 
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6.4. Results and Discussion 
6.4.1 The Deposition of Salbutamol Sulphate and Beclomethasone Dipropionate 
.. 
6.4.1.1 Desorption Electrospray Ionization Mass Spectrometry 
Figure 6.1 shows DESI maps of the molecular ion of BDP (543 m/z) and SS (240 m/z) over 1cm x 
1cm areas of plates 4, 5 and 6 of the ACI from the SS BDP 100 formulation. Figure 6.2 shows an 
example mass spectrum of both the API molecular ions from within a single drug spot on plate 4 
of the same deposition profile. The chemical images for both APls in figure 6.1 show very clear 
drug spot concentrations, and it is apparent that the DESI technique has succeeded in resolving 
multiple API deposits across a macroscale surface. These concentrated deposits are the result of 
. particle impactions directly below the ACI stage nozzles above each plate. Notably the spread of 
the API deposition can be seen to decrease with increasing plate number, reflecting the 
decreasing nozzle size. However what is apparent from both figures is the differing 
predominance of BDP to S5. The images are scale matched for comparison, and it is 
subsequently evident that a very intense 5S signal can be detected from each of the API spots, 
but that the comparative BDP spot is significantly weaker in intensity. This is true across all the 
plates that were imaged and most noticeable on plate 5. The apparent lack of BDP is further 
evidenced by comparing the mass spectrums in figure 6.2. 
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Figure 6.1: lcm x lcm DESI chemical maps of deposited beclomethasone dipropionate (543 m/z) and 
salbutamol sulphate (240 m/z) from an 55 BOP 100 HFA134a pMDI formulation on plates 4, 5 and 6 of 
Andersen Cascade Impactor 
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Figure 6.2: Representative DESI spectra of the parent BOP (543 m/z) and 55 (240 m/z) molecular ions 
from within a single drug spot from a 55 BOP 100 formulation on plate 4 of an Andersen Cascade 
Impactor 
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The signal detected for SS is approximately 12x stronger than that for BDP. What these chemical 
images and spectra infer is therefore that on these key fine particle plates, there is a significantly 
smaller proportion of BDP than SS. This observation must be tempered to some degree by the 
technical limitation of DESI in that the desorption efficiency of the two APls is likely to differ. 
While the DESI plume was optimized with respect to the materials available, the differing 
chemistries of the two APls may be reflected in the extent of desorption of each into the 
methanol : water mobile phase under raster. However further compensation was made by 
increasing the pressure of the system. As quantification was not desired this allowed the 
aerosolization of most of the powder impact of the spatial area under analysis, thereby reducing 
the bias of desorption efficacy. Significantly the lack of BDP observed was consistent with the 
ACI results from chapter 5, thereby adding further evidence that there exists a critical mass loss 
of BDP from the HFA134a system. 
6.4.1.2 Raman Spectroscopy 
Figure 6.3 shows the reference Raman spectra collected at 532nm for BDP and SS as analyzed 
from the parent API powders. The· SS spectrum showed several key features including strong 
broad bands in the 2800-3200 cm-l region. This is composed of an overlap of the v(NH) band at 
3160 cm- l , the v(CH2) and v(CH3) bands at 3062 cm-t, the vas(CH3) band at 2985 cm-t, the v(CH) 
attached to an aliphatic (OH) at 2927 cm- l , the v(CH2) atta·ched to aliphatic (OH) band at 2899 
cm- l and the v(CH3) band at 2880 cm- l (Ali et ai, 2008). However most of these peaks were 
common to BDP with the exception of the v(NH) band, explaining the slightly less intense broad 
band in the same region. However a very strong aromatic C=C stretch at 1662 cm- l was unique 
to.BDP, and with the concurrent strong dominant vas(C -QH) band at 978 cm- l seen on the SS 
spectra (along with several other unique bands) the single spectral window of 500cm- l to 
2000cm-l was subsequently chosen to map with and reference from. These single window 
spectra were then used to model for the hyperspectral mapping data from plates 3 and 4, and 
the scores returned according to these references are displayed in figure 6.4. The BDP signal was 
mapped as red and the BDP signal mapped as green. As figure 6.4 therefore demonstrates, 
there is a distinct predominance of SS compared to BDP across both the fine particle plates 
imaged. 
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Figure 6.3: Reference Raman Spectra of BOP and SS at 532nm (Green Laser) 
Plate 3 
Plate 4 
Figure 6.4: Raman Spectroscopy derived scores map of a 250J,1m diameter circular area of plate 3 and 
plate 4 deposition of SS and BOP from a SS BOP 100 formulation 
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Plate 4 shows no BOP score at all, while plate 3 shows minima-I areas of BOP coverage. The 
Raman maps do show more concentrated particulate deposition on plate 4 with comparison to 
plate 3, but the spatial resolution of map was insufficient to resolve individual particle character. 
The scores maps therefore identify larger areas of strong API character, but because of the 
relative abundance of 55 it is therefore possible that if the 55 and BOP particles are clo,sely 
associated that the increased mass of 55 (that would be expected from the ACI and OESI work) 
leads to an overwhelming of the BOP signal, or the inability to resolve it. However for the 
purpose of further confirming the relative absence of BOP, further refinement of the Raman 
mapping was not deemed necessary as it was deliberated that the Raman maps collected 
support the lack of BOP reaching even the lowest fine particle plate. 
6.4.1.3 Differential Scanning Calorimetry of Extracted BOP 
Figure 6.5 shows the differential scanning thermograms of both the parent BOP and the BOP 
extracted from the BOP 100 formulation following HFA134a evaporation. While both traces can 
be seen to show the expected melting endotherm of BOP at around 211°C, the extracted BOP 
also shows a shallow but broad endotherm beginning at about 61°C, maximizing at BlOC, and 
ending at approximately 100°C. This endotherm is not seen on the thermogram for the parent 
API, but was consistent across all three extracted BOP samples. The transition suggests some 
form of rearrangement, which may represent one of several processes. It is possible that the 
BOP has undergone a solvate based reaction in the neat HFA134a. This may be hydration via the 
water load of the propellant to the mono-hydrate, where this transition represents the 
dehydration process. Or it is also possible that the BOP has clathrated with the HFA134a, and 
this endotherm represents a declathration process. Considering the temperature at which the 
endotherm occurs and the known infrequency of BOP HFA134a clathrate occurrence (Bouhroum 
et ai, 2009), it is more likely representative of the former hypothesis. Unfortunately due to the 
lack of available BOP mass extracted and formulations available to re-extract, it was not possible 
to further analyze greater masses of the formulated BOP via techniques such as XRO or ATR-IR 
to better characterize the exact BOP product. Yet it is clear that there has been a change in the 
physicochemical state of the BOP that may reflect its exceptionally poor deposition 
performance. If hydration has occurred it is possible that this has led to changes in surface 
energy, particle size and agglomeration behavior that has instigated device retention. 
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Figure 6.5: Representative differential scanning calorimetry thermograms of anhydrous BOP (green) and 
the BOP extracted from the BOP 100 formulation (red) after propellant evaporation. 
All the formulations produced for analysis in chapter 5 were done so without any other 
excipients bar the propellant and the APls. It is well known that stabilizing excipients are critical 
for the long term stability of many APls in the new HFA formulations, due to the polarity of the 
solvent (as described in chapter 1). It is possible therefore that even on the short t imes scales 
between manufacture and use, that without the commonly employed co-solvents such as 
ethanol, the BDP has desolvated and crystallized out of suspension. This would explain why very 
little BDP is detectable on any analysis post actuation, as the remainder of the mass has been 
retained in the canister. Further analysis of this effect is necessary. 
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6.4.2 Investigating the Co-Deposition of Salmeterol Xinafoate and Fluticasone 
Propionate 
6.4.2.1 Scanning Electron Microscopy 
. Figure 6.6 shows four SEM images of an API deposit from a 55 FP 100 pMDI formulation on a 
SPM sample disc extracted from plate 5 of an ACI at differing magnifications and orientations. 
Figure 6.6: SEM Images of an API deposit from a SS FP 100 formulation In an Andersen Cascade 
Impactor. A) xl00 Image of entire deposit and surrounding scatter, B) xSOO image of deposit periphery, 
C) x7S0 image of deposit center and D) xSOO Image with 4S· sample tilt of entire API deposit. 
The individual particle character can easily be seen by SEM, as evidenced best in figure 6.6 C. 
Here we can see multiple irregularly shaped particles approximately Sllm in diameter. However 
while particle morphology can be determined there is no obvious distinction between SX and FP 
particles. What the images do show is that the center of these deposits become very 
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concentrated at this plate range. In all four images in figure 6.6 the center of the deposit shows 
significant particle overlay with no bare plate. This gradually trends towards smaller 
agglomerates and more diffuse scatter, before individual particles can be discerned on the plate 
surface several hundred microns away. With the nozzle size reducing with plate to plate 
progression, the particles that are depOSited here were forced to do so in a smaller spatial area, 
thereby generating a smaller more concentrated deposit than would be the case further up the 
stack. 
When looking directly onto the drug spot in figure 6.6 A, it appears as if the center of the 
deposit shows elevation and is proud of the peripheral particles. This impression is maintained 
by figure 6.6 B. However when we introduce tilt to the sample and image the deposit from a 45° 
angle (fig. 6.6 D) we can see that although the particles are more concentrated there is in fact 
not a significant increase in particle elevation in the center. It is likely in fact that the heavy 
concentrations of the particles at the center of the deposit insulate each other from the 
conductive metal substrate be':leath. This means that despite the gold coating by sputtering, 
these insulated particles remain less able to conduct the incident electrons and are more likely 
to show charging behavior than those directly on the metal substrate. Perhaps more 
fundamentally, with particle overlay it is also possible that the sub layers are not well gold 
coated, therefore being very likely to charge. This charging effect is visualized as a whitening of 
the center of the spot. Regions nearer the metal surface are less likely to charge thanks to 
electron dissipation, and therefore remain visually darker. Collectively the effect is to artificially 
suggest more significant elevation than is the case. 
However the technique is useful in generating a real appreciation of the particle to particle 
association in the impacted drug spot, and in visualizing the impacted particle morphologies. 
This information can then be used to help better understand the subsequent chemical 
characterizations. 
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6.4.2.2 Desorption Electrospray Ionization Mass Spectrometry 
Figures 6.7 and 6.8 show the DESI maps of the molecular ions of SX (417 m/z) and FP (523 m/z) 
respectively. All the images within' the individual figures are scale matched for comparison. 
What both figures show is that definitive drug deposits below the ACI stage nozzles can be 
broadly identified by both the signature ions for the two APls on plate 2 and downwards. Figure 
6.7 shows a signal for SX that builds from a weak but diffuse arrangement of six deposits on 
plate 2, to a very strong signal for SX on plate 4. Plates 2, 3 and especially 4 show significant SX 
scatter. This occurs almost to the point of overlap on the plate 4 map. This may simply reflect 
the cross over between the increasing mass of deposition according to aerodynamic character 
and the reducing nozzle size concentrating deposits. However it is also possible that with the . 
increased mass on plate 4 there is some agitation of the deposits by the DESI plume as it rasters 
across nearby areas. Plates 5 and 6 continue to show strong spatial signals for SX in nine 
deposits, but the scatter is much reduced. Several of the drug deposits show slightly 
heterogeneous morphologies that may either reflect nozzle variability (blockages or imprecision) 
or knock on movement of the deposits due to the force of the DESI plume. Plate 7, shows a 
weaker and again slightly more diffuse signal for SX across three deposits. This compares very 
similarly with the spectral mapping of FP in figure 6.6. Here nothing but the uncoordinated dot 
of the signature ion can be identified on plates 0 and 1 before on plate 2 a diffuse spatial 
arrangement into nine deposits can be seen with a weak FP signal. Unexpectedly plate 3 shows 
very little coordinated FP signal and the differentiation of the deposits with scale matching is 
lost. Plate 4 however shows a strong FP spatial signal arrangement into six clear deposits with 
three poorly defined but still aligned peripheral spots. This plate again shows the most 
significant spot scatter, before plates 5 and 6 show more concentrated and consistent FP 
deposits. Plate 6 shows a stronger signal for FP in the nozzle deposits than plate 5, which may 
reflect either the signal boosting impact of a more heavily concentrated and smaller deposit, or 
simply be due to the variability of the DESI process. 
It is worth clarifying that the signal strength of each plate deposits cannot be absolutely linked 
to quantification due to the variability of the desorption and ionization efficiency brought about 
by the chemistries of the APIS and also the physical nature of each deposit i.e. concentrated 
mounds, and diffuse scatter. Therefore it is not to be assumed that figure 6.6 shows more FP on 
plate 6 than plate 5, but it does suggest a significantly strong presence of the API that allows for 
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Figure 6.7: 1cm x 1cm DESI chemical maps of deposited salmeterol xinafoate (417 m/z) from an SX FP 
100 HFA134a pMDI formulation on plates 1-7 of an Anderson Cascade Impactor 
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Figure 6.8: 1cm x 1cm DESI chemical maps of deposited fluticasone propionate (523 m/z) from an SX FP 
100 HFA134a pMDI formulation on plates 1-7 of an Anderson Cascade Impactor 
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the characterization of the drug deposits. Plate 7 on figure 6.8 shows three very well defined 
and small deposits. 
, 
What we can see from figures 6.7 and 6.8 is that both SX and FP can be identified in the same 
drug deposits by DESI. This is not unexpected as each deposit is multi-particulate and the forced 
impaction by ACI use means that the impaction of any API will only ever occur under each 
nozzle. DES I currently lacks sufficient spatial resolution to be used to define individual particle 
chemical character, and therefore particle to particle localization with respect to API 
combinations. However we can see a broad overlap of the API signals in the each spot and 
indeed even for the deposits that show irregular morphologies such as the central deposit on 
plate 6, the irregular features conSistently show signal from both APls. Yet the detracting 
information is that the SX spatial signal consistently outlines broader areas around each API 
spot, where the FP signal is always more concentrated to the middle. This is most pronounced 
on plate 7 where the FP signal shows three very defined and concentrated spots but the SX 
image shows a much less concentrated and diffuse scatter around the same deposits. As 
previously explained this may not be explicitly linked to co-deposition character due to 
differences in DESI uptake efficiency that may mask true mass equivalence. Therefore if FP 
desorbs and ionizes less efficiently than SX the signal strength from areas of lower concentration 
such as the edges of each deposit would not show spectrally as well as the same areas of SX. It 
should also be further borne in mind that from the ACI work in chapter 5 we expect to see 
greater mass of SX reaching the fine particle plates, and the broader spatial signal may simply 
reflect the higher mass of SX at the peripheral regions of each deposit superseding a 
hypothetical signal minimum. 
6.4.2.3 Raman Spectroscopy 
Figure 6.9 shows the ~ e f e r e n c e e spectra from 1100cm·l to 1800cm·l for SX, FP and the ACI plate 
at 78Snm. The distinct differences in Raman banding between the two APls in this single 
window spectrum can be seen. The distinct and very strong aromatic C=C stretch at around 
1662 cm-l is again unique to the corticosteroid, while the four bands between 13S0cm-l and 
147Scm-l representing the 6(OCH2) deformation, 6(C-H) deformations and ring stretches 
respectively, generate a very unique fingerprint for SX. Subsequently these reference spectra 
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Figure 6.9: Reference NIR Raman spectra (78Snm) of salmeterol xinafoate, fluticasone propionate and 
the stainless steel ACI plate. 
were used to model the hyperspectral data sets acquired from the Raman mapping runs 
acquired on the ACI plates. Figures 6.10 and 6.11 show the overlay of a 100llm x 100llm 
modeled hyperspectral spatial dataset according to the above references, onto the microscope 
image of particles deposited on plate 4 of the ACI from a SX 100 and FP 100 formulation 
respectively. SX was modeled in red, FP green and the ACI plate blue. As is apparent from both 
figures, the individual API systems showed a strong correlation between particle deposition and 
the modeled Raman spectra obtained. Figure 6.10 shows a very good correlation of the red SX 
map to the particle surface distribution. Figure 6.11 does again shows a strong correlation 
between the green FP Raman score and the particle distribution. In this instance however there 
is a shift in spatial positioning. This can be attributed to drift of the lens through the mapping 
duration, but the areas of the Raman map modeled to fit the FP reference do appear to 
correspond well to the particle bodies captured in the bright field image. Notably both figures 
show some degree of artifact incidence. Both maps show areas mapped as strong blue (plate) 
and individual pixels modeled as the absent API. These artifacts are likely the consequence of 
only running a single spectrum per pixel. This was done to significantly reduce scan time, but 
renders the mapping process more susceptible to anomalous readings that may occur as a result 
of instrumental variation, loss of signal due to topographic differences or even contamination . In 
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Figure 6.10: lOOllm x lOOllm hyperspectral Raman spectroscopy derived scores modeled overlay to 
salmeterol xinafoate deposition from a SX 100 formulation on plate 4 of an Andersen Cascade Impactor. 
-50 o 50 
Figure 6.11: lOOllm x 100llm hyperspectral Raman spectroscopy derived scores modeled overlay to 
fluticasone propionate deposition from a FP 100 formulation on plate 4 of an Andersen Cascade 
Impactor. 
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general these areas do not impede the generally positive correlation of the individual 
particulates to the Raman scores obtained. 
Figure 6.12 shows two representative images of the overlay of the Raman derived scores model 
for SX and FP onto the particles deposited from a SX FP 100 formulation. Both images within the 
figure show similar characteristics. There is a strong correlation of the Raman scores obtained to 
the particle distribution on the ACI plate surface. Both SX and FP can be identified as strong red 
and green components of the entire particle masses. As would be expected considering the ACI 
results obtained in chapter 5, there is significantly more SX coverage of the mapping area than 
FP. However the distinction of the FP particulate areas can be made. This can be seen to suggest 
that the SX and FP particles are indeed often found as part of the same larger agglomerates. 
There are very few solely separate FP or SX agglomerates, with green particle masses seemingly 
often attached to the edges of larger SX agglomerates. This lends credence to the theory that 
the two APls are co-associated on impaction. This may therefore refled the co-association of 
the two APls in the airstrear:n upon aerosolization and a theory of critical agglomerate 
constitution being key to subsequent airstream kinetics and deposition performance. There are 
also several other features of interest in both these images that were seen repetitively across 
small areas of the Raman maps acquired. These include the appearance of several transparent 
particle features, several intense yellow or blue areas of mapping. 
Figure 6.13 shows a 120(,1m x 200(,1m overlay of the Raman scores for SX and FP onto particles 
from a SS FP 50 formulation. It further shows the distinct association of the FP and SX particles 
even with a reduced particle mass. It also highlights the same anomalous features described 
above, and the figure includes example point spectra of both these anomalies and the strong SX 
and FP signals for comparison. Easily identifiable are the SX and FP spectra from the strong red 
and green areas overlapping particle bodies. In figure 6.10 A, figure 6.11 and most prominently 
in 6.12 B the transparent dispersed particle features can be seen on the bright field images. 
These only appear in the mapping area i.e. that exposed to the NIR laser. The fluid-like and 
crystalline appearance of these features would therefore suggest that these may be the product 
of a melting process. The lack of a definitive Raman signal from these features and the very low 
signal return can be seen in figure 6.13 C. This low, indistinct signal makes it unclear as to what 
has melted or undergone a transformation under the laser source. Because of the nature of the 
formulations, the only components present on the ACI plates should be the SX and the FP. FP 
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Figure 6.12: 100l1m x 100l1m hyperspectral Raman spectroscopy derived scores model of salmeterol 
xinafoate and fluticasone propionate deposition from a 55 FP 100 formulation on plate 4 of an 
Andersen Cascade Impactor in two separate deposits A and B 
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Figure 6.13: 1 2 0 ~ m m x 2 0 0 ~ m m Raman spectroscopy derived scores model of salmeterol xinafoate and 
fluticasone propionate deposition from a SS FP SO formulation on plate 4 of an Andersen Cascade 
Impactor and associated point spectra of A) SX B) FP C) transparent anomaly and D) yellow anomaly 
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has a melting point of around 290°C while SX has a melting point of around 124°C, suggesting 
that if this is the melt of one of the APls it would more likely be SX. The extent of these melts 
varied from image to image, with figure 6.12 B showing the most significant level and figure 6.12 
A showing the least. What can be seen across the images collected was the nature of these 
melted particles to be near the periphery of larger particles and often near large exposed areas 
of the ACI plate. This may infer that this transition occurred as a process of heat radiation. This 
would occur as the ACI plate heated under continual exposure to the laser source as it was 
rastering. Therefore large particle masses shielding the plate surface reduce this phenomenon, 
and the occurrence of these features, but in areas of large expanses of bare plate, NIR laser 
exposure heats the plate gradually and this is conducted to proximal SX particulates that may 
eventually exceed their melting point. What is unclear is to why these subsequently give a very 
poor Raman signal. 
Figure 6.13 0 also shows the point spectrum from one of the intense yellow 'flares' that 
, 
occurred in various areas of several mapping images. This spectrum shows that the Raman 
signal is very intense but unrefined and uncharacteristic of any of the principal components of 
the formulation. As such the reference model imposed assigns the most likely character based 
on percentage match to the references given, and the intenSity of the spectrum is reflected in 
the colour intensity shown. It is therefore likely that these areas reflect either some degree of 
contamination, or more likely are the effect of some photo reactive process with an impuritY 
such as fluorescence. This is given support by the nonlinear baseline of the spectrum. Because 
each pixel point was only analyzed by one spectrum, with no repeats, that means that any such 
anomalous regions will not be averaged out wIth subsequent exposure. The intense yelloW 
features and the intense blue features showed very similar spectra profiles. The principal 
difference was that the yellow regions were modeled more towards SX while the blue more the 
ACI plate. In real terms neither really showed any consistency with either spectral reference. 
Figure 6.14 shows the optical microscope image through the lOx objective lens of an entire API 
spot from a SX FP 50 formulation as deposited on plate 4 of an ACI run. Figure 6.15 shows the 
corresponding Raman derived scores model for SX and FP (via mapping using the x50 lens) for 
the same surface area. These figures in conjunction show a very good correlation between the 
visual particles and the SX and FP modeling of the Raman spectra. All major particulate features 
can be corresponded from figure to figure and both SX and FP character can be discerned. Once 
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Figure 6.14: 6 0 0 ~ m m x 8 0 0 ~ m m optical microscope image of a deposited API spot from a SX FP 50 HFA134a 
formulation on plate 4 of an Anderson Cascade Impactor 
Figure 6.15: 6 0 0 ~ m m x 8 0 0 ~ m m Raman spectroscopy derived scores model of salmeterol xinafoate and 
fluticasone propionate deposition from a SX FP 50 formulation on plate 4 of an Andersen Cascade 
Impactor 
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Figure 6.16: 6 0 0 ~ m m x 8 0 0 ~ m m optical microscope mage of a deposited API spot from a SX FP 100 
HFA134a formulation on plate 4 of an Anderson Cascade Impactor 
Figure 6.17: 6 0 0 ~ m m x 8 0 0 ~ m m Raman spectroscopy derived scores model of salmeterol xinafoate and 
fluticasone propionate deposition from a SX FP 100 formulation on plate 4 of an Andersen Cascade 
Impactor 
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more the proportionally greater abundance of SX across the entire spot can be seen, and 
therefore the existence of several SX only particle bodies is unsurprising. However while the 
localization of FP particles can again be seen to be co-existent with many SX particle bodies, 
there is also evidence over this scale of separate FP particulates. This is especially true at the 
periphery of the API spots. Figure 6.16 shows the optical microscope image of an entire API spot 
on plate 4 of an ACI from a SX FP 100 formulation. This mass doubling from the SX FP 50 spot 
can be visualized clearly by comparing the images. The center of the spot is now much more 
concentrated and particle scatter to the periphery has increased. 
Figure 6.17 shows the Raman derived hyperspectral data modeling for SX and FP across part of 
this same API spot in figure 6.16 with bias on the x and y axis to focus on the peripheral particle 
scattering. The figure shows the concentrated particle mass at the center of the spot, and the 
decreasing gradient of distribution as we move outwards. Notably particle scatter can still be 
characterized up by the Raman as far away as 350llm - 400ilm from the spot center. In the 
center of the concentrated API, deposit, there is again a large degree of co-localization of the 
two APIS, with the predominant SX particles inter-dispersed with associated FP particles. Small 
and infrequent individual particle bodies can be distinguished. However as with the SX FP 50 
formulation, as we move from the center of the spot to the periphery, we start to see more and 
more separate particles corresponding to each API. Approximately 250llm away from the 
deposit center, there is more separate character than combined. This directly opposes the trend 
at the center of the spots and may suggest that the co-deposition of the two APls in the ACI is 
actually the result of interaction at the plate, rather than in the formulation and in the airstream 
leading to deposition. In this circumstance the FP and SX particles have agglomerated at the 
point of impaction according to particle-particle contact as particles exit the airstream and 
impact into the surface and each other. Particles that are only just unable to remain in the 
airstream, deposit to the outside of the API spots and do not subsequently contact further API 
particles and deposit alone. However it is also equally possible that the particles at the edge of 
each API spot are moved there by collisions from the center mass. The subsequent actuations of 
the pMDI formulation provide more and more API particles that inertially impact onto 
previously deposited particles. This may forcibly displace the previous material, leading to 
destructive relocation of these particles. As such the breakup of SX and FP agglomerates could 
occur, resulting in peripherally dispersed API particles. 
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6.4.2.4 Principal Component Image Analysis of Hyperspectral Time of Flight Secondary Ion 
Mass Spectrometry Data 
The first step in the ToF-SIMS analysis of the SX and FP ACI plates was to analyze the acquired 
hyperspectral data by PCA to determine the number of factors to model for by subsequent MCR 
analysis. Figures 6.16 to 6.19 show the PCA image analysis of ACt plates 4 to 7 (in the negative or 
positive spectrum as indicated). The analysis was done for all plates from 0 to 7 in both positive 
and negative spectrums. From these figures it can be seen that the PCA analysis alone does not 
consistently model for the visual definition of the impacted drug spots. Figure 6.21 shows that 
the 1st principal component (PC) intensely highlights coordinated variants within the small 
impact spot on plate 7 and on figure 6.19 PC2 models the drug spot on plate 5. This was also the 
case with some additional spectral datasets but figures 6.18 and 6.20 show the more common 
peripheral spot definition by the primary prinCipal components. This is not unexpected because 
while the technique identifies combinations of chemical spectra that reflect the correlations and 
anti-correlations of the variant ions across the image, certain chemical components may be 
projected onto multiple factors and therefore become difficult to categorise in a co-ordinated 
fashion. 
The Eigenvalue plots show that the majority of the variance in the datasets is projected onto the 
first 1 to 4 PCs. There is a slight exception in figure 6.20, where a larger spread onto further PCs 
can be seen, but this is highlighted as a general anomaly, with only three more spectral datasets 
(positive and negative spectral datasets for plate 6 and plate 2) showing similar Eigenvalue plots 
among the total 14. Even for these datasets however, when we look at the visual projection of 
the scores onto the first 12 PCs we can see little discrimination in structural differences after 
PC4. Beyond this component there appears to be little variability besides minimal alteration to 
the background composition. This is the same in figure 6.16 and the majority of the other plate 
data sets. Figures 6.17 and 6.19 appear to show some coherent variability on later PCs (PC 11 in 
figure 6.19 and PC 6 in figure 6.21), yet in these instances the variability projected as 
Eigenvalues onto these components is minimal. From the PCA images generated it is possible to 
infer that there is a large degree of background variability across the ACI plates. A significant 
number of components seemingly represent variance in the distribution of plate components, . 
with respect to the spatial positioning of deposited API. A 'halo' effect can be seen across many· 
of the primary principal components around the drug spots themselves, which may suggest the 
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Figure 6.18: Positive Spectrum Eigenvalue plot and PCA score images on principal components 1 - 12 
from a 5 0 0 ~ m m x 5 0 0 ~ m m area around a single API spot from a SX FP 100 formulation on plate 4 of an 
Andersen Cascade Impactor 
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Figure 6.19: Negative Spectrum Eigenvalue plot and PCA score images on principal components 1 - 12 
from a S O O ~ m m x S O O ~ m m area around a single API spot from a SX FP 100 formulation on plate 5 of an 
Andersen Cascade Impactor 
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Figure 6.20: Positive Spectrum Eigenvalue plot and PCA score images on principal components 1 - 12 
from a SOOl1m x SOOl1m area around a single API spot from a SX FP 100 formulation on plate 6 of an 
Andersen Cascade Impactor 
281 
Chapter 6 - Investigating the Co-Deposition of Active Pharmaceutical Ingredients from HFA134a 
pMDI systems 
Negative Spectrum Eigenvalues for Plate 7 
1200 · 
1000 t · 
800 . 
(/) 
Q) 
:J 
ro 600 > c 
Q) 
0> 
iii 
400 . 
~ ~ . 
200 . 
.. 
0 
, 
2 4 6 8 10 12 14 16 18 20 
Principal Component Number 
Figure 6.21: Negative Spectrum Eigenvalue plot and PCA score images on principal components 1 - 12 
from a SOOllm x SOOllm area around a single API spot from a SX FP 100 formulation on plate 7 of an 
Andersen Cascade Impactor 
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segregation of chemical constituents. This in turn may reflect API separation. However as 
already stated, PCA alone is not always the most suitable analysis of hyperspectral images. 
Hence the PCA data was used to determine that subsequent MCR analysis should be based 
around a 4 component model. 
6.4.2.5 Multivariate Curve Resolution Image Analysis of Hyperspectral Time of Flight 
Secondary Ion Mass Spectrometry Data 
The ToF SIMS datasets were subject to MCR analysis with modeling for 4 components. Figure 
6.22 shows the resulting MCR images for all the ACI plates analyzed from the positive spectrum, 
while figure 6.23 shows the same but from the negative spectrum. In these figures it can be 
seen visually that in nearly all instances the API deposits appear to have been identified by a 
positive correlation of MCR scores within one of the four MCR components modeled. The only 
exception is from the data in t ~ e e negative spectrum on plate 0 of the ACI, where no positive 
chemical arrangement matches the particles deposited. However the distinct negative 
correlation from the components assembled does provide an outline of what appears to be the 
particle matter. In general however as we move down the plates from plate 0 we see single 
sparsely arranged positively identified particulate arrangements, begin to increase in frequency 
across plates 1, 2 and 3 before on plate 4 there is a distinct overlap into a central mass. Plates 4, 
5, 6 and 7 show more and more coherent and smaller central chemical structures by MCR 
identification. 
For the early plates (PO - P3) the remaining components of each plate seem to represent various 
indistinct chemical arrangements that surround the API deposits. However in the later plates, 
(P4 - P7) with the exception of plate 5, there is the distinct appearance of a 'corona' or strong 
outline of the central particulate mass. In order to identify this and the other features 
designated by the MCR component images it was necessary to look at the loadings on each 
component. Figures 6.24, 6.25, 6.26 and 6.27 show the positive spectrum loadings on the MCR 
components 1 to 4 for the plate 5 data respectively. This is included along with the assignments 
of the evident key ion mass contributors and the parent chemical surface they are most likely to 
have come from. Figures 6.28, 6.29, 6.30 and 6.31 show the negative spectrum equivalents of 
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the same information. These figures are representative of the work done on all the components 
across all the plates. 
From figure 6.24 we can see that the central region identified by MCR component 1 has a few 
key ions with significant loadings. The most prominent ion contributor, with a loading of 7.1OE-01 
was C7H7+' This ion, as identified by looking at the reference samples, and by chemical 
deconstruction can be attributed to a fragment of SX inclusive of the tail aromatic ring. While a 
couple of the other more prominent ions can be found universally in the FP SX and plate 
references, the rest of the other key ions can again all be matched as shown to one of the APls 
or the other. As such it is evident that this central chemically distinct feature is a combination of 
FP and SX, and most definitively the API deposit structure. By looking at figure 6.28 and MCR 
component 1 in the negative spectrum the same conclusion can be drawn. Here where a similar 
central chemically defined feature is evident, the most important ion mass contributors can be 
assigned as CllH70 r and ClOH70-, both natural fragments of the betaragonist. While both these 
component images have the most contribution from SX derived fragments, and this was 
generally true of most of the API containing component images, it is important to note that they 
also do show significant contributions from ion fragments derived from FP. Ions such as C3HsO+, 
C3HsOr , CH 2SF- and F- can all be seen to be significant contributors to the MCR component. The 
later plates show more of bias towards the contribution of the SX ions, but this expected as the 
from the ACI work carried out previously, it is known that mass of SX relative to FP increases at 
the fine particle plates are reached . At higher (lower plate number) plates such as plate 0 and 1 
the most dominant API ion in the API components were derived from FP. More importantly 
however is that in figures 6.24 and 6.28, aside from some universally derived (both APls and 
background) ion fragments there are no ions that can be directly attributed to the background 
plate. What this tells us is that these components describe the principal mass of the API 
deposition. For the remainder of the plates, this observation was consistent. In all instances 
(with the exception of the negative spectrum plate 0 MCR images), an API specific component 
can be identified visually and then with chemical confirmation. The first plates, 0 - 2 do show 
some slight overlap with background derived ions, but this is not unexpected given the much 
less concentrated covering of the API particles from the larger nozzles and reduced mass at that 
plate level giving rise to more surface exposure. 
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Figure 6.22: SOOllm x SOOllm images of the positive spectrum MeR scores 
on four components for plates 0 - 7 of a SX FP 100 pMDI deposit 
Chapter 6 -Investigating the Co-Deposition of Active Pharmaceutical Ingredients from HFA134a 
pMDI systems 
PO 
Pi 
P2 
P3 
P4 
PS 
P6 
P7 
Cl C2 C3 C4 
~ ~ ... 
.. " ~ -
. -
1 : 
- : -
Figure 6.23: 5 0 0 ~ m m x 5 0 0 ~ m m images of the negative spectrum MeR scores 
on four components for plates 0 -7 of a SX FP 100 pMDI deposit 
Chapter 6 - Investigating the Co-Deposition of Active Pharmaceutical Ingredients from HFA134a 
pMDI systems 
14.00(.(11 1 
2 
. . 
loadings on Component 1 (+) 
Assignment Mass 
CJH_7 91.056113 
C_4H_7+ 55 .056329 
C_ 3H_ 5+ 41.039753 
C_ 3H_7NO+ 73 .054359 
CH_4N+ 30.035172 
C_3H_50+ 57.035535 
C_ 2H_5+ 29.039775 
C_2H_6N+ 44 .051937 
C_8H8_0f 139.052869 
C_6H_13SNO+ 147.065461 
... 
'00 
loadings on Camp. 1 (8.91%) 
7.10E-Ol 
2.80E-Ol 
2 .74E-Ol 
2 .69E-Ol 
2 .57E-01 
1.97E-01 
1.50E-Ol 
1.47E-01 
1.04E-01 
1.0lE-01 
Derivative 
5X 
U 
U 
5X+FP 
5X 
FP 
FP 
5X 
FP 
5X 
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Figure 6.25: Positive Spectrum loadings and ion mass assignments on MCR component 2 of plate 5 of a 
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Figure 6.27: Positive Spectrum loadings and ion mass assignments on MCR component 4 of plate 5 of a 
SX FP 100 formulation deposit 
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Figure 6.28: Negative Spectrum loadings and ion mass assignments on MCR component 1 of plate 5 of a 
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Loadings on Component 2 (-J 
... 
. . . 
:: _"'.'1> ... ,. .. ~ ~..... ~ ~ ....... . 
... 
.,.dSc:o.OI'ICooo\p2{!7O'Wo1 
r Ass,,"ment M •• 
a- 15.994797 
OH - 11.002626 
C_1H- 25.00104 
(H- n .OO19'" 
'_2- 21.99983. 
('(>-1- 99.916649 
( - 12.00010 
PO_ 2- 62.964161 
(HO_I - 44.991569 
(,pO_ S· 16Z.l1I6S4 
( _1HO- 41.00]916 
(,pO_4. 146.19)069 
. 
sao 
lo. eUnp on (omp. 2 (5 .70'" 
'.11E-Ol 
4.97E·Ol 
lADE·Qt 
3.01(·01 
1..5 E-O 1 
13 5E-Ol 
1.1IE-Ol 
' .'lE-OI 
t .tlE·01 
9.04(·01 
I.3U·01 
7A4( 01 
. 
... 
OertvaUon 
U 
aKD 
U 
aKD 
aKD 
aKD 
OKD 
Figure 6.29: Negative Spectrum loadings and ion mass assignments on MCR component 2 of plate 5 of a 
SX FP 100 formulation deposit 
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Figure 6.30: Negative Spectrum loadings and ion mass assignments on MCR component 3 of plate 5 of a 
SX FP 100 formulation deposit 
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Figure 6.31: Negative Spectrum loadings and ion mass assignments on MCR component 4 of plate 5 of a 
SX FP 100 formulation deposit 
290 
Chapter 6 -Investigating the Co-Deposition of Active Pharmaceutical Ingredients from HFA134a 
pMDI systems 
As figures 6.25, 6.26, 6.27 and their negative spectrum equivalents, figures 6.29, 6.30 and 6.31 
subsequently show, the remaining components are described by ion masses that are typically 
attributable to the background plate. The stainless steel ACI plate showed consistent and 
repetitive metal ion contributions (Cr+, K+, Na+, CaOH+) in the positive spectrum, sulfur and 
phosphate group ions (P03-, POr,SOd in the negative spectrum. These were abundant in the 
plate reference and distinguish the remaining MCR components from the API containing 
component. In plate 5 as an example there was no significant contribution to any of the 
remaining three MCR components from ion masses deriving from either SX or FP. With respect 
to the other plates this was also generally the case. In some instances there was the occasional 
low ion mass loading on a component that was associated with either of the two APIS. Examples 
include the presence of fluorinated ions in the negative spectrum of the 3rd MCR component of 
the negative spectrum analysis of plate 3. While FP should be the only fluorine containing entity 
present, there is the capacity for fluorinated contamination to have left small traces on the plate 
surfaces. Regardless it is worth noting that these loadings were not the most significant 
contributors to the MCR component. 
However as mentioned already, in agreement with the PCA images in figures 6.18, 6.19, 6.20 
and 6.21 the MCR component images in figures 6.22 and 6.23 do show some component images 
that present what appears to be a corona effect around the API component. This halo effect is 
distinct on plates 4,6 and 7, but despite some suggestion of it by PCA not on plate 5 or the other 
plates. To identify whether these apparent surface features are related to any particular 
chemical moieties figures 6.32 and 6.33 show these extracted MCR components and their 
primary ion contributors from the positive and negative spectrum respectively, alongside the 
requisite assignment and suggested material source. What is apparent from both figures is that 
the principal contributions to all these MCR component images appear to be background (ACI 
plate) derived ions. There are a lot of small hydrocarbon ions e.g. C3HS+' C3H,+, C2Hs+ and metal 
ions e.g. Na+, Ca+ and Cr+ in the positive spectrum, as well as small oxygenated species such as 
. 
0-, OH-, 503- and P03- in the negative spectrum that were particularly prevalent in the ACI plate 
reference. Some of these ions were however found universally across all the reference samples, 
and this makes it more difficult to identify the source. However there are also some ions that 
contribute to all these component images that are particularly associated with the APls. Whilst 
their loadings on the component are much reduced from the top contributing ions, they are still 
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listed as within the top ten or so ions that define the MCR chemical map. Such examples include 
the C3H7NO+, C2H6N+, C10H70 3- and ClOH70- ions from SX, the C2HsO+, CsHg+ and F- ions from FP. 
This data may suggest that this apparent corona is actually a region of the plate where the 
scatter of some API particles supplements the already high levels of small hydrocarbons, or 
oxygenated species which in turn is then modeled as a separate MCR component by variance. 
Certainly there is no evidence that there is segregation of the APls into separate regions of the 
API spot. That we can see strong contributions from both APls in the components reflecting the 
API deposit, as well as weaker contributions from both APls again to these 'artificial' corona 
components, suggests that both APls are distributed throughout the API spot. That this halo 
effect does not appear on the MCR components for plates above plate 4, and grows in intensity 
with the concentrating of the spot material as we move to smaller nozzle sizes (down to plate 7) 
might further infer that a matrix effect is being observed. This is to say that the intensity of the 
detected secondary ion signal is directly affected by the chemical constitution of the 
surrounding material 'matrix' (Belu et al 2003). As we have seen with the SEM images, the 
overlay of the API particles in the center of the deposit leads to alterations in electron 
conductivity because of insulation from the metal surface. In a similar fashion, as we 
concentrate the API powder into a smaller area and generate particle. stacked deposits, the 
material at the peak of the resultant mound is unlikely to possess the same secondary ion 
yielding characteristics as those that lie on the metal plate. It is therefore possible that the 
secondary ion yield from the center of the insulating particle stack is less than that of the 
peripheral material which on a conductive surface generates high secondary ion yields. This 
artificial alteration to secondary ion yield coupled with the surface specific ions localized to this 
area may therefore lead to what appears to be such a 'halo' or 'corona' effect. With larger 
nozzles and less concentrated API particle mass, this effect is significantly reduced and hence 
not visible on plates 0 to 3. 
To reinforce the hypothesis that the APls are co-combined within one component by MCR 
analysis, and that the apparent 'halo' effect is artificial, figure 6.34 shows single ion ToF-SIMS 
images of the plate 7 drug spot using three ions that represent SX, FP and the plate background. 
The ion intensities presented next to the images reflect the intensity from the reference samples 
so as to infer the ion genesis. What the figure illustrates is that both the SX and FP derived ions 
(CllH70 3- and C3Hs0 2-) originate from the center of the deposit. While the S03- ion 
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Image of $CQ(9S on Camp 3 (13.43%) 
Assignment Mass Loadings on Comp. 4 (29.44%) Derivation 
P4 '_lH_S+ 41.039753 3.70E-Ol u C_3H_7+ 43.055997 3 .69E.()1 U C_ZH_S+ 29.039775 2.78E'()1 FP_BKD 
C3 + eaOH+ 56.966562 2.6SE-Ol BKD C_2H_3+ 27.02361 2.64E-01 BKD 
Cr+ 51.941347 2.61E'()1 BKD 
C_ 4H_7+ 55.056329 2.59£-<11 u 
C_3H_1NO+ 73.054359 1.95E'()1 SX 
X+ 38.965187 1.72E..()1 BKD 
C_3H_3+ 39.023154 1.SBE.{)1 U 
C_4H_S+ 53.039748 1.56E.()1 BKD 
No+ 22.990562 1.32E'()1 BKD 
C_2H_50+ 45.035558 1.29E'()1 FP 
C_SH_9+ 69.07371 1.15E.()1 FP 
Co+ 39.962807 1.15E'()1 BKD 
2<) 40 60 80 ' 00 120 
Assignm ent Moss Loadings on Com po 3 (4.73%, Derivat ion 
eaOH+ 56.966562 4.35E'()1 BKD 
K+ 38.965187 4 .14E'()1 BKD 
P6 C_2H_5+ 29.039775 2.98E.()1 FP_BKD C_3HJ+ 43.055997 2.78E'()1 U 
C3 C_2H_3+ 27.02361 2.54E.()1 BKD + SiH_13N_S+ 111.094614 2.38E'()1 BKD 
C_4H_7+ 55.056329 2.14E'()1 u 
C_3H_S+ 41.039753 2.QlE-Ol U 
C_2H_30+ 43.019969 1.70E'()1 U 
C_3H_8N+ 58.067553 1.43E.o1 BKD 
C_3H_30+ 55.020287 1.26E'()1 U 
Co+ 39.962807 1.20£-01 BKD 
Cr+ 51.941347 1.12E.o1 BKD 
C_3H_7NO+ 73.054359 l.l1E'()1 SX 
Image of Scores on Comp 1 (6.55%) 
Assignment Moss Loodlne' on Com p. 1 (6.55%) Derivat ion 
C_3H_S+ 41.039753 4.44£-01 U 
2<) No+ 22 .990562 2.82E.()1 BKD 
P7 C_2H_30+ 43 .019969 2.79E'()1 U 40 C_2H_S+ 29.039775 2.62E'()1 FP_BKD 
C_2H_3+ 27.02361 2.43E.()1 BKD 
C1 + 60 C_4H_7+ 55.056329 2.35E.()1 SX_BKD Cr+ 51 .941341 2.21E-<Jl BKD 
60 C_3H_7+ 43.055997 1.84E..()1 U 
C_ 4H_S+ 53.039748 1.69E'()1 BKD 
'00 
C_3H_30+ 55.020287 1.64E'()1 U 
C_3H_3+ 39.023154 l.SSE'()l U 
C_2H_6N+ 44.051937 1.55E.()1 SX 
'2<) 
CH_4N+ 30.035112 1.50£-01 SX 
2<) 40 60 80 ' 00 '2<) 
Figure 6.32: Positive Spectrum loadings and ion mass assignments on MeR components showing halo 
effect. 
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5o_3-
PO_3-
AsH_S().. 
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CN-
5o_2-
C_2H-
PO_2-
OH-
CNo. 
o. 
Mass Loadings on Com p. 3 (4 .42%) Derivat ion 
15.994797 6 . 2 5 E ~ 1 1 U 
17.002626 5 . 0 4 E ~ 1 1 U 
13.007948 4 . 0 1 E ~ 1 1 U 
25.00804 2 . 4 4 E ~ 1 1 U 
187.036428 1 . 7 2 E ~ 1 1 5X 
12.000142 1 . 6 8 E ~ 1 1 U 
23.999838 1.44E.{)1 U 
143.047044 1 . 4 2 E ~ 1 1 5X 
78.959878 1 . 4 1 E ~ 1 1 81(0 
73.030266 536H2 FP 
14.015663 4 . 7 0 E ~ 2 2 U 
65.00361 4 . 1 6 E ~ 2 2 5X 
49.007959 4 . 0 8 E ~ 2 2 U 
18.998425 4 . 0 7 E ~ 2 2 FP 
Mass loadings on Com p. 4 (8.96%) Derivat ion 
78.959878 5.52Hl 81(0 
62.964261 3 . 8 9 E ~ 1 1 BKO 
26.003951 2 . 8 1 E ~ 1 1 BKO 
25.00804 2 . 6 5 E E 1 1 U 
79.95886 2 . 4 1 E ~ 1 1 BKO 
41.999973 2 . 3 2 E ~ 1 1 BKO 
96.961056 2 . 0 8 E ~ 1 1 U 
17.002626 2 . 0 0 E ~ 1 1 U 
41 .003936 l . . 5 E ~ 1 1 U 
15.994797 1 . 7 5 E ~ 1 1 U 
49.007959 1 . 5 2 E ~ 1 1 U 
44.998569 1 . . 9 9 ~ 1 1 BKO 
Mass Loadinss on Compo 2 (12.73%) Derivation 
96.961056 6.61E-Ol U 
79.95886 4 . 5 7 E ~ 1 1 BKO 
78.959878 3 . 4 1 E ~ 1 1 BKO 
95.952742 2 . 3 6 E ~ 1 1 BKO 
80.967366 2 . 1 2 E ~ 1 1 BKO 
26.003951 1 . . 6 E ~ 1 1 BKO 
63.962572 1.28Hl BKO 
25.00804 l . 2 1 E ~ 1 1 U 
62.964161 1 . . 8 E E 1 1 BKO 
17.002626 1 . 0 7 E ~ 1 1 BKO 
41.999973 l.06Hl BKO 
15.994797 1.02Hl BKO 
Figure 6.33: Negative Spectrum loadings and ion mass assignments on MeR components showing halo 
effect. 
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Figure 6.34: Negative spectrum single ion images of an Andersen Cascade Impactor plate 7 55 FX 100 
deposit w ith the relative intensities of each ion found in the sample references. 
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associated heavily with the background shows an intense band around this spot that 
corresponds to the halo seen via MeR modeling. However when we look at the 504- ion which 
shows low intensity counts but is relatively much closer across all the three surfaces, there is an 
exaggerated halo, with an overlap into the API spot. This seems to confirm that the halo is a 
function of exaggerated low intensity ion character by matrix effect. The MeR components 
presented above show a similar pattern for all the plates where this effect can be observed. 
Furthermore, all the strong API signals show a very good coherence on an ion by ion basis to the 
MeR described API components across all the plates. 
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6.5 Conclusions 
From the complementary data presented on API co-localization several conclusions can be 
drawn. Firstly, the complementary use of multiple surface specific analytical mapping 
techniques provides a wealth of physicochemical information describing the broad deposition 
character of individual drug spots produced 'in-vitro' of a binary pMDI system. The combination 
of SX arid FP, which has previously been suggested to be more effective 'in-vivo' thanks to 
increased levels of co-deposition of the two API particles appears to show significant co-
deposited character by SEM, DESI, ToF-SIMS and Raman spectroscopy. All these techniques used 
evidenced particular strengths and weaknesses in making an assessment of co-deposition 
character and the physical make-up of the API deposits themselves. 
SEM was unable to define the localization of SX with respect to FP by virtue of particle 
morphology alone. However it did highlight the composition of an API deposit and in particular 
the particle concentrating effect of the lower plates. Here where nozzle size decreases the 
impacted particles become more spatially confined. Particle overlay in the center of these lower 
plate spots becomes very significant, and this in turn leads to an influence on the SEM images 
returned. As the centrally deposited particulates insulate each other from the surface they are 
less able to dissipate electron charge then those particles spread on the metal substrate. This 
leads to a false intensity impression that suggests a significant particle 'mound'. However by 
rotating the sample to 45° it was seen that this height impression is false, and that although the 
central regions were highly concentrated with particle agglomerates, they did not stack to 
exaggerated heights. As we move from the center of each API spot we see smaller and smaller 
agglomerates, eventually dispersing to individual particles. 
DESI suffered from a lack of spatial resolution that would· not allow individual particulate 
definition or the appropriate assessment of an individual drug spot. Furthermore there remains 
a question of the bias introduced by the relationship of two separate and distinct chemical 
entities to the solvent in the DESI plume. Differences in desorption and ionization efficiencies 
mean that, it is difficult to assess accurately the broad quantification of mass equivalence in a 
given location. However the technique is relatively very rapid, and requires no special 
preparation of the samples. It is easily applied to large surface areas, and is still able to allow the 
broad localization of the two APls within single drug spots. This therefore suggests that it offers 
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the opportunity for macroscale high throughput analysis. The DESI data collected in this chapter 
seemed to suggest that sx and FP could both be found within the same drug spots, spreading 
from the center out. However the stronger SX signal suggested this API was more broadly 
scattered from each spot, with FP more centrally contained. It is likely however that this reflects 
the better desorption character and greater mass of SX deposited on the fine particle plates. 
Raman spectroscopy showed the best facility to assign chemical character to individual particles 
with confidence and thereby assess the individual particle co-ordination. By operating with a 
spatial resolution of ljlm it was possible to see that the vast majority of the FP particles 
mapped, were co-associated with SX particles. This was especially true in the center of each 
deposit. However as we move further away from the center of each spot, the frequency of 
independent API particles increases. Therefore the question of whether the particles co-deposit 
straight from the airstream or actually upon the impaction surface was raised. While the Raman 
maps were particularly useful in relating chemical identity to individual particles, at both small 
scales and across entire spots, they were very time consuming to run with the larger scan s i z ~ s s
taking several days to complete. In an attempt to reduce the run time, repeat spectra were not 
performed at each pixel point which meant the Raman maps were liable to anomalous spectra 
collection. In some instances photo reactive processes, such as fluorescence, interfered with the 
Raman signal and generated false modeling data. Furthermore the process proved to be 
partially destructive, with some API particles showing melting behavior under the NIR laser 
(78Snm) as a result of the ACI plate radiating heat. This was already with a longer wavelength 
laser than would have been desired, due to unworkable fluorescence of SX under a green laser 
(S32nm), which further reduced the Raman intensity of the samples, and prolonged run times. 
This suggests that Raman spectroscopy should be used for more detailed small spatial scale 
analysis of particle co-ordination experimentation. 
ToF-SIMS combined with a multivariate approach to analysis generates image analysis data that 
again highlights the co-localization of the two APls. Individual particle character was generally 
lost due to the overlap of variants analyzed (fragment ion masses), but following PCA analysiS in 
order to define an MCR image analysis, the SIMS data yielded MCR components that show 
consistently strong API drug spots across all the ACI plates. These components were defined by 
ion mass loadings from ions that were confidently derived from both SX and FP, suggesting 
these areas were a blend of the two APIS. Both PCA and MCR analysis of the lower fine particle 
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plates seemed to suggest some form of peripheral surface feature surrounding the primary API 
spot, but this was attributed to a matrix effect borne of the concentrating effect of the smaller 
nozzle sizes on the API particles. Similarly to the SEM data, the insulation of the particles from 
the plate surface led to separate secondary ion yields depending on spatial location. 
In collusion the techniques utilized suggest that there is high level co-deposition of SX and FP 
from a combination pMDI formulation on ACI plates. While the co-localization of the two APls 
can be seen broadly in all the techniques (except SEM) the Raman data specifically shows FP and 
SX particles in co-association. While the degree of this co-association diminishes with distance 
from the center of the deposits, there is sufficient evidence to suggest that the two APls either 
undergo a particular association in the airstream that leads to co-deposition or, co-deposit with 
adhesive contact on the impacted surface. This data therefore further supports the research 
carried out previously evidencing that these two APls have a strong tendency to co-associate 
post-actuation. It is therefore viable to hypothesize that this observation may be intrinsically 
linked to the force balance of the, system. Unfortunately it has not been possible to compare this 
formulation with another force balance characterized combination, so as to assess the 
relationship of a force balance to co-deposition further. The apparent instability of BDP in a 
HFA134a suspension without additional excipients has been highlighted, and the retention of 
this API made further deposition characterization alongside SS difficult and significantly less 
viable. In this instance the inability of Raman spectroscopy to identify more than the faintest 
BDP deposit, and the very low BDP mass spectra intensities returned with DESI meant little more 
could be followed up with respect to deposition analysis. With further BDP material and 
formulation, it would be of great interest to identify the exact changes that had occurred in the 
HFA134a propellant by XRPD or FT-IR spectroscopy so as to define the instability fully. 
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7.0 Final Conclusions 
7.1 General Introduction 
This thesis has examined the application of the AFM based CAB approach to the force 
quantification of real (as formulated) and semi-model active pharmaceutical ingredients for 
inhalation. It has further gone on to link measured force balances of binary combinations of 
APls, to the 'in-vitro' deposition performance of the co-formulated drugs, as examined by 
aerodynamic particle sizing and chemical mapping. Work has focused on the constraints and 
adaptability of using surface specific analytical techniques to qualify and quantify the force 
relationship between combination APls, screen their depOSition performance, and establish any 
casual links as appropriate. Below follows a concise summary of the chapters of the thesis in 
sequence. 
7.2 Application of the CAB Approach to Inhalation Materials with 'Non-
Ideal' Surfaces 
Chapter 3 attempted to use CAB methodology to describe the force balance between 
combinations of API particles and pMOI component surfaces. Micronized particles of BOP and 
two BOP clathrate polymorphs (with relatively smooth and large particle surfaces) were 
attached to AFM tips as functional probes and challenged to the surfaces of a stainless steel 
metering chamber, uncoated aluminium canister wall and fluorinated ethylene propylene 
coated canister. Prior characterisation of the component materials using SEM and AFM showed 
surfaces that were in the region of 20-40 times rougher than typical recrystallized CAB 
substrates. Combined with API cohesive surfaces that ranged from 12-100 times rougher than 
normal CAB substrates the attempted CAB balances failed. Tip series from all the APls showed 
little linear correlation, and the plotting of several tip values on opposing sides of the 
adhesive/cohesive divide within a CAB plot, was indicative that the contact regimes between the 
adhesive and cohesive surfaces were not showing sufficient parity. This reflected a loss of 
normalisation capability for the adhesion forces, making them incomparable. This failure was 
attributed to the relatively large surface rugosity of the 'raw' materials in combination with the 
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use of very large functional particle tips (some in the region of 60j..lm) that exacerbated such 
topographical variability. While the model as a whole was seen to have failed, the constant rank 
affinity of all the APls did seem to suggest that the FEP coated canister underwent the least 
forceful interaction with all three BOP polymorphic forms, which supported its use as a force 
modulator. 
7.3 Application of the CAB approach to, and Characterization of Semi-
Model Inhalation Substrates 
Chapter 4 used the information from chapter 3 to direct the selective functionalization of AFM 
tips with small and well defined API particles, for use with compressed (reduced rugosity) 
powder substrates of API. The compressed substrates were characterised by AFM, SEM and Osc. 
The improved facility to perform surface energy measurements indicated more consistent 
surface topographies, and allowed a rank assessment of the API surface interactivities from 
which to choose combinations for further investigation. The AFM and SEM images of SS and BOP 
showed surface roughness reductions of the magnitude of 14-20 times from unprocessed. This 
rendered powder compacts with surface roughness values equivocal to 10-15 times rougher 
than usual CAB substrates. These surfaces were successfully utilised to produce a broad force 
balance by adapted CAB methodology. SS showed a cohesively dominated relationship with BOP 
(CAB ratio 1.69, R2 0.57), while BOP showed an adhesively dominated relationship with SS (CAB 
ratio 0.35, R2 0.57). The coefficient of determination with respect to the linear fitting of the tip 
series gave confidence to the force balance as a rough descriptor of the relationship of the two 
APls. A second CAB balance using salmeterol xinafoate (SX) and fluticasone propionate (FP) was 
then performed and generated a force balance with a stronger linear regression. SX had a mildly 
cohesive relationship with FP (CAB ratio LOS, R2 0.97) while FP had an adhesively dominated 
relationship with SX (CAB ratio 0.63, R2 0.63). These results together suggested that the use of 
semi-model substrates and tightly controlled functional technique had brought the 
topographical variability within a tolerance of an adapted CAB approach. However, the 
visualisation of the AFM and SEM images coupled with OSC analysis suggested that the 
compression process might have induced physicochemical changes that would compromise the 
viability of these semi-model replacements. This requires further investigation 
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7.4 The Cohesive Adhesive Balance of Inhalation Formulations and their 
'in-vitro' Deposition Performance 
Chapter 5 used combinations of SS with BOP, and SX with FP in HFA134a pMOI systems to 
evaluate the link between the force balance of the materials and their 'in-vitro' deposition 
performance in an Andersen cascade impactor. The SX and FP pMOI systems showed that the 
co-formulation of the two APls improved the fine particle performance of FP, but worsened the 
fine particle performance of SX. This effect was exacerbated with increased formulation mass. It 
was concluded that the effect might be linked to the force balance of the system and the impact 
on aerodynamic particle behaviours. As FP interacts with more force with SX than itself, it would 
form stronger bound and bigger particle agglomerates when co-formulated. These agglomerates 
would then be subject to greater drag forces in the airstream upon aerosolization, aiding the 
deagglomeration process and dispersion to smaller depositing particle matter. FP only 
agglomerates would be smaller initially, being subject to lesser drag forces and dispersing less 
well. The reverse is hypothesised for SX, where co-formulation effectively dilutes agglomerate 
strength and size, and perversely may increase effective aerodynamic particle size. This effect 
could not be duplicated or compared with the SS and BOP combination. While there was some 
evidence of a declining fine particle performance of SS and of improving fine particle 
performance of BOP on co-formulation, there was a consistent critical loss of BOP mass across 
all BOP formulations. The lack of recovered BOP mass suggested instability in the manufactured 
pMOI systems leading to device retention. This requires further analysis. 
7.5 Investigating the Co-Deposition of Salmeterol Xinafoate and 
Fluticasone Propionate from a HFA134a Pressurized Metered Dose Inhaler 
System 
Chapter 6 went on to provide an extensive array of physical and chemical data characterization 
of the 'in-vitro' deposition of the combined SX and FP pMOI system. Complementary techniques 
such as SEM, OESI, Raman spectrometry and ToF-SIMS (with multivariate curve resolution 
analysis) combined to show that the two APls could be identified as having co-localised within 
deposits on an ACI plate. Only Raman spectroscopy was able to resolve particle by particle 
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chemical identity using a NIR mapping process, but its long run times, and anomalous point 
propensity alongside the physical damage (melting) of the APls makes it less suitable for rapid 
throughput investigations over large spatial scales. Techniques like DESI were much faster and 
could quickly confirm the presence 'of both APls, but concerns about differences in ionization 
and desorption efficiencies coupled with poor spatial resolution limit its use to broad and 
macroscale mapping procedures. SEM imaging was able to identify particle morphologies, but 
not distinguish the two APls apart. 
Multivariate analysis of the ToF-SIMS data provided confirmation of the blend of two APls within 
deposits with no discernible segregation. Although some component images suggested a 'halo' 
effect, with a combination of API and predominant background character, this was unique to 
highly concentrated drug spots on the lower plates. Here a particle 'mound' was likely to induce 
a matrix effect where differences in ionisation efficiency and topographical differences arise as 
the incident beam moves from plate to concentrated (insulated) drug spot. While the 
techniques were able to identify and characterise both APls from an 'in-vitro' deposit, it was 
unclear whether the ACI material was at all representative of the complex deposition 
mechanisms 'in-vivo' and therefore whether any observed co-deposition was pre-determined by 
aerodynamic interaction, or by forced mixing on the plate. It is possible that the force balance of 
the two APls improves the co-deposition frequency of this particular formulation with respect to 
other combinations of API, but this requires further research for comparison with other 
quantified systems. 
7.6 Future Research Suggestions 
The work in this thesis has generated several points of interest, and also lays the basis for 
further investigation into broader aspects of the field. Of particular note, better characterisation 
of the impact of the compression of APls into powder compacts is needed. DSC suggested that 
the compression process may have changed the polymorphic balance of SX, with more form II as 
a consequence. Further investigation, using such techniques as FT-IR or confocal Raman would 
be appropriate to ascertain the extent, type and location of any polymorphic change with 
respect to both SX, and the others APls. This is important because the use of a semi-model 
substrate has been suggested as more faciJe and potentially representative model of an API than 
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the traditional CAB substrates (molecularly smooth crystals). Yet this is detracted from if in the 
process of producing a powder compact the physical form has been altered. 
~ ~ Another area where follow up would be recommended is into the instability of BDP within·a 
pure HFA134a system. The commonplace use of co-solvents and surfactants was deliberately 
avoided in these studies so as to avoid compromising the force balance between composite 
materials. It was assumed that the short lifespan between manufacturing and using the pMDI 
canisters would therefore negate stability issues, which are normally mid- to late- lifetime 
issues. However the obvious device retention of BDP from all BDP formulations as seen by 
deposition analysis, was compounded by evidence in the DSC traces of additional endothermic 
processes in the extracted API. It would be of great benefit to identify this transition, and with 
the availability of more extractable product run more analytical techniques such as XRD or FT-IR 
to identify what changes have been brought about and understand the process. 
Moving forward generally, two areas of further research would be particularly beneficial. Firstly, 
this body of work was based on the principle of using a simple AFM based methodology to 
identify a force trend with demonstrable impact on pMDI formulation behaviour. However the 
array of solvent forces experienced by API particles within a propellant such as HFA134a, 
contribute significantly to API character, and specifically can determine adhesive behaviour. 
Therefore while it is a success to link a basic force balance between two APls to performance 
from a HFA pMDI system, the natural progression of the work is to perform a balance in a model 
propellant (e.g. decafluoropentane) to compare the results and evaluate the impact of solvent 
forces on a given force balance. Working with AFM to perform colloidal probe microscopy based 
experimentation in liquid media (especially that which is volatile) suffers from technical 
difficulties and detracts from the goal of a rapid and uncomplicated screening tool. However a 
force balance in such conditions would better describe the actual force balance of a pMDI 
combination in a given solvent, and would then allow the impact of subsequent force 
modulators, such as surfactants, to be evaluated alongside the API combinations. 
Secondly, the characterization work achieved in chapter 6 generated a large array of chemical 
and physical information surrounding the SX and FP deposits. However while some of this was 
novel, and could be used to better understand the 'in-vitro' mechanics of the system, it would 
be made more significant if the process was repeated with further combinations of APls, 
especially those with differing force balances. If alterations to fine particle performance, particle 
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co-ordination in deposits and morphological characteristics could be qualified or and quantified 
for comparison, a better understanding of the influence of a range of force balances would be 
obtained. This would potentially allow the whole CAB process to function as a quick and simple 
formulation screen, in prospective formulations, and between suggested combinations of drugs, 
thereby validating the methodology. 
It is my hope that some of these issues and questions can be addressed by further research to 
expand upon the information and insight I have been able to gain throughout the last 3 years. 
Matthew Piggott 
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